National Cancer Institute

Division of Extramural Activities
Annual Report 2010



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Personalized Immunotherapy: Identify the Cancer Antigen and Create the Anti-Tumor T Cell

Adoptive cell therapy (ACT) is a treatment approach for cancer that involves the infusion of large numbers of autologous T lymphocytes with anti-cancer activity.[1] ACT has many advantages compared to other forms of immunotherapy. Large numbers of anti-tumor T cells highly selected for activity against the cancer can be grown in culture for infusion into the patient. ACT is also the only type of immunotherapy that enables substantial modification of the host to create a microenvironment in which the T cells can successfully attack and destroy the cancer.

ACT using tumor infiltrating lymphocytes (TIL) expanded in vitro and infused into the cancer patient has proved highly successful for the treatment of patients with metastatic melanoma. In a series of 93 patients utilizing transfer of autologous TIL following a variety of lymphodepleting preparative regimens, objective response rates by Response Evaluation Criteria in Solid Tumors (RECIST) criteria varied from 49 to 72 percent.[2,3,4] Complete durable regressions were seen in 20 percent of patients and all have remained disease free ongoing from 3 to 8 years after treatment. Thus, ACT represents the most potent treatment now available for patients with metastatic melanoma. TIL with anti-tumor activity, however, can be obtained only from patients with melanoma and this has led us to develop techniques for the genetic engineering of normal circulating lymphocytes to convert them into cells with anti-tumor activity.

Genetic engineering of lymphocytes involves the use of retroviral vectors that can be used to insert genes encoding anti-tumor antigen receptors into normal lymphocytes. Thus, normal circulating lymphocytes can be genetically engineered to express these anti-tumor receptors, grown to large numbers and used for treatment of the autologous cancer patient.[5,6] This approach has opened the door to the use of adoptive cell therapy for the treatment of a variety of cancer types in addition to melanoma.

Lymphocytes genetically engineered to express anti-tumor T cell receptors or chimeric antigen receptors now have been used to successfully treat patients with B cell lymphomas and chronic lymphocytic leukemia[7], synovial cell sarcoma[8], as well as patients with melanoma[5,6]. Recently, the use of T cell receptors that target cancer-testis antigens has made it possible to use ACT to treat patients with common epithelial malignancies.[8,9] Cancer-testis antigens are molecules that are expressed during fetal development but are not expressed in any adult normal tissue (except the testis, which is immunologically protected) but are re-expressed on approximately one-quarter to one-third of all common cancers. Personalized immunotherapy is thus being developed in which tumors are resected, tested for antigen expression, and based on the specific antigen expressed by the cancer, an appropriate receptor is utilized to genetically engineer that patient's lymphocytes. The lymphocytes are then grown to large numbers for use in the treatment of that patient.

This represents the ultimate in personalized immunotherapy since the receptor is specifically selected based on the expression profile of that patient's tumor and a new drug (the patient's own genetically engineered lymphocytes) are used for treatment. This form of personalized immunotherapy is currently being studied in the Surgery Branch of the National Cancer Institute.

References:

1. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, & Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. *Nat. Rev. Cancer* 2008;8:299-308.
2. Rosenberg SA, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. *Clin. Cancer Res.* 2011;17:4550-4557.
3. Dudley ME, et al. Cancer regression and autoimmunity in patients after clonal repopulation with anti-tumor lymphocytes. *Science* 2002;298:850-854.
4. Dudley ME, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. *J. Clin. Oncol.* 2008;26:5233-5239.
5. Morgan RA, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. *Science* 2006;314:126-129.
6. Johnson LA, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. *Blood* 2009;114:1537-1544.
7. Kochenderfer JN, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. *Blood* 2010;116:4099-4102.
8. Robbins PF, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. *J. Clin. Oncol.* 2011;29:917-924.
9. Chinnasamy N, et al. A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. *J. Immunol.* 2011;186:685-696.

National Cancer Institute

Division of Extramural Activities
Annual Report 2010



Cover Images: **Personalized immunotherapy**. The Surgery Branch, NCI, approach to personalized immunotherapy is shown in this diagram. A tumor is excised from a patient and analyzed for the expression of shared tumor antigens. A series of retroviral vectors encoding T cell receptors that recognize each of a large number of shared antigens are now available and can be used to insert these anti-tumor antigen T cell receptors into the patient's own lymphocytes. These genetically engineered lymphocytes with anti-tumor activity are then expanded in culture and infused into the cancer patient. Objective cancer regressions have been seen in clinical trials utilizing T cell receptors against MAGE-A3, NY-ESO-1, MART-1 and gp100, and a chimeric antigen receptor against CD19.

Images and narrative are courtesy of Dr. Steven A. Rosenberg, Chief, Surgery Branch, National Cancer Institute, NIH.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Contents

Introduction 1
Overview of the Division of Extramural Activities. 3
Special Activities in the Office of the Director, DEA 4
Program Coordination: A Resource for New Funding Initiatives 5
Grant Referral: A First Point of Contact for NCI Grant Applicants and Receipt of Applications 6
Peer Review—The Next Step 8
NCI Grant and RFA Funding 17
American Recovery and Reinvestment Act. 19
Supporting Peer Review Consultants. 20
DEA's Role in Advisory Activities 22
Committee Management Activities 27
Portfolio Tracking and Analysis 30
Information Resources Management 34
Organizational Structure of the Division of Extramural Activities. 36

Figures

Figure 1. Receipt and Referral of NCI Grant Applications, FY2006 – 2010 6
Figure 2. DEA Review Workload, FY2006 – 2010 10
Figure 3. P01, SPORE, and Other Multi-Component Research Applications Reviewed, FY2006 – 2010 11
Figure 4. Numbers of Career Development (CD) and Training and Education (T&E) Applications Reviewed, FY2006 – 2010 13
Figure 5. Technology Initiatives Applications Reviewed, FY2006 – 2010 15
Figure 6. NCI Grant and RFA Funding Percentages by Concept Area, FY2009 17
Figure 7. NCI Grant and RFA Funding Percentages by Concept Area, FY2010 18
Figure 8. BSA Approved RFA Concept Set-Asides by Division/Office/Center 18
Figure 9. FY2010 Success Rates for Applications in High Incidence Cancers 32
Figure 10. FY2010 Success Rates for Applications in Selected Special Interest Categories 33

Tables

Table 1a. Requests for Applications (RFAs) Published by the NCI in FY2010, Sorted by Date of Publication 48
Table 1b. Requests for Applications (RFAs) Published by the NCI in FY2010, Sorted by Division, Office, and Center 49
Table 2. NCI Participation in Trans-NIH Requests for Applications (RFAs) in FY2010, Sorted by Date of Publication 50
Table 3a. Program Announcements (PAs) Published by the NCI in FY2010, Sorted by Date of Publication 52
Table 3b. Program Announcements (PAs) Published by the NCI in FY2010, Sorted by Division, Office, and Center 53
Table 4. NCI Participation in Trans-NIH Program Announcements (PAs) in FY2010, Sorted by Date of Publication 54
Table 5. Applications Received for Referral by the NCI/DEA in FY2010, Sorted by Mechanism 56

Table 6. Grant and Cooperative Agreement Applications Reviewed by the NCI/DEA in FY2010, Sorted by Mechanism . . . 58
Table 7. Applications Reviewed by NCI Initial Review Group (IRG) Subcommittees and Special Emphasis Panels (SEPs) in FY2010 . . . 59
Table 8. Summary of Investigator-Initiated P01 Applications Reviewed, Sorted by NCAB Meeting, in FY2010 . . . 59
Table 9. Summary of Investigator-Initiated P01 Applications Reviewed, Sorted by NCI Program Division, in FY2010 . . . 59
Table 10. Requests for Applications (RFAs) Reviewed by the NCI/DEA in FY2010 . . . 60
Table 11. Program Announcements (PAs) Reviewed by the NCI/DEA in FY2010 . . . 62
Table 12. Requests for Proposals (RFPs) Reviewed by the NCI/DEA in FY2010 . . . 64
Table 13. Summary of NCI Grant Awards by Mechanism in FY2010 . . . 66
Table 14. Average Total Cost and Number of Research Project Grant Awards Sorted by Division, Office, Center, and Mechanism From FY2006 - FY2010 . . . 68
Table 15. NCI Organ and Related Site-Specific Dollars for FY2006 - FY2010 – Annual Percent Change . . . 71
Table 16. NCI Special Interest Category (SIC) Dollars for FY2006 - FY2010 – Annual Percent Change . . . 79
Table 17. NCI Funding of Foreign Research Grants in FY2010 . . . 98
Table 18. Foreign Components of U.S. Domestic Research Grants in FY2010 . . . 101
Table 19. NCI Participation in Trans-NIH ARRA Requests for Applications (RFAs) in FY2010, Sorted by Date of Publication . . . 103
Table 20. ARRA Applications Received for Referral by the NCI/DEA in FY2010, Sorted by Mechanism . . . 104
Table 21. NCI ARRA Funding by Anatomical Site for FY2010 . . . 105
Table 22. NCI ARRA Dollars by Science Areas for FY2010 . . . 106

Appendixes

Appendix A: Activities of the National Cancer Advisory Board (NCAB) . . . 108
Appendix B: Activities of the Board of Scientific Advisors (BSA) . . . 110
Appendix C: List of Chartered Committees . . . 111
Appendix D: NCI Initial Review Group Consultants . . . 132
Appendix E: NCI Grant Mechanisms and Descriptions . . . 184
Appendix F: Glossary of Acronyms . . . 194
Appendix G: Cancer Information Sources on the Internet . . . 197

Introduction

The Division of Extramural Activities (DEA) is the organizational component of the National Cancer Institute (NCI) responsible for coordinating the scientific review of extramural research before funding and for the systematic surveillance of that research after funding. The Division solicits advice from individuals or committees of experts on the technical and scientific merit of grants, cooperative agreements, and contracts. The peer review process is important to science in that it allows good ideas to surface and to be judged on their merit and promise. The peer review system is the keystone for ensuring that the best science is supported.

The DEA coordinates the activities of: (1) the National Cancer Advisory Board (NCAB), which consists of members appointed by the President, and conducts the second-level review of grants and cooperative agreements and advises the Director, NCI, on policy for the conduct of the National Cancer Program; (2) the Board of Scientific Advisors (BSA) with distinguished scientists from outside the NCI and representatives from the advocacy community advises the NCI leadership on the progress and future direction of the NCI extramural program, evaluates NCI extramural programs, and reviews NCI-initiated research concepts; and (3) extramural training opportunities for NCI program and review staff.

As a Division, we: evaluate the content of all extramural research funded by the NCI and annually track the NCI research portfolio of more than 7,800 research and training awards by using consistent budget-linked scientific information to provide a basis for budget projections; maintain extensive records of this research and provide specialized analyses of the costs, goals, and accomplishments of the research; and serve as an NCI resource to others for reporting and dissemination of the NCI's research portfolio. The DEA monitors budgetary limitations for grant applications; participates in establishing policies to expedite funding; and initiates and implements changes to applications, guidelines, and award processes. The Division also: coordinates, for the NCI, the review and response to appeals from applicants regarding the peer review process or the subsequent disposition and management of grants, cooperative agreements, and contracts; and responds and coordinates requests from the NIH Office of Extramural Research's Agency Extramural Research Integrity Officer for information and assistance regarding scientists (or institutions) supported by NCI research funds who were the subject of allegations, inquiries, and/or investigations of possible research misconduct.

The intent of this annual report is to provide insight and useful information about the research funding process and the role of the DEA in support of NCI's mission. A comprehensive look at each of the major areas of responsibility within the Division is provided. The data presented cover Fiscal Year (FY) 2010 (1 October 2009 – 30 September 2010) and provide data comparison with previous years.

To implement a biomedical research program of the highest quality, the NCI draws on the national pool of scientists actually engaged in research for assistance in selecting the best research and training projects. We sincerely want to thank the more than 2,300 researchers, clinicians, and advocates who gave unselfishly of their time in FY2010 and have contributed to the continuing success of NCI's peer review and advisory activities.

Paulette S. Gray, Ph.D.
Director
Division of Extramural Activities

Division of Extramural Activities



Overview of the Division of Extramural Activities

The paramount goal of the National Cancer Institute (NCI) is to develop the knowledge base that will ultimately lessen the impact of cancer. Among the most important contributors to this base are the outstanding extramurally funded scientists supported by the NCI through grants, contracts, and cooperative agreements. The DEA was established within the NCI to provide the Institute and the scientific community with expert scientific review of the merits of extramural research. An important part of DEA's mission is to manage and coordinate the second level of grants review by the National Cancer Advisory Board (NCAB) and the concept review of all new and reissued Requests for Applications (RFAs) and research and development (R&D) Requests for Proposals (RFPs) with the Board of Scientific Advisors (BSA).

The **Committee Management Office** (CMO) provides oversight of all NCI-chartered advisory boards and committees, working groups, task forces, chartered review groups, and serves as an NIH service center for the National Center for Complementary and Alternative Medicine, the NIH Council of Councils and a Department of Health and Human Services (HHS) chartered advisory committee. The CMO provides policy guidance and assistance to ensure that the NCI and client Institutes operate within the appropriate Federal Advisory Committee Act (FACA), the Government in Sunshine Act, and various other policies, procedures, and guidelines.

The DEA also provides effective and timely coordination of program initiatives from the initial concept stage through publication of RFAs, PAs, Notices, and RFPs, and, finally, through the peer review of grant and cooperative agreement applications and contract proposals. The **Office of Referral, Review, and Program Coordination** (ORRPC), with four branches, was established for: (1) development and issuance of NCI program initiatives; (2) coordination of grant referral; and (3) management of NCI review activities. Review activities include the organization and management of peer review for all RFAs, R&D RFPs, Program Announcements with Special Receipt (PARs), and multi-component grant applications. The program coordination responsibilities of the DEA, in cooperation with NCI extramural program divisions, offices, and centers, extend to the development of all new extramural program guidelines and funding opportunity announcements (FOAs).

Another program coordination activity is the development and maintenance of referral guidelines for assignment of grant applications to the NCI. These guidelines, included in the *Referral Guidelines for Funding Components of PHS*, are critical to the development of program initiatives across the NIH, as well as to the prompt referral of unsolicited grant applications to the NCI. These guidelines differ from the NCI Internal Referral Guidelines, which are vital to the prompt referral of grant applications to the appropriate NCI program areas.

The **Research Analysis and Evaluation Branch** (RAEB) works closely with the NCI Office of Budget and Finance to provide budget-linked portfolio data for NCI grants and contracts. In doing so, the Institute has the capability of responding expeditiously to congressional and other inquiries. This Branch has historical budget-linked portfolio data that go back to the 1930s.

The DEA conducts continual evaluation of program initiatives and coordinates policies and procedures to ensure that all aspects are as clear and accessible as possible to staff, advisory groups, and applicants. To facilitate this evaluation, the **Office of Extramural Applications** (OEA), through the **Applied Information Systems Branch** (AISB), maintains a Web-based information system to provide key information on new initiatives. This Web-based information system includes early notice of approved concepts, listings of active PAs and recently published RFAs, and policies related to the clearance of new program initiatives. This information is provided in both public Internet (**http://deainfo.nci.nih.gov/funding.htm**) and NCI limited-access Intranet versions. Both RAEB and AISB were actively involved in elevating the DEA Funded Research Portfolio Web Site to become the NCI Funded Research Portfolio (NFRP) Web Site (**http://fundedresearch.cancer.gov**).

Special Activities in the Office of the Director, DEA

In addition to managing and coordinating the extramural operations described in this report, the DEA Office of the Director (OD) is a focal point and repository of information and policies related to various funding mechanisms for NIH grants, staff and awardee responsibilities, eligibility requirements, receipt dates for all granting mechanisms, and special programs. The DEA OD is, for example, the coordinating center for submission of applications for special NIH-wide awards, such as the James A. Shannon Director's Award, the Institutional Development Awards (IDeAs), and the Research Enhancement Awards Program (REAP).

The DEA OD ensures that the NCI meets the congressional mandate to promote increased participation of women, children, and members of minority and medically underserved populations in the research areas of cancer cause, prevention, control, diagnosis, and treatment. The NIH Revitalization Act of 1993 mandates that women and members of minority groups be included as subjects in each research project, unless there are clear scientific or ethical reasons that inclusion is inappropriate with respect to the health of the subject or the purpose of the research. Administrative procedures allow NCI staff to resolve inclusion problems after initial review of grant applications that are otherwise highly meritorious. In the event that a grantee believes the proposed study does not warrant or require inclusion of women or minority groups, he or she can apply for a waiver of this requirement. The DEA Director is the appeals officer for the NCI and has the authority to grant waivers. In FY2010, 27 applications with preliminary bars to award were received by the DEA. Through corrective action, working with the applicants and program directors, all bars to award were brought into compliance before awards were made.

Additionally, the DEA Director serves as the locus for implementation and oversight of NCI policies concerning extramural research integrity and serves as a resource to all NCI staff with questions in this area. In this role, the DEA OD works to address concerns about extramural research misconduct, misuse of human and animal research subjects, financial mismanagement, and financial conflict of interest involving NCI-supported research. The DEA Director functions as the NCI Research Integrity Officer (RIO) and receives from the appropriate sources all documents related to research misconduct for transmittal and reporting to relevant sources. In FY2010, 10 cases of alleged research misconduct involving NCI funding were opened and under investigation by the Office of Research Integrity, HHS, and referred to the Director, DEA. Eight cases were closed, and none of the cases were found to involve research misconduct.*

Extramural Staff Training

Program and Review Extramural Staff Training Office (PRESTO)

The Program and Review Extramural Staff Training Office (PRESTO) was created in 2010 to develop and coordinate the training of scientific Program and Review Staff, and other extramural staff (i.e., in the Division of Extramural Activities Support and Office of Grants Administration) upon request. The broad mission of PRESTO, which resides in the DEA OD, is to increase the knowledge base of new and experienced staff and optimize their effectiveness in supporting the goals of NCI. To accomplish this mission, the office will: (1) design and implement a broad-based curriculum for Program and Review staff; (2) provide training on specialized topics related to understanding of and compliance with NIH policies; and (3) identify and/or develop resources to facilitate individual learning and performance. PRESTO also will collaborate with the Trans NCI-Extramural Awareness Group (TEAG) and the NCI Office of Workforce Development to provide customized job-related training and career development opportunities. Finally, the office will monitor the participation of extramural staff in NIH- and NCI-sponsored training activities as well as continuously evaluate the efficacy of these activities.

*Cases found to involve research misconduct are published in the *Federal Register* and *NIH Guide for Grants and Contracts*.

Program Coordination: A Resource for New Funding Initiatives

The DEA performs critical functions in the development of new strategic funding initiatives at the NCI and in the coordination of their publication as Funding Opportunity Announcements, which comprise both RFAs and Program Announcements (PAs). Specifically, members of the **Program Coordination and Referral Branch** (PCRB) provide expert assistance to NCI program staff members as they work to develop and publish new FOAs. PCRB staff members disseminate various operating policies and procedures pertaining to extramural funding programs. To maintain consistency and completeness, under PCRB coordination, all new and reissued NCI FOAs, Notices, and various associated guidelines are reviewed, edited as needed, and cleared through the DEA before being forwarded to the NIH Office of Extramural Research for approval and publication in the *NIH Guide for Grants and Contracts* and on Grants.gov. In these steps, PCRB staff members help to streamline and clarify FOA technical parameters and requirements as well as optimize accuracy, precision, and clarity of their presentation in proper format. PCRB verifies consistency with NIH-wide requirements, provides quality control, and coordinates timelines throughout the development and publication processes. Overall, these services ensure the high quality and timely availability of NCI's funding opportunities for cancer researchers as prospective applicants.

Tables 1a and **1b** show the variety of NCI-issued RFAs in FY2010, and **Table 2** lists RFAs issued by other NIH institutes or centers (ICs) that the NCI has joined as a participating partner. **Tables 3a** and **3b** show the variety of PAs issued by the NCI in FY2010, and **Table 4** lists PAs issued by other NIH ICs that the NCI has joined as a participating partner.

In early 2006, the NIH began the process of transitioning to the electronic (instead of paper-based) submission of grant applications through Grants.gov (**http://www.grants.gov**), which is the online grant application submission portal of the Federal Government. The DEA has played a lead role in helping the NCI and its customers' transition to the electronic submission of all types of grant applications. PCRB staff members have been heavily involved in conversions and reissuances of NCI FOAs so that the applications would be submitted electronically to the NIH through use of the SF424 application package and Grants.gov. Greater than 80 percent of NIH grant applications are now submitted electronically in this way. As a representative on the NIH SF424 Application eSubmission IC Liaisons Group, the PCRB provides relevant information and timely updates to all NCI extramural staff members on activities and results related to the transition from paper to electronic grant applications. The Branch also serves as a direct source of guidance on this topic for individual program directors and their applicants. The Referral Office has transitioned from paper-based to electronic referral of applications as each grant mechanism has transitioned from the former to the latter mode of submission. The RO staff collaborated with NCI information technology staff members and their contractors to successfully develop and deploy an improved Awaiting Receipt of Application (ARA) management system (permission for special application receipts), which contributes to an improved efficiency of service for the NCI's grant applicants and awardees. In addition to referral responsibilities, PCRB Scientific Review Officers (SRO) also managed the review of 386 student loan repayment program (LRP) contract proposals in FY2010.

Grant Referral: A First Point of Contact for NCI Grant Applicants and Receipt of Applications

In FY2010, a total of 13,935 grant applications were submitted to the NCI for funding with appropriated funds (see Figure 1 and Table 5). These included applications for 50 different types of funding award mechanisms (see Appendix E), including the Investigator-Initiated Research Project (R01), Career Development Awards (K series), Research Program Project (P01), Cancer Center Support Grant (CCSG, P30), Specialized Program of Research Excellence (SPORE, P50), Small Research Project (R03), Exploratory/Developmental Project (R21), Exploratory/Developmental Phase II Project (R33), Small Business Technology Transfer (STTR) Grant (R41/R42), Small Business Innovation Research (SBIR) Grant (R43/R44), and U-series (Cooperative Agreements) mechanisms.

All applications submitted to the National Institutes of Health (NIH) are assigned to an Institute or Center (IC). The IC in turn has a structure in place to address internal assignments. DEA's **Program Coordination and Referral Branch** is responsible for receipt, referral, and assignment of applications as well as for program (i.e., scientific initiative and funding opportunity) development functions. Upon receipt of primary and secondary assignments of applications to the NCI by the NIH Center for Scientific Review (CSR), DEA Referral Officers (ROs): (1) assign all incoming applications to one of the 50 NCI extramural research program areas; (2) track program acceptance; and (3) whenever necessary, negotiate transfers of grant applications to and from other NIH ICs and even other HHS research fund-

Figure 1. Receipt and Referral of NCI Grant Applications* FY2006 - 2010



*Includes NCI Primary and Secondary applications received and referred.

ing agencies, such as the Agency for Healthcare Research and Quality (AHRQ) and the Centers for Disease Control and Prevention (CDC).

The ROs distribute all of the applications that are to be directly reviewed by NCI DEA-managed peer review groups. These applications include those for Program Projects (P01), Planning Grants (P20), Cancer Centers (P30), Specialized Centers (P50), Conference Grants (R13), Small Grants (R03), certain Phased Innovation Grants (R21/R33), Training Grants (T32 and R25), K-series Career Development Grants, certain traditional R01 Research Project Grants (such as large clinical trials), and Cooperative Agreement (U-series) applications.

The first point of contact for applicants is often the Referral Office (RO). The RO is the receipt point for Letters of Intent (LOIs) from potential applicants for multi-component P01 and R13 grants and applications for Academic Research Enhancement Award (AREA, R15) grants for research at institutions and organizations that have little or no current NIH grant award support. Additionally, applicants contact the Referral Office for information about NCI programs, their eligibility to apply, the relevance of their proposed research to the missions of various NCI programs, and the names and contact information of NCI program staff members to guide them through the application process. In addition, ROs work with program staff members to determine and/or verify the responsiveness of R21 exploratory/developmental grant applications to the specific FOAs.

DEA's RO serves as the primary NCI contact locus for the extramural scientific community in need of information related to funding opportunities, mechanisms, policies, processes, procedures, new initiatives announced as RFAs or PAs, and the peer review process. In addition, the ROs assist members of the extramural community in navigating NIH and NCI Web pages to obtain current information, forms, and guidelines.

Peer Review—The Next Step

Once applications are referred to the NCI and the appropriate program, they must be reviewed. The high caliber of NCI-sponsored research is maintained through a peer review process in which experts in the appropriate fields review and score the merit/impact of research grant applications and contract proposals. The peer review mechanism helps to ensure that the NCI uses its resources wisely and funds research that has the potential to make a significant contribution to science and medicine. The NCI's extramural programs and activities are funded primarily through peer reviewed grants and cooperative agreements. Programs that are funded through research and development contracts also are subject to peer review, including contract-supported projects conducted within the intramural research program.

The peer review system of the NIH consists of two sequential levels of review mandated by statute. The first level is of grant applications assigned to the NCI. This review is performed by either an NIH CSR study section, a chartered NCI Initial Review Group (IRG) subcommittee, or an NCI Special Emphasis Panel (SEP), whose primary purpose is to review and evaluate the scientific merit/impact of research grant and cooperative agreement applications. The second level of review, which is for program relevance, is conducted by the National Cancer Advisory Board.

Most investigators are familiar with the NIH CSR study sections, which have primary responsibility for managing the peer review of investigator-initiated Research Project (R01) and fellowship applications. It is less widely known, however, that grant applications representing requests for more than 50 percent of the NCI's extramural budget are reviewed by chartered IRGs and SEPs that are directly formed and managed within the NCI by the DEA. Peer review managed by either the CSR or the DEA is usually determined by the choice of grant mechanism.

The NCI has no direct input into the selection of peer reviewers who serve on CSR study sections. In contrast, members of the NCI IRG and SEPs are selected by DEA review staff, with suggestions from NCI program staff. All chartered DEA review subcommittee members are approved by the Director, DEA, based on their knowledge of the various disciplines and fields related to cancer. There are six active NCI IRG specialized review subcommittees; for example, Subcommittee A reviews Cancer Centers, Subcommittee H reviews Clinical Cooperative Groups, and Subcommittee I reviews career development applications. (The membership of NCI-chartered subcommittees may be found in **Appendix C** (**pp. 111-131**) and at **http://deainfo.nci.nih.gov/advisory/irg.htm.**) IRG members are appointed for varying terms of service, which may be up to 6 years. DEA SEPs may be formed to review grant applications received in response to RFAs and PARs, other specialized applications, or R&D contract proposals received in response to RFPs. Members of such panels are selected on a one-time, as-needed basis to review specific grant and cooperative agreement applications, or contract proposals. Additional information about NCI SEPs can be accessed at **http://deainfo.nci.nih.gov/advisory/sep.htm**.

Both the SEPs and IRGs provide advice on the scientific and technical merit/impact of applications for research and research training grants, cooperative agreements, and contract proposals relating to scientific areas relevant to cancer. DEA SROs manage the scientific reviews of grant applications and R&D contract proposals, including the selection of peer reviewers and the overall administration of the peer review process.

The peer review of grant applications generally occurs in the fall, winter, and spring prior to the February, June, and September NCAB meetings, respectively.

Enhancing Peer Review

In June 2007, the NIH initiated an effort to formally review the NIH extramural funding system to address the many challenges that the increasing breadth, complexity, and interdisciplinary nature of modern research has created. NCI staff members and grantees participated in NIH external and internal working groups identifying the challenges and making recommendations regarding enhancements to the review system. A final report with recommendations in the following four broad areas was released in March 2008: (1) engage the best reviewers; (2) improve the quality and transparency of review; (3) ensure balanced and fair reviews across scientific fields and career stages, and reduce administrative burden; and (4) provide continuous review of the peer review process.

In January 2010, restructured paper PHS 398 and electronic SF 424 (R&R) applications were implemented to align the structure of the application with review criteria used by reviewers in their assessment of scientific and technical merit of grants and cooperative agreements (NOT-OD-09-149). In addition, to help reduce the administrative burden placed on applicants, reviewers, and staff members, the NIH shortened the length of the application with page limits for competing applications. This change will focus applicants and reviewers on the essentials of the science that are needed for a fair and comprehensive review of the application. Shorter applications may have additional benefits for reviewers such as mitigating information overload, and/or enabling a larger number of reviewers to read each application and participate in review in a more informed manner. To ensure that all reviewers thoroughly understood the enhanced review criteria, the new scoring system, the new critique template, and their new responsibilities for criterion scoring, all DEA SROs conducted orientation teleconferences prior to the FY2010 review meetings.

Review Workload

In FY2010, the DEA organized, managed, and reported the review of a total of 2,146 grant and cooperative agreement applications (see Table 6) **and 623 contract proposals** (see Table 12) **assigned to the NCI for funding with appropriated dollars.** The total number of grant, cooperative agreement applications, and contract proposals reviewed in FY2010 was 2,769 (see Figure 2). Table 7 provides a summary of the applications reviewed by NCI IRG subcommittees and SEPs. Twenty meetings of the NCI IRG subcommittees and 119 SEPs were convened to review and evaluate grant applications and contract proposals of various types. In addition, there were 16 site visits and 89 other review-associated meetings, such as orientation teleconferences, applicant interviews, and fact-finding review panel workgroups. Approximately 2,345 peer reviewers and expert consultants served on the NCI DEA-managed IRG subcommittees, SEPs, and workgroups in FY2010 (see Appendixes C and D). Members were selected because they are authorities in relevant fields of biomedical research or because they represent informed consumer perspectives.

Peer Review Functions

The **Office of Referral, Review, and Program Coordination** (ORRPC) is responsible for the coordination and management of the review of grants, cooperative agreements, and contracts for the Institute, and oversees three review branches and a referral branch. The review branches are responsible for organizing, managing, and reporting the scientific peer review of applications for a wide variety of grant mechanisms and topics. Reviews are conducted by one of the six subcommittees of the NCI IRG or by one of the specially convened SEPs as shown in Table 7.

The **Research Programs Review Branch** (RPRB) and the **Resources and Training Review Branch** (RTRB) are primarily responsible for the peer review of a variety of unsolicited multi-component and career development grant applications (see Table 6). The RPRB has primary responsibility for review of unsolicited P01s and Specialized Programs of Research Excellence (SPORE, P50) applications involving translational research focused on various organ sites. All of these applications are reviewed by SEPs. The RTRB

Figure 2. DEA Review Workload*
FY2006 - 2010



*Withdrawn applications are not included. LRP contracts are not included in the RFAs.

manages the six active subcommittees of the NCI IRG (see Appendix D). Specifically, the RTRB has primary responsibility for review of applications for cancer centers, cancer training and career development, and cancer clinical trials, as well as for managing the corresponding six subcommittees of the NCI IRG.

The Special Review and Logistics Branch (SRLB) organizes and manages peer review primarily for grant applications in response to most of NCI's RFAs, specialized PARs, and R&D contract proposals submitted in response to RFPs; all of these reviews are conducted by SEPs. In addition, the Program Coordination and Referral Branch often collaborates with the review branches to assist in the review of special initiatives and also has responsibility for the review of conference grant and loan repayment program applications.

SROs in these review units prepare the summary statements of the evaluations and recommendations for each review committee meeting. Each principal investigator for an application also receives the summary statement as do the NCAB members for second-level review.

Many of the reviews conducted by the RTRB, including those of the Cancer Center Support Grant (P30) and Cooperative Clinical Trials Grant (U10) applications, involve a two-tier initial peer review process. Normally, the first tier of the review involves either a site visit to the applicant's institution, an applicant interview in the Washington, DC, area, or a teleconference by an expert review panel; these review formats provide an opportunity for the reviewers to question the applicants directly to clarify issues in the application, thereby enhancing the review process. The review panel members prepare a draft review

report, which is then considered, along with the application, by the relevant subcommittee of the NCI IRG. Two of the six active NCI subcommittees of the NCI IRG serve as the "parent committees" for final scoring of applications after expert panel reviews: Subcommittee A is the "parent committee" for Cancer Center Support Grant (P30) applications and Subcommittee H is the "parent committee" for review of Cooperative Clinical Trials (primarily U10) applications. The other four subcommittees of the NCI IRG (Subcommittees F, G, I, and J) review all of the career development, training, and education grant applications submitted to the NCI.

Research Programs Review Branch

Program Project (P01) Applications

A significant proportion of the effort of the RPRB during FY2010 was associated with the review of unsolicited P01 applications. During FY2010, the SROs in the RPRB organized and managed the review of 109 new, renewal (recompeting), resubmitted (amended), and revised (supplemental) P01 applications (see Table 8), which was a higher P01 workload than the NCI has seen in the past 4 years, as shown in Figure 3. Approximately 52 percent of the applications were proposing new multidisciplinary research programs, and one third of the applications were amended (see Table 8). Sixty (55%) of the 109 applications were referred to NCI's Division of Cancer Treatment and Diagnosis (DCTD) (see Table 9). The 109 applications requested almost $259 million in total costs for the first year (see Table 9) and more than $1.35 billion in total costs for all years. Of the 109 P01 applications reviewed in FY2010, 22 (20%) included multiple PIs.

P01 applications are reviewed in groups of up to 10 applications by a one-tier, "paper only" review process. All review panels are constituted as SEPs, with reviewers recruited based on the expertise needed for the applications being reviewed. The applications are grouped based on

Figure 3. P01, SPORE, and Other Multi-Component Research Applications Reviewed* FY2006 - 2010



*Withdrawn applications are not included.
†Non-SPORE applications.

science, typically into four to six SEPs. Although the groupings vary depending on the applications that are received in each review round, the SEPs typically address: molecular biology; cellular and tissue biology; prevention, epidemiology, and control; discovery and development; and clinical studies. A SEP may include applications representing a continuum of research from basic through translational studies. The SEP reviewers evaluate and score projects, cores, and integration, and then assign the overall impact/priority score to each application.

Specialized Centers of Research Excellence (P50)

The other major responsibility for RPRB during FY2010 was the peer review of applications received for the NCI SPORE. These large, complex multidisciplinary P50 research center applications focus on translational research directly applicable to human disease in various organ sites. During FY2010, the RPRB organized and managed five SEPs for the review of a total of 34 SPORE applications, continuing the high SPORE review workload seen during 2007 (see Figure 3). These 34 applications addressed multiple organ sites, with the following distribution of applications: Brain (2); Breast (5); GI (5); Gyn (1); HN (2); Leukemia (2); Lymphoma (2); Lung (1); Myeloma (1); Pancreas (1); Prostate (2); Ovary (4); Skin (4); Esophagus (1); and Sarcoma (1). Overall, 20 (59%) of the 34 applications were for new SPOREs, and 14 (41%) of the 34 applications were renewal applications. The applications requested approximately $85 million in total costs for the first year of support.

Also following the trend seen in 2008, the SPORE review workload for each round continues to be very diverse. There were nine applications addressing seven organ sites reviewed for the February 2010 NCAB meeting, 19 applications addressing 12 organ sites for the June 2010 NCAB meeting, and six applications addressing four organ sites were reviewed for the September 2010 NCAB meeting.

The large number of new and amended organ site applications resulted in increased complexity for the RPRB Scientific Review Officers who manage the SPORE revediews. Due to the complexity of the review, the special review criteria and the large number of reviewers required for the diverse research proposed, the SROs who organize the SPORE reviews routinely conduct orientation conference calls with all of the reviewers 3 to 4 weeks before the review meeting to explain the special features of the SPORE program and the special review criteria. The orientation teleconferences were particularly important during 2010 due to the restructuring of the SPORE applications to align the structure with the review criteria used by reviewers in their assessment of scientific and technical merit of the applications.

Resources and Training Review Branch

In FY2010, the Resources and Training Review Branch administered six NCI IRG subcommittees (A, F, G, H, I, and J). This Branch has the responsibility for review of applications for multidisciplinary cancer centers, cooperative clinical trials groups, institutional training and education programs, and career development awards. Staff also participate in the reviews of other funding mechanisms within the DEA.

The reviews conducted by the RTRB subcommittees are of two types: (1) the complex, multidisciplinary applications, such as Cancer Center Support Grants (P30s), and multi-institutional clinical trial cooperative group—statistical center cooperative agreements (U10s) applications; and (2) individual component training and career development awards. The review formats for the multi-component applications generally involve a two-step initial review. The first step of the review for Cancer Centers involves a site visit to the applicant institution. Each group of experts serves as a fact-finding body to clarify any issues or information related to the application through discussion with the applicants. This first committee prepares a draft report that is presented, with the full application, for discussion, evaluation, and final scoring by the appropriate parent subcommittee (NCI IRG Subcommittee A for cancer centers and Subcommittee H for clinical trials). The U10 applications for support

of the operational aspects of the clinical trial cooperative groups are reviewed by applicant interview at the parent subcommittee meeting, which eliminates a separate trip for reviewers and, thus, reduces the reviewer burden. Scoring by a parent Subcommittee provides for a more uniform evaluation of applications than scoring by individual review teams. The individual component applications are reviewed by a chartered subcommittee. Please note that the NCI's clinical trial enterprise is undergoing review, and changes in clinical trial approval and possible funding are expected in the future. These changes will likely affect the operation of Subcommittee H.

NCI Cancer Centers

FY2010 was a significant year for the review of Cancer Center Support (P30) applications. The CCSG FOA was released in conjunction with revisions to the guidelines and other supporting documents.

The Scientific Review Officer for NCI-Subcommittee A played a major role in drafting the CCSG FOA and the subsequent drafting of guidelines for both applicants and reviewers. PAR-11-005, the FOA for Cancer Centers, was released on October 12, 2010. During FY2010, Subcommittee A reviewed 15 applications.

Training and Career Development

Between 2007 and 2009, the number of applications for career development awards had declined. Currently, there is a significant increase from 385 applications in 2009 to 474 in 2010. The number of training grant applications remained nearly constant at 157 (see Figure 4).

Clinical Cooperative Groups

The SRO for Subcommittee H (Clinical Cooperative Groups) manages the review of the NCI Clinical Trials Cooperative Group Program and works closely with the Clinical Investigations

Figure 4. Numbers of Career Development (CD) and Training and Education (T&E) Applications Reviewed* FY2006 - 2010



CD Grant Mechanisms: F32, F33, K01, K05, K07, K08, K22, K23, K24, K25, K99; T&E Grant Mechanisms: R25, T15, T32, K12.
*Withdrawn applications and RFA CA09-016 for D43 applications are not included.

Branch staff of the NCI Cancer Therapy Evaluation Program (CTEP).

In FY2010, the members of Subcommittee H reviewed 22 applications from four of the major adult Cooperative Groups and four applications from smaller components of the overall Cooperative Group enterprise. Late in FY2010, the NCI initiated a new effort, entitled "Transforming the NCI Clinical Trials Enterprise," to fully evaluate and upgrade the Cooperative Group Program. Although this process is ongoing, and until a new Funding Opportunity Announcement (FOA) and Guidelines document for the Cooperative Group Program are written and approved, the NCI is not accepting new or competing U10 Cooperative Agreement applications that request funding for the Cooperative Groups. It is anticipated that the NCI will again be receiving applications for Subcommittee H review in FY2013.

Other RTRB Activities

To assist reviewers in preparing for their participation in peer review, Reviewer Guides are maintained for all of the application types reviewed by the RTRB. These Reviewer Guides were updated for the newly reissued FOAs and for electronic receipt. This resource was especially helpful for the subcommittee members who evaluate Training and Career development grant applications, because most reviewers on each subcommittee review several types of applications. The Reviewer Guides contain general information on peer review and NIH rules on use of human subjects, as well as specific instructions for each of the mechanisms to be reviewed by that subcommittee. These mechanism-specific guides have been completed for all education, training, and career development types of applications that are reviewed in the RTRB, and for the Cancer Centers and Clinical Cooperative Group applications that are evaluated by Subcommittees A and H.

Special Review and Logistics Branch

The SRLB organizes and manages peer review primarily for grant applications submitted in response to NCI RFAs and specialized PARs as well as for contract proposals submitted in response to specific RFPs. The reviews are conducted with SEPs and involve recruiting scientists with the appropriate expertise for each review meeting. During FY2010, the DEA reviewed 2,085 applications received in response to 36 RFAs and 41 PAs/PARs.

Following approval of RFA concepts by the NCI Scientific Program Leaders (SPL) and BSA, program staff members prepare RFA initiatives for publication in the *NIH Guide for Grants and Contracts*. DEA staff members, including members of the SRLB, assist in critically reading the draft documents and providing recommendations for clarity relative to application requirements and review criteria. In an RFA, a specific, published dollar amount is set aside by the Institute, whereas for a PAR, there is no dollar set-aside and no requirement for BSA review. Table 10 lists the RFAs and number of related applications that were reviewed by the DEA in FY2010. Table 11 presents the number of applications submitted in response to PAs or PARs, the review of which is shared by the SRLB, the RPRB, and the RTRB. The Institute also issues RFP solicitations seeking offers for contract awards to support activities targeted to highly specific institute goals.

Technology Research Applications

The majority of technology research initiatives use the R21 Exploratory/Developmental award mechanism and the R33 Exploratory/Developmental Phase II award mechanism. The R21 mechanism is intended to encourage exploratory/developmental research by providing support for exploratory pilot projects in the early stages of project development. The R33 mechanism is suitable for projects where "proof-of-principle" of the proposed technology or methodology already has been established and supportive preliminary data are available. Both of these mechanisms are well suited for technology development. In FY2010, 292 technology applications for Exploratory/Developmental grants (R21) and Exploratory/Developmental Phase II grants (R33) were reviewed under 10 RFAs. In addition, 31

cooperative agreement (U01) applications were reviewed for "Quantitative Imaging for Evaluation of Responses to Cancer Therapies" and seven P50 applications for "*In Vivo* Cellular and Molecular Imaging Centers." In addition, 119 applications were submitted to four RFAs supporting Centers of Cancer Nanotechnology Excellence (CCNE), Cancer Nanotechnology Platform Partnerships, and R25 and K99 training initiatives. This represented an increase in applications received in response to RFAs in FY2010 (447), compared to FY2009 (336) (see Figure 5).

The Small Business Innovation Research (SBIR) program supports Phase I feasibility applications (R43), Phase II applications (R44), and Fast-Track applications (R43/R44). In 2009, there was the first issuance of the SBIR Phase II Bridge Award RFA designed to "bridge the gap" between the end of the Phase II award and commercial development. The total number of SBIR applications received and reviewed in 2010 (25) represents a 74 percent decrease from the number submitted in 2009 (95).

Multi-Component Research Applications

Figure 3 describes the historic and current workload for multi-component grant applications. In addition to the FOAs for SPORE and Cancer Centers, there were an additional eight multi-component initiatives: NIH-Supported Centers for Population Health and Health Disparities (CA09-001); Transdisciplinary Cancer Genomics Research: Post-Genome Wide Association (Post-GWA) Initiative (CA09-002); The Integrative Cancer Biology Program (ICBP): Centers for Cancer Systems Biology (CCSB) (CA09-011); Centers of Cancer Nanotechnology Excellence (CCNEs) (CA09-012); Community Networks Program (CNP) Centers for Reducing Cancer Disparities through Outreach, Research and Training (CA09-032); Transdisciplinary Research in Energetics and Cancer (CA10-006); Compre-

Figure 5. Technology Initiatives Applications Reviewed* FY2006 - 2010



*Withdrawn applications are not included.
†2010 includes: R21, R25, R33, P50, U01, U54, K99/R00.

hensive Partnerships to Reduce Cancer Health Disparities (CA10-503); and *In vivo* Cellular and Molecular Imaging Centers (ICMICs) (PAR09-147).

Small Grant Programs

Several small grant (R03) PAR program initiatives stimulated increased interest in the applicant community. These included support of many new investigators and pilot studies: PARs in cancer prevention (PAR-08-055); cancer epidemiology (PAR-08-237); and behavior research in cancer control (PAR-09-003). In FY2009, there were 406 applications submitted in response to the three initiatives (*DEA Annual Report 2009*). In FY2010, those same initiatives attracted 351 applications, a significant decrease. In FY2010, an additional 109 R03 applications were submitted under other Program Announcements and were reviewed in CSR.

Research and Development Contract Proposals

The DEA SRLB and PCRB reviewed 623 R&D contract proposals (including 386 Loan Repayment Program applications) received in response to 38 RFPs. Of those 38 RFPs, 33 were part of the Omnibus Solicitation for Small Business Innovation Research (SBIR) published each fall (Phase I and II topics) (Table 12). During review, several elements of each proposal are individually evaluated and scored, with the combined score indicating the overall merit. After negotiations, contract awards result from the RFP solicitation. Phase II SBIR proposals can be submitted only at the request of the Institute. To facilitate the contract review process, the SRLB has been working with the staff of DEA's Applied Information Systems Branch to develop a series of Web-based documents to be used for contract peer review.

NCI Grant and RFA Funding

The Board of Scientific Advisors (BSA) is responsible for advising the NCI Director on the extramural program and the future direction and funding of each Division's extramural research. As such, it provides concept review for NCI-sponsored RFAs. Figures 6 and 7 show total NCI Grant and RFA funding according to scientific concept area in FY2009 and FY2010. Figure 8 shows RFA concepts that the BSA approved from FY2007 and FY2010 according to the sponsoring NCI Division, Office, and Center.

Table 13 presents a summary of total funding of NCI grant awards by mechanism for FY2010. In Table 14, a comparison is made of the average cost and number of NCI R01, P01, R03, R13, R21, P30, P50, U01, U10, and U19 grants awarded in FY2006 through FY2010 according to the extramural divisions, offices, and centers.

Trends in grant funding according to scientific discipline and organ site are provided in Tables 15 and 16. Table 17 reports NCI's funding of foreign research grants in FY2010, and Table 18 reports foreign components of U.S. domestic research grants in FY2010. **Note:** Some grant awards made during a fiscal year may have been for grant applications reviewed in a prior fiscal year. The staff of the Research Analysis and Evaluation Branch (RAEB) indexed all American Recovery and Reinvestment Act (ARRA) funded projects by anatomical site and science areas for FY2010 (Tables 21 and 22).

Figure 6. NCI Grant and RFA Funding Percentages by Concept Area FY2009



Percents represent Total Funding and RFA Funding for the Concept Area as a percentage of Total NCI Grants. Concept Area (% of Total Funding to Total NCI Grants; % of RFA Funding to Total NCI Grants)

Figure 7. NCI Grant and RFA Funding Percentages by Concept Area FY2010



Percents represent Total Funding and RFA Funding for the Concept Area as a percentage of Total NCI Grants.
Concept Area (% of Total Funding to Total NCI Grants; % of RFA Funding to Total NCI Grants)

Figure 8. BSA Approved RFA Concept Set-Asides by Division/Office/Center



Legend:

DCB	Division of Cancer Biology
DCCPS	Division of Cancer Control and Population Sciences
DCP	Division of Cancer Prevention
DCTD	Division of Cancer Treatment and Diagnosis
OD	Office of the Director
OD-OCTR	Office of the Director - Office of Centers, Training, and Resources
OD-CRCHD	Office of the Director - Center to Reduce Cancer Heath Disparities
OD-OHAM	Office of the Director - Office of HIV and AIDS Malignancy
OD-CSSI	Office of the Director - Center for Strategic Scientific Initiatives
OD-OBBR	Office of the Director - Office of Biorepositories and Biospecimen Research
OD-SBIRDC	Office of the Director - Small Business Innovation Research Development Center
TRANS-1	NCI (DCCPS), Trans-NIH
TRANS-2	NCI (DCTD), Trans-NIH

* Indicates co-funding among NCI Divisions/Offices/Centers.

American Recovery and Reinvestment Act

The American Recovery and Reinvestment Act of 2009 (ARRA, i.e., The Recovery Act or The Stimulus Act) is an economic stimulus package enacted by Congress in February 2009. The ARRA stimulus was intended to create jobs, promote investment and consumer spending, and address neglected challenges. The United States (U.S.) Department of Health and Human Services (HHS) received $145.7 billion of the stimulus funds for a variety of health-related activities, including new programs at the NIH. The NIH received $10.4 billion in ARRA funds for FY2009 and FY2010, of which the NCI received almost $1.3 billion. To advance NCI's strategic vision of accelerating cancer research and advancing innovations that would make a difference in the lives of those affected by cancer, seven objectives were to: (1) accelerate and expand cancer research; (2) advance personalized cancer treatment and prevention; (3) redesign informatics infrastructure; (4) revamp the clinical trials system; (5) strengthen the research workforce; (6) improve the care and quality of life for cancer patients; and (7) collaborate for greater impact. To achieve these objectives, ARRA funds were used to increase funding of meritorious grant applications that fell beyond the usual payline (NOT-OD-09-078), provide administrative supplements for equipment, expand research goals to already funded grants (NOT-OD-09-056), significantly expand several onoing NCI programs addressing personalized medicine for cancer, and to participate in several NIH-wide ARRA initiatives. These initiatives were to provide competitive supplements to existing grants based on peer review evaluation (NOT-OD-09-058); the NIH Challenge Grants in Health and Science Research (RC1) (RFA-OD-09-003); Research and Research Infrastructure "Grand Opportunities" (RC2) (RFA-OD-09-004); and Biomedical Research Core Centers to Enhance Research Resources (P30 grants for faculty recruitment) (RFA-OD-09-005). NCI participation in trans-NIH ARRA RFAs is summarized in **Table 19**, and **Table 20** lists the different types of ARRA solicited applications received by the DEA for referral. The referral staff in PCRB referred all competitive applications assigned to the NCI to the appropriate program area. As previously indicated, RAEB indexed all ARRA-funded projects by anatomical site and science areas for FY2010 (**Tables 21** and **22**).

Supporting Peer Review Consultants

Ensuring that highly qualified individuals are available for expert review of grant applications and contract proposals requires an efficient administrative support system. The DEA's **Scientific Review and Evaluation Activities** (SREA) unit, residing within the NCI **Committee Management Office**, supports the NCI peer review process by compensating consultants for their services on the NCI IRG subcommittees or SEPs and by reimbursing them for their travel and other expenses (see **Appendixes C** and **D**). The SREA staff also approves and processes payments for other activities related to review, including contract-supported ticketing services and hotel contracts.

The NCI SREA program is a multi-million dollar program. The staff members of CMO continue to oversee the successful reconciliation of peer review costs charged against the SREA account; identify erroneous charges; and keep an extensive tracking sheet on all costs related to approximately 139 peer review associated meetings to successfully manage the budget. The CMO is able to provide the DEA Director with a clear picture of funds spent against the SREA budget throughout the year to ensure there are enough funds to cover all NCI peer review activities.

During FY2010, more than 2,345 consultants were reimbursed flat-rate payments and honoraria for serving at more than 139 peer review meetings (**Appendix D**). Teleconference meeting costs and airline tickets were paid expeditiously throughout the year, and SREA staff ensured the timely review and approval of 113 hotel contracts and 115 hotel invoices. There were 5,190 instances of honoraria and flat rate payment to NCI peer review consultants.

On February 1, 2010, the NIH Center for Scientific Review implemented the CSR Hotel Centralization Program in which NCI is a participant. CSR acts as a service center to the NCI in the final processing of peer review meeting hotel contracts and invoices.

The SREA staff members work diligently to ensure reviewers are reimbursed in a timely manner and when appropriate, contact NCI reviewers regarding unpaid and returned reimbursements. This is done by sending monthly e-mail alerts to unpaid reviewers after each and every meeting. Once the unpaid reviewer has completed the Secure Payee Registration System (SPRS) process, a final e-mail is sent alerting the reviewer of their SPRS registration status, when payment can be expected, and the amount of reimbursement. The SROs have expressed their gratitude to the members of the SREA team for tracking the reviewers' payments and ensuring that they are reimbursed in a timely manner.

Due to these proactive efforts by the SREA staff, only 36 out of the 5,190 instances of honoraria and flat rate payment to NCI peer review consultants were not paid in FY2010. The implementation of the SPRS reimbursement system in January 2009 also has played a major role in the reduction of the number of unpaid reviewer reimbursements.

The CMO and SREA programs created new training materials and conducted monthly training sessions for new and current NIH Division of Extramural Activities Support (DEAS) staff. These training sessions encompass all facets of the peer review process as it relates to the Committee Management Office and SREA (i.e., the importance of Federal Advisory Committee Act [FACA]; an overview of NCI advisory committees; pre and post committee management meeting activities for NCI peer review meetings; peer review meeting logistics; and, the components of the NIH reimbursement process).

The SREA staff use their extensive knowledge of the NIH SREA program to provide guidance

and ongoing assistance to NCI SROs, DEAS, and peer review consultants with questions or concerns regarding meeting logistics and the NIH reimbursement process.

The SREA staff collaborates with the Associate Director, ORRPC, ORRPC Branch Chiefs, CMO, and SROs on the development of NCI SREA policies and procedures. On an ongoing basis, they monitor and evaluate current SREA activities and initiate changes and improvements when warranted. The NCI Committee Management Procedures for Peer Review Meetings training book, which contains detailed guidelines, policies, and procedures for all aspects of SREA activities, is updated as needed. This training book is given to all NCI SROs and Extramural Support Assistants (ESAs) as a reference guide to important CMO and SREA policies and procedures that are imperative to the peer review process and the integrity of NCI's mission.

In FY2010, the NCI SREA Team Lead actively participated in various NIH-wide SREA related working groups such as the BPA Hotel Renewal and Institute/Center (IC) Hotel Centralization Pilot Program. Such involvement has allowed the NCI SREA staff members to provide advice and guidance on the development and implementation of significant changes to the NIH Scientific Review Evaluation Activities Program managed by the NCI.

DEA's Role in Advisory Activities

Beyond its central role in coordinating the referral of grants and peer review, perhaps the most far-reaching role the DEA plays across the NCI is the coordination and administration of NCI's nine chartered Federal advisory committees (see Appendix C). The memberships and activities of these advisory bodies are coordinated by the Office of the Director, DEA, and the Committee Management Office, DEA, in consultation with the NCI Director. A primary responsibility of the DEA is coordination of the activities of the NCAB, whose members are appointed by the President and whose responsibilities include conducting the second-level review of grant and cooperative agreement applications, as well as advising the NCI Director on policy for the conduct of the National Cancer Program. The DEA also coordinates administration of the Board of Scientific Advisors (BSA), the body responsible for the oversight and concept review of the extramural programs and initiatives of the NCI. Under the various chartered committees, working groups are formed to address and make recommendations on several important areas of cancer research related to basic research, clinical trials, diverse populations, cancer advocacy, treatment, cancer control, drug development, prevention, communication, education, and so on. As such, the DEA plays a major role in the development and issuance of PAs, PARs, and RFAs, the major extramural program initiatives used by the NCI to fund extramural research. The DEA Director serves as Executive Secretary to the NCAB and the BSA. (See Appendixes A and B for highlights of the activities of these Boards in FY2010 and Appendix C for a list of current chartered committee members.)

Major NCI Advisory Bodies Administered by the DEA

National Cancer Advisory Board (NCAB). NCI's principal advisory body is the Presidentially appointed NCAB. The Board advises the Department of Health and Human Services (HHS) Secretary and the NCI Director on issues related to the entire National Cancer Program and provides a second level of review for grant applications referred to the NCI and for the Food and Drug Administration (FDA) (see Appendix A).

President's Cancer Panel (PCP). The PCP consists of three members appointed by the President, who by virtue of their training, experience, and background, are exceptionally qualified to appraise the National Cancer Program. At least two members of the Panel are distinguished scientists or physicians, and the third member is a nationally recognized cancer research advocate. The Panel monitors the development and execution of the activities of the National Cancer Program, and reports directly to the President. Any delays or hindrances in the rapid execution of the Program are immediately brought to the attention of the President.

Board of Scientific Advisors (BSA). The BSA represents the scientific community's voice in NCI-supported extramural science. The Board, composed of distinguished scientists from outside the NCI and representatives from the advocacy community, advises the NCI leadership on the progress and future direction of the Institute's Extramural Research Program. The Board evaluates NCI extramural programs and policies, and reviews concepts for new research opportunities and solicitations, to ensure that a concept is meritorious and consistent with the Institute's mission (see Appendix B).

Boards of Scientific Counselors (BSCs) for Basic Sciences, and for Clinical Sciences and Epidemiology. The two BSCs, managed through the Office of the Director (OD), NCI, advise the Institute leadership on the progress and future direction of NCI's Intramural Research Program residing in the Center for Cancer Research (CCR) and

NCI Advisory Boards

NCAB New Members

Dr. Marcia Cruz-Correa
University of Puerto Rico
Comprehensive Cancer Center



Dr. Kevin Cullen
University of Maryland
Cancer Center

Dr. Olufunmilayo F. Olopade
University of Chicago
Pritzker School of Medicine

Dr. Jonathan Samet
University of Southern California
Keck School of Medicine

Dr. William Sellers
Novartis Institutes for
Biomedical Research, Inc.

BSA New Members

Dr. Arul Chinnaiyan
University of Michigan Medical School

Dr. Ronald DePinho
The University of Texas M.D. Anderson Cancer Center

Dr. Betty Ferrell
City of Hope National Medical Center

Dr. Maria Martinez
The University of Arizona

BSA Retirees

Dr. Susan Curry with Dr. Schilsky

Dr. William Dalton with Dr. Schilsky

Dr. James Heath with Dr. Schilsky

Dr. Kathleen Mooney with Dr. Schilsky

the Division of Cancer Epidemiology and Genetics (DCEG). These groups of scientific experts from outside the NCI evaluate the performance and productivity of NCI staff scientists through periodic site visits to intramural laboratories and provide evaluation and advice on the course of research for each Laboratory and Branch.

Director's Consumer Liaison Group (DCLG). The DCLG advises the Director, National Cancer Institute (NCI), with respect to promoting research outcomes that are in the best interest of cancer patients. To this end, the DCLG will conduct these activities with the intent to identify new approaches, promote innovation, recognize unforeseen risks or barriers, and identify unintended consequences that could result from NCI decisions or actions. Additionally, the DCLG will provide insight into enhancing input, optimizing outreach, and promoting strong collaborations, all with respect to non-scientist stakeholders.

Clinical Trials and Translational Research Advisory Committee (CTAC). The CTAC advises and makes recommendations to the Director, NCI, NCI Deputy Directors, and the Director of each NCI Division on the NCI-supported national clinical trials enterprise to build a strong scientific infrastructure by bringing together a broadly developed and engaged coalition of stakeholders involved in the clinical trials process. In addition, the Committee makes recommendations regarding the effectiveness of NCI's translational research management and administration program, including needs and opportunities across disease sites, patient populations, translational developmental pathways, and the range of molecular mechanisms responsible for cancer development. CTAC also will advise on the appropriate magnitude for dedicated translational research priorities and recommend allocation of translational research operations across organizational units, programs, disease sites, populations, developmental pathways, and molecular mechanisms. This responsibility encompasses oversight of all trials, both extramural and intramural. The Committee provides broad scientific and programmatic advice on the investment of taxpayer dollars in clinical trials and supportive science.

NCI Initial Review Group (IRG). The IRG, composed of six active subcommittees, reviews grant and cooperative agreement applications for centers, clinical cooperative groups, research projects, and research training activities in the areas of cancer cause, diagnosis, treatment, and prevention. Members may be appointed as standing committee members with overlapping terms of up to 6 years, or as "temporary" members with all of the rights and obligations of committee membership, including the right to vote on recommendations in which the individual fully participated as a reviewer for a specific meeting. Consultants also may be invited to serve as special experts or *ad hoc* members to provide information or advice. These individuals generally serve on site visit groups or work groups providing critical information to the chartered advisory subcommittees responsible for initial peer review.

NCI Special Emphasis Panels (SEPs). The SEPs advise the Director, NCI, and the Director, DEA, regarding research grant and cooperative agreement applications, contract proposals, and concept reviews relating to basic and clinical sciences, and applied research and development programs of special relevance to the NCI. Membership of a SEP is fluid, with individuals designated to serve for individual meetings rather than for fixed terms. These individuals have all of the rights and obligations of committee membership, including the right to vote on recommendations.

Committee Management Activities

The NCI **Committee Management Office** (CMO) is critical to the continued success of all NCI Federal advisory committee activities, including Boards, Advisory Committees, working groups, and review panels. CMO provides expert advice to the Director, NCI, Deputy Directors, NCI, the Director, DEA, NCI, and other senior-level Institute/Center/Office/Client staff on all rules, regulations, guidelines, policies, procedures, etc. governing the Federal Advisory Committee Act (FACA). This service includes direction, accurate advice, and sound guidance to NCI and Service Center clients. These clients include the NIH National Center for Complementary and Alternative Medicine (NCCAM), the HHS Secretary's Advisory Committee on Genetics, Health, and Society (SACGHS) and the NIH Council of Councils. CMO provides expert advice to senior staff officials on matters pertaining to legal directives for the management and stewardship of 19 chartered advisory committees. In addition, the office successfully continues to oversee the logistical planning and support of four National Cancer Advisory Board meetings, three Board of Scientific Advisors meetings, and numerous other NCI Board meetings, subcommittees, and work groups.

As a service center for the Office of the Director, NIH and NCCAM, the CMO continued to provide exceptional service to these client-Institutes on the management of their Federal advisory committees. Services that were provided to the Service Center clients included a review of OGE-450s of new NCCAM Council and SACGHS advisory committee members. This included the vetting of and in-depth understanding of the Emoluments Clause of the U.S. Constitution, Foreign Gifts and Decorations Act, Ethics Reform Act, Ethics in the Government Act, Criminal Conflict of Interest Statutes, and Standards of Ethical Conduct. Additionally, CMO provided support for other important Federal advisory committee activities, including preparation of charter renewals, nomination slates, *Federal Register* notices, annual and fiscal year reports. As a result, CMO is very successful in the management and implementation of the NCCAM and SACGHS Client Ethics and committee management program.

Routine responsibilities throughout the year include the following:

- Participated in numerous meetings providing expert advice on working groups, FACA, and Special Government Employee (SGE) rules and regulations.
- Responded to requests from senior NCI and client staff on various non-FACA meetings and working group concerns.
- Continued to provide a standard training plan for NIH Division of Extramural Administrative Support (DEAS) staff on committee management and Scientific Review and Evaluation Activities (SREA) activities in DEA. With this plan in place, DEAS staff have regularly scheduled training on committee management and SREA activities.
- The Committee Management IMPAC II Module is an integral part of the day-to-day activities in the management of advisory committees. As such, CMO regularly provides feedback to the Committee Management Users Group (CMUG) Representative on potential modifications to the Module. Additionally, staff also has participated in several NIH pilots throughout the year.

Highlights of FY2010 CMO activities include the following:

- Successfully passed two audits in 2010. The first audit, conducted by the Office of Federal Advisory Committee Policy

(OFACP) entailed a full review of all NCI and client-Institutes advisory board member personnel files, official meeting files, Conflict of Interest (COI) files, and charters. The CMO received an exceptional rating, with the Office cited as an example of how files should be maintained. The second audit was conducted by HHS/Office of General Counsel. This Office conducted a review of all the NCI Special Government Employee (SGE) COI files. The auditors found that the NCI CMO maintained each file in accordance with established regulations and dispositions and as a result, they had very few comments and/or questions relating to these documents. For both audits, the CMO coordinated the review of all files, ensuring that all documents and forms were in adherence with Manual Issuance 1743-Keeping and Destroying records.

- The "Big Snow" of 2010 brought several challenges for the February NCAB meeting. As a result of the challenging weather conditions, the February NCAB meeting had to be rescheduled expeditiously for the Institute to have grant review approval. CMO staff worked throughout the storm and contacted Board members to alert them of the meeting changes as well as coordinated requirements for meeting and lodging space and other complex logistics. As a result, the February meeting was a success for the Institute and grant review approval was completed on schedule.

- At the February 2010 National Cancer Advisory Board Meeting (NCAB) meeting, the Board established an *Ad hoc* Working Group to Create a Strategic Scientific Vision for the National Cancer Program and Review Progress of the National Cancer Institute. The membership of this Working Group was composed of high-profile scientists, researchers, medical oncologists, CEOs of pharmaceutical companies, and representatives from other prestigious cancer institutions. The *Ad hoc* Working Group met three times in FY2010. At the request of the NCI DEA Director, the CMO coordinated all of the venues for these meetings and numerous Co-Chair meetings; processed all travel/honoraria for more than 45 participants and speakers for each meeting; and coordinated the logistics and complex meeting space requirements.

- Presented on the following topics at Brown Bag sessions for DEA staff:

  - NCI Committee Management and SREA Activities – Updates
  - Federal Advisory Committees Overview for ESAs and SROs
  - Scientific Review and Evaluation Award (SREA) – Hotel Centralization of Peer Review Meetings.

- At the request of the Assistant Director, DEA, the CMO reviewed various DEA guidelines throughout the year to determine whether they were correct and consistent with FACA regulations. Documents reviewed included the *DEA Consumer Guide, NCAB Orientation Book,* and *BSA Orientation Book*.

- Provided training to SROs and DEAS staff members throughout the year on various facets of committee management and SREA. Training included the following:

  - Federal Advisory Committee Act Overview
  - CM IMPAC II Module – Coding of Meeting Attendees and Creation of Meeting Rosters
  - SREA Policies and Procedures
  - Temporary and SEP Member Waiver Policy Procedures
  - Overview of Member and Race/Ethnicity and Other Advisory Committee Statistical Data
  - Pre and Post Meeting Procedures (including COI procedures):
    - Attendance List
    - Official Meeting Files.

- Meeting Logistics:
  - Hotel Contracts and Invoice Process
  - Reviewing Banquet Event Orders
  - World Travel Service Guidelines
  - Teleconference Meeting Service Providers
  - Secure Payee Registration System Registration Process
  - Reviewer Reimbursements: Flat Rate and Exceptions
- Coding of Meeting Attendees in IMPACII.

- The CMO met with the ORRPC Associate Director on several occasions to discuss SREA issues and met with several Executive Secretaries to orient them on their roles and responsibilities related to the advisory committees and discuss the policies and procedures. The CMO also participated in several conference calls to discuss various topics such as NIH Ethics procedures for SGEs.

- Responded to several FOIA requests, initiated a cleanup of SEP female/minority data, and oversaw travel authorizations and vouchering of more than 100 SGE travel expenses.

- Continued to provide exceptional leadership for all SREA activities ensuring that 5,190 instances of NCI peer reviewer reimbursements were paid expeditiously and all peer review meeting costs were tracked appropriately to provide the DEA Director with budget estimates for FY2010. Additionally, the CMO was responsible for reviewing 113 hotel contracts to ensure that the proper language was used; *per diem* for sleeping room rates were in accordance with government regulations; appropriate local and state taxes were being applied to lodging, meeting room, and audiovisual rates; and the attrition rate was no less than 20 percent of the sleeping room block. At the request of the NCI DEA Director, the CMO also coordinated responses to an NCI SREA Risk Assessment that was conducted by the Office of Management Assessment, NCI.

- At the request of the NCI DEA Director, developed several orientation briefing books on NCI's Federal advisory committees for the incoming NCI Director.

- Participated in several NIH pilots throughout the year. These included the NIH CSR SREA Hotel Centralization Pilot meeting to discuss concerns and map out procedures that CSR will follow when reviewing and invoicing NCI peer review hotel contracts. Additionally, CMO participated in the CM J2EE testing of the new CM Module.

- Participated in the following NIH/NCI working groups:
  - Food Service Working Group—tasked to make recommendations on healthy food choices, cafeteria space, and meeting room space.
  - Shady Grove Facilities Working Group—tasked to review required Branch space to ensure it meets the needs of current office space.
  - OFACP 1810 Working Group—tasked to rewrite the manual issuance and develop new and innovative practices for ensuring SGEs are in compliance with all COI and Ethics regulations.

- Provided logistical support for the NCI Board of Scientific Advisors, caBIG Working Group. For these weekly teleconference meetings, the CMO was responsible for attending and taking notes, ensuring COI certifications are signed, and any reimbursement costs are submitted in a timely manner.

Portfolio Tracking and Analysis

The DEA's **Research Analysis and Evaluation Branch** (RAEB) is the officially designated contact for scientific information on NCI-supported research. The NCI needs consistent budget-linked scientific information across all of its scientific programs to analyze the Institute's portfolio, make budget projections, and disseminate information about cancer. The DEA conducts analyses to project future NCI research expenditures and to provide budget justifications to Congress. The work of the RAEB allows the DEA to respond immediately to requests for information from NCI staff, the broader NIH community, and requesters nationally and worldwide regarding the NCI Funded Research Portfolio (http://fundedresearch.cancer.gov). The RAEB reviews both unfunded applications and funded extramural grants supported by the NCI to consistently link scientific categories to budget categories on all Institute programs. These capabilities are based on a sophisticated system of indexing in which research documentation staff analyze grant applications to classify each project for its degree of relevance to Special Interest Category (SIC) and Organ Site Codes (SITE). SIC Codes are meant to describe in a consistent way the major scientific disciplines that are of stated or growing interest to the NIH, HHS, Congress, and the public. A critical characteristic of these data is comparability from one fiscal year to the next. Trends in funding from FY2006 through FY2010 for selected organ sites and SIC Codes are presented in Tables 15 and 16; Table 17 reports NCI funding of foreign research grants in FY2010 and Table 18 reports foreign components of U.S. domestic research grants in FY2010. In addition, RAEB staff scientifically indexed all ARRA-funded projects presented in Tables 21 and 22. RAEB staff act as DEA or NCI representatives on NCI or NIH-wide scientific reporting initiatives. These groups and committees deal with various aspects of NIH grants and contracts or tracking and reporting on areas of special interest to the NIH, NCI, and/or Congress.

FY2010 Highlights

- Provided information to numerous requesters, for example: Funding for research relevant to Ductal Carcinoma *In Situ* FY2004-FY2008, Public health genomics – FY2008 and FY2009, Cord blood research, Data on addiction (tobacco, alcohol, etc.) and behavior, Early life exposure and cancer, Cancer survivorship and diet/nutrition, Nutrition prevention and angiogenesis, Metabolomics and nutrition, Bone Marrow Failure Disease, and Prostate imaging.
- Indexed and coded nearly 16,000 funded and unfunded applications.
- Supported the NCI Funded Research Portfolio (NFRP) Web Site by providing scientific indexing for NCI-funded extramural projects (http://fundedresearch.cancer.gov).
- Added SIC codes for Image Guided Therapy and Response to Therapy.
- Continued coordination with the NCI Office of Budget and Finance (OBF) to update and align budget reporting categories.
- Chaired the NCI Accrual Working Group to prepare data for biennial reporting of NCI compliance with Congressional Health Disparities reporting requirements, and represented the NCI on the NIH Population Tracking and Inclusion Committee.
- Served on the Extramural Program Management Committee (EPMC) Portfolio Analysis Focus Group on Research Management. The results will be used to help describe the current research management environment at the NIH and desirable next steps to enable better research management at the NIH.
- Served as DEA representative to the NCI Communications Committee.
- Served as DEA representative to the NCI Planning and Evaluation Special Interest Group (SIG).
- Conducted a staff workshop resulting in updated indexing standards and metrics.

- Continued data quality comparison checks with DCTD program staff for RAEB multicomponent clinical trials coding.
- Developed a process for coding of translational research projects according to the Translational Research Working Group pathways.
- Supported the ICR Partners (ICRP), a group of international cancer funding organizations, by coding NCI extramural projects to the common scientific outline (CSO) and participating in the ICRP.

Extramural Research by Foreign Research Institutions and Extramural NCI Research Grants With a Foreign Research Component

In FY2010, the NCI allocated $20.2 million to support 68 grants received by foreign research institutions. These foreign grants are listed by country, mechanism, disease area, and total funding support in Table 17. Canadian institutions received the most funding from the NCI, with 29 grants totaling $10.1 million. R01 is the most common mechanism funded, with 39 grants receiving $13.8 million. Disease areas receiving the most NCI funding to foreign institutions were breast ($3.5 million), colon ($3.1 million), lung ($2.5 million), leukemia ($1.4 million), and prostate ($1.1 million).

In FY2010, the NCI supported 245 U.S. domestic grants involving a total of 391 foreign components. These grants are listed in Table 18 by country, mechanism, and number of grants. Because many grants have multiple foreign contributors, the total count is greater than the total number of grants. Canadian and the United Kingdom institutions are the NCI's most frequent collaborators, with 50 and 43 grants, respectively. The R01 is the most common mechanism used for collaborations, with 209 grants.

FY2010 Funding of Foreign Institutions

(See Table 17 for more information.)

Country	Grants #	Funding $
Canada	29	$10,075,463
Australia	7	$2,702,795
United Kingdom	9	$1,685,221
France	2	$1,309,580
Israel	9	$1,200,436
Spain	5	$963,951
Belgium	1	$482,054
India	1	$403,444
Sweden	1	$386,237
Germany	1	$379,595
Switzerland	2	$366,050
Ireland	1	$200,545

Success Rates of Extramural Science Categories

The RAEB assigns scientific indexing to both funded and unfunded applications, so it is possible to calculate success rates for funding in scientific categories. For example, the following figures and associated tables illustrate success rates for the High Incidence Cancers based on SEER data, and for selected Special Interest Categories (Figures 9 and 10).

Success rates were calculated by dividing the total number of applications newly funded in 2010 (type 1 and 2 grants) by: the total number of applications and the total number of applications recommended for funding. The remaining applications are those not recommended by peer review for funding.

Figure 9. FY2010 Success Rates for Applications in High Incidence Cancers



	All Applications Received			Applications Recommended for Funding			Relevant Dollars in Thousands
	Number Received	Number Awarded	Success Rates	Number Recommended for Funding	Number Awarded	Success Rates	
Kidney	177	70	39.5%	126	70	55.6%	$5,973
Non-Hodgkins Lymphoma	397	128	32.2%	268	128	47.8%	$19,286
Leukemia	593	191	32.2%	392	191	48.7%	$45,056
Uterus	68	20	29.4%	44	20	45.5%	$5,929
Colon, Rectum	917	262	28.6%	564	262	46.5%	$63,155
Melanoma	407	116	28.5%	265	116	43.8%	$25,760
Lung	981	274	27.9%	629	274	43.6%	$70,136
Ovary	418	108	25.8%	257	108	42.0%	$40,350
Prostate	1,118	281	25.1%	673	281	41.8%	$69,792
Breast	2,164	465	21.5%	1,262	465	36.8%	$162,504
Pancreas	503	104	20.7%	308	104	33.8%	$27,471
Stomach	48	9	18.8%	31	9	29.0%	$1,517
Bladder	224	40	17.9%	128	40	31.3%	$3,184
Oral Cavity	84	14	16.7%	45	14	31.1%	$2,757
Thyroid	48	8	16.7%	28	8	28.6%	$1,224

Figure 10. FY2010 Success Rates for Applications in Selected Special Interest Categories



	All Applications Received			Applications Recommended for Funding			Relevant Dollars in Thousands
	Number Received	Number Awarded	Success Rates	Number Recommended for Funding	Number Awarded	Success Rates	
Genomics	721	239	33.1%	461	239	51.8%	$86,311
Oncogenes	1,325	415	31.3%	901	415	46.1%	$105,361
Obesity	172	50	29.1%	105	50	47.6%	$13,639
Inflammation	395	114	28.9%	235	114	48.5%	$24,062
Prevention	1,037	264	25.5%	628	264	42.0%	$82,900
Angiogenesis	473	120	25.4%	303	120	39.6%	$19,000
Metastasis	1,403	353	25.2%	883	353	40.0%	$87,938
Early Detection	891	221	24.8%	537	221	41.2%	$81,699
Biomarkers	1,851	430	23.2%	1,107	430	38.8%	$128,961
Diagnosis	2,179	475	21.8%	1,296	475	36.7%	$166,906
Therapy	4,585	962	21.0%	2,679	962	35.9%	$351,624

Information Resources Management

The **Applied Information Systems Branch** (AISB) provides integrated computer support, information technology expertise, and information systems development for the DEA. The AISB maintains and monitors the DEA Internet and Intranet websites; designs, develops, and maintains Division-specific software applications; administers and maintains various DEA servers; provides help desk support; provides oversight of hardware and connectivity; and serves as a liaison with the NIH Center for Information Technology (CIT) and the NCI Center for Biomedical Informatics and Information Technology (CBIIT). Its mission is critical to the Division in communicating current information technology activities and new developments to all components of the NCI and NIH as well as to external reviewer and applicant communities.

DEA's Information Technology and Information Systems contracts are managed by the AISB. The AISB has a computer support team to track staff requests, manage the Division's computer equipment inventory, and provide computer-related training, as needed. Specific projects utilizing the technologies and services provided by the AISB are described under the appropriate functions of the DEA throughout this report. For FY2010, specific AISB accomplishments are highlighted below.

System Administration and Desktop Support

- Installed and configured Secure Sockets Layer (SSL) encryption certificates for three production servers.
- Set up and administered additional Microsoft SharePoint websites (4 internal, 1 external) for DEA workgroups.
- Upgraded DEA server power capability with the repair and replacement of the Symmetra power backup system module and batteries, respectively.
- Coordinated the efforts of NCI staff and outside consultants in support of the Certification and Accreditation (C&A) submission for FLARE (Fiscal Linked Analysis of Research Emphasis) and DEA GSS (General Support System) applications. Defined application functionality; implemented system configurations, server maintenance routines, security plans and application vulnerability scanning; and identified effectiveness of inherited and local policy security controls.

Major DEA Internet/Intranet Development

- Deployed newly designed DEA Internet pages with improved user interface and navigation, and more efficient web management.
- Converted static HTML content to PDF format resulting in a 66 percent reduction of DEA Internet pages.
- Incorporated monthly HHS 508 scans and issue management into web management procedures.

Application Development Projects

- Deployed the redesigned Glossary application.
- Implemented review and analysis of IRG Reports search criteria and report categories with DEA Office of Referral, Review and Program Coordination staff and deployed modifications to the IRG Reports application.
- Completed implementation of the new NCAB web application, which includes the NCI Electronic Early Concurrence (EEC) voting for NCAB members and NCI program staff. The NCAB web application also provides automated features for administering and managing EEC voting results.

- Performed enhancements to the NCI Funded Research Portfolio (NFRP) application to provide support for tracking ARRA-funded (American Recovery and Reinvestment Act) grants and dynamic search form list elements.
- Provided enhancements to the NCI I2E Program Coding application, which included features for percent selection; comments for each coding record; improved user interface, navigation, and coding sheet report; and the coding of amendments separately.

Development and Support of Software Applications for the Research Analysis and Evaluation Branch's (RAEB) Scientific Coding and Analysis

- Coordinated user support, application enhancement and environment management, scientific coding data management, dissemination and reporting to FLARE. Major enhancements included: translational research coding; ARRA grants and contracts tracking; and database download, subproject data validation, and integration processes.

User Training

AISB staff provided user training and ongoing support for Adobe Connect Web Conferencing, Microsoft SharePoint services, and Secure E-mail Transfer utility to promote increased usage of collaborative tools in the work environment. Other user training performed by AISB staff included the Review Material Preparation application, Subversion version control, and Blackberry PDA usage.

AISB Staff Involvement

AISB staff were involved with many NCI and NIH information systems and information technology groups and organizations, including:

- NCI Change Management Group
- NCI Coding QA/QC Team
- NCI Division, Office and Centers IT Contacts Group
- NCI Science Management Workspace
- NCI Subproject Re-engineering Users Group
- NIH CIT Architecture Review Board
- NIH SharePoint Users Forum
- NIH Server Consolidation Planning Team
- NIH Electronic Council Book and Query View Reporting Steering Committee
- NIH eRA RCDC Data Analysis Working Group/Power User Group
- NIH eRA Review Users Group (RUG)
- NIH eRA Subproject Re-engineering Focus Group
- NIH eRA Technical Coordinators Group.

Organizational Structure of the Division of Extramural Activities

Office of the Director

- Directs and administers the operations of the Division, including those activities relating to grant review and administration, contract review, and Advisory Committee and Board activities.
- Directly coordinates and manages the NCAB and the BSA.
- Coordinates coding of NCI's grant portfolio.
- Initiates, coordinates, and implements Institute policies and procedures relating to grants and contracts reviews.
- Oversees the NCI's Committee Management Office.
- Implements NCI policies regarding extramural research integrity.
- Advises the Scientific Program Leadership Committee, NCI, on extramural guidelines, review, advisory activities, and implementation strategies.
- Coordinates NCI extramural staff training requirements with the NIH.
- Represents the NCI on the NIH Institute-wide Extramural Program Management Committee (EPMC) with responsibility for development of extramural policy and procedures across all NIH Institutes and Centers.
- Oversees inclusion of gender, minority, and children.
- Serves as the NCI Research Integrity Office.
- Coordinates, develops, and implements extramural policy.

Paulette Gray, Ph.D.	**Director**
Vacant	**Deputy Director**
Cedric Long, Ph.D.	**Assistant Director**
Patricia Marek, M.B.A.	**Special Assistant to the Director**
Kathy Tiong*	**Program Analyst**
Barbara Hider	**Secretary**
Judi Ziegler	**Secretary**

*Joined in 2010.

Committee Management Office, OD

- Coordinates functionally related Federal advisory committee activities across the Institute and its client-Institutes. The office manages NCI advisory committees, and serves as an NIH service center for the NIH National Center for Complementary and Alternative Medicine, the NIH Council of Councils and a HHS chartered advisory committee to ensure that appropriate policies and procedures are in place to conduct the designated mission of each committee.
- Acts as a Service Center to provide advisory committee policy and management services to the Office of Biotechnology Activities, Office of the Director, NIH, and the NCCAM.
- Provides policy guidance to the NCI and client-Institute staff on administrative and technical aspects of Federal advisory committees; coordinates activities with all other NCI advisory committees; implements policies and procedures designed to avoid conflicts in the nomination, selection, and recruitment of board members; implements CM Module guidelines and procedures to ensure that all committee-related data are correctly entered into the database for preparation and submission of required annual reports to the President of the United States, HHS, and NIH; provides logistical support for NCAB and BSA meetings, subcommittees, and work groups; and facilitates NCAB and BSA committee-related travel.
- Researches and evaluates conflict of interest and foreign activities issues for client-Institutes and provides advice on resolutions affecting advisory committee members serving as special government employees.
- Provides administrative support for the peer review system by: compensating consultants for their services on NCI IRG subcommittees and SEPs; reimbursing consultants for travel and other expenses; and approving and processing payments for other activities related to review such as hotel contracts and teleconferencing.

Claire Harris ..... **Committee Management Officer**
Andrea Collins ..... **Deputy Committee Management Officer**
Linda Southworth ..... **Senior Committee Management Specialist**
Malaika Staff ..... **Senior Committee Management Specialist**
Natasha Copeland ..... **Committee Management Specialist**
Hing Lee ..... **Committee Management Specialist**
Alonda Lord ..... **Committee Management Specialist**
Ricardo Rawle ..... **Committee Management Specialist**
Kate Reardon ..... **Committee Management Specialist**
Kimberly Taylor ..... **Committee Management Specialist**

Program and Review Extramural Staff Training Office

- Develops and implements both broad-based and focused curricula for NCI Program and Review staff.
- Coordinates training for other extramural staff (i.e., in the Division of Extramural Activities Support and Office of Grants Administration) upon request.
- Identifies and/or develops resources (electronic and human) to facilitate learning and optimal individual, group, and organizational performance.
- Collaborates with other entities (including NCI Office of Workforce Development) to provide customized job-related training and career development opportunities.
- Monitors participation of extramural staff in NIH- and NCI-sponsored training activities.

Michael Small, Ph.D. ..... Chief
Vacant ..... Health Scientist Administrator
Vacant ..... Health Scientist Administrator
Vacant ..... Program Analyst
Vacant ..... Program Analyst
Vacant ..... Program Analyst
Vacant ..... Program Analyst

Office of Referral, Review, and Program Coordination

- Coordinates program concept development; publication functions; and receipt, referral, and assignment of all NCI applications.
- Coordinates review activities of the SRLB, RTRB, RPRB, and PCRB.

David Maslow, Ph.D.	**Associate Director**
Catherine Battistone	**Program Analyst**
Linda Brown	**Program Specialist**
Linda Coleman	**Committee Management Specialist**

Special Review and Logistics Branch

- Plans, manages, and assists in the scientific merit review of special grant and cooperative agreement applications (received in response to RFAs and PARs) and the technical merit review of contract proposals (received in response to RFPs).
- Identifies and recommends appropriate review committee members and site visitors, as required for the review of assigned applications and proposals.
- Provides the SROs and other support staff for the technical review committees.
- Serves as the information and coordination center for all grant applications and contract proposals pending review by the Branch.
- Provides input and advice on grant and contract review policy and procedures, application and proposal patterns, and research trends and other related information, as required.
- Coordinates second-level review activities of the NCAB with staff of other NCI Divisions, other Branches of the Division, and the Office of Grants Administration.
- Provides logistical support for primary- and second-level review activities in support of other Division and Institute units.

Kirt Vener, Ph.D. ..... **Chief**
Thomas Vollberg, Ph.D. ..... **Deputy Chief**

Special Review Unit

Kenneth Bielat, Ph.D. ..... **Scientific Review Officer**
Jeffrey DeClue, Ph.D. ..... **Scientific Review Officer**
Sherwood Githens, Ph.D. ..... **Scientific Review Officer**
Irina Gordienko, Ph.D. ..... **Scientific Review Officer**
Gerald Lovinger, Ph.D. ..... **Scientific Review Officer**
Savvas Makrides, Ph.D. ..... **Scientific Review Officer**
Thu Nguyen ..... **Program Analyst**
Lalita Palekar, Ph.D. ..... **Scientific Review Officer**
Joyce Pegues, Ph.D. ..... **Scientific Review Officer**
Marvin Salin, Ph.D. ..... **Scientific Review Officer**
Ellen Schwartz, Ph.D.* ..... **Scientific Review Officer**
Cliff Schweinfest, Ph.D.* ..... **Scientific Review Officer**
Viatcheslav Soldatenkov, Ph.D. ..... **Scientific Review Officer**
Adriana Stoica, Ph.D. ..... **Scientific Review Officer**
Zhiqiang Zou, Ph.D.* ..... **Scientific Review Officer**

Review Processing and Distribution Unit

Adrian Bishop ..... **Mail and File Clerk**
Sanjeeb Choudhry ..... **Mail and File Clerk**
Robert Kruth ..... **Mail and File Clerk**
Clara Murphy ..... **Program Assistant**

*Joined in 2010.

Program Coordination and Referral Branch

- Serves as the information and coordination point within the NCI for the development, clearance, publication, and tracking of all NCI extramural program (funding) initiatives, which include all RFAs, PAs, and Notices submitted for publication in the *NIH Guide for Grants and Contracts*, and also on Grants.gov, which is a Federal-wide online portal for electronic submission of grant applications.
- Coordinates the development and periodic revision of referral (i.e., application assignment) guidelines within the NCI for both external and internal use.
- Coordinates the development of shared (referral) interest statements with other NIH Institutes and Centers (ICs) so that grant applications of possible or real mutual interest can be properly assigned for receipt, review, and/or funding.
- Serves as liaison to the Center for Scientific Review (CSR), NIH, to ensure the appropriate referrals (i.e., assignments) of grant applications to the Institute and the transfers of grant applications between the NCI and other NIH ICs.
- Refers new (Type 1) applications to the appropriate cancer activity area(s) according to the NCI Internal Referral Guidelines that define the program interests of each of the 50 cancer activity areas (which typically represent program branches in the NCI extramural divisions).
- Semi-automatically refers amended and competing continuation (Type 2) applications to the cancer activity area that accepted the previously submitted application (with quality control measures performed to ensure the accuracy of referrals).
- Coordinates requests from program staff for application status changes (including corrections of application assignments and numbers, which is done in collaboration with NCI program staff, CSR referral staff, and referral staff of other ICs and agencies) and for acceptance of grant assignments.
- Serves as the NCI contact point and liaison to involved parties at the NIH for approval of the use of cooperative agreement mechanisms and for conversion of grants to cooperative agreements.
- Works with NCI program and review staff and with NIH referral liaisons to address unresolved referral and review issues with the CSR and other NIH ICs.
- Receives and distributes advance copies of applications to review and program staff.
- Receives Letters of Intent from applicants (principal investigators) intending to submit large budget grants (including, but not limited to, program projects and cooperative agreements for clinical trials).
- By handling communications with applicants and NCI program staff members, coordinates approvals (and disapprovals) of the NCI to sponsor the submission of individual conference (R13) grant applications.
- Serves as the primary point of contact and assistance at the NCI for applicants who want to apply for an Academic Research Enhancement Award (i.e., the NIH R15 AREA grant mechanism).
- Processes and tracks requests for submissions of large-budget grant applications that allow them to be received at the NIH, peer reviewed, and possibly awarded by the NCI.
- Maintains database records of prospective large-budget grant and conference grant applications for each council round.
- Serves as the primary NCI information and referral point for the extramural scientific community on a broad range of subjects, including grant guidelines, application information, new initiatives announced as RFAs or PAs, and the review process.

- Assists the extramural community in navigating the NIH and NCI Web pages to help users obtain current information, forms, and guidelines.
- Directs applicants to the appropriate SROs and Program Directors for information regarding the status of the review and award of their grant applications.
- Tracks and analyzes trends of CSR referral to study sections and resultant review outcomes.
- Provides data and data analyses on funding opportunities and on the receipt and referral of grant applications to NCI senior staff members and committees.

Christopher L. Hatch, Ph.D.	**Chief**
David Contois	**Referral Officer, NCI/NIH Referral Liaison**
Anandarup Gupta, Ph.D.	**RFA/PA Coordinator, Scientific Review Officer**
Leota Hall	**Referral Officer, NCI/NIH Referral Liaison**
Natacha P. Lassègue	**Program Analyst**
Kimberly Morris†	**Program Support Assistant**
Bratin Saha, Ph.D.	**Referral Officer, Scientific Review Officer**
Jan Woynarowski, Ph.D.	**RFA/PA Coordinator, Scientific Review Officer**

†Left in 2010.

Research Programs Review Branch

- Plans, coordinates, and manages the scientific merit review of program project grants, specialized centers, and other grant mechanisms, as necessary, by chartered review committees and Special Emphasis Panels.
- Arranges for and participates in onsite assessments of the research capabilities and facilities of selected applicants.
- Identifies and recommends appropriate review committee members and site visitors, as required, for the review of assigned applications.
- Provides input and advice on grant review policy and procedures, application patterns, research trends, and other related information, as required.
- Coordinates grant review activities with staff of other NCI Divisions and other DEA Branches.

Olivia Bartlett, Ph.D. ..... **Chief**
Virginia Wray, Ph.D. ..... **Deputy Chief**
Shakeel Ahmad, Ph.D. ..... **Scientific Review Officer**
Monica Congo ..... **Program Specialist**
Majed Hamawy, Ph.D., M.B.A. ..... **Scientific Review Officer**
Wlodek Lopaczynski, M.D., Ph.D. ..... **Scientific Review Officer**
Caron Lyman, Ph.D. ..... **Scientific Review Officer**
David Ranson, Ph.D. ..... **Scientific Review Officer**
Michael Small, Ph.D.† ..... **Scientific Review Officer**
Shamala Srinivas, Ph.D. ..... **Scientific Review Officer**
Peter Wirth, Ph.D. ..... **Scientific Review Officer**

†Moved to PRESTO in FY2010.

Resources and Training Review Branch

- Plans, coordinates, and manages the scientific merit review of cancer center, clinical cooperative group, training, education, and career development grant and cooperative agreement applications by chartered review committees and Special Emphasis Panels.
- Arranges for and participates in onsite assessments of the research capabilities and facilities of selected applicants.
- Identifies and recommends appropriate review committee members and site visitors, as required, for the review of assigned applications.
- Provides input and advice on grant review policy and procedures, application patterns, and research trends and other related information, as required.
- Coordinates grant review activities with staff of other NCI Divisions, other DEA Branches, and the Center for Scientific Review.

Robert E. Bird, Ph.D. ..... **Chief**
Lynn Amende, Ph.D. ..... **Scientific Review Officer**
Gail Bryant, M.D. ..... **Scientific Review Officer**
Jeannette Korczak, Ph.D. ..... **Scientific Review Officer**
Ilda McKenna, Ph.D. ..... **Scientific Review Officer**
Timothy Meeker, M.D. ..... **Scientific Review Officer**
Sergei Radaev, Ph.D. ..... **Scientific Review Officer**
Sonya Roberson, Ph.D. ..... **Scientific Review Officer**
Denise M. Santeufemio ..... **Program Specialist**

Office of Extramural Applications

- Coordinates activities of the Research Analysis and Evaluation Branch and the Applied Information Systems Branch.
- Provides budget-linked research portfolio data and coordinates the information management of extramural NCI-supported research.

Amir Sahar-Khiz, Ph.D., M.B.A., PMP ..... **Associate Director**
Justin Rhoderick ..... **Program Analyst**

Research Analysis and Evaluation Branch

- Serves as the Institute's officially designated, centralized source of scientific information and science-based budget information on NCI-supported research.
- Analyzes and classifies the science content of all Institute-supported research projects.
- Analyzes the distribution of funds among research areas; these analyses serve as a basis for budget projections.
- Reports and answers inquiries on the scientific and budgetary aspects of Institute-funded research, including research grants, center grants, training grants, and research contracts.
- Maintains liaisons with other organizations involved in related classification activities.
- Documents the need for proposed RFAs by comparing RFA concepts with existing NCI-supported research and with unsolicited applications.

Marilyn Gaston ..... **Chief**
Edward Kyle ..... **Deputy Chief**

Research Documentation

- Analyzes and indexes grants and contracts for the Branch's computerized systems.
- Analyzes extramural projects for relevance to SICs and Anatomic Sites to determine the officially reported figures for Institute support and to provide a basis for budget projections.
- Maintains liaison with other offices within the Institute to ensure consistent reporting of data.
- Monitors the results of Institute grant-supported research.
- Assists other NCI organizations by indexing NCI research projects for attributes other than SICs and Sites, for example, Common Scientific Outline (CSO) Codes and AIDS Categories.

Edward Kyle	**Lead Biologist/Team Leader**
Beth Buschling	**Biologist**
Beverly Johnson, M.S.	**Biologist**
Ernestyne Watkins, M.S.	**Biologist**
Bernard Whitfield	**Biologist**
Tyrone Wilson	**Biologist**

Technical Operations, Inquiry, and Reporting

- Provides specialized data querying, archiving, and reporting functions for the Division and the Institute.
- Coordinates Institute data reporting with the NCI Office of Budget and Financial Management, NIH Population Tracking and Inclusion Committee, and others.
- Answers inquiries from Congress, the public, the press, and others concerning any phase of Institute-supported work.
- Conducts in-depth analyses of extramural research data, including trends analyses.
- Identifies emerging priority areas for data collection and analysis.
- Ensures that terms and categories for indexing are updated and reflect current trends in cancer research, and maintains a thesaurus of term definitions.
- Manages RAEB's FLARE grants documentation and indexing database, ensuring reliability and completeness of its contents.
- Maintains and updates archival document files.
- Works with contractors and the AISB to refine RAEB's computer applications to meet the Branch's needs and resolve FLARE computer application problems for the Branch.
- Represents the DEA as its communications coordinator in the Office of Communications and Education Steering Committee.

Gail Blaufarb, M.S.	**Lead Biologist/Team Leader**
Clarissa Douglas	**Program Specialist**
William Clark, M.S.	**Biologist**
Vacant	**Biological Statistician**
Vacant	**Epidemiologist**

Applied Information Systems Branch

- Fulfills the information technology (IT) requirements of the Division; coordinates information resources management (IRM) activities with other relevant NCI and NIH units; and provides high-quality information analysis, design, development, and coordination of applications in support of the Division's business processes.
- Serves as the focal point for the Division in the development, deployment, and application of specialized software and databases required for the conduct of review, referral, coding, advisory, and other extramural applications.
- Serves as the liaison with the NCI Center for Biomedical Informatics and Information Technology (CBIIT) staff; NCI computer professionals; NCI units charged with execution of extramural IRM functions; trans-NIH functional units such as the CSR, Office of Policy for Extramural Research Administration (OPERA), and Office of Extramural Research (OER); and the IMPAC II and NIH eRA (electronic Research Administration) staff and systems.
- Supports connectivity and design of Internet and Intranet applications.
- Establishes, administers, and monitors commercial support contracts to provide design, production, and maintenance for microcomputer equipment and information storage and retrieval systems that are not covered by CBIIT.
- Formulates DEA-specific office automation policy.
- Provides staff/lead users with technical support and training for DEA IT applications.
- Coordinates general user support and training with NCI and NIH services.
- Provides Division-specific applications of video teleconferencing and audiovisual services in support of review and Board activities.
- Provides management with recommendations for establishing and implementing policies for conducting Division computer-assisted presentations, as necessary.
- Reviews user-created applications and recommends and/or designs changes to improve efficiency and effectiveness.

Gregory Fischetti ..... **Chief**

Application Development and Operations Team

- Analyzes and coordinates life-cycle development of software for the Division.
- Develops and designs applications to support the Division's business practices, including user guides.
- Develops, administers, and monitors contracts for acquisition, support, and maintenance of database systems.
- Administers office automation contracts as well as DEA-wide Blanket Purchase Agreements for computer equipment maintenance and supplies.
- Formulates office automation policy, system development, and eRA/IMPAC II operations for the Division.
- Coordinates internal user groups and the provision of training for specific DEA applications and the use of office automation equipment technology.

William Ireland† ..... **Team Leader**
Todd Hardin* ..... **Team Leader**
Deborah Buranich ..... **Information Technology Specialist**

*Joined in 2010.
†Left in 2010.

Richard Florence ..... **Information Technology Specialist**
Roderick James ..... **Information Technology Specialist**
Teresa Park ..... **Information Technology Specialist**
Raymond Vidal* ..... **Information Technology Specialist**

Information Management Team

- Designs and maintains the Division's Intranet and Internet sites and pages, and identifies documents to be placed on the NCI website to make Division information more accessible to the public.
- Develops new web-based software applications that will enhance the productivity and efficiency of extramural processes within the DEA and the distribution of Division information throughout the NCI.
- Coordinates application development and supports the Research Analysis and Evaluation Branch in the areas of scientific coding and analysis.
- Establishes partnerships and ongoing communications with staff and external customers to foster openness and collaboration in accomplishing the information initiatives of the Division.
- Works with DEA staff to ensure the current utility and linkages of documents placed on the web.

Elaine Taylor ..... **Team Leader**
Michael Hu* ..... **Information Technology Specialist**
Joshua Rhoderick ..... **Information Technology Specialist**
Lorrie Smith ..... **Information Technology Specialist**

*Joined in 2010.

Table 1a. Requests for Applications (RFAs) Published by the NCI in FY2010

Sorted by Date of Publication

Date of Publication	RFA	Mechanism	Title	Division, Office and Center
10/2/2009	CA09-032	U54	Community Networks Program (CNP) Centers for Reducing Cancer Disparities Through Outreach, Research and Training	CRCHD
10/9/2009	CA09-014	R25	Cancer Nanotechnology Training Centers (CNTCs)	CSSI
	CA09-015	K99	Pathway to Independence Award in Cancer Nanotechnology Research	
10/26/2009	CA10-001	R21	Innovative and Early-Stage Development of Emerging Technologies in Biospecimen Science	CSSI
	CA10-002	R33	Validation and Advanced Development of Emerging Technologies in Biospecimen Science	
	CA10-003	R21	Application and Early Stage Development of Emerging Technologies in Cancer Research	
	CA10-004	R33	Validation and Advanced Development of Emerging Technologies for Cancer Research	
	CA10-005	R21	Innovative Technology Development for Cancer Research	
11/6/2009	CA10-008	U01	State and Community Tobacco Control Policy and Media Research	DCCPS
11/24/2009	CA10-006	U54	Transdisciplinary Research in Energetics and Cancer	DCCPS
12/1/2009	CA10-007	U01	Cancer Immunotherapy Trials Network	DCTD
12/3/2009	CA10-501	U01	Coordination Center for Transdisciplinary Research in Energetics and Cancer (Limited Competition)	DCCPS
12/24/2009	CA10-502	U01	AIDS Malignancy Clinical Trials Consortium (Limited Competition)	OHAM
1/5/2010	CA10-009	R44	SBIR Phase II Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics Toward Commercialization	SBIRDC
2/16/2010	CA10-503	U54	Comprehensive Partnerships to Reduce Cancer Health Disparities (Limited Competition)	CRCHD
6/25/2010	CA10-016	U24	Clinical Proteomic Technologies for Cancer Initiative (CPTC): Proteome Characterization Centers	CSSI
7/16/2010	CA10-010	U10	Community Clinical Oncology Program Groups	DCP
	CA10-011		Community Clinical Oncology Program Research Bases	
	CA10-012		Minority-Based Community Clinical Oncology Program Groups	
8/13/2010	CA10-014	U54	Barretts Esophagus Translational Research Network	DCP
	CA10-015	U01	Coordinating Center for the Barretts Esophagus Translational Research Network	
8/27/2010	CA10-017	R13	Scientific Meetings for Creating Interdisciplinary Research Teams in Basic Behavioral and Social Science Research	DCCPS
9/14/2010	CA10-013	R43, R44	Innovative Emerging Molecular Analysis Technologies (SBIR)	SBIRDC
9/30/2010	CA10-021	U54	Tumor Microenvironment Network (TMEN)	DCB

Source: Office of Referral, Review and Program Coordination.

Table 1b. Requests for Applications (RFAs) Published by the NCI in FY2010

Sorted by Division, Office, and Center

Division, Office and Center	RFA	Mechanism	Title	Date of Publication
CRCHD	CA09-032	U54	Community Networks Program (CNP) Centers for Reducing Cancer Disparities through Outreach, Research and Training	10/2/2009
CRCHD	CA10-503	U54	Comprehensive Partnerships to Reduce Cancer Health Disparities (Limited Competition)	2/16/2010
CSSI	CA09-014	R25	Cancer Nanotechnology Training Centers (CNTCs)	10/9/2009
	CA09-015	K99	Pathway to Independence Award in Cancer Nanotechnology Research	
CSSI	CA10-001	R21	Innovative and Early-Stage Development of Emerging Technologies in Biospecimen Science	10/26/2009
	CA10-002	R33	Validation and Advanced Development of Emerging Technologies in Biospecimen Science	
	CA10-003	R21	Application and Early Stage Development of Emerging Technologies in Cancer Research	
	CA10-004	R33	Validation and Advanced Development of Emerging Technologies for Cancer Research	
	CA10-005	R21	Innovative Technology Development for Cancer Research	
CSSI	CA10-016	U24	Clinical Proteomic Technologies for Cancer Initiative (CPTC): Proteome Characterization Centers	6/25/2010
DCB	CA10-021	U54	Tumor Microenvironment Network (TMEN)	9/30/2010
DCCPS	CA10-008	U01	State and Community Tobacco Control Policy and Media Research	11/6/2009
DCCPS	CA10-006	U54	Transdisciplinary Research in Energetics and Cancer	11/24/2009
DCCPS	CA10-501	U01	Coordination Center for Transdisciplinary Research in Energetics and Cancer (Limited Competition)	12/3/2009
DCCPS	CA10-017	R13	Scientific Meetings for Creating Interdisciplinary Research Teams in Basic Behavioral and Social Science Research	8/27/2010
DCP	CA10-010	U10	Community Clinical Oncology Program Groups	7/16/2010
	CA10-011		Community Clinical Oncology Program Research Bases	
	CA10-012		Minority-Based Community Clinical Oncology Program Groups	
DCP	CA10-014	U54	Barretts Esophagus Translational Research Network	8/13/2010
	CA10-015	U01	Coordinating Center for the Barretts Esophagus Translational Research Network	
DCTD	CA10-007	U01	Cancer Immunotherapy Trials Network	12/1/2009
OHAM	CA10-502	U01	AIDS Malignancy Clinical Trials Consortium (Limited Competition)	12/24/2009
SBIRDC	CA10-009	R44	SBIR Phase II Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics toward Commercialization	1/5/2010
SBIRDC	CA10-013	R43, R44	Innovative Emerging Molecular Analysis Technologies (SBIR)	9/14/2010

Source: Office of Referral, Review and Program Coordination.

Table 2. NCI Participation in Trans-NIH Requests for Applications (RFAs) in FY2010

Sorted by Date of Publication

Date of Publication	RFA	Mechanism	Title	Division, Office and Center	Issuing NIH-IC
10/23/2009	ES09-008	U01	Limited Competition: Continuation of Studies on Early Environmental Exposures and Human Puberty	DCCPS	ES
	ES09-009		Environmental Influences During Windows of Susceptibility in Breast Cancer Risk		
	ES09-010		Coordinating Center for the Breast Cancer and the Environment Research Program		
10/23/2009	RM09-022	R01	Roadmap Transformative Research Projects Program	*	NIH/RM†
11/10/2009	RM09-002	U54	National Centers for Biomedical Computing	*	NIH/RM†
11/16/2009	HL10-020	U01	Effectiveness Research on Smoking Cessation in Hospitalized Patients	DCCPS	HL
12/2/2009	RM09-012	R01	Membrane Protein Production for Structure Determination	*	NIH/RM†
12/3/2009	RM09-016	R01	Developing Technologies for Improved *In Vivo* Epigenetic Imaging or Analysis	*	NIH/RM†
12/3/2009	RM09-020	R01	Development of New Tools for Computational Analysis of Human Microbiome Project Data	*	NIH/RM†
	RM09-021	R21			
1/26/2010	RM10-001	U54	Institutional Clinical and Translational Science Award	*	NIH/RM†
2/4/2010	RM10-002	R01	Science of Behavior Change: Finding Mechanisms of Change in the Laboratory and the Field	DCCPS	NIH/RM†
2/24/2010	RM10-006	U01	Advancing Regulatory Science Through Novel Research and Science-Based Technologies	*	NIH/RM†
2/26/2010	RM10-003	U54	Large Scale Production of Perturbagen-Induced Cellular Signatures	*	NIH/RM†
2/26/2010	RM10-007	U01	Production of Human Proteins to Be Used for Generating Affinity Reagents	*	NIH/RM†
3/2/2010	HL11-002	R01	Common Pathogenetic Mechanisms of Lung Cancer and COPD	DCP	HL
3/15/2010	TW10-008	R24	The Medical Education Partnership Initiative (MEPI)	CCT	FIC
5/7/2010	OD10-014	R25	Limited Competition: Strengthening Behavioral and Social Science in Medical School Education	CCT	NIH
5/18/2010	AI10-022	R21	U.S.-India Bilateral Collaborative Research Partnerships (CRP) on the Prevention of HIV/AIDS and Co-Morbidities	OHAM	AI
7/7/2010	ES10-002	R01	Epigenomics of Human Health and Disease	DCCPS	ES
7/9/2010	RM10-008	DP1	2011 NIH Directors Pioneer Award Program	*	NIH/RM†
7/12/2010	RM10-009	DP2	2011 NIH Directors New Innovator Award Program	*	NIH/RM†
8/3/2010	DA11-003	R01	Effects of the Social Environment on Health: Measurement, Methods and Mechanisms	DCCPS	DA
8/4/2010	RM10-010	R01	NIH Common Fund Transformative Research Projects Program	*	NIH/RM†

continued

*All NCI Divisions, Offices and Centers may participate.
†Road Map.
Source: Office of Referral, Review and Program Coordination.

Table 2. NCI Participation in Trans-NIH Requests for Applications (RFAs) in FY2010

Sorted by Date of Publication

Date of Publication	RFA	Mechanism	Title	Division, Office and Center	Issuing NIH-IC
8/5/2010	AI10-030	U01	International Epidemiologic Databases to Evaluate AIDS (IeDEA)	OHAM	AI
8/5/2010	HD11-101	R01	Sleep and Social Environment: Basic Biopsychosocial Processes	DCCPS	HD
	HD11-102	R21	Sleep and Social Environment: Basic Biopsychosocial Processes		
8/6/2010	RM10-004	U01	Advanced Technologies for Detection of Perturbation-Induced Cellular Signatures	*	NIH/RM†
	RM10-005		Computational Tool Development and Integrative Data Analysis for LINCS	*	NIH/RM†
8/10/2010	AG11-010	R21	Basic Research on Self-Regulation	DCB	AG
8/11/2010	HL11-013	U10	Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Core Clinical Centers	DCTD	HL
	HL11-028		Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Data Coordinating Center		
8/13/2010	ES10-007	R01	Validation and Field Testing of New Tools for Characterizing the Personal Environment	DCCPS	ES
8/13/2010	RM10-015	R21	Economics of Prevention	DCCPS	NIH/RM†
	RM10-016		Science of Structure, Organization and Practice Design in the Efficient Delivery of Effective Healthcare		
8/17/2010	GM11-003	R01	Exceptional, Unconventional Research Enabling Knowledge Acceleration (EUREKA)	DCB	GM
8/17/2010	HL11-033	R01	Psychosocial Stress and Behavior: Integration of Behavioral and Physiological Processes	DCCPS	HL
	HL11-034	R21	Development of Comprehensive and Conceptually-Based Measures of Psychosocial Stress		
	HL11-035	R01	Basic Mechanisms Influencing Behavioral Maintenance		
8/23/2010	AT11-001	R01	Mechanistic Research on CAM Natural Products	DCP	AT
9/10/2010	RM10-011	U54	Knockout Mouse Phenotyping	DCB	NIH/RM†
	RM10-012	U54	Knockout Mouse Phenotyping Project Database		
	RM10-013	U42	Knockout Mouse Production and Cryopreservation		
9/14/2010	NR11-002	R25	NIH Basic Behavioral and Social Science Opportunity Network (OppNet) Short-term Interdisciplinary Training Program for New and Early-Stage Investigators	CCT	NR
9/23/2010	HD10-001	U54	Systems-Oriented Pediatric Obesity Research and Training (SPORT) Center of Excellence	DCCPS	HD

Table 3a. Program Announcements (PAs) Published by the NCI in FY2010

Sorted by Date of Publication

Date of Publication	PA	Mechanism	Title	Division, Office and Center
10/2/2009	PAR10-003	P50	Specialized Programs of Research Excellence (SPOREs) in Human Cancer for Years 2010, 2011, and 2012	DCTD
11/16/2009	PA10-025	R01	Development, Application, and Evaluation of Prediction Models for Cancer Risk and Prognosis	DCTD, DCCPS
	PA10-026	R21		
11/16/2009	PA10-027	R01	Obesity Policy Research: Evaluation and Measures	DCCPS
	PA10-028	R21		
	PA10-029	R03		
11/24/2009	PA10-031	R01	Epigenetic Approaches in Cancer Epidemiology	DCCPS
	PA10-032	R21		
11/24/2009	PA10-035	R01	Prioritizing Molecular Targets for Cancer Prevention With Nutritional Combinations	DCP
12/10/2009	PA10-052	R01	School Nutrition and Physical Activity Policies, Obesogenic Behaviors and Weight Outcomes	DCP
	PA10-053	R21		
	PA10-054	R03		
1/6/2010	PA10-079	R43, R44	Image-Guided Cancer Interventions (SBIR)	SBIRDC, DCTD
1/7/2010	PA10-080	R41, R42	Image-Guided Cancer Interventions (STTR)	
3/8/2010	PAR10-126	U01	Strategic Partnering to Evaluate Cancer Signatures (SPECS II)	DCTD
3/17/2010	PA10-088	R21	Exploratory Cancer Prevention Studies Involving Molecular Targets for Bioactive Food Components	DCP
3/26/2010	PAR10-155	K12	Paul Calabresi Career Development Award for Clinical Oncology	CCT
4/12/2010	PAR10-165	R25	National Cancer Institute (NCI) Cancer Education and Career Development Program	CCT
4/16/2010	PAR10-169	R01	Academic-Industrial Partnerships for Translation of *In Vivo* Imaging Systems for Cancer Investigations	DCTD
5/27/2010	PAR10-208	U01	The Role of Microbial Metabolites in Cancer Prevention and Etiology	DCP
9/16/2010	PAR10-283	U01	Core Infrastructure and Methodological Research for Cancer Epidemiology Cohorts	DCCPS
9/21/2010	PAR10-286	U43, U44	Cancer Diagnostic and Therapeutic Agents Enabled by Nanotechnology (SBIR)	SBIRDC, CSSI
9/29/2010	PAR10-290	R01	Research on Malignancies in the Context of HIV/AIDS	OHAM, DCB,DCCPS
	PAR10-291	R21		

Source: Office of Referral, Review and Program Coordination.

Table 3b. Program Announcements (PAs) Published by the NCI in FY2010

Sorted by Division, Office, and Center

Division, Office and Center	PA	Mechanism	Title	Date of Publication
CCT	PAR10-155	K12	Paul Calabresi Career Development Award for Clinical Oncology	3/26/2010
CCT	PAR10-165	R25	National Cancer Institute (NCI) Cancer Education and Career Development Program	4/12/2010
DCCPS	PA10-027	R01	Obesity Policy Research: Evaluation and Measures	11/16/2009
	PA10-028	R21		
	PA10-029	R03		
DCCPS	PA10-031	R01	Epigenetic Approaches in Cancer Epidemiology	11/24/2009
	PA10-032	R21		
DCCPS	PAR10-283	U01	Core Infrastructure and Methodological Research for Cancer Epidemiology Cohorts	9/16/2010
DCP	PA10-035	R01	Prioritizing Molecular Targets for Cancer Prevention With Nutritional Combinations	11/24/2009
DCP	PA10-052	R01	School Nutrition and Physical Activity Policies, Obesogenic Behaviors and Weight Outcomes	12/10/2009
	PA10-053	R21		
	PA10-054	R03		
DCP	PA10-088	R21	Exploratory Cancer Prevention Studies Involving Molecular Targets for Bioactive Food Components	3/17/2010
DCP	PAR10-208	U01	The Role of Microbial Metabolites in Cancer Prevention and Etiology	5/27/2010
DCTD	PAR10-003	P50	Specialized Programs of Research Excellence (SPOREs) in Human Cancer for Years 2010, 2011, and 2012	10/2/2009
DCTD, DCCPS	PA10-025	R01	Development, Application, and Evaluation of Prediction Models for Cancer Risk and Prognosis	11/16/2009
	PA10-026	R21		
DCTD	PAR10-126	U01	Strategic Partnering to Evaluate Cancer Signatures (SPECS II)	3/8/2010
DCTD	PAR10-169	R01	Academic-Industrial Partnerships for Translation of *In Vivo* Imaging Systems for Cancer Investigations	4/16/2010
OHAM, DCB,DCCPS	PAR10-290	R01	Research on Malignancies in the Context of HIV/AIDS	9/29/2010
	PAR10-291	R21		
SBIRDC, DCTD	PA10-079	R43, R44	Image-Guided Cancer Interventions (SBIR)	1/6/2010
	PA10-080	R41, R42	Image-Guided Cancer Interventions (STTR)	1/7/2010
SBIRDC, CSSI	PAR10-286	U43, U44	Cancer Diagnostic and Therapeutic Agents Enabled by Nanotechnology (SBIR)	9/21/2010

Source: Office of Referral, Review and Program Coordination.

Table 4. NCI Participation in Trans-NIH Program Announcements (PAs) in FY2010

Sorted by Date of Publication

Date of Publication	PAR	Mechanism	Title	Division, Office and Center	Issuing NIH-IC
10/5/2009	PAR10-006	R01	Mechanisms, Models, Measurement, and Management in Pain Research	DCP	NINR
	PAR10-007	R21			
	PAR10-008	R03			
10/14/2009	PA10-009	R01	Bioengineering Research Grants	DCTD	NIBIB
	PA10-010	R21			
10/29/2009	PAR10-016	R21	Enabling Technologies in DNA Repair Research	DCP	NIEHS
10/30/2009	PAR10-018	R01	Accelerating the Pace of Drug Abuse Research Using Existing Epidemiology, Prevention, and Treatment Research Data	DCCPS	NIDA
11/25/2009	PA10-036	T32	Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants	CCT	NIH
12/1/2009	PAR10-038	R01	Dissemination and Implementation Research in Health	DCCPS	NIMH
	PAR10-039	R03			
	PAR10-040	R21			
12/16/2009	PA10-059	K08	Mentored Clinical Scientist Research Career Development Award (Parent)	CCT	NIH
	PA10-061	K24	Midcareer Investigator Award in Patient-Oriented Research (Parent)		
	PA10-063	K99, R00	NIH Pathway to Independence Award (Parent)		
12/17/2009	PA10-060	K23	Mentored Patient-Oriented Research Career Development Award (Parent)	CCT	NIH
	PA10-062	K25	Mentored Quantitative Research Development Award (Parent)		
12/17/2009	PA10-067	R01	Research Project Grant (Parent)	*	NIH
12/24/2009	PA10-070	R15	Academic Research Enhancement Award (Parent)	*	NIH
1/4/2010	PA10-071	R13, U13	NIH Support for Conferences and Scientific Meetings (Parent)	*	NIH
1/15/2010	PA10-050	R43, R44	PHS 2010-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR)	SBIRDC	NIH
	PA10-051	R41, R42	PHS 2010-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR)		
2/3/2010	PA10-106	R13	Scientific Meetings for Creating Interdisciplinary Research Teams	DCCPS	NIH
2/16/2010	PA10-109	F31	Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral Fellowships to Promote Diversity in Health-Related Research (Parent-Diversity)	CCT	NIH
3/12/2010	PAR10-133	R01	Understanding and Promoting Health Literacy	DCCPS	OBSSR
	PAR10-134	R03			
	PAR10-135	R21			
3/18/2010	PAR10-136	R01	Behavioral and Social Science Research on Understanding and Reducing Health Disparities	DCCPS	OBSSR
	PAR10-137	R21			

continued

*All NCI Divisions, Offices, and Centers may participate.
Source: Office of Referral, Review and Program Coordination.

Table 4. NCI Participation in Trans-NIH Program Announcements (PAs) in FY2010

Sorted by Date of Publication

Date of Publication	PAR	Mechanism	Title	Division, Office and Center	Issuing NIH-IC
3/19/2010	PAR10-145	R01	Social Network Analysis and Health	DCCPS	OBSSR
	PAR10-146	R21			
3/24/2010	PA10-152	R01	Diet Composition and Energy Balance	DCP	NIDDK
4/9/2010	PA10-164	R21	Identification and Characterization of Molecular Targets Within the mTOR Pathway With Potential to Impact Healthspan and Lifespan	DCP	NIA
4/30/2010	PAR10-182	R21	Assay Development for High Throughput Molecular Screening	DCTD	NIH
5/27/2010	PA10-209	R01	Biology of Manual Therapies	DCB	NCCAM
	PA10-210	R21			
6/10/2010	PA10-213	R01	Development of Assays for High-Throughput Screening for Use in Probe and Pre-Therapeutic Discovery	DCTD	NIH
6/18/2010	PAR10-219	D43	AIDS International Training and Research Program (AITRP)	CCT	FIC
7/1/2010	PAS10-226	R21	Advancing Novel Science in Womens Health Research (ANSWHR)	OD	ORWH
7/9/2010	PA10-228	R01	Structural Biology of Membrane Proteins	DCB	NIGMS
7/21/2010	PAR10-234	R01	Bioengineering Research Partnerships (BRP)	DCTD	NIBIB
7/21/2010	PAR10-235	R21	Climate Change and Health: Assessing and Modeling Population Vulnerability to Climate Change	DCCPS	NIEHS
7/22/2010	PA10-236	R01	Health Promotion Among Racial and Ethnic Minority Males	DCCPS	NINR
	PA10-237	R21			
7/30/2010	PA10-239	R01	Nutrition and Alcohol-Related Health Outcomes	DCP	NIAAA
	PA10-241	R21			
8/10/2010	PAR10-257	D43	Chronic, Non-Communicable Disease and Disorder Across the Lifespan: FIC Training Award	CCT	FIC
9/14/2010	PAR10-279	R43	Robotics Technology Development and Deployment (RTD2)	SBIRDC	NIH
9/15/2010	PAR10-278	R01	Limited Competition for the Global Research Initiative Program, Basic/Biomedical Sciences	DCB	FIC
	PAR10-280	R01	Limited Competition for the Global Research Initiative Program, Behavioral/Social Sciences	DCCPS	FIC

Table 5. Applications Received for Referral by the NCI/DEA in FY2010*†

Sorted by Mechanism

Mechanism	Activity Code	Totals by Activity	Applications by NCAB			Total Costs Requested First Year
			Feb	June	Sept	
International Training Grants in Epidemiology (FIC)	D43	49	10	39	0	$19,497,601
NIH Director's Pioneer Award (NDPA)	DP1	4	0	4	0	$2,000,000
NIH Director's New Innovator Awards	DP2	1	0	1	0	$1,500,000
Individual Predoctoral NRSA for M.D./Ph.D. Fellowships (ADAMHA)	F30	1	0	0	1	$ ‡
Predoctoral Individual National Research Service Award	F31	120	35	52	33	$ ‡
Postdoctoral Individual National Research Service Award	F32	455	115	180	160	$ ‡
National Research Service Award for Senior Fellows	F33	4	2	1	1	$ ‡
Research Project	I01	1	0	1	0	$584,111
Research Scientist Development Award – Research and Training	K01	31	14	11	6	$3,758,982
Research Scientist Award	K05	10	3	4	3	$1,338,865
Academic/Teacher Award	K07	72	23	26	23	$10,130,125
Clinical Investigator Award	K08	97	30	32	35	$15,025,255
Physician Scientist Award (Program)	K12	8	5	3	0	$4,568,758
Career Enhancement Award	K18	1	0	1	0	$116,374
Career Transition Award	K22	52	17	18	17	$8,525,940
Mentored Patient-Oriented Research Development Award	K23	66	26	17	23	$10,575,071
Midcareer Investigator Award in Patient-Oriented Research	K24	8	4	2	2	$1,691,065
Mentored Quantitative Research Career Development	K25	27	17	4	6	$3,650,111
Career Transition Award	K99	195	54	88	53	$21,074,042
Institutional Career Enhancement Award	KM1	1	0	0	1	$764,212
Research Program Projects	P01	114	35	41	38	$277,037,993
Exploratory Grants	P20	16	0	0	16	$3,459,417
Center Core Grants	P30	24	14	5	5	$111,120,688
Biotechnology Resource Grant Program	P41	1	1	0	0	$3,674,050
Specialized Center	P50	93	46	41	6	$203,992,471
Research Project	R01	6,418	2,042	2,380	1,996	$2,969,140,565

continued

*Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications and withdrawn applications.

‡NRSA Stipend Levels include: (Pre-doc = $21,180) and (Post-doc Level 0 through Level 7 = $37,740 - $52,068).

Table 5. Applications Received for Referral by the NCI/DEA in FY2010*†

Sorted by Mechanism

Mechanism	Activity Code	Totals by Activity	Applications by NCAB			Total Costs Requested First Year
			Feb	June	Sept	
Small Research Grants	R03	504	162	184	158	$38,695,611
Conferences	R13	122	51	41	30	$4,625,261
Academic Research Enhancement Awards (AREA)	R15	203	37	89	77	$69,651,592
Exploratory/Developmental Grants	R21	2,771	823	1,010	938	$648,856,660
Resource-Related Research Projects	R24	61	0	0	61	$77,188,064
Education Projects	R25	84	28	44	12	$28,263,787
Exploratory/Developmental Grants Phase II	R33	65	16	24	25	$28,571,277
Method to Extend Research in Time (MERIT) Award	R37	11	5	4	2	$5,270,837
Small Business Technology Transfer (STTR) Grants – Phase I	R41	160	45	54	61	$29,411,465
Small Business Technology Transfer (STTR) Grants – Phase II	R42	41	14	12	15	$19,707,624
Small Business Innovation Research Grants (SBIR) – Phase I	R43	1,066	336	373	357	$202,750,685
Small Business Innovation Research Grants (SBIR) – Phase II	R44	291	83	99	109	$158,959,529
High Priority, Short Term Project Award	R56	15	4	9	2	$ ‡
High Impact Research and Research Infrastructure Programs – Multi-Year Funding	RC4	1	0	1	0	$256,518
Research Enhancement Award	SC1	20	8	8	4	$5,510,117
Pilot Research Project	SC2	18	4	9	5	$2,284,588
Continuing Education Training Program	T15	2	0	2	0	$199,048
Institutional National Research Service Award	T32	78	29	33	16	$26,945,310
NRSA Short-Term Research Training	T35	1	0	1	0	$45,317
Research Project (Cooperative Agreements)	U01	341	36	214	91	$292,035,311
Cooperative Clinical Research (Cooperative Agreements)	U10	51	48	0	3	$104,241,837
Conference (Cooperative Agreement)	U13	2	0	2	0	$100,000
Research Program (Cooperative Agreement)	U19	15	15	0	0	$45,331,984
Resource-Related Research Project (Cooperative Agreements)	U24	25	0	24	1	$21,128,577
Specialized Center (Cooperative Agreements)	U54	114	22	67	25	$237,648,104
Exploratory/Developmental Cooperative Agreement Phase I	UH2	4	0	4	0	$816,240
Overall Totals		**13,935**	**4,259**	**5,259**	**4,417**	**$5,721,721,039**

*Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications and withdrawn applications.

‡Dollar level negotiated at the time of award.

Table 6. Grant and Cooperative Agreement Applications Reviewed by the NCI/DEA in FY2010*

Sorted by Mechanism

Mechanism	Activity Code	Totals by Activity	Applications by NCAB			Total Costs RequestedFirst Year
			Feb	June	Sept	
International Training Grants in Epidemiology (FIC)	D43	20	0	20	0	$10,565,861
Research Scientist Development Award – Research and Training	K01	28	12	10	6	$3,758,982
Research Scientist Award	K05	9	3	3	3	$1,338,865
Academic/Teacher Award	K07	69	23	24	22	$10,130,125
Clinical Investigator Award	K08	76	23	25	28	$11,947,314
Physician Scientist Award (Program)	K12	5	5	0	0	$3,072,992
Career Enhancement Award	K18	1	0	1	0	$116,374
Career Transition Award	K22	41	16	14	11	$8,525,940
Mentored Patient-Oriented Research Development Award	K23	55	23	12	20	$9,323,216
Midcareer Investigator Award in Patient-Oriented Research	K24	7	4	2	1	$1,314,632
Mentored Quantitative Research Career Development	K25	24	15	3	6	$3,214,583
Career Transition Award	K99	164	41	74	49	$18,738,405
Research Program Projects	P01	109	32	39	38	$258,954,802
Exploratory Grants	P20	16	0	0	16	$3,459,417
Center Core Grants	P30	16	6	5	5	$100,466,446
Specialized Center	P50	77	45	26	6	$181,315,123
Research Project	R01	79	5	71	3	$35,638,687
Small Research Grants	R03	351	116	128	107	$27,837,142
Conferences	R13	78	30	29	19	$3,138,462
Exploratory/Developmental Grants	R21	245	57	85	103	$76,409,469
Education Projects	R25	82	26	44	12	$28,263,787
Exploratory/Developmental Grants Phase II	R33	47	10	18	19	$22,989,457
Small Business Innovation Research Grants (SBIR) – Phase II	R44	25	0	0	25	$27,848,253
Continuing Education Training Program	T15	1	0	1	0	$97,705
Institutional National Research Service Award	T32	69	25	31	13	$25,752,900
Research Project (Cooperative Agreements)	U01	261	13	174	74	$216,533,440
Cooperative Clinical Research (Cooperative Agreements)	U10	51	48	0	3	$104,241,837
Conference (Cooperative Agreement)	U13	1	0	1	0	$50,000
Research Program (Cooperative Agreement)	U19	9	9	0	0	$26,641,337
Resource-Related Research Project (Cooperative Agreements)	U24	25	0	24	1	$21,128,577
Specialized Center (Cooperative Agreements)	U54	105	21	64	20	$233,890,911
Overall Totals		**2,146**	**608**	**928**	**610**	**$1,476,705,041**

*Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications and withdrawn applications.

Table 7. Applications Reviewed by NCI IRG Subcommittees and Special Emphasis Panels (SEPs) in FY2010*

NCI IRG Subcommittee	Types of Applications Reviewed	Number of Applications	Total Costs Requested First Year
A - Cancer Centers	P30	15	$93,002,394
F - Manpower and Training	K99, T32	207	$40,624,922
G - Education	K05, K01, K23, K22, K24, K07, K08, R25, K12, K25	96	$24,974,221
H - Clinical Groups	U10, U24	25	$61,469,893
I - Career Development	K08, K22, T15, K25, K18, K01	150	$23,609,820
J - Population and Patient-Oriented Trial	K07, K23	120	$18,453,252
Totals - NCI IRG Subcommittees		613	$262,134,502
Total SEPs	D43, K01, K07, K12, K22, K23, K25, K99, P01, P20, P30, P50, R01, R03, R13, R21, R25, R33, R44, T32, U01, U10, U13, U19, U24, U54, U54	**1,533**	**1,214,570,539**
Total		**2,146**	**$1,476,705,041**

*Source: Office of Referral, Review and Program Coordination. IMPACII. Application count includes Secondary assignments. 18 Withdrawn applications have been subtracted from the total count.

Table 8. Summary of Investigator-Initiated P01 Applications Reviewed, Sorted by NCAB Meeting, in FY2010

Type of Application	Applications by Board			FY 2010 Total
	February 2010	June 2010	September 2010	
New	12	9	19	40
Resubmitted New	4	9	4	17
Renewal	11	10	8	29
Resubmitted Renewal	4	9	5	18
Revisions	1	2	2	5
Total	**32**	**39**	**38**	**109**

*Source: Office of Referral, Review and Program Coordination.

Table 9. Summary of Investigator-Initiated P01 Applications Reviewed, Sorted by NCI Program Division, in FY2010

Program Division	Number of Applications	Total Costs Requested First Year	Total Costs for Requested Period
Center to Reduce Cancer Health Disparities (CRCHD)	1	$722,453	$3,434,076
Division of Cancer Biology (DCB)	24	$43,535,693	$226,188,320
Division of Cancer Control and Population Sciences (DCCPS)	13	$47,160,337	$247,593,931
Division of Cancer Prevention (DCP)	11	$29,427,200	$155,031,262
Division of Cancer Treatment and Diagnosis (DCTD)	60	$138,109,119	$725,946,404
Total	**109**	**$258,954,802**	**$1,358,193,993**

*Source: Office of Referral, Review and Program Coordination.

Table 10. Requests for Applications (RFAs) Reviewed by the NCI/DEA in FY2010*

Title of Initiative	RFA Number	Activity Codes	Applications by NCAB Round				Total Costs Requested First Year
			Totals	Feb	June	Sept	
NIH-Supported Centers for Population Health and Health Disparities (CPHHD)	CA09-001	P50	36	36	0	0	$80,699,865
Transdisciplinary Cancer Genomics Research: Post-Genome Wide Association (Post-GWA) Initiative	CA09-002	U19	9	9	0	0	$26,641,337
Innovative and Applied Emerging Technologies in Biospecimen Science	CA09-004	R21	22	9	13	0	$5,373,421
	CA09-005	R33	4	1	3	0	$1,455,576
Application and Use of Transformative Emerging Technologies in Cancer Research	CA09-006	R21	35	14	21	0	$9,942,446
	CA09-007	R33	24	9	15	0	$11,555,690
Innovative Technology Development for Cancer Research	CA09-008	R21	85	34	51	0	$28,610,080
The Integrative Cancer Biology Program (ICBP): Centers for Cancer Systems Biology (CCSB)	CA09-011	U54	21	21	0	0	$65,724,665
Centers of Cancer Nanotechnology Excellence (CCNEs)	CA09-012	U54	24	0	24	0	$76,024,343
Cancer Nanotechnology Platform Partnerships	CA09-013	U01	50	0	50	0	$30,378,917
Cancer Nanotechnology Training Centers (CNTCs)	CA09-014	R25	24	0	24	0	$10,028,569
Pathway to Independence Award in Cancer Nanotechnology Research	CA09-015	K99	21	0	21	0	$2,507,307
Developing Research Capacity in Africa for Studies on HIV-Associated Malignancies	CA09-016	D43	20	0	20	0	$10,565,861
The Early Detection Research Network: Biomarker Developmental Laboratories	CA09-017	U01	77	0	77	0	$60,527,182
Early Detection Research Network: Clinical Validation Centers	CA09-018	U01	15	0	15	0	$13,903,227
The Early Detection Research Network: Biomarker Reference Laboratories	CA09-019	U24	10	0	10	0	$4,562,280
Early Detection Research Network: Data Management and Coordinating Center and Statistics and Biomarker Resource Center	CA09-020	U24	5	0	5	0	$4,128,644
Community Clinical Oncology Program	CA09-022	U10	21	21	0	0	$38,246,645
Minority-Based Community Clinical Oncology Program	CA09-023	U10	6	6	0	0	$5,057,435
Cancer Intervention and Surveillance Modeling Network (CISNET)	CA09-025	U01	7	0	7	0	$7,933,900
The Biology of Estrogen Receptor-Negative Breast Cancer in Various Racial and Ethnic Groups	CA09-026	U01	20	0	0	20	$12,533,785
Community Networks Program (CNP) Centers for Reducing Cancer Disparities Through Outreach, Research and Training	CA09-032	U54	40	0	40	0	$42,594,019

continued

* Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications. 106 withdrawn applications have been subtracted from the total count.

Table 10. Requests for Applications (RFAs) Reviewed by the NCI/DEA in FY2010*

Title of Initiative	RFA Number	Activity Codes	Applications by NCAB Round				Total Costs Requested First Year
			Totals	Feb	June	Sept	
Limited Competition: Support for Human Specimen Banking in NCI-Supported Clinical Trials – Cooperative Group Banks (CGB)	CA09-504	U24	9	0	9	0	$11,905,517
Innovative and Early-Stage Development of Emerging Technologies in Biospecimen Science	CA10-001	R21	11	0	0	11	$2,614,672
Validation and Advanced Development of Emerging Technologies in Biospecimen Science	CA10-002	R33	1	0	0	1	$480,000
Application and Early Stage Development of Emerging Technologies in Cancer Research	CA10-003	R21	24	0	0	24	$7,111,490
Validation and Advanced Development of Emerging Technologies for Cancer Research	CA10-004	R33	18	0	0	18	$9,498,191
Innovative Technology Development for Cancer Research	CA10-005	R21	67	0	0	67	$22,534,642
Transdisciplinary Research in Energetics and Cancer	CA10-006	U54	16	0	0	16	$37,349,614
Cancer Immunotherapy Trials Network	CA10-007	U01	4	0	0	4	$7,801,909
State and Community Tobacco Control Policy and Media Research	CA10-008	U01	23	0	0	23	$32,249,516
SBIR Phase II Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics Toward Commercialization	CA10-009	R44	25	0	0	25	$27,848,253
Coordination Center for Transdisciplinary Research in Energetics and Cancer (Limited Competition)	CA10-501	U01	1	0	0	1	$1,938,890
AIDS Malignancy Clinical Trials Consortium (Limited Competition)	CA10-502	U01	1	0	0	1	$4,680,000
Comprehensive Partnerships to Reduce Cancer Health Disparities (Limited Competition)	CA10-503	U54	4	0	0	4	$12,198,270
Exceptional, Unconventional Research Enabling Knowledge Acceleration (EUREKA)	GM10-009	R01	69	0	69	0	$21,890,647
Totals			**849**	**160**	**474**	**215**	**$749,096,805**

* Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications. 106 withdrawn applications have been subtracted from the total count.

Table 11. Program Announcements (PAs) Reviewed by the NCI/DEA in FY2010*

Title of Initiative	RFA Number	Activity Codes	Applications by NCAB Round				Total Costs Requested First Year
			Totals	Feb	June	Sept	
Research Project Grant (Parent)	PA07-070 PA10-067	R01	9	5	2	2	$12,786,571
NIH Support for Conferences and Scientific Meetings (Parent)	PA08-149 PA10-071	R13	77	30	29	18	$3,088,500
		U13	1	0	1	0	$50,000
Pilot studies in Pancreatic Cancer (R21)	PA08-208	R21	1	0	0	1	$222,718
Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants	PA08-226 PA10-036	T32	63	21	29	13	$22,380,626
NIH Pathway to Independence Award (Parent)	PA09-036 PA10-063	K99	143	41	53	49	$16,231,098
Midcareer Investigator Award in Patient-Oriented Research (Parent)	PA09-037 PA10-061	K24	7	4	2	1	$1,314,632
Mentored Quantitative Research Development Award (Parent)	PA09-039 PA10-062	K25	24	15	3	6	$3,214,583
Mentored Clinical Scientist Research Career Development Award (Parent)	PA09-042 PA10-059	K08	72	19	25	28	$11,282,906
Mentored Patient-Oriented Research Career Development Award (Parent)	PA09-043 PA10-060	K23	49	22	9	18	$8,354,526
Career Enhancement Award for Stem Cell Research	PA09-110	K18	1	0	1	0	$116,374
Mechanisms, Models, Measurement, and Management in Pain Research	PA10-006	R01	1	0	0	1	$961,469
Scientific Meetings for Creating Interdisciplinary Research Teams	PA10-106	R13	1	0	0	1	$49,962
Paul Calabresi Career Development Award for Clinical Oncology	PAR06-449	K12	5	5	0	0	$3,072,992
National Cancer Institute (NCI) Cancer Education and Career Development Program	PAR06-511	R25	9	6	3	0	$3,892,013
Specialized Programs of Research Excellence (SPOREs) in Human Cancer for the Year 2008 and 2009	PAR08-020	P50	28	9	19	0	$71,732,663
Cancer Prevention Research Small Grant Program	PAR08-055	R03	122	42	45	35	$9,687,765
Cancer Education Grants Program	PAR08-120	R25	49	20	17	12	$14,343,205
Quantitative Imaging for Evaluation of Responses to Cancer Therapies	PAR08-225	U01	31	11	9	11	$22,423,237
Small Grants Program for Cancer Epidemiology	PAR08-237	R03	137	41	49	47	$10,929,105
		U01	1	0	1	0	$75,250
Small Grants for Behavioral Research in Cancer Control	PAR09-003	R03	92	33	34	25	$7,220,272

continued

*Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications. 45 withdrawn applications have been subtracted from the total count.

Table 11. Program Announcements (PAs) Reviewed by the NCI/DEA in FY2010*

Title of Initiative	RFA Number	Activity Codes	Applications by NCAB Round				Total Costs Requested First Year
			Totals	Feb	June	Sept	
National Cancer Institute Program Project Applications	PAR09-025	P01	99	28	37	34	$256,278,779
Collaborative Research in Integrative Cancer Biology and the Tumor Microenvironment	PAR09-026	U01	27	0	15	0	$18,116,803
NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity	PAR09-050	K08	4	4	0	0	$664,408
NCI Mentored Patient-Oriented Research Career Development Award to Promote Diversity	PAR09-051	K23	6	1	3	2	$968,690
NCI Mentored Research Scientist Development Award to Promote Diversity	PAR09-052	K01	28	12	10	6	$3,758,982
NCI Transition Career Development Award to Promote Diversity	PAR09-069	K22	16	5	6	5	$2,935,929
Cancer Prevention, Control, Behavioral, and Population Sciences Career Development Award	PAR09-078	K07	69	23	24	22	$10,130,125
Established Investigator Award in Cancer Prevention and Control	PAR09-088	K05	9	3	3	3	$1,338,865
The NCI Transition Career Development Award	PAR09-089	K22	25	11	8	6	$5,590,011
Etiology, Prevention, and Treatment of Hepatocellular Carcinoma	PAR09-147	P01	1	0	0	1	$3,205,702
In vivo Cellular and Molecular Imaging Centers (ICMICs)	PAR09-157	P50	7	0	7	0	$13,893,641
Feasibility Studies for Collaborative Interaction for Minority Institution/Cancer Center Partnership	PAR09-201	P20	16	0	0	16	$3,459,417
Specialized Programs of Research Excellence (SPOREs) in Human Cancer for Years 2010, 2011, and 2012	PAR10-003	P50	6	0	0	6	$14,985,193
Totals			**1,236**	**411**	**444**	**381**	**$558,757,012**

* Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications. 45 withdrawn applications have been subtracted from the total count.

Table 12. Requests for Proposals (RFPs) Reviewed by the NCI/DEA in FY2010*

Announcement/ Topic Number	Announcement Title	Workload Round	No. of Proposals
Topic 229 (Phase II)	Development of Molecular Pharmacodynamic Assays for Targeted Therapies	Jan-10	1
Topic 249 (Phase II)	System to Analyze and Support Biomarker R&D Strategies	Jan-10	1
Topic 251 (Phase II)	Development of Anticancer Agents	Jan-10	1
N01-PC-95001-20	SEER R&D Contracts	Jan-10	15
Topic 255	Development of Anticancer Agents	Jun-10	41
Topic 275	Development of Generic Antibodies for the Treatment of Cancer	Jun-10	7
Topic 278	Data Harmonization and Advanced Computation of Population Health Data	Jun-10	2
Topic 279	Facilitating the Transfer of Statistical Methodology Into Practice	Jun-10	2
Topic 288 (FT) (Phase I: 7) (Phase I & II: 1)	Development of Alternative Affinity Capture Reagents for Cancer Proteomics Research	Jun-10	9
Topic 257	Biopsy Instruments and Devices That Preserve Molecular Profiles in Tumors	Jun-10	2
Topic 284	Alternative Biospecimen Stabilization and Storage Solutions	Jun-10	4
Topic 272 (FT) (Phase I: 18) (Phase I & II: 1)	Point of Care Analysis of Circulating Tumor Cells for Cancer Diagnostics, Prognosis, and Treatment	Jun-10	20
Topic 258	Innovative Devices to Protect Radiosensitive Organs and Structures During Radiation Therapy	Jun-10	3
Topic 271 (FT) (Phase I: 4) (Phase I & II: 1)	Development of Molecular Pharmacodynamic Assays for Targeted Therapies	Jun-10	6
Topic 273	Process Analytic Technologies (PAT) for Biologics: Innovative Methods for Monitoring and Analyzing Product Quality and Safety During Manufacture of Cancer Therapeutics	Jun-10	4
Topic 274 (FT) (Phase I: 3) (Phase I & II: 1)	Quantitative Cell-Based Imaging for Clinical Diagnosis and Treatment	Jun-10	5
Topic 276	Development of Novel Medicinal Food Products for the Mitigation of the Side-Effects of Cancer Chemotherapy	Jun-10	3
Topic 277	Companion Diagnostics: Predictive and Prognostic Tests Enabling Personalized Medicine in Cancer Therapy	Jun-10	11
Topic 283	Development of a Molecular Diagnostic Assay to Detect Basal-Like Breast Cancer	Jun-10	5
Topic 280	Direct Sequencing of Nucleic Acids Without Clonal Amplification or Synthesis for the Molecular Characterization of Cancer	Jun-10	3

continued

* NCI reviewed a total of 623 proposals. The proposals were in response to SBIR Contract Solicitations – Phase I (167) and Fast Track Phase I/II (12), Phase II (20), RFP (38), and Loan Repayment (386).
Source: Office of Referral, Review and Program Coordination.

Table 12. Requests for Proposals (RFPs) Reviewed by the NCI/DEA in FY2010*

Announcement/ Topic Number	Announcement Title	Workload Round	No. of Proposals
Topic 290	siRNA Resource for Synthetic Lethal Screening of DNA Repair and Damage Signaling Networks	Jun-10	2
Topic 281 (FT) (Phase I: 15) (Phase I & II: 2)	Biosensors for Early Cancer Detection and Risk Assessment	Jun-10	19
Topic 285	Multifunctional Therapeutics and Theranostics Based on Nanotechnology	Jun-10	18
Topic 286	Nanotechnology Imaging Agents or Devices for Improved Detection of Cancer	Jun-10	4
Topic 287	Nanotechnology Sensing Platforms for Improved Cancer Detection	Jun-10	9
Topic 247 (Phase II)	Portable e-Technology Diet and Physical Activity Tools for Consumers	Jun-10	2
Topic 245 (Phase II)	Assay Systems for Drug Efficacy in Cancer Stem Cells	Jun-10	1
Topic 229 (Phase II)	Development of Molecular Pharmacodynamic Assays for Targeted Therapies	Jun-10	3
N01-CM-07011-68	Preclinical Toxicology Study of Drugs Developed for Cancer and Other Diseases	Oct-10	9
N01-CM-07014-39	Preclinical Pharmacokinetic and Pharmacological Studies With Anticancer and Other Therapeutic Agents	Oct-10	14
Topic 241 Phase II	Multifunctional Therapeutics Based on Nanotechnology	Oct-10	2
Topic 246 Phase II	Integrating Patient-Reported Outcomes in Hospice and Palliative Care Practices	Oct-10	3
Topic 236 Phase II	Antibody Array for Cancer	Oct-10	1
Topic 266 Phase II	Nanotechnology Imaging and Sensing Platforms for Improved Diagnosis of Cancer	Oct-10	1
Topic 251 Phase II	Development of Anticancer Agents	Oct-10	1
Topic 252 Phase II	Nanotechnology Imaging and Sensing Platforms for Improved Diagnosis of Cancer	Oct-10	3
OD09-109	Loan Repayment		76
OD09-108	Loan Repayment		310
Total			**623**

*NCI reviewed a total of 623 proposals. The proposals were in response to SBIR Contract Solicitations - Phase I (167) and Fast Track Phase I/II (12), Phase II (20), RFP (38), and Loan Repayment (386).
Source: Office of Referral, Review and Program Coordination.

Table 13. Summary of NCI Grant Awards by Mechanism in FY2010*†

Mechanism	Award Count	Award Dollars	Avg. Cost	% of NCI Total Grants		Competing Requested	Competing Awarded	Success Rate
				Number	Dollars			
Research Project Grants (RPG)								
Traditional Research Grants – R01/ RL1	3,654	1,323,672,506	362,253	55.8 %	40.2 %	4,234	823	19.4 %
Program Projects – P01	140	280,531,316	2,003,795	2.1 %	8.5 %	107	26	24.3 %
Small Grants – R03	181	14,194,636	78,423	2.8 %	0.4 %	397	51	12.8 %
Exploratory/Developmental Research – R21	415	83,950,394	202,290	6.3 %	2.6 %	1,847	204	11.0 %
Phased Innovation Grant (Phase 2) – R33	16	5,582,998	348,937	0.2 %	0.2 %	10	1	10.0 %
Bridge Award – R56	0	8,343	8,343	0.0 %	0.0 %	0	0	0.0 %
Pathway to Independence – R00	55	13,664,732	248,450	0.8 %	0.4 %	0	0	0.0 %
Exploratory/Development Cooperative Agreements – UH2/UH3	0	0	0	0.0 %	0.0 %	4	0	0.0 %
Merit Awards – R37	61	31,497,479	516,352	0.9 %	1.0 %	11	11	100.0 %
NIH Director Pioneer Award (NDPA) – DP1	5	6,020,750	1,204,150	0.1 %	0.2 %	0	0	0.0 %
NIH Director New Innovator Awards – DP2	1	2,512,500	2,512,500	0.0 %	0.1 %	1	1	100.0 %
Academic Research Enhancement Awards (AREA) – R15	24	7,539,489	314,145	0.4 %	0.2 %	120	24	20.0 %
Request for Applications	143	49,694,791	347,516	2.2 %	1.5 %	324	42	13.0 %
Cooperative Agreements – RFA-U01/U19	132	150,728,848	1,141,885	2.0 %	4.6 %	192	53	27.6 %
Cooperative Agreements – U01/U19	44	37,461,190	851,391	0.7 %	1.1 %	91	17	18.7 %
Small Business Innovation Research	180	74,032,215	411,290	2.7 %	2.3 %	937	118	12.6 %
Small Business Technology Transfer – R41/R42	27	11,637,000	431,000	0.4 %	0.4 %	136	16	11.8 %
Program Evaluation – R01	0	75,329,000	75,329,000	0.0 %	2.3 %	0	0	0.0 %
Subtotal, RPG	**5,079**	**2,168,058,187**	**426,951**	**77.4 %**	**66.0 %**	**8,411**	**1,387**	**16.5 %**
Other Research								
Cooperative Conference Grants – U13	1	17,500	17,500	0.0 %	0.0 %	1	1	100.0 %
Conference Grants – D43/R13	95	7,245,563	76,269	1.5 %	0.2 %	74	63	85.1 %
Training Conference Grants – T15/RL9	6	684,718	114,120	0.1 %	0.0 %	1	1	100.0 %
Cancer Education Awards – R25	91	35,444,448	389,499	1.4 %	1.1 %	88	23	26.1 %
Research/Resource Grant – R24/U24	43	67,143,270	1,561,471	0.7 %	2.0 %	27	4	14.8 %
Research Enhancement Award – SC1	3	1,017,368	339,123	0.0 %	0.0 %	1	1	100.0 %
Pilot Research Project – SC2	3	331,072	110,357	0.0 %	0.0 %	1	0	0.0 %
Clinical Cooperative Groups	131	248,690,814	1,898,403	2.0 %	7.6 %	67	53	79.1 %
Clinical Cooperative Groups – CCCT	0	5,796,369	5,796,369	0.0 %	0.2 %	0	0	0.0 %

continued

* A grant award count of zero showing a dollar amount represents either administrative supplements to existing grants, which are not factored into the grant count but are factored into the average cost of an award, or co-funded grants, which are not factored into the grant count for the NCI but are factored into the average cost of an award.

† Courtesy of the Office of Extramural Finance and Information Analysis.

Table 13. Summary of NCI Grant Awards by Mechanism in FY2010*†

Mechanism	Award Count	Award Dollars	Avg. Cost	% of NCI Total Grants		Competing Requested	Competing Awarded	Success Rate
				Number	Dollars			
Minority Biomedical Research Support – S06	0	466,056	466,056	0.0 %	0.0 %	0	0	0.0 %
Exploratory Grants – Cooperative Agreement (NCI) – U56	2	861,734	430,867	0.0 %	0.0 %	0	0	0.0 %
Subtotal, Other Research	**375**	**367,698,912**	**980,530**	**5.7 %**	**11.1 %**	**260**	**146**	**56.2 %**
Centers								
Core	78	284,372,284	3,645,799	1.2 %	8.6 %	29	19	65.5 %
Core – CCCT	0	6,351,601	6,351,601	0.0 %	0.2 %	0	0	0.0 %
Center for AIDS Research (CFAR) – OHAM – P30	0	5,132,279	5,132,279	0.0 %	0.2 %	0	0	0.0 %
Spore Grants	64	133,809,992	2,090,781	1.0 %	4.1 %	39	9	23.1 %
Other P50/P20	21	38,764,973	1,845,951	0.3 %	1.2 %	32	7	21.9 %
Specialized Center (Cooperative Agreement)	102	142,702,148	1,399,041	1.6 %	4.3 %	106	47	44.3 %
Subtotal, Centers	**265**	**611,133,277**	**2,306,163**	**4.1 %**	**18.6 %**	**206**	**82**	**39.8 %**
National Research Service Awards (NRSA)								
NRSA Institutional Award	168	58,294,400	346,990	2.6 %	1.8 %	75	31	41.3 %
NRSA Fellowships	211	9,270,137	43,934	3.2 %	0.3 %	348	89	25.6 %
Subtotal, NSRA	**379**	**67,564,537**	**178,271**	**5.8 %**	**2.1 %**	**423**	**120**	**28.4 %**
Careers								
Career Enhancement Award for Stem Cell Research	0	0	0	0.0 %	0.0 %	1	0	0.0 %
Mentored Clinical Scientist – K08	83	12,407,403	149,487	1.3 %	0.4 %	71	22	31.0 %
Preventive Oncology Award – K07	97	13,277,602	136,882	1.5 %	0.4 %	63	13	20.6 %
Mentored Career Award – K12	18	12,921,961	717,887	0.3 %	0.4 %	4	2	50.0 %
Temin Award – K01/KL1	77	10,823,198	140,561	1.2 %	0.3 %	24	8	33.3 %
Clinical Research Track – K22	30	4,963,203	165,440	0.5 %	0.2 %	39	10	25.6 %
Mentored Patient-Oriented Research Career Development Award – K23	40	5,812,090	145,302	0.6 %	0.2 %	35	5	14.3 %
Mid-Career Investigator in Patient-Oriented Research Award – K24	20	3,421,684	171,084	0.3 %	0.1 %	8	5	62.5 %
Mentored Quantitative Research Career Development Award – K25	25	3,311,271	132,451	0.4 %	0.1 %	21	4	19.0 %
Established Investigator Award in Cancer Prevention & Control – K05	21	3,134,227	149,249	0.3 %	0.1 %	7	3	42.9 %
Pathway to Independence – K99	41	4,841,663	118,089	0.6 %	0.1 %	127	28	22.0 %
Subtotal, Careers	**452**	**74,914,302**	**165,740**	**7.0 %**	**2.3 %**	**400**	**100**	**25.0 %**
Total	**6,549**	**3,289,369,215**	**502,270**	**100.0 %**	**100.0%**	**9,700**	**1,835**	**18.9%**

* A grant award count of zero showing a dollar amount represents either administrative supplements to existing grants, which are not factored into the grant count but are factored into the average cost of an award, or co-funded grants, which are not factored into the grant count for the NCI but are factored into the average cost of an award.

† Courtesy of the Office of Extramural Finance and Information Analysis.

Table 14. Average Total Cost*† and Number of Research Project Grant Awards Sorted by Division, Office, Center, and Mechanism From FY2006 - FY2010‡

	FY 2006		FY 2007		FY 2008		FY 2009		FY 2010		Percent Change 2006 - 2010	
	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost
R01 Average Cost of Award												
NCI Overall	3,909	331	3,849	329	3,732	335	3,573	350	3,655	362	-6.5%	9.37%
DCB	2,132	300	2,050	294	1,923	298	1,792	308	1,783	313	-16.4%	4.3%
DCP	225	394	231	392	247	368	246	388	261	399	16.0%	1.1%
DCTD	1,087	312	1,083	308	1,055	317	1,042	327	1,107	336	1.8%	7.8%
DCCPS	459	464	478	474	490	484	478	515	486	561	5.9%	20.8%
OD (CRCHD, OCC, CSSI, CCT, OHAM, etc.)	6	2,148	7	1,751	17	917	15	977	18	911	200.0%	-57.6%
P01 Average Cost of Award												
NCI Overall	173	1,963	172	1,901	158	1,932	151	2,002	140	2,004	-19.08%	2.09%
DCB	70	1,677	65	1,584	58	1,675	60	1,729	56	1,783	-20.0%	6.4%
DCP	12	2,133	13	2,047	11	1,916	9	1,931	7	1,737	-41.7%	-18.6%
DCTD	82	2,148	84	2,067	77	2,069	69	2,215	64	2,188	-22.0%	1.8%
DCCPS	8	2,270	9	2,367	11	2,306	12	2,174	12	2,161	50.0%	-4.8%
OD (CRCHD, OCC, CSSI, CCT, OHAM, etc.)	1	2,349	1	2,442	1	2,397	1	2,220	1	2,576	0.0%	9.7%
R03 Average Cost of Award												
NCI Overall	218	76	284	76	256	77	239	77	181	78	-16.97%	2.63%
DCB	3	78	5	73	9	75	15	76	8	78	166.7%	0.3%
DCP	96	76	122	77	107	78	91	78	56	78	-41.7%	3.3%
DCTD	3	95	8	78	9	73	12	76	10	77	233.3%	-18.7%
DCCPS	116	75	149	76	131	75	119	77	107	79	-7.8%	4.1%
OD (CRCHD, OCC, CSSI, CCT, OHAM, etc.)	0	0	0	0	0	47*	2	47	0	0	0.0%	0.0%
R21 Average Cost of Award												
NCI Overall	405	174	437	180	466	198	447	205	415	202	2.47%	16.09%
DCB	59	145	64	161	74	183	75	193	77	188	30.5%	29.7%
DCP	47	166	48	163	55	169	50	174	50	187	6.4%	12.7%
DCTD	228	191	250	194	248	214	236	218	198	218	-13.2%	14.2%
DCCPS	70	150	75	158	87	180	85	195	82	185	17.1%	23.2%
OD (CRCHD, OCC, CSSI, CCT, OHAM, etc.)	1	239	0	160*	2	230	1	204	8	217	700.0%	-9.4%

continued

*A grant award count of zero showing a dollar amount represents either administrative supplements to existing grants, which are not factored into the grant count but are factored into the average cost of an award, or co-funded grants, which are not factored into the grant count for the NCI but are factored into the average cost of an award.

†In thousands.

‡Courtesy of the Office of Extramural Finance and Information Analysis.

Table 14. Average Total Cost*† and Number of Research Project Grant Awards Sorted by Division, Office, Center, and Mechanism From FY2006 - FY2010‡

	FY 2006		FY 2007		FY 2008		FY 2009		FY 2010		Percent Change 2006 - 2010	
	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost
U01/U19 Average Cost of Award												
NCI Overall	146	1,040	145	1,010	125	906	110	1,035	131	1,091	-10.27%	4.9%
DCB	26	840	26	850	23	870	28	776	28	776	7.7%	-7.7%
DCP	9	696	15	469	9	402	7	366	35	741	288.9%	6.6%
DCTD	65	1,251	61	1,293	56	1,051	39	1,417	28	1,461	-56.9%	16.7%
DCCPS	45	921	43	886	32	564	32	678	23	1,598	-48.9%	73.6%
OD (CRCHD, OCC, CSSI, CCT, OHAM, etc.)	1	951	0	307*	5	2,534	4	3,159	17	1,039	1,600.0%	9.3%
R13 Average Cost of Award												
NCI Overall	85	16	81	15	92	34	80	36	95	76	11.76%	375.0%
DCB	43	8	42	8	40	9	33	10	36	9	-16.3%	10.8%
DCP	10	11	8	18	4	12	8	15	8	12	-20.0%	5.3%
DCTD	14	7	16	12	24	11	19	13	19	12	35.7%	62.1%
DCCPS	13	42	10	29	11	30	14	24	17	20	30.8%	-51.5%
OD (CRCHD, OCC, CSSI, CCT, OHAM, etc.)	5	57	5	52	13	162	6	307	15	418	200.0%	636.6%
U10 Average Cost of Award												
NCI Overall	123	1,912	138	1,728	133	1,773	134	1,750	131	1,937	6.5%	1.31%
DCP	60	1,485	72	1,250	72	1,275	73	1,254	71	1,330	18.3%	-10.4%
DCTD	63	2,316	66	2,246	61	2,360	61	2,344	60	2,655	-4.8%	14.6%
OD (CRCHD, OCC, CSSI, CCT, OHAM, etc.)	0	110	0	147	0	0	0	0	0	0	0.0%	-100.0%
P30 Average Cost of Award												
NCI Overall	63	4,098	63	4,229	64	4,217	65	4,337	66	4,446	4.76%	8.49%
DCP	2	823	0	0	0	0	0	0	0	0	-100.0%	-100.0%
DCTD	0	4,106*	0	5,215*	0	0	0	0	0	0	0.0%	-100.0%
DCCPS	0	250*	0	319*	0	0	0	0	0	0	0.0%	-100.0%
OD (CRCHD, OCC, CSSI, CCT, OHAM, etc.)	61	4,134	63	4,141	64	4,217	65	4,337	66	4,446	8.2%	7.5%

continued

*A grant award count of zero showing a dollar amount represents either administrative supplements to existing grants, which are not factored into the grant count but are factored into the average cost of an award, or co-funded grants, which are not factored into the grant count for the NCI but are factored into the average cost of an award.

†In thousands.

‡Courtesy of the Office of Extramural Finance and Information Analysis.

Table 14. Average Total Cost*† and Number of Research Project Grant Awards Sorted by Division, Office, Center, and Mechanism From FY2006 - FY2010‡

	FY 2006		FY 2007		FY 2008		FY 2009		FY 2010		Percent Change 2006 - 2010	
	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost
P50 Average Cost of Award												
NCI Overall	75	2,138	80	1,957	60	2,055	71	1,967	75	2,081	0.0%	-2.67%
DCP	0	0	0	0	0	0	0	0	0	400*	0.0%	100.0%
DCTD	8	1,974	9	1,591	60	2,051	64	2,025	65	2,101	712.5%	6.5%
DCCPS	12	1,830	12	1,746	0	0	7	1,334	10	1,847	-16.7%	0.9%
OD (CRCHD, OCC, CSSI, CCT, OHAM, etc.)	55	2,229	59	2,056	0	262*	0	766*	0	617*	-100.0%	-72.3%
SBIR Average Cost of Award												
NCI Overall	225	379	231	356	274	314	219	367	180	411	-20.0%	8.44%
CRCHD	0	0	0	0	0	0	0	0	0	85*	0.0%	100.0%
CSSI	1	250	1	250	0	0	0	0	0	0	-100.0%	-100.0%
DCB	26	347	33	284	23	268	0	0	0	0	-100.0%	-100.0%
DCP	22	231	14	341	16	318	0	0	0	0	-100.0%	-100.0%
DCTD	153	409	163	378	165	342	4	318	0	0	-100.0%	-100.0%
DCCPS	23	361	20	314	13	326	0	0	0	0	-100.0%	-100.0%
SBIRDC	0	0	0	0	57	251	215	368	180	411	100.0%	100.0%
STTR Average Cost of Award												
NCI Overall	39	286	47	242	38	297	42	277	27	431	-30.77%	50.7%
DCB	2	490	2	292	3	189	0	0	0	0	-100.0%	-100.0%
DCP	3	453	3	300	3	325	0	0	0	0	-100.0%	-100.0%
DCTD	33	264	41	238	27	297	1	138	0	0	-100.0%	-100.0%
DCCPS	1	119	1	107	2	301	0	0	0	0	-100.0%	-100.0%
SBIRDC	0	0	0	0	3	368	41	280	27	431	100.0%	100.0%
U54 Average Cost of Award												
NCI Overall	27	2,222	42	1,778	44	1,802	56	1,939	93	1,453	244.44%	-34.61%
CRCHD	0	0	15	961	17	1,161	21	1,274	51	1,066	100.0%	100.0%
CSSI	8	3,655	8	3,635	8	3,683	16	3,311	18	2,776	125.0%	-24.0%
DCB	15	1,426	15	1,483	15	1,407	15	1,327	20	1,492	33.3%	4.6%
DCCPS	4	2,339	4	2,236	4	2,242	4	2,238	4	230	0.0%	-90.2%

*A grant award count of zero showing a dollar amount represents either administrative supplements to existing grants, which are not factored into the grant count but are factored into the average cost of an award, or co-funded grants, which are not factored into the grant count for the NCI but are factored into the average cost of an award.

†In thousands.

‡Courtesy of the Office of Extramural Finance and Information Analysis.

Table 15. NCI Organ and Related Site-Specific Dollars for FY2006 - FY2010 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2006	2007	2008	2009	2010	Average Percent Change/yr.
Adrenal	***Number of Grants***	***16***	***14***	***9***	***7***	***9***	
	Relevant Grant Dollars	2,104,429	1,795,342	490,757	443,049	908,434	
	Total Count	***16***	***14***	***9***	***7***	***9***	
	Total Relevant Dollars	2,104,429	1,795,342	490,757	443,049	908,434	**1.99**
Anus	***Number of Grants***	***24***	***16***	***13***	***17***	***14***	
	Relevant Grant Dollars	1,559,451	1,605,089	1,717,104	2,585,470	1,996,111	
	Number of Contracts	***5***	***5***	***5***	***5***	‡	
	Relevant Contract Dollars	627,144	794,336	744,588	778,300	‡	
	Total Count	***29***	***21***	***18***	***22***	***14***	
	Total Relevant Dollars	2,186,595	2,399,425	2,461,692	3,363,770	1,996,111	**2.08**
Bladder	***Number of Grants***	***318***	***261***	***230***	***219***	***208***	
	Relevant Grant Dollars	19,435,786	17,496,016	20,612,527	20,834,546	18,941,518	
	Number of Contracts	***19***	***18***	***17***	***16***	***3***	
	Relevant Contract Dollars	1,122,764	580,571	417,443	340,792	25,113	
	Total Count	***337***	***279***	***247***	***235***	***211***	
	Total Relevant Dollars	20,558,550	18,076,587	21,029,970	21,175,338	18,966,631	**-1.37**
Bone Marrow	***Number of Grants***	***215***	***138***	***101***	***75***	***92***	
	Relevant Grant Dollars	24,097,113	23,646,795	15,453,422	16,586,714	13,124,422	
	Total Count	***215***	***138***	***101***	***75***	***92***	
	Total Relevant Dollars	24,097,113	23,646,795	15,453,422	16,586,714	13,124,422	**-12.51**
Bone, Cartilage	***Number of Grants***	***207***	***131***	***110***	***84***	***98***	
	Relevant Grant Dollars	22,491,041	20,571,396	16,585,539	16,835,159	18,014,359	
	Number of Contracts	***1***	***1***	***1***	‡	‡	
	Relevant Contract Dollars	9,735	10,124	10,529	‡	‡	
	Total Count	***208***	***132***	***111***	***84***	***98***	
	Total Relevant Dollars	22,500,776	20,581,520	16,596,068	16,835,159	18,014,359	**-4.86**
Brain	***Number of Grants***	***580***	***534***	***536***	***464***	***498***	
	Relevant Grant Dollars	108,386,416	118,668,961	121,777,889	125,530,253	131,178,363	
	Number of Contracts	***15***	***15***	***15***	***14***	***3***	
	Relevant Contract Dollars	472,730	322,417	436,218	215,004	217,734	
	Total Count	***595***	***549***	***551***	***478***	***501***	
	Total Relevant Dollars	108,859,146	118,991,378	122,214,107	125,745,257	131,396,097	**4.85**
Breast	***Number of Grants***	***2,064***	***2,041***	***1,999***	***1,958***	***1,934***	
	Relevant Grant Dollars	538,017,526	532,031,369	517,943,650	542,409,702	569,062,367	
	Number of Contracts	***43***	***44***	***44***	***36***	***32***	
	Relevant Contract Dollars	10,196,441	8,013,038	6,480,995	7,420,959	7,908,595	
	Total Count	***2,107***	***2,085***	***2,043***	***1,994***	***1,966***	
	Total Relevant Dollars	548,213,967	540,044,407	524,424,645	549,830,661	576,970,962	**1.35**
Central Nervous System	***Number of Grants***	***177***	***82***	***70***	***42***	***43***	
	Relevant Grant Dollars	14,749,010	12,808,969	8,892,769	5,765,488	6,255,071	
	Number of Contracts	***1***	***1***	***1***	***1***	‡	
	Relevant Contract Dollars	60,000	150,000	450,000	374,998	‡	
	Total Count	***178***	***83***	***71***	***43***	***43***	
	Total Relevant Dollars	14,809,010	12,958,969	9,342,769	6,140,486	6,255,071	**-18.20**

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 15. NCI Organ and Related Site-Specific Dollars for FY2006 - FY2010 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2006	2007	2008	2009	2010	Average Percent Change/yr.
Cervix	***Number of Grants***	***412***	***343***	***321***	***298***	***298***	
	Relevant Grant Dollars	72,279,783	68,615,877	57,532,246	51,605,675	61,579,940	
	Number of Contracts	***26***	***23***	***23***	***23***	***5***	
	Relevant Contract Dollars	3,858,553	6,467,605	5,783,915	7,479,618	4,759,619	
	Total Count	***438***	***366***	***344***	***321***	***303***	
	Total Relevant Dollars	76,138,336	75,083,482	63,316,161	59,085,293	66,339,559	**-2.87**
Childhood Leukemia	***Number of Grants***	***155***	***125***	***131***	***123***	***148***	
	Relevant Grant Dollars	40,590,854	40,753,571	43,226,882	42,335,965	49,924,922	
	Total Count	***155***	***125***	***131***	***123***	***148***	
	Total Relevant Dollars	40,590,854	40,753,571	43,226,882	42,335,965	49,924,922	**5.58**
Colon, Rectum	***Number of Grants***	***1,087***	***1,037***	***1,011***	***963***	***984***	
	Relevant Grant Dollars	226,041,459	241,436,522	242,315,525	237,991,020	245,295,756	
	Number of Contracts	***47***	***44***	***46***	***38***	***16***	
	Relevant Contract Dollars	12,231,181	8,736,401	8,206,006	7,934,699	6,412,331	
	Total Count	***1,134***	***1,081***	***1,057***	***1,001***	***1,000***	
	Total Relevant Dollars	238,272,640	250,172,923	250,521,531	245,925,719	251,708,087	**1.41**
Connective Tissue	***Number of Grants***	***111***	***83***	***70***	***55***	***51***	
	Relevant Grant Dollars	12,116,869	10,865,081	12,574,363	10,709,782	10,417,011	
	Total Count	***111***	***83***	***70***	***55***	***51***	
	Total Relevant Dollars	12,116,869	10,865,081	12,574,363	10,709,782	10,417,011	**-3.04**
Embryonic Tissue, Cells	***Number of Grants***	***30***	***20***	***9***	***6***	***10***	
	Relevant Grant Dollars	4,380,318	3,170,012	1,779,062	694,792	1,477,847	
	Total Count	***30***	***20***	***9***	***6***	***10***	
	Total Relevant Dollars	4,380,318	3,170,012	1,779,062	694,792	1,477,847	**-4.94**
Esophagus	***Number of Grants***	***245***	***155***	***133***	***129***	***100***	
	Relevant Grant Dollars	19,401,168	20,497,757	18,768,511	24,435,190	25,599,073	
	Number of Contracts	***3***	***3***	***3***	‡	‡	
	Relevant Contract Dollars	265,420	349,150	258,939	‡	‡	
	Total Count	***248***	***158***	***136***	***129***	***100***	
	Total Relevant Dollars	19,666,588	20,846,907	19,027,450	24,435,190	25,599,073	**7.61**
Eye	***Number of Grants***	***22***	***17***	***13***	***11***	***13***	
	Relevant Grant Dollars	1,761,592	2,134,820	1,850,716	1,910,869	2,168,685	
	Total Count	***22***	***17***	***13***	***11***	***13***	
	Total Relevant Dollars	1,761,592	2,134,820	1,850,716	1,910,869	2,168,685	**6.16**
Gall Bladder	***Number of Grants***	***79***	***9***	***3***	***4***	***1***	
	Relevant Grant Dollars	1,216,340	997,955	462,516	372,129	212,356	
	Total Count	***79***	***9***	***3***	***4***	***1***	
	Total Relevant Dollars	1,216,340	997,955	462,516	372,129	212,356	**-33.52**
Gastrointestinal Tract	***Number of Grants***	***189***	***86***	***68***	***62***	***51***	
	Relevant Grant Dollars	17,561,561	13,865,217	9,411,464	9,143,226	8,649,596	
	Number of Contracts	***3***	***4***	‡	‡	‡	
	Relevant Contract Dollars	515,957	176,140	‡	‡	‡	
	Total Count	***192***	***90***	***68***	***62***	***51***	
	Total Relevant Dollars	18,077,518	14,041,357	9,411,464	9,143,226	8,649,596	**-15.89**

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.

Table 15. NCI Organ and Related Site-Specific Dollars for FY2006 - FY2010 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2006	2007	2008	2009	2010	Average Percent Change/yr.
Genital System, Female	***Number of Grants***	***93***	***32***	***15***	***9***	***12***	
	Relevant Grant Dollars	2,206,848	1,885,968	1,408,356	578,518	1,255,368	
	Number of Contracts	***5***	***5***	***5***	***5***	***5***	
	Relevant Contract Dollars	718,073	735,936	651,232	666,439	336,493	
	Total Count	***98***	***37***	***20***	***14***	***17***	
	Total Relevant Dollars	2,924,921	2,621,904	2,059,588	1,244,957	1,591,861	**-10.87**
Genital System, Male	***Number of Grants***	***14***	***10***	***7***	***6***	***6***	
	Relevant Grant Dollars	1,385,219	1,329,596	1,304,477	1,466,575	549,031	
	Number of Contracts	***6***	***6***	***5***	***5***	***5***	
	Relevant Contract Dollars	948,230	745,318	651,232	666,439	336,493	
	Total Count	***20***	***16***	***12***	***11***	***11***	
	Total Relevant Dollars	2,333,449	2,074,914	1,955,709	2,133,014	885,524	**-16.56**
Head and Neck	***Number of Grants***	***339***	***241***	***234***	***214***	***204***	
	Relevant Grant Dollars	41,903,847	37,004,472	42,337,050	41,932,591	41,468,691	
	Number of Contracts	***4***	***4***	***4***	***5***	***7***	
	Relevant Contract Dollars	2,184,528	2,272,727	2,252,606	1,433,714	1,897,174	
	Total Count	***343***	***245***	***238***	***219***	***211***	
	Total Relevant Dollars	44,088,375	39,277,199	44,589,656	43,366,305	43,365,865	**-0.03**
Heart	***Number of Grants***	***52***	***31***	***24***	***20***	***15***	
	Relevant Grant Dollars	4,421,887	3,186,004	2,919,031	2,361,956	2,148,483	
	Total Count	***52***	***31***	***24***	***20***	***15***	
	Total Relevant Dollars	4,421,887	3,186,004	2,919,031	2,361,956	2,148,483	**-16.11**
Hodgkins Lymphoma	***Number of Grants***	***199***	***90***	***91***	***72***	***54***	
	Relevant Grant Dollars	19,854,920	15,324,741	15,616,622	13,631,008	9,846,229	
	Number of Contracts	***1***	‡	‡	‡	‡	
	Relevant Contract Dollars	4,758	‡	‡	‡	‡	
	Total Count	***200***	***90***	***91***	***72***	***54***	
	Total Relevant Dollars	19,859,678	15,324,741	15,616,622	13,631,008	9,846,229	**-15.35**
Kaposi Sarcoma	***Number of Grants***	***129***	***110***	***99***	***81***	***92***	
	Relevant Grant Dollars	20,882,959	20,905,539	20,543,363	18,551,830	17,444,041	
	Number of Contracts	***1***	‡	‡	‡	‡	
	Relevant Contract Dollars	89,789	‡	‡	‡	‡	
	Total Count	***130***	***110***	***99***	***81***	***92***	
	Total Relevant Dollars	20,972,748	20,905,539	20,543,363	18,551,830	17,444,041	**-4.43**
Kidney	***Number of Grants***	***291***	***224***	***209***	***210***	***227***	
	Relevant Grant Dollars	23,699,315	23,713,721	26,064,122	26,856,193	26,983,931	
	Number of Contracts	***2***	***3***	‡	***1***	***2***	
	Relevant Contract Dollars	383,447	74,757	‡	47,891	274,436	
	Total Count	***293***	***227***	***209***	***211***	***229***	
	Total Relevant Dollars	24,082,762	23,788,478	26,064,122	26,904,084	27,258,367	**3.22**
Larynx	***Number of Grants***	***14***	***7***	***4***	***5***	***3***	
	Relevant Grant Dollars	363,886	333,234	94,951	387,226	99,159	
	Total Count	***14***	***7***	***4***	***5***	***3***	
	Total Relevant Dollars	363,886	333,234	94,951	387,226	99,159	**38.37**

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.

Table 15. NCI Organ and Related Site-Specific Dollars for FY2006 - FY2010 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2006	2007	2008	2009	2010	Average Percent Change/yr.
Leukemia	***Number of Grants***	***860***	***800***	***735***	***703***	***680***	
	Relevant Grant Dollars	208,117,244	190,978,673	187,378,267	192,236,365	210,799,140	
	Number of Contracts	***4***	***3***	***3***	***2***	***3***	
	Relevant Contract Dollars	394,852	55,441	159,480	228,944	1,495,139	
	Total Count	***864***	***803***	***738***	***705***	***683***	
	Total Relevant Dollars	208,512,096	191,034,114	187,537,747	192,465,309	212,294,279	0.68
Liver	***Number of Grants***	***422***	***307***	***303***	***280***	***294***	
	Relevant Grant Dollars	55,976,697	60,837,509	60,131,598	58,730,034	60,616,338	
	Number of Contracts	***3***	***4***	***2***	***1***	–	
	Relevant Contract Dollars	193,919	160,124	46,630	124,807	–	
	Total Count	***425***	***311***	***305***	***281***	***294***	
	Total Relevant Dollars	56,170,616	60,997,633	60,178,228	58,854,841	60,616,338	2.01
Lung	***Number of Grants***	***1,040***	***1,010***	***966***	***961***	***965***	
	Relevant Grant Dollars	219,304,292	205,648,922	211,422,479	210,440,490	243,602,747	
	Number of Contracts	***40***	***37***	***42***	***35***	***23***	
	Relevant Contract Dollars	10,211,039	8,081,836	8,194,888	7,217,782	7,815,307	
	Total Count	***1,080***	***1,047***	***1,008***	***996***	***988***	
	Total Relevant Dollars	229,515,331	213,730,758	219,617,367	217,658,272	251,418,054	2.62
Lymph Node	***Number of Grants***	***28***	***26***	***23***	***18***	***15***	
	Relevant Grant Dollars	3,744,942	4,278,957	5,090,890	4,206,917		
	Total Count	***28***	***26***	***23***	***18***	***15***	
	Total Relevant Dollars	3,744,942	4,278,957	5,090,890	4,206,917	2,542,477	-5.92
Lymphatic System	***Number of Grants***	***14***	***8***	***9***	***9***	***4***	
	Relevant Grant Dollars	929,037	868,599	1,008,473	972,288	2,542,477	
	Total Count	***14***	***8***	***9***	***9***	***4***	
	Total Relevant Dollars	929,037	868,599	1,008,473	972,288	472,471	-11.35
Melanoma	***Number of Grants***	***531***	***502***	***506***	***454***	***457***	
	Relevant Grant Dollars	99,155,226	88,841,117	91,542,259	86,581,615	472,471	
	Number of Contracts	***1***	***2***	†	***2***	‡	
	Relevant Contract Dollars	47	261,078	†	276,130	‡	
	Total Count	***532***	***504***	***506***	***456***	***457***	
	Total Relevant Dollars	99,155,273	89,102,195	91,542,259	86,857,745	86,127,945	-3.34
Mesothelioma	***Number of Grants***			***19***	***18***	***15***	
	Relevant Grant Dollars			5,258,514	4,954,819	5,530,460	
	Total Count	‡	‡	***19***	***18***	***15***	
	Total Relevant Dollars	‡	‡	5,258,514	4,954,819	5,530,460	2.92
Muscle	***Number of Grants***	***91***	***56***	***42***	***37***	***37***	
	Relevant Grant Dollars	7,889,102	7,555,840	7,152,012	6,535,783	6,049,875	
	Total Count	***91***	***56***	***42***	***37***	***37***	
	Total Relevant Dollars	7,889,102	7,555,840	7,152,012	6,535,783	6,049,875	-6.40

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.

Table 15. NCI Organ and Related Site-Specific Dollars for FY2006 - FY2010 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2006	2007	2008	2009	2010	Average Percent Change/yr.
Myeloma	***Number of Grants***	***254***	***224***	***197***	***234***	***234***	
	Relevant Grant Dollars	28,398,277	28,812,062	34,920,892	40,008,777	41,740,236	
	Number of Contracts	***1***	‡	***2***	‡	***1***	
	Relevant Contract Dollars	400,000	‡	28,000	‡	199,860	
	Total Count	***255***	***224***	***199***	***234***	***235***	
	Total Relevant Dollars	28,798,277	28,812,062	34,948,892	40,008,777	41,940,096	**10.16**
Nervous System	***Number of Grants***	***44***	***29***	***33***	***29***	***30***	
	Relevant Grant Dollars	3,543,181	4,185,349	5,617,294	4,847,016	5,271,048	
	Total Count	***44***	***29***	***33***	***29***	***30***	
	Total Relevant Dollars	3,543,181	4,185,349	5,617,294	4,847,016	5,271,048	**11.84**
Neuroblastoma	***Number of Grants***	***128***	***87***	***95***	***100***	***98***	
	Relevant Grant Dollars	21,002,400	16,114,373	16,372,549	17,189,208	17,861,575	
	Total Count	***128***	***87***	***95***	***100***	***98***	
	Total Relevant Dollars	21,002,400	16,114,373	16,372,549	17,189,208	17,861,575	**-3.19**
Non-Hodgkins Lymphoma	***Number of Grants***	***615***	***589***	***570***	***523***	***455***	
	Relevant Grant Dollars	102,657,943	103,225,943	102,077,543	100,604,178	97,937,059	
	Number of Contracts	***2***	‡	‡	‡	‡	
	Relevant Contract Dollars	120,047	‡	‡	‡	‡	
	Total Count	***617***	***589***	***570***	***523***	***455***	
	Total Relevant Dollars	102,777,990	103,225,943	102,077,543	100,604,178	97,937,059	**-1.19**
Nose, Nasal Passages	***Number of Grants***	***20***	***11***	***10***	***10***	***14***	
	Relevant Grant Dollars	982,591	786,737	835,744	676,153	1,627,236	
	Total Count	***20***	***11***	***10***	***10***	***14***	
	Total Relevant Dollars	982,591	786,737	835,744	676,153	1,627,236	**26.97**
Not Site Specific§	***Number of Grants***	***2,229***	***2,243***	***2,304***	***2,196***	***2,079***	
	Relevant Grant Dollars	571,408,058	578,625,792	595,117,368	604,058,911	608,746,346	
	Number of Contracts	***185***	***213***	***214***	***186***	***162***	
	Relevant Contract Dollars	174,879,823	186,310,560	357,711,859	432,722,194	191,360,124	
	Total Count	***2,414***	***2,456***	***2,518***	***2,382***	***2,241***	
	Total Relevant Dollars	746,287,881	764,936,352	952,829,227	1,036,781,105	800,106,470	**3.26**
Oral Cavity	***Number of Grants***	‡	‡	***43***	***49***	***52***	
	Relevant Grant Dollars	‡	‡	5,505,263	8,783,998	11,138,288	
	Number of Contracts	‡	‡	***1***	‡	‡	
	Relevant Contract Dollars	‡	‡	1,188,000	‡	‡	
	Total Count	‡	‡	***44***	***49***	***52***	
	Total Relevant Dollars	‡	‡	6,693,263	8,783,998	11,138,288	**29.02**
Ovary	***Number of Grants***	***536***	***438***	***419***	***398***	***413***	
	Relevant Grant Dollars	84,634,021	85,320,484	81,047,163	92,438,385	96,565,010	
	Number of Contracts	***16***	***14***	***16***	***16***	***11***	
	Relevant Contract Dollars	6,492,044	5,595,233	5,782,543	6,099,306	5,217,503	
	Total Count	***552***	***452***	***435***	***414***	***424***	
	Total Relevant Dollars	91,126,065	90,915,717	86,829,706	98,537,691	101,782,513	**3.01**

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.
§Not Site Specific = no specific site specified in application, applicable to many sites.

Table 15. NCI Organ and Related Site-Specific Dollars for FY2006 - FY2010 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2006	2007	2008	2009	2010	Average Percent Change/yr.
Pancreas	***Number of Grants***	***484***	***377***	***405***	***401***	***424***	
	Relevant Grant Dollars	73,056,449	71,482,007	81,507,036	83,917,076	90,502,908	
	Number of Contracts	***3***	***1***	***4***	***1***	***1***	
	Relevant Contract Dollars	98,070	10,124	358,204	124,807	159,140	
	Total Count	***487***	***378***	***409***	***402***	***425***	
	Total Relevant Dollars	73,154,519	71,492,131	81,865,240	84,041,883	90,662,048	**5.69**
Parathyroid	***Number of Grants***	***5***	***3***	***3***	***4***	‡	
	Relevant Grant Dollars	210,422	195,111	167,518	103,991	‡	
	Total Count	***5***	***3***	***3***	***4***	‡	
	Total Relevant Dollars	210,422	195,111	167,518	103,991		**-39.84**
Penis	***Number of Grants***	***10***	***6***	***7***	***4***	***5***	
	Relevant Grant Dollars	2,938,868	2,720,503	3,031,187	752,499	2,667,920	
	Total Count	***10***	***6***	***7***	***4***	***5***	
	Total Relevant Dollars	2,938,868	2,720,503	3,031,187	752,499	2,667,920	**45.84**
Pharynx	***Number of Grants***	***101***	***36***	***32***	***52***	***14***	
	Relevant Grant Dollars	2,690,172	2,833,144	2,785,503	4,449,521	1,521,576	
	Number of Contracts	***1***	***1***	***1***	‡	‡	
	Relevant Contract Dollars	1,039,529	1,162,260	1,188,000	‡	‡	
	Total Count	***102***	***37***	***33***	***52***	***14***	
	Total Relevant Dollars	3,729,701	3,995,404	3,973,503	4,449,521	1,521,576	**-11.81**
Pituitary	***Number of Grants***	***20***	***9***	***6***	***7***	***7***	
	Relevant Grant Dollars	1,773,322	920,804	606,496	482,208	627,219	
	Total Count	***20***	***9***	***6***	***7***	***7***	
	Total Relevant Dollars	1,773,322	920,804	606,496	482,208	627,219	**-18.16**
Prostate	***Number of Grants***	***1,231***	***1,139***	***1,101***	***1,028***	***1,030***	
	Relevant Grant Dollars	259,195,963	267,487,905	252,666,154	250,572,712	265,054,420	
	Number of Contracts	***44***	***41***	***46***	***38***	***24***	
	Relevant Contract Dollars	11,056,314	9,212,924	9,220,125	8,857,832	8,108,959	
	Total Count	***1,275***	***1,180***	***1,147***	***1,066***	***1,054***	
	Total Relevant Dollars	270,252,277	276,700,829	261,886,279	259,430,544	273,163,379	**0.35**
Reticuloendothelial System	***Number of Grants***	***97***	***64***	***49***	***30***	***24***	
	Relevant Grant Dollars	15,200,490	12,745,312	8,704,661	7,424,753	4,220,047	
	Total Count	***97***	***64***	***49***	***30***	***24***	
	Total Relevant Dollars	15,200,490	12,745,312	8,704,661	7,424,753	4,220,047	**-26.43**
Respiratory System	***Number of Grants***	***9***	***4***	***5***	***3***	***3***	
	Relevant Grant Dollars	439,171	400,761	448,324	484,204	400,921	
	Total Count	***9***	***4***	***5***	***3***	***3***	
	Total Relevant Dollars	439,171	400,761	448,324	484,204	400,921	**-1.52**
Retinoblastoma	***Number of Grants***	***54***	***24***	***25***	***23***	***20***	
	Relevant Grant Dollars	3,340,918	3,691,685	4,536,603	3,582,106	2,599,952	
	Total Count	***54***	***24***	***25***	***23***	***20***	
	Total Relevant Dollars	3,340,918	3,691,685	4,536,603	3,582,106	2,599,952	**-3.77**

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.

Table 15. NCI Organ and Related Site-Specific Dollars for FY2006 - FY2010 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2006	2007	2008	2009	2010	Average Percent Change/yr.
Salivary Glands	***Number of Grants***	***19***	***4***	***4***	***4***	***5***	
	Relevant Grant Dollars	209,785	166,982	216,951	219,489	281,931	
	Total Count	***19***	***4***	***4***	***4***	***5***	
	Total Relevant Dollars	209,785	166,982	216,951	219,489	281,931	**9.79**
Skin	***Number of Grants***	***339***	***301***	***274***	***243***	***227***	
	Relevant Grant Dollars	60,922,777	56,840,776	48,382,761	44,850,024	43,190,271	
	Number of Contracts	***2***	‡	‡	***1***	‡	
	Relevant Contract Dollars	329,251	‡	‡	200,000	‡	
	Total Count	***341***	***301***	***274***	***244***	***227***	
	Total Relevant Dollars	61,252,028	56,840,776	48,382,761	45,050,024	43,190,271	**-8.27**
Small Intestine	***Number of Grants***	***39***	***28***	***23***	***21***	***19***	
	Relevant Grant Dollars	3,954,403	3,616,287	1,913,855	2,322,269	2,154,757	
	Total Count	***39***	***28***	***23***	***22***	***19***	
	Total Relevant Dollars	3,954,403	3,616,287	1,913,855	2,371,765	2,154,757	**-10.21**
Spleen	***Number of Grants***	***6***	***7***	***5***	***4***	***3***	
	Relevant Grant Dollars	413,583	553,101	579,727	190,652	243,170	
	Total Count	***6***	***7***	***5***	***4***	***3***	
	Total Relevant Dollars	413,583	553,101	579,727	190,652	243,170	**-0.25**
Stomach	***Number of Grants***	***210***	***82***	***74***	***64***	***65***	
	Relevant Grant Dollars	10,012,191	10,528,229	8,736,659	11,212,686	10,776,732	
	Number of Contracts	***4***	***2***	***2***	‡	‡	
	Relevant Contract Dollars	26,052	20,391	21,086	‡	‡	
	Total Count	***214***	***84***	***76***	***64***	***65***	
	Total Relevant Dollars	10,038,243	10,548,620	8,757,745	11,212,686	10,776,732	**3.06**
Testis	***Number of Grants***	***84***	***49***	***39***	***30***	***27***	
	Relevant Grant Dollars	7,358,824	7,845,968	6,649,429	4,704,354	4,216,762	
	Number of Contracts	***2***	‡	‡	‡	‡	
	Relevant Contract Dollars	120,126	‡	‡	‡	‡	
	Total Count	***86***	***49***	***39***	***30***	***27***	
	Total Relevant Dollars	7,478,950	7,845,968	6,649,429	4,704,354	4,216,762	**-12.49**
Thymus	***Number of Grants***	***78***	***12***	***9***	***6***	***4***	
	Relevant Grant Dollars	1,468,311	1,140,409	944,461	702,233	397,192	
	Total Count	***78***	***12***	***9***	***6***	***4***	
	Total Relevant Dollars	1,468,311	1,140,409	944,461	702,233	397,192	**-27.15**
Thyroid	***Number of Grants***	***63***	***47***	***50***	***47***	***52***	
	Relevant Grant Dollars	9,085,097	7,167,262	9,785,919	10,773,542	10,900,704	
	Number of Contracts	***1***	***1***	***2***	‡	‡	
	Relevant Contract Dollars	19,469	20,248	161,058	‡	‡	
	Total Count	***64***	***48***	***52***	***47***	***52***	
	Total Relevant Dollars	9,104,566	7,187,510	9,946,977	10,773,542	10,900,704	**6.71**

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.

Table 15. NCI Organ and Related Site-Specific Dollars for FY2006 - FY2010 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2006	2007	2008	2009	2010	Average Percent Change/yr.
Trachea, Bronchus	***Number of Grants***	***6***	***3***	***3***	***3***	***2***	
	Relevant Grant Dollars	209,385	256,970	283,631	332,875	112,364	
	Total Count	***6***	***3***	***3***	***3***	***2***	
	Total Relevant Dollars	209,385	256,970	283,631	332,875	112,364	**-3.95**
Uterus	***Number of Grants***	***156***	***112***	***109***	***107***	***80***	
	Relevant Grant Dollars	19,089,141	16,188,704	14,240,551	14,708,946	12,006,415	
	Number of Contracts	***2***	***2***	‡	‡	‡	
	Relevant Contract Dollars	158,504	37,500	‡	‡	‡	
	Total Count	***158***	***114***	***109***	***107***	***80***	
	Total Relevant Dollars	19,247,645	16,226,204	14,240,551	14,708,946	12,006,415	**-10.75**
Vagina	***Number of Grants***	***7***	***4***	***5***	***3***	***4***	
	Relevant Grant Dollars	556,373	485,811	395,049	374,910	275,471	
	Total Count	***7***	***4***	***5***	***3***	***4***	
	Total Relevant Dollars	556,373	485,811	395,049	374,910	275,471	**-15.75**
Vascular	***Number of Grants***	***170***	***130***	***96***	***65***	***55***	
	Relevant Grant Dollars	31,595,551	24,320,429	16,401,823	13,022,343	12,429,452	
	Number of Contracts	***1***	***–***	***–***	***–***	***–***	
	Relevant Contract Dollars	54	–	–	–	–	
	Total Count	***171***	***130***	***96***	***65***	***55***	
	Total Relevant Dollars	31,595,605	24,320,429	16,401,823	13,022,343	12,429,452	**-20.19**
Wilms Tumor	***Number of Grants***	***20***	***17***	***17***	***16***	***15***	
	Relevant Grant Dollars	4,204,127	3,686,340	3,748,439	4,249,920	3,792,626	
	Total Count	***20***	***17***	***17***	***16***	***15***	
	Total Relevant Dollars	4,204,127	3,686,340	3,748,439	4,249,920	3,792,626	**-2.00**

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2006 - FY2010 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2006	2007	2008	2009	2010	Average Percent Change/yr.
Adoptive Cell Immunotherapy	***Number of Grants***	***273***	***266***	***264***	***250***	***249***	
	Relevant Grant Dollars	81,309,062	78,652,209	74,709,142	65,455,904	71,169,780	
	Number of Contracts		***1***	‡	‡	‡	
	Relevant Contract Dollars		149,291	‡	‡	‡	
	Total Count	***273***	***267***	***264***	***250***	***249***	
	Total Relevant Dollars	81,309,062	78,801,500	74,709,142	65,455,904	71,169,780	**-2.98**
Advanced Manufacturing Technology	***Number of Grants***	***46***	***36***	***26***	***16***	***15***	
	Relevant Grant Dollars	9,986,543	8,330,740	4,715,021	3,032,054	3,285,087	
	Number of Contracts	***9***	***8***	***6***	***7***	***1***	
	Relevant Contract Dollars	2,188,049	2,507,029	796,198	2,189,910	106,000	
	Total Count	***55***	***44***	***32***	***23***	***16***	
	Total Relevant Dollars	12,174,592	10,837,769	5,511,219	5,221,964	3,391,087	**-25.11**
Aging	***Number of Grants***	***1,716***	***1,587***	***1,511***	***1,311***	***1,066***	
	Relevant Grant Dollars	160,658,738	162,147,038	152,249,919	135,080,359	113,349,368	
	Number of Contracts	***38***	***34***	***39***	***26***	***7***	
	Relevant Contract Dollars	5,296,251	4,441,352	5,277,985	4,221,489	2,424,616	
	Total Count	***1,754***	***1,621***	***1,550***	***1,337***	***1,073***	
	Total Relevant Dollars	165,954,989	166,588,390	157,527,904	139,301,848	115,773,984	**-8.38**
AIDS	***Number of Grants***	***792***	***657***	***492***	***413***	***412***	
	Relevant Grant Dollars	118,693,337	113,664,239	103,344,122	98,869,614	91,837,776	
	Number of Contracts	***11***	***11***	***8***	***10***	***3***	
	Relevant Contract Dollars	2,949,251	2,534,209	2,461,012	4,070,295	504,083	
	Total Count	***803***	***668***	***500***	***423***	***415***	
	Total Relevant Dollars	121,642,588	116,198,448	105,805,134	102,939,909	92,341,859	**-6.61**
Alternative Medicine, Direct	***Number of Grants***	***326***	***339***	***369***	***371***	***373***	
	Relevant Grant Dollars	66,699,630	74,353,346	97,318,620	85,029,188	89,420,040	
	Number of Contracts	***7***	***6***	***4***	***3***	***2***	
	Relevant Contract Dollars	404,940	763	791	610	1,149,412	
	Total Count	***333***	***345***	***373***	***374***	***375***	
	Total Relevant Dollars	67,104,570	74,354,109	97,319,411	85,029,798	90,569,452	**8.89**
Alternative Medicine, Indirect	***Number of Grants***	***90***	***76***	***57***	***48***	***44***	
	Relevant Grant Dollars	21,796,008	20,093,511	13,189,399	8,017,376	8,714,472	
	Total Count	***90***	***76***	***57***	***48***	***44***	
	Total Relevant Dollars	21,796,008	20,093,511	13,189,399	8,017,376	8,714,472	**-18.17**
Alzheimers Dementia	***Number of Grants***	***18***	***8***	***6***	***7***	***4***	
	Relevant Grant Dollars	874,500	688,918	519,280	643,620	508,810	
	Total Count	***18***	***8***	***6***	***7***	***4***	
	Total Relevant Dollars	874,500	688,918	519,280	643,620	508,810	**-10.71**
Arctic Research	***Number of Grants***	***10***	***8***	***7***	***5***	***3***	
	Relevant Grant Dollars	1,885,425	708,426	965,121	593,726	684,462	
	Total Count	***10***	***8***	***7***	***5***	***3***	
	Total Relevant Dollars	1,885,425	708,426	965,121	593,726	684,462	**-12.35**
Arthritis	***Number of Grants***	***13***	***9***	***4***	***6***	***4***	
	Relevant Grant Dollars	971,730	675,986	558,858	269,326	400,562	
	Total Count	***13***	***9***	***4***	***6***	***4***	
	Total Relevant Dollars	971,730	675,986	558,858	269,326	400,562	**-12.71**
Asbestos	***Number of Grants***	***18***	***16***	***14***	***10***	***11***	
	Relevant Grant Dollars	3,636,412	2,167,075	3,033,759	2,598,119	3,428,084	
	Total Count	***18***	***16***	***14***	***10***	***11***	
	Total Relevant Dollars	3,636,412	2,167,075	3,033,759	2,598,119	3,428,084	**4.29**

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2006 - FY2010 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2006	2007	2008	2009	2010	Average Percent Change/yr.
Ataxia Telangiectasia	***Number of Grants***	***40***	***23***	***23***	***21***	***19***	
	Relevant Grant Dollars	4,268,322	3,510,779	3,327,580	3,679,780	2,938,837	
	Total Count	***40***	***23***	***23***	***21***	***19***	
	Total Relevant Dollars	4,268,322	3,510,779	3,327,580	3,679,780	2,938,837	**-8.13**
Autoimmune Diseases	***Number of Grants***	***89***	***61***	***55***	***45***	***37***	
	Relevant Grant Dollars	8,288,993	6,772,469	6,844,086	5,221,927	4,320,535	
	Total Count	***89***	***61***	***55***	***45***	***37***	
	Total Relevant Dollars	8,288,993	6,772,469	6,844,086	5,221,927	4,320,535	**-14.55**
Behavior Research	***Number of Grants***	***973***	***984***	***1,072***	***1,093***	***1,104***	
	Relevant Grant Dollars	295,292,484	300,881,659	280,067,448	297,188,165	314,205,359	
	Number of Contracts	***19***	***20***	***18***	***14***	***10***	
	Relevant Contract Dollars	7,525,850	7,837,430	7,038,853	4,360,635	3,248,062	
	Total Count	***992***	***1,004***	***1,090***	***1,108***	***1,116***	
	Total Relevant Dollars	302,818,334	308,719,089	287,106,301	301,598,796	318,626,425	**1.41**
Bioengineering	***Number of Grants***	***659***	***648***	***661***	***593***	***543***	
	Relevant Grant Dollars	177,374,684	169,947,069	166,106,195	146,299,426	143,101,038	
	Number of Contracts	***22***	***33***	***43***	***19***	***19***	
	Relevant Contract Dollars	21,865,446	23,767,460	23,284,472	9,802,298	5,212,765	
	Total Count	***681***	***681***	***704***	***612***	***562***	
	Total Relevant Dollars	199,240,130	193,714,529	189,390,667	156,101,724	148,313,803	**-6.89**
Bioinformatics	***Number of Grants***	***679***	***625***	***647***	***609***	***613***	
	Relevant Grant Dollars	157,473,478	146,352,339	153,069,578	162,286,911	175,538,540	
	Number of Contracts	***21***	***31***	***35***	***21***	***16***	
	Relevant Contract Dollars	24,378,307	44,985,173	61,976,197	23,191,871	18,412,975	
	Total Count	***700***	***656***	***682***	***630***	***629***	
	Total Relevant Dollars	181,851,785	191,337,512	215,045,775	185,478,782	193,951,515	**2.11**
Biological Carcinogenesis Non-Viral	***Number of Grants***	***52***	***56***	***61***	***68***	***65***	
	Relevant Grant Dollars	7,791,241	10,156,057	10,028,377	13,031,273	13,043,584	
	Number of Contracts	***1***	***1***	***1***	‡	‡	
	Relevant Contract Dollars	11,790	11,790	11,788	‡	‡	
	Total Count	***53***	***57***	***62***	***68***	***65***	
	Total Relevant Dollars	7,803,031	10,167,847	10,040,165	13,031,273	13,043,584	**14.73**
Biologics/Biological Response Modifiers	***Number of Grants***	***2,582***	***2,467***	***2,415***	***2,122***	***1,900***	
	Relevant Grant Dollars	868,245,618	848,648,865	770,905,944	696,719,623	670,058,289	
	Number of Contracts	***48***	***45***	***35***	***36***	***22***	
	Relevant Contract Dollars	40,384,350	36,827,103	49,274,072	42,544,872	21,405,546	
	Total Count	***2,630***	***2,512***	***2,450***	***2,158***	***1,922***	
	Total Relevant Dollars	908,629,968	885,475,968	820,180,016	739,264,495	691,463,835	**-6.56**
Biomaterials Research	***Number of Grants***	***147***	***144***	***156***	***131***	***141***	
	Relevant Grant Dollars	28,533,189	28,978,407	29,002,753	27,561,068	21,212,069	
	Number of Contracts	***4***	***7***	***9***	‡	***4***	
	Relevant Contract Dollars	1,592,835	220,708	876,528	‡	1,548,783	
	Total Count	***151***	***151***	***165***	***131***	***145***	
	Total Relevant Dollars	30,126,024	29,199,115	29,879,281	27,561,068	22,760,852	**-6.48**
Biomedical Computing	***Number of Grants***	***180***	***296***	***430***	***467***	***532***	
	Relevant Grant Dollars	36,796,243	62,125,716	91,622,068	113,451,117	137,845,989	
	Number of Contracts	***23***	***36***	***52***	***21***	***19***	
	Relevant Contract Dollars	27,624,233	45,656,485	62,638,913	61,682,516	61,163,296	
	Total Count	***203***	***332***	***482***	***488***	***551***	
	Total Relevant Dollars	64,420,476	107,782,201	154,260,981	175,133,633	199,009,285	**34.40**

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2006 - FY2010 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2006	2007	2008	2009	2010	Average Percent Change/yr.
Birth Defects	***Number of Grants***	***89***	***83***	***75***	***61***	***64***	
	Relevant Grant Dollars	10,394,543	12,986,117	12,667,124	11,547,343	12,310,466	
	Total Count	***89***	***83***	***75***	***61***	***64***	
	Total Relevant Dollars	10,394,543	12,986,117	12,667,124	11,547,343	12,310,466	**5.06**
Bone Marrow Transplantation	***Number of Grants***	***234***	***149***	***140***	***146***	***140***	
	Relevant Grant Dollars	55,183,665	57,685,687	47,434,124	52,111,916	54,507,621	
	Number of Contracts	‡	‡	‡	***1***	‡	
	Relevant Contract Dollars	‡	‡	‡	49,496	‡	
	Total Count	***234***	***149***	***140***	***147***	***140***	
	Total Relevant Dollars	55,183,665	57,685,687	47,434,124	52,161,412	54,507,621	**0.31**
Breast Cancer Detection	***Number of Grants***	***529***	***528***	***525***	***508***	***498***	
	Relevant Grant Dollars	110,725,677	106,217,059	108,220,945	104,769,617	99,759,605	
	Number of Contracts	***22***	***25***	***28***	***22***	***13***	
	Relevant Contract Dollars	3,992,990	3,226,170	2,767,443	2,928,506	3,632,816	
	Total Count	***551***	***553***	***553***	***530***	***511***	
	Total Relevant Dollars	114,718,667	109,443,229	110,988,388	107,698,123	103,392,421	**-2.54**
Breast Cancer Early Detection	***Number of Grants***	***259***	***251***	***240***	***219***	***225***	
	Relevant Grant Dollars	57,685,294	55,363,825	53,893,623	45,876,009	47,143,457	
	Number of Contracts	***3***	***5***	***6***	***1***	***3***	
	Relevant Contract Dollars	594,498	677,184	470,851	420,996	1,506,703	
	Total Count	***262***	***256***	***246***	***220***	***228***	
	Total Relevant Dollars	58,279,792	56,041,009	54,364,474	46,297,005	48,650,160	**-4.15**
Breast Cancer Education	***Number of Grants***	***166***	***154***	***144***	***142***	***149***	
	Relevant Grant Dollars	19,687,158	19,875,523	16,003,803	17,412,166	16,743,662	
	Total Count	***166***	***154***	***144***	***142***	***149***	
	Total Relevant Dollars	19,687,158	19,875,523	16,003,803	17,412,166	16,743,662	**-3.39**
Breast Cancer Epidemiology	***Number of Grants***	***226***	***200***	***191***	***182***	***189***	
	Relevant Grant Dollars	61,898,572	57,628,754	54,730,727	54,666,482	64,674,588	
	Number of Contracts	***6***	***4***	***3***	***1***	***5***	
	Relevant Contract Dollars	299,285	775,166	308,692	51,500	336,493	
	Total Count	***232***	***204***	***194***	***183***	***194***	
	Total Relevant Dollars	62,197,857	58,403,920	55,039,419	54,717,982	65,011,081	**1.59**
Breast Cancer Genetics	***Number of Grants***	***409***	***427***	***429***	***429***	***453***	
	Relevant Grant Dollars	96,192,982	96,343,475	97,895,528	104,276,046	116,708,177	
	Number of Contracts	***3***	***3***	***3***	***8***	***5***	
	Relevant Contract Dollars	1,144,999	1,110,467	1,064,606	2,655,595	2,418,766	
	Total Count	***412***	***430***	***432***	***437***	***458***	
	Total Relevant Dollars	97,337,981	97,453,942	98,960,134	106,931,641	119,126,943	**5.28**
Breast Cancer Prevention	***Number of Grants***	***247***	***252***	***237***	***223***	***211***	
	Relevant Grant Dollars	33,184,596	33,900,951	24,443,078	23,625,542	20,573,617	
	Number of Contracts	***6***	‡	‡	‡	‡	
	Relevant Contract Dollars	1,297,818	‡	‡	‡	‡	
	Total Count	***253***	***252***	***237***	***223***	***211***	
	Total Relevant Dollars	34,482,414	33,900,951	24,443,078	23,625,542	20,573,617	**-11.46**
Breast Cancer Rehabilitation	***Number of Grants***	***164***	***159***	***157***	***156***	***165***	
	Relevant Grant Dollars	18,338,266	19,883,798	18,496,683	22,053,106	23,414,402	
	Number of Contracts	‡	***1***	‡	‡	‡	
	Relevant Contract Dollars	‡	149,973	‡	‡	‡	
	Total Count	***164***	***160***	***157***	***156***	***165***	
	Total Relevant Dollars	18,338,266	20,033,771	18,496,683	22,053,106	23,414,402	**6.74**

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2006 - FY2010 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2006	2007	2008	2009	2010	Average Percent Change/yr.
Breast Cancer Screening	***Number of Grants***	***205***	***194***	***190***	***182***	***194***	
	Relevant Grant Dollars	27,746,356	25,068,440	22,935,243	21,132,490	22,564,554	
	Number of Contracts	***1***	***1***	‡	‡	‡	
	Relevant Contract Dollars	27,241	18,848	‡	‡	‡	
	Total Count	***206***	***195***	***190***	***182***	***194***	
	Total Relevant Dollars	27,773,597	25,087,288	22,935,243	21,132,490	22,564,554	**-4.83**
Breast Cancer Treatment	***Number of Grants***	***737***	***712***	***715***	***676***	***699***	
	Relevant Grant Dollars	152,347,399	157,072,191	159,717,667	175,287,152	191,699,483	
	Number of Contracts	***20***	***18***	***17***	***20***	***11***	
	Relevant Contract Dollars	4,123,370	3,175,991	2,845,506	2,908,754	1,962,093	
	Total Count	***757***	***730***	***732***	***696***	***710***	
	Total Relevant Dollars	156,470,769	160,248,182	162,563,173	178,195,906	193,661,576	**5.54**
Breast Cancer-Basic	***Number of Grants***	***867***	***855***	***807***	***773***	***781***	
	Relevant Grant Dollars	161,696,570	157,238,472	152,092,109	161,805,933	168,864,512	
	Number of Contracts	***8***	***8***	***8***	***9***	***9***	
	Relevant Contract Dollars	713,135	685,736	559,354	1,532,199	1,977,194	
	Total Count	***875***	***863***	***815***	***782***	***790***	
	Total Relevant Dollars	162,409,705	157,924,208	152,651,463	163,338,132	170,841,706	**1.37**
Cancer Survivorship	***Number of Grants***	***584***	***593***	***604***	***596***	***627***	
	Relevant Grant Dollars	188,120,539	188,415,629	189,504,238	197,965,376	233,784,991	
	Number of Contracts	***22***	***27***	***26***	***22***	***7***	
	Relevant Contract Dollars	3,289,962	4,021,835	3,743,947	2,901,978	2,202,035	
	Total Count	***606***	***620***	***630***	***618***	***634***	
	Total Relevant Dollars	191,410,501	192,437,464	193,248,185	200,867,354	235,987,026	**5.60**
Carcinogenesis, Environmental	***Number of Grants***	***1,660***	***1,591***	***1,478***	***1,407***	***1,316***	
	Relevant Grant Dollars	512,929,610	478,853,048	416,898,310	388,760,406	395,790,431	
	Number of Contracts	***36***	***34***	***34***	***26***	***19***	
	Relevant Contract Dollars	17,523,975	18,994,043	16,619,490	10,219,303	7,165,859	
	Total Count	***1,696***	***1,625***	***1,512***	***1,433***	***1,335***	
	Total Relevant Dollars	530,453,585	497,847,091	433,517,800	398,979,709	402,956,290	**-6.51**
Cervical Cancer Education	***Number of Grants***	***48***	***38***	***48***	***42***	***49***	
	Relevant Grant Dollars	5,499,731	6,476,819	6,078,672	5,288,307	6,669,506	
	Total Count	***48***	***38***	***48***	***42***	***49***	
	Total Relevant Dollars	5,499,731	6,476,819	6,078,672	5,288,307	6,669,506	**6.18**
Chemoprevention	***Number of Grants***	***605***	***595***	***603***	***581***	***554***	
	Relevant Grant Dollars	148,968,908	147,147,622	127,214,057	122,199,190	110,809,302	
	Number of Contracts	***40***	***36***	***26***	***20***	***9***	
	Relevant Contract Dollars	35,404,335	31,817,172	30,237,119	34,586,263	14,907,908	
	Total Count	***645***	***631***	***629***	***601***	***563***	
	Total Relevant Dollars	184,373,243	178,964,794	157,451,176	156,785,453	125,717,210	**-8.80**
Chemoprevention, Clinical	***Number of Grants***	***138***	***140***	***130***	***134***	***136***	
	Relevant Grant Dollars	45,529,536	40,528,158	33,077,734	32,365,770	31,292,583	
	Number of Contracts	***20***	***19***	***12***	***7***	***2***	
	Relevant Contract Dollars	17,350,886	12,265,652	11,367,607	11,187,869	1,568,183	
	Total Count	***158***	***159***	***142***	***141***	***138***	
	Total Relevant Dollars	62,880,422	52,793,810	44,445,341	43,553,639	32,860,766	**-14.60**

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2006 - FY2010 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2006	2007	2008	2009	2010	Average Percent Change/yr.
Chemotherapy	***Number of Grants***	***1,309***	***1,338***	***1,350***	***1,318***	***1,265***	**-0.82**
	Relevant Grant Dollars	479,649,709	497,798,503	474,245,547	491,407,371	486,445,892	
	Number of Contracts	***35***	***37***	***31***	***24***	***23***	
	Relevant Contract Dollars	25,415,072	24,643,133	23,279,025	18,985,236	16,237,585	
	Total Count	***1,344***	***1,375***	***1,381***	***1,342***	***1,288***	
	Total Relevant Dollars	505,064,781	522,441,636	497,524,572	510,392,607	502,683,477	**-0.06**
Child Health	***Number of Grants***	***245***	***226***	***208***	***173***	***180***	
	Relevant Grant Dollars	65,611,289	62,633,467	55,722,419	41,893,936	35,485,301	
	Number of Contracts	***4***	***3***	***1***	***1***	***1***	
	Relevant Contract Dollars	229,444	10,124	10,529	94,045	100,000	
	Total Count	***249***	***229***	***209***	***174***	***181***	
	Total Relevant Dollars	65,840,733	62,643,591	55,732,948	41,987,981	35,585,301	**-13.95**
Childhood Cancers	***Number of Grants***	***624***	***500***	***504***	***477***	***495***	
	Relevant Grant Dollars	167,308,419	159,209,507	164,775,607	163,353,861	166,272,586	
	Number of Contracts	***5***	***5***	***5***	***1***	***1***	
	Relevant Contract Dollars	3,973,147	3,801,832	1,431,001	1,990,858	2,938,868	
	Total Count	***629***	***505***	***509***	***478***	***496***	
	Total Relevant Dollars	171,281,566	163,011,339	166,206,608	165,344,719	169,211,454	**-0.26**
Chronic Myeloproliferative Disorders	***Number of Grants***	***153***	***130***	***124***	***115***	***129***	
	Relevant Grant Dollars	40,928,680	37,298,741	31,066,792	31,864,056	33,259,274	
	Total Count	***153***	***130***	***124***	***115***	***129***	
	Total Relevant Dollars	40,928,680	37,298,741	31,066,792	31,864,056	33,259,274	**-4.66**
Clinical Trials, Diagnosis	***Number of Grants***	***208***	***193***	***180***	***177***	***158***	
	Relevant Grant Dollars	76,698,423	60,241,052	52,919,647	46,050,747	49,365,161	
	Number of Contracts	***19***	***17***	***20***	***15***	***14***	
	Relevant Contract Dollars	26,949,542	23,143,799	22,227,173	20,599,926	21,295,518	
	Total Count	***227***	***210***	***200***	***192***	***172***	
	Total Relevant Dollars	103,647,965	83,384,851	75,146,820	66,650,673	70,660,679	**-8.68**
Clinical Trials, Other	***Number of Grants***	***194***	***213***	***202***	***196***	***231***	
	Relevant Grant Dollars	54,518,862	55,628,143	57,804,488	55,185,455	64,532,028	
	Number of Contracts	***4***	***5***	***5***	***2***	***3***	
	Relevant Contract Dollars	17,971,168	27,588,310	35,442,454	1,800,000	2,199,778	
	Total Count	***198***	***218***	***207***	***198***	***234***	
	Total Relevant Dollars	72,490,030	83,216,453	93,246,942	56,985,455	66,731,806	**1.27**
Clinical Trials, Prevention	***Number of Grants***	***115***	***127***	***152***	***160***	***162***	
	Relevant Grant Dollars	49,191,485	51,851,105	51,014,829	52,476,013	56,851,445	
	Number of Contracts	***21***	***19***	***14***	***10***	***4***	
	Relevant Contract Dollars	20,795,263	18,950,376	17,487,767	17,750,174	10,044,105	
	Total Count	***136***	***146***	***166***	***170***	***166***	
	Total Relevant Dollars	69,986,748	70,801,481	68,502,596	70,226,187	66,895,550	**-1.08**
Clinical Trials, Therapy	***Number of Grants***	***734***	***707***	***709***	***657***	***636***	
	Relevant Grant Dollars	416,997,967	426,525,232	394,416,421	381,371,267	383,892,811	
	Number of Contracts	***17***	***16***	***16***	***16***	***17***	
	Relevant Contract Dollars	17,033,180	24,919,354	20,555,120	45,809,933	43,398,794	
	Total Count	***751***	***723***	***725***	***673***	***653***	
	Total Relevant Dollars	434,031,147	451,444,586	414,971,541	427,181,200	427,291,605	**-0.27**

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.

†Relevant Dollars = portion of the funded amount relevant to a specific site.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2006 - FY2010 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2006	2007	2008	2009	2010	Average Percent Change/yr.
Combined Treatment Modalities	***Number of Grants***	***582***	***558***	***572***	***601***	***679***	
	Relevant Grant Dollars	315,272,769	336,759,452	329,900,253	330,893,890	366,302,744	
	Number of Contracts	***2***	***1***	***1***	***1***	***4***	
	Relevant Contract Dollars	2,691,020	2,404,801	1,141,539	1,990,858	3,372,144	
	Total Count	***584***	***559***	***573***	***602***	***683***	
	Total Relevant Dollars	317,963,789	339,164,253	331,041,792	332,884,748	369,674,888	**3.97**
Cost Effectiveness	***Number of Grants***	***189***	***176***	***177***	***172***	***173***	
	Relevant Grant Dollars	24,089,869	25,250,379	27,408,881	27,223,170	27,186,831	
	Number of Contracts	***6***	***6***	***5***	***3***	***2***	
	Relevant Contract Dollars	143,070	149,213	791	610	186,230	
	Total Count	***195***	***182***	***182***	***175***	***175***	
	Total Relevant Dollars	24,232,939	25,399,592	27,409,672	27,223,780	27,373,061	**3.15**
Diabetes	***Number of Grants***	***83***	***64***	***59***	***53***	***47***	
	Relevant Grant Dollars	9,294,437	7,129,217	7,044,678	6,202,451	3,530,526	
	Total Count	***83***	***64***	***59***	***53***	***47***	
	Total Relevant Dollars	9,294,437	7,129,217	7,044,678	6,202,451	3,530,526	**-19.88**
Diagnosis	***Number of Grants***	***1,914***	***1,918***	***1,985***	***1,911***	***1,855***	
	Relevant Grant Dollars	601,829,953	575,537,825	573,452,204	559,042,065	553,036,713	
	Number of Contracts	***71***	***78***	***94***	***71***	***66***	
	Relevant Contract Dollars	41,099,420	37,162,748	48,739,504	36,236,631	38,373,345	
	Total Count	***1,985***	***1,996***	***2,079***	***1,982***	***1,921***	
	Total Relevant Dollars	642,929,373	612,700,573	622,191,708	595,278,696	591,410,058	**-2.03**
Diethylstilbestrol	***Number of Grants***	***3***	***3***	***3***	‡	***2***	
	Relevant Grant Dollars	386,587	399,512	405,296	‡	210,443	
	Number of Contracts	***5***	***5***	***5***	***5***	***5***	
	Relevant Contract Dollars	1,436,144	1,471,870	1,302,461	1,332,877	1,345,965	
	Total Count	***8***	***8***	***8***	***5***	***7***	
	Total Relevant Dollars	1,822,731	1,871,382	1,707,757	1,332,877	1,556,408	**-2.81**
Dioxin	***Number of Grants***	***19***	***13***	***10***	***10***	***12***	
	Relevant Grant Dollars	1,338,159	1,284,000	1,364,134	1,268,488	1,736,256	
	Total Count	***19***	***13***	***10***	***10***	***12***	
	Total Relevant Dollars	1,338,159	1,284,000	1,364,134	1,268,488	1,736,256	**8.01**
DNA Repair	***Number of Grants***	***744***	***716***	***699***	***633***	***600***	
	Relevant Grant Dollars	158,513,601	157,601,803	135,428,622	122,923,808	128,813,944	
	Number of Contracts	***–***	***–***	***–***	***–***	***2***	
	Relevant Contract Dollars	–	–	–	–	399,599	
	Total Count	***744***	***716***	***699***	***633***	***602***	
	Total Relevant Dollars	158,513,601	157,601,803	135,428,622	122,923,808	129,213,543	**-4.69**
Drug Development	***Number of Grants***	***1,883***	***1,941***	***2,077***	***2,087***	***2,091***	
	Relevant Grant Dollars	510,158,014	528,991,781	526,752,390	538,758,282	550,899,818	
	Number of Contracts	***87***	***100***	***86***	***75***	***82***	
	Relevant Contract Dollars	56,024,902	59,479,332	89,847,891	51,239,667	50,932,059	
	Total Count	***1,970***	***2,041***	***2,163***	***2,162***	***2,173***	
	Total Relevant Dollars	566,182,916	588,471,113	616,600,281	589,997,949	601,831,877	**1.60**
Drug Discovery	***Number of Grants***	***300***	***308***	***366***	***364***	***377***	
	Relevant Grant Dollars	64,055,213	74,279,785	79,667,568	81,268,839	74,170,074	
	Number of Contracts	***14***	***23***	***18***	***11***	***18***	
	Relevant Contract Dollars	8,986,969	9,753,535	9,345,219	13,478,230	11,779,829	
	Total Count	***314***	***331***	***384***	***375***	***395***	
	Total Relevant Dollars	73,042,182	84,033,320	89,012,787	94,747,069	85,949,903	**4.53**

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2006 - FY2010 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2006	2007	2008	2009	2010	Average Percent Change/yr.
Drug Resistance	***Number of Grants***	***621***	***627***	***646***	***631***	***634***	
	Relevant Grant Dollars	114,954,619	117,103,635	109,833,907	111,827,085	117,323,805	
	Number of Contracts	‡	‡	‡	***1***	***2***	
	Relevant Contract Dollars	‡	‡	‡	37,181	395,550	
	Total Count	***621***	***627***	***646***	***632***	***636***	
	Total Relevant Dollars	114,954,619	117,103,635	109,833,907	111,864,266	117,719,355	**0.69**
Drugs – Natural Products	***Number of Grants***	***609***	***630***	***647***	***634***	***640***	
	Relevant Grant Dollars	135,786,976	143,442,656	134,532,430	150,196,945	143,114,167	
	Number of Contracts	***7***	***13***	***5***	***4***	***4***	
	Relevant Contract Dollars	2,420,015	1,026,873	240,346	593,175	1,375,565	
	Total Count	***616***	***643***	***652***	***638***	***644***	
	Total Relevant Dollars	138,206,991	144,469,529	134,772,776	150,790,120	144,489,732	**1.38**
Early Detection	***Number of Grants***	***961***	***949***	***936***	***869***	***839***	
	Relevant Grant Dollars	284,552,065	265,030,226	240,604,537	222,168,970	227,060,938	
	Number of Contracts	***24***	***31***	***40***	***20***	***17***	
	Relevant Contract Dollars	26,082,652	23,894,581	23,057,128	21,156,276	21,353,066	
	Total Count	***985***	***980***	***976***	***889***	***856***	
	Total Relevant Dollars	310,634,717	288,924,807	263,661,665	243,325,246	248,414,004	**-5.34**
Effectiveness Research	***Number of Grants***	***203***	***174***	***135***	***156***	***199***	
	Relevant Grant Dollars	55,184,257	48,830,097	38,991,088	52,087,249	59,933,366	
	Number of Contracts	***5***	***5***	***4***	***1***	***2***	
	Relevant Contract Dollars	811,384	435,033	216,123	252,597	560,081	
	Total Count	***208***	***179***	***139***	***157***	***201***	
	Total Relevant Dollars	55,995,641	49,265,130	39,207,211	52,339,846	60,493,447	**4.16**
Endocrinology	***Number of Grants***	***888***	***880***	***846***	***787***	***716***	
	Relevant Grant Dollars	184,061,755	172,460,886	152,810,901	160,349,292	144,586,939	
	Number of Contracts	***7***	***8***	***8***	***6***	***5***	
	Relevant Contract Dollars	2,391,532	1,710,706	1,442,461	2,042,874	1,345,965	
	Total Count	***895***	***888***	***854***	***793***	***721***	
	Total Relevant Dollars	186,453,287	174,171,592	154,253,362	162,392,166	145,932,904	**-5.72**
Energy Balance	***Number of Grants***	***136***	***128***	***117***	***109***	***104***	
	Relevant Grant Dollars	37,235,484	39,387,827	37,250,439	34,684,820	30,844,556	
	Number of Contracts	***2***	***4***	***5***	***2***	***1***	
	Relevant Contract Dollars	872,505	1,047,129	1,916,049	1,575,000	4,885	
	Total Count	***138***	***132***	***122***	***111***	***105***	
	Total Relevant Dollars	38,107,989	40,434,956	39,166,488	36,259,820	30,849,441	**-4.84**
Epid.-Biochemical	***Number of Grants***	***591***	***584***	***581***	***560***	***544***	
	Relevant Grant Dollars	183,123,612	191,467,862	187,522,766	186,146,991	207,004,532	
	Number of Contracts	***11***	***13***	***10***	***11***	***9***	
	Relevant Contract Dollars	12,350,991	12,716,700	13,132,622	22,350,084	22,230,209	
	Total Count	***602***	***597***	***591***	***571***	***553***	
	Total Relevant Dollars	195,474,603	204,184,562	200,655,388	208,497,075	229,234,741	**4.15**
Epidemiology	***Number of Grants***	***117***	***154***	***184***	***203***	***238***	
	Relevant Grant Dollars	19,259,641	30,658,644	35,362,320	48,391,387	58,955,769	
	Number of Contracts	***10***	***14***	***12***	***11***	***12***	
	Relevant Contract Dollars	2,969,431	3,123,091	40,155,271	6,923,651	7,967,822	
	Total Count	***127***	***168***	***196***	***214***	***250***	
	Total Relevant Dollars	22,229,072	33,781,735	75,517,591	55,315,038	66,923,591	**42.44**

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2006 - FY2010 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2006	2007	2008	2009	2010	Average Percent Change/yr.
Epidemiology, Environmental	***Number of Grants***	***576***	***571***	***534***	***518***	***487***	
	Relevant Grant Dollars	181,471,817	177,174,581	165,826,605	157,183,612	169,765,154	
	Number of Contracts	***26***	***27***	***24***	***21***	***16***	
	Relevant Contract Dollars	16,130,038	17,552,030	16,439,893	24,581,051	24,953,396	
	Total Count	***602***	***598***	***558***	***539***	***503***	
	Total Relevant Dollars	197,601,855	194,726,611	182,266,498	181,764,663	194,718,550	**-0.25**
Epigenetics	***Number of Grants***	***565***	***642***	***699***	***722***	***771***	
	Relevant Grant Dollars	110,993,391	121,281,851	115,349,385	139,887,622	161,834,223	
	Number of Contracts	***1***	***1***	***2***	***4***	***3***	
	Relevant Contract Dollars	135,200	144,400	302,567	653,292	549,598	
	Total Count	***566***	***643***	***701***	***726***	***774***	
	Total Relevant Dollars	111,128,591	121,426,251	115,651,952	140,540,914	162,383,821	**10.39**
Gene Mapping, Human	***Number of Grants***	***768***	***655***	***554***	***493***	***436***	
	Relevant Grant Dollars	173,051,349	138,302,632	119,648,785	153,658,315	158,894,763	
	Total Count	***768***	***655***	***554***	***493***	***436***	
	Total Relevant Dollars	173,051,349	138,302,632	119,648,785	153,658,315	158,894,763	**-0.43**
Gene Mapping, Non-Human	***Number of Grants***	***428***	***358***	***327***	***274***	***243***	
	Relevant Grant Dollars	64,302,734	57,173,146	49,897,071	40,329,713	37,746,569	
	Total Count	***428***	***358***	***327***	***274***	***243***	
	Total Relevant Dollars	64,302,734	57,173,146	49,897,071	40,329,713	37,746,569	**-12.35**
Gene Transfer, Clinical	***Number of Grants***	***148***	***81***	***58***	***37***	***28***	
	Relevant Grant Dollars	19,854,706	16,880,605	9,063,499	11,261,635	8,086,568	
	Total Count	***148***	***81***	***58***	***37***	***28***	
	Total Relevant Dollars	19,854,706	16,880,605	9,063,499	11,261,635	8,086,568	**-16.31**
Genetic Testing Research, Human	***Number of Grants***	***456***	***470***	***460***	***380***	***335***	
	Relevant Grant Dollars	194,792,804	175,117,006	153,581,370	128,833,823	115,367,220	
	Number of Contracts	***3***	***4***	***4***	***3***	***3***	
	Relevant Contract Dollars	1,144,999	1,210,690	1,064,606	1,308,355	1,325,744	
	Total Count	***459***	***474***	***464***	***383***	***338***	
	Total Relevant Dollars	195,937,803	176,327,696	154,645,976	130,142,178	116,692,964	**-12.12**
Genomics	***Number of Grants***	***209***	***360***	***603***	***758***	***837***	
	Relevant Grant Dollars	65,532,011	93,564,965	160,617,624	233,634,493	276,653,749	
	Number of Contracts	***6***	***6***	***7***	***11***	***9***	
	Relevant Contract Dollars	220,027	248,376	37,387,078	2,893,716	2,573,478	
	Total Count	***215***	***366***	***610***	***769***	***846***	
	Total Relevant Dollars	65,752,038	93,813,341	198,004,702	236,528,209	279,227,227	**47.81**
Health Literacy	***Number of Grants***	***26***	***54***	***74***	***78***	***93***	
	Relevant Grant Dollars	3,740,896	9,318,204	14,713,919	19,259,445	21,151,000	
	Number of Contracts	***1***	***3***	***6***	***2***	***1***	
	Relevant Contract Dollars	750,016	494,973	462,228	2,242,507	2,225,682	
	Total Count	***27***	***57***	***80***	***80***	***94***	
	Total Relevant Dollars	4,490,912	9,813,177	15,176,147	21,501,952	23,376,682	**55.89**
Health Promotion	***Number of Grants***	***596***	***575***	***567***	***550***	***535***	
	Relevant Grant Dollars	214,012,699	216,311,569	188,789,768	189,856,649	156,169,759	
	Number of Contracts	***32***	***30***	***31***	***29***	***12***	
	Relevant Contract Dollars	22,035,096	17,599,722	17,490,115	12,155,514	8,239,835	
	Total Count	***628***	***605***	***598***	***579***	***547***	
	Total Relevant Dollars	236,047,795	233,911,291	206,279,883	202,012,163	164,409,594	**-8.35**

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2006 - FY2010 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2006	2007	2008	2009	2010	Average Percent Change/yr.
Healt Care Delivery	***Number of Grants***	***108***	***177***	***233***	***260***	***323***	
	Relevant Grant Dollars	25,730,955	46,244,456	58,703,422	79,491,611	99,249,496	
	Number of Contracts	***9***	***15***	***19***	***7***	***9***	
	Relevant Contract Dollars	3,838,069	5,067,214	4,471,971	4,206,677	4,637,640	
	Total Count	***117***	***192***	***252***	***267***	***332***	
	Total Relevant Dollars	29,569,024	51,311,670	63,175,393	83,698,288	103,887,136	**38.31**
Helicobacter	***Number of Grants***	***38***	***39***	***39***	***39***	***34***	
	Relevant Grant Dollars	5,122,426	7,219,894	5,876,269	8,224,164	8,078,008	
	Number of Contracts	***1***	***1***	***1***	‡	‡	
	Relevant Contract Dollars	11,790	11,790	11,788	‡	‡	
	Total Count	***39***	***40***	***40***	***39***	***34***	
	Total Relevant Dollars	5,134,216	7,231,684	5,888,057	8,224,164	8,078,008	**15.04**
Hematology	***Number of Grants***	***1,639***	***1,729***	***1,646***	***1,531***	***1,472***	
	Relevant Grant Dollars	466,737,567	479,959,002	468,003,334	451,773,304	466,847,932	
	Number of Contracts	***13***	***11***	***10***	***6***	***6***	
	Relevant Contract Dollars	2,475,432	1,466,168	1,465,173	906,834	1,967,879	
	Total Count	***1,652***	***1,740***	***1,656***	***1,537***	***1,478***	
	Total Relevant Dollars	469,212,999	481,425,170	469,468,507	452,680,138	468,815,811	**0.03**
Hematopoietic Stem Cell Research	***Number of Grants***	***536***	***496***	***486***	***467***	***396***	
	Relevant Grant Dollars	128,413,283	117,664,534	114,552,753	114,121,151	113,380,226	
	Number of Contracts	***5***	***5***	***5***	***5***	***1***	
	Relevant Contract Dollars	1,257,050	1,345,185	1,177,713	727,386	999,936	
	Total Count	***541***	***501***	***491***	***472***	***397***	
	Total Relevant Dollars	129,670,333	119,009,719	115,730,466	114,848,537	114,380,162	**-3.04**
Hormone Replacement Therapy	***Number of Grants***	***81***	***61***	***49***	***41***	***33***	
	Relevant Grant Dollars	11,862,343	10,834,905	6,714,658	7,098,888	3,175,346	
	Total Count	***81***	***61***	***49***	***41***	***33***	
	Total Relevant Dollars	11,862,343	10,834,905	6,714,658	7,098,888	3,175,346	**-24.06**
Hospice	***Number of Grants***	***75***	***72***	***57***	***45***	***45***	
	Relevant Grant Dollars	13,683,873	13,724,054	9,075,982	8,363,251	9,344,380	
	Number of Contracts	‡	‡	***4***	‡	***1***	
	Relevant Contract Dollars	‡	‡	612,259	‡	999,998	
	Total Count	***75***	***72***	***61***	***45***	***46***	
	Total Relevant Dollars	13,683,873	13,724,054	9,688,241	8,363,251	10,344,378	**-4.78**
Human Genome	***Number of Grants***	‡	‡	***219***	***408***	***533***	
	Relevant Grant Dollars	‡	‡	72,721,075	157,617,076	224,387,803	
	Number of Contracts	‡	‡	***1***	***3***	***2***	
	Relevant Contract Dollars	‡	‡	149,975	2,392,888	2,260,666	
	Total Count	‡	‡	***220***	***411***	***535***	
	Total Relevant Dollars	‡	‡	72,871,050	160,009,964	226,648,469	**80.61**
Iatrogenesis	***Number of Grants***	***243***	***245***	***288***	***275***	***257***	
	Relevant Grant Dollars	***51,588,948***	***50,173,643***	***55,716,691***	***65,399,334***	***61,577,955***	
	Number of Contracts	***6***	***5***	***6***	***7***	***5***	
	Relevant Contract Dollars	1,455,176	1,471,870	2,202,346	2,532,672	1,345,965	
	Total Count	***249***	***250***	***294***	***282***	***262***	
	Total Relevant Dollars	53,044,124	51,645,513	57,919,037	67,932,006	62,923,920	**4.86**

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2006 - FY2010 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2006	2007	2008	2009	2010	Average Percent Change/yr.
Imaging	***Number of Grants***	***1,004***	***1,058***	***1,100***	***1,047***	***1,045***	
	Relevant Grant Dollars	301,581,698	299,804,703	300,082,605	289,428,387	298,744,722	
	Number of Contracts	***34***	***30***	***40***	***27***	***32***	
	Relevant Contract Dollars	24,210,506	19,391,655	32,833,674	18,714,802	21,851,672	
	Total Count	***1,038***	***1,088***	***1,140***	***1,074***	***1,077***	
	Total Relevant Dollars	325,792,204	319,196,358	332,916,279	308,143,189	320,596,394	**-0.28**
Immunization	***Number of Grants***	‡	‡	***477***	***420***	***442***	
	Relevant Grant Dollars	‡	‡	116,732,773	109,830,817	116,267,543	
	Number of Contracts	‡	‡	***1***	***2***	–	
	Relevant Contract Dollars	‡	‡	14,808,841	1,370,729	–	
	Total Count	‡	‡	478	422	442	
	Total Relevant Dollars	‡	‡	131,541,614	111,201,546	116,267,543	**-5.45**
Inflammation	***Number of Grants***	‡	‡	***328***	***365***	***418***	
	Relevant Grant Dollars	‡	‡	59,043,221	66,040,358	81,746,863	
	Number of Contracts	‡	‡	***1***	***1***	‡	
	Relevant Contract Dollars	‡	‡	7,404,421	98,991	‡	
	Total Count	‡	‡	***329***	***366***	***418***	
	Total Relevant Dollars	‡	‡	66,447,642	66,139,349	81,746,863	**11.57**
Information Dissemination	***Number of Grants***	***1,014***	***945***	***902***	***853***	***861***	
	Relevant Grant Dollars	295,754,182	275,833,072	246,350,342	247,182,186	231,787,714	
	Number of Contracts	***77***	***76***	***72***	***57***	***38***	
	Relevant Contract Dollars	92,133,423	75,698,744	74,153,319	72,776,903	72,642,039	
	Total Count	***1,091***	***1,021***	***974***	***910***	***899***	
	Total Relevant Dollars	387,887,605	351,531,816	320,503,661	319,959,089	304,429,753	**-5.81**
Metastasis	***Number of Grants***	***1,443***	***1,546***	***1,585***	***1,574***	***1,527***	
	Relevant Grant Dollars	331,822,888	345,942,774	346,736,699	365,861,233	361,870,802	
	Number of Contracts	***6***	***6***	***8***	***8***	***7***	
	Relevant Contract Dollars	1,250,744	868,175	1,033,247	1,183,914	1,325,290	
	Total Count	***1,449***	***1,552***	***1,593***	***1,582***	***1,534***	
	Total Relevant Dollars	333,073,632	346,810,949	347,769,946	367,045,147	363,196,092	**2.22**
Mind/Body Research	***Number of Grants***	***110***	***103***	***83***	***82***	***75***	
	Relevant Grant Dollars	17,742,213	15,650,555	13,979,085	14,158,379	17,883,028	
	Total Count	***110***	***103***	***83***	***82***	***75***	
	Total Relevant Dollars	17,742,213	15,650,555	13,979,085	14,158,379	17,883,028	**1.28**
Molecular Disease	***Number of Grants***	***4,772***	***4,845***	***4,996***	***5,003***	***4,962***	
	Relevant Grant Dollars	1,580,537,686	1,577,174,333	1,563,937,623	1,615,324,573	1,670,263,492	
	Number of Contracts	***19***	***24***	***23***	***35***	***31***	
	Relevant Contract Dollars	8,248,034	8,406,934	7,309,485	12,253,807	9,144,621	
	Total Count	***4,791***	***4,869***	***5,019***	***5,038***	***4,993***	
	Total Relevant Dollars	1,588,785,720	1,585,581,267	1,571,247,108	1,627,578,380	1,679,408,113	**1.42**
Molecular Imaging	***Number of Grants***	***172***	***333***	***523***	***617***	***650***	
	Relevant Grant Dollars	67,815,895	105,359,905	147,326,896	174,956,716	164,707,342	
	Number of Contracts	***3***	***4***	***9***	***11***	***15***	
	Relevant Contract Dollars	869,490	1,013,254	1,650,977	2,239,610	4,042,324	
	Total Count	***175***	***337***	***532***	***628***	***665***	
	Total Relevant Dollars	68,685,385	106,373,159	148,977,873	177,196,326	168,749,666	**27.27**

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2006 - FY2010 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2006	2007	2008	2009	2010	Average Percent Change/yr.
Molecular Targeted Prevention	***Number of Grants***	***114***	***159***	***219***	***237***	***252***	
	Relevant Grant Dollars	26,784,643	34,942,948	39,335,671	46,986,672	39,235,184	
	Number of Contracts	‡	‡	***1***	‡	***1***	
	Relevant Contract Dollars	‡	‡	74,930	‡	74,750	
	Total Count	***114***	***159***	***220***	***237***	***253***	
	Total Relevant Dollars	26,784,643	34,942,948	39,410,601	46,986,672	39,309,934	**11.53**
Molecular Targeted Therapy	***Number of Grants***	***907***	***1,149***	***1,405***	***1,483***	***1,515***	
	Relevant Grant Dollars	242,765,138	312,853,050	393,453,935	404,674,238	407,096,513	
	Number of Contracts	***8***	***13***	***19***	***9***	***21***	
	Relevant Contract Dollars	3,704,202	3,032,933	2,742,385	2,305,444	6,175,491	
	Total Count	***915***	***1,162***	***1,424***	***1,492***	***1,536***	
	Total Relevant Dollars	246,469,340	315,885,983	396,196,320	406,979,682	413,272,004	**14.46**
Nanotechnology	***Number of Grants***	***558***	***492***	***496***	***430***	***461***	
	Relevant Grant Dollars	139,475,922	116,707,923	114,866,489	113,651,594	122,072,696	
	Number of Contracts	***8***	***14***	***22***	***10***	***20***	
	Relevant Contract Dollars	2,000,479	910,600	38,850,232	3,523,067	7,338,362	
	Total Count	***566***	***506***	***518***	***440***	***481***	
	Total Relevant Dollars	141,476,401	117,618,523	153,716,721	117,174,661	129,411,058	**0.12**
Neurofibromatosis	***Number of Grants***	***45***	***30***	***27***	***26***	***34***	
	Relevant Grant Dollars	6,443,759	4,151,165	4,166,356	6,209,557	7,560,557	
	Total Count	***45***	***30***	***27***	***26***	***34***	
	Total Relevant Dollars	6,443,759	4,151,165	4,166,356	6,209,557	7,560,557	**8.90**
Nursing Research	***Number of Grants***	***88***	***86***	***71***	***58***	***54***	
	Relevant Grant Dollars	17,597,195	17,454,501	14,422,508	12,056,800	13,918,717	
	Total Count	***88***	***86***	***71***	***58***	***54***	
	Total Relevant Dollars	17,597,195	17,454,501	14,422,508	12,056,800	13,918,717	**-4.79**
Nutrition-Fiber	***Number of Grants***	***49***	***36***	***29***	***21***	***19***	
	Relevant Grant Dollars	8,854,194	9,144,679	7,461,435	6,750,851	2,058,728	
	Number of Contracts	***1***	‡	‡	‡	‡	
	Relevant Contract Dollars	135	‡	‡	‡	‡	
	Total Count	***50***	***36***	***29***	***21***	***19***	
	Total Relevant Dollars	8,854,329	9,144,679	7,461,435	6,750,851	2,058,728	**-23.54**
Nutrition	***Number of Grants***	***905***	***914***	***887***	***866***	***830***	
	Relevant Grant Dollars	215,219,096	230,745,569	208,303,563	202,932,362	198,165,748	
	Number of Contracts	***19***	***19***	***19***	***16***	***14***	
	Relevant Contract Dollars	4,827,538	4,126,230	4,410,022	13,115,073	13,792,873	
	Total Count	***924***	***933***	***906***	***882***	***844***	
	Total Relevant Dollars	220,046,634	234,871,799	212,713,585	216,047,435	211,958,621	**-0.76**
Nutrition Monitoring	***Number of Grants***	***92***	***76***	***52***	***46***	***45***	
	Relevant Grant Dollars	21,039,187	22,183,358	12,732,118	14,363,776	11,311,406	
	Number of Contracts	***2***	***4***	***4***	***3***	‡	
	Relevant Contract Dollars	73,787	596,492	898,128	800,214	‡	
	Total Count	***94***	***80***	***56***	***49***	***45***	
	Total Relevant Dollars	21,112,974	22,779,850	13,630,246	15,163,990	11,311,406	**-11.61**
Obesity	***Number of Grants***	***240***	***236***	***235***	***232***	***251***	**1.21**
	Relevant Grant Dollars	49,717,620	54,166,986	49,154,604	52,150,701	47,992,367	
	Number of Contracts	***5***	***6***	***7***	***5***	–	
	Relevant Contract Dollars	145,263	447,594	899,253	801,220	–	
	Total Count	***245***	***242***	***242***	***237***	***251***	
	Total Relevant Dollars	49,862,883	54,614,580	50,053,857	52,951,921	47,992,367	**-0.60**

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2006 - FY2010 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2006	2007	2008	2009	2010	Average Percent Change/yr.
Occupational Cancer	***Number of Grants***	***84***	***66***	***64***	***51***	***57***	
	Relevant Grant Dollars	11,190,048	8,696,174	9,326,436	8,119,594	10,901,093	
	Number of Contracts	***5***	***5***	***6***	***3***	***2***	
	Relevant Contract Dollars	1,601,690	2,524,418	1,695,741	850,154	224,000	
	Total Count	***89***	***71***	***70***	***54***	***59***	
	Total Relevant Dollars	12,791,738	11,220,592	11,022,177	8,969,748	11,125,093	**-2.16**
Oncogenes	***Number of Grants***	***2,559***	***2,477***	***2,354***	***2,194***	***2,031***	
	Relevant Grant Dollars	658,402,443	621,281,231	552,856,295	518,552,721	515,190,558	
	Number of Contracts	***6***	***5***	***4***	***6***	***3***	
	Relevant Contract Dollars	1,593,958	1,438,471	1,347,905	2,229,506	2,074,867	
	Total Count	***2,565***	***2,482***	***2,358***	***2,200***	***2,034***	
	Total Relevant Dollars	659,996,401	622,719,702	554,204,200	520,782,227	517,265,425	**-5.84**
Organ Transplant Research	***Number of Grants***	***291***	***203***	***199***	***192***	***182***	
	Relevant Grant Dollars	69,200,514	74,100,547	64,935,205	65,966,217	66,404,117	
	Number of Contracts	‡	‡	‡	***1***	‡	
	Relevant Contract Dollars	‡	‡	‡	49,496	‡	
	Total Count	***291***	***203***	***199***	***193***	***182***	
	Total Relevant Dollars	69,200,514	74,100,547	64,935,205	66,015,713	66,404,117	**-0.76**
Osteoporosis	***Number of Grants***	***11***	***7***	***8***	***9***	***8***	
	Relevant Grant Dollars	1,692,180	1,291,894	1,596,851	913,593	411,172	
	Total Count	***11***	***7***	***8***	***9***	***8***	
	Total Relevant Dollars	1,692,180	1,291,894	1,596,851	913,593	411,172	**-24.46**
Pain	***Number of Grants***	***209***	***189***	***170***	***161***	***147***	
	Relevant Grant Dollars	21,839,235	19,956,772	16,642,839	16,576,535	16,468,439	
	Number of Contracts	‡	‡	***2***	‡	***2***	
	Relevant Contract Dollars	‡	‡	230,355	‡	1,299,610	
	Total Count	209	189	172	161	149	
	Total Relevant Dollars	21,839,235	19,956,772	16,873,194	16,576,535	17,768,049	**-4.66**
Palliative Care	***Number of Grants***	***217***	***211***	***186***	***167***	***161***	
	Relevant Grant Dollars	30,180,811	31,002,487	24,209,640	22,111,289	20,897,707	
	Number of Contracts	***1***	***2***	***5***	‡	***2***	
	Relevant Contract Dollars	33,630	247,473	612,259	‡	2,198,445	
	Total Count	***218***	***213***	***191***	***167***	***163***	
	Total Relevant Dollars	30,214,441	31,249,960	24,821,899	22,111,289	23,096,152	**-5.90**
PAP Testing	***Number of Grants***	***127***	***123***	***117***	***105***	***106***	
	Relevant Grant Dollars	17,766,146	16,109,246	13,323,361	10,352,147	10,627,523	
	Number of Contracts	‡	‡	‡	‡	***1***	
	Relevant Contract Dollars	‡	‡	‡	‡	45,000	
	Total Count	***127***	***123***	***117***	***105***	***107***	
	Total Relevant Dollars	17,766,146	16,109,246	13,323,361	10,352,147	10,672,523	**-11.46**
Pediatric Research	***Number of Grants***	***897***	***763***	***685***	***685***	***685***	
	Relevant Grant Dollars	248,484,026	233,892,539	208,184,370	212,351,643	212,337,590	
	Number of Contracts	***8***	***6***	***6***	***3***	***7***	
	Relevant Contract Dollars	4,195,055	3,811,957	1,471,436	2,134,899	4,384,833	
	Total Count	***905***	***769***	***691***	***688***	***692***	
	Total Relevant Dollars	252,679,081	237,704,496	209,655,806	214,486,542	216,722,423	**-3.59**

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2006 - FY2010 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2006	2007	2008	2009	2010	Average Percent Change/yr.
Personlized Health Care	***Number of Grants***	‡	***589***	***652***	***632***	***630***	
	Relevant Grant Dollars	‡	225,012,995	214,006,481	199,252,033	183,230,229	
	Number of Contracts	‡	***13***	***15***	***17***	***21***	
	Relevant Contract Dollars	‡	31,772,058	33,822,151	35,742,085	37,543,010	
	Total Count	‡	***602***	***667***	***649***	***651***	
	Total Relevant Dollars	‡	256,785,053	247,828,632	234,994,118	220,773,239	**-3.68**
Pesticides	***Number of Grants***	***31***	***25***	***21***	***14***	***12***	
	Relevant Grant Dollars	1,924,786	1,414,843	1,508,700	909,530	531,371	
	Number of Contracts	***2***	***2***	***2***	***2***	***2***	
	Relevant Contract Dollars	803,160	1,528,886	845,205	701,197	224,000	
	Total Count	***33***	***27***	***23***	***16***	***14***	
	Total Relevant Dollars	2,727,946	2,943,729	2,353,905	1,610,727	755,371	**-24.20**
Pharmacogenetics	***Number of Grants***	***252***	***268***	***319***	***310***	***312***	
	Relevant Grant Dollars	58,516,939	62,777,011	74,057,323	70,646,463	53,813,379	
	Number of Contracts	‡		***3***	***2***	‡	
	Relevant Contract Dollars	‡	149,518	1,039,064	150,000	‡	
	Total Count	***252***	***269***	***322***	***312***	***312***	
	Total Relevant Dollars	58,516,939	62,926,529	75,096,387	70,796,463	53,813,379	**-0.71**
Prevention	***Number of Grants***	***1,281***	***1,273***	***1,293***	***1,294***	***1,246***	
	Relevant Grant Dollars	386,566,823	390,136,455	356,228,797	346,953,036	324,621,692	
	Number of Contracts	***53***	***51***	***43***	***36***	***20***	
	Relevant Contract Dollars	40,519,391	42,187,416	41,680,021	46,984,156	28,993,208	
	Total Count	***1,334***	***1,324***	***1,336***	***1,330***	***1,266***	
	Total Relevant Dollars	427,086,214	432,323,871	397,908,818	393,937,192	353,614,900	**-4.49**
Proteomics	***Number of Grants***	***343***	***441***	***542***	***543***	***564***	
	Relevant Grant Dollars	68,782,088	83,307,623	99,199,104	98,691,096	105,713,144	
	Number of Contracts	***9***	***17***	***23***	***14***	***13***	
	Relevant Contract Dollars	967,097	1,967,090	39,204,878	4,666,075	3,710,715	
	Total Count	***352***	***458***	***565***	***557***	***577***	
	Total Relevant Dollars	69,749,185	85,274,713	138,403,982	103,357,171	109,423,859	**16.28**
Radiation, Electromagnetic Fields	***Number of Grants***	***11***	***7***	***7***	***5***	***5***	
	Relevant Grant Dollars	606,916	1,246,146	821,382	235,460	794,902	
	Total Count	***11***	***7***	***7***	***5***	***5***	
	Total Relevant Dollars	606,916	1,246,146	821,382	235,460	794,902	**59.37**
Radiation, Ionizing	***Number of Grants***	***258***	***219***	***192***	***143***	***137***	
	Relevant Grant Dollars	43,036,389	36,870,333	31,992,559	24,747,402	24,942,689	
	Number of Contracts	***6***	***5***	***6***	***1***	‡	
	Relevant Contract Dollars	1,366,054	1,290,859	940,864	200,000	‡	
	Total Count	***264***	***224***	***198***	***144***	***137***	
	Total Relevant Dollars	44,402,443	38,161,192	32,933,423	24,947,402	24,942,689	**-13.01**
Radiation, Ionizing Diagnosis	***Number of Grants***	***117***	***176***	***231***	***236***	***284***	
	Relevant Grant Dollars	36,205,864	45,615,274	50,150,240	60,711,962	67,228,830	
	Number of Contracts	***6***	***4***	***5***	***3***	***2***	
	Relevant Contract Dollars	1,581,778	1,203,666	270,167	465,803	1,127,414	
	Total Count	***123***	***180***	***236***	***239***	***286***	
	Total Relevant Dollars	37,787,642	46,818,940	50,420,407	61,177,765	68,356,244	**16.17**

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2006 - FY2010 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2006	2007	2008	2009	2010	Average Percent Change/yr.
Radiation, Ionizing Radiotherapy	***Number of Grants***	***703***	***696***	***680***	***635***	***605***	
	Relevant Grant Dollars	227,637,796	216,965,316	207,665,565	199,422,427	197,773,842	
	Number of Contracts	***8***	***6***	***4***	***4***	***3***	
	Relevant Contract Dollars	1,957,241	985,654	47,500	545,157	226,116	
	Total Count	***711***	***702***	***684***	***639***	***608***	
	Total Relevant Dollars	229,595,037	217,950,970	207,713,065	199,967,584	197,999,958	**-3.62**
Radiation, Low-level Ionizing	***Number of Grants***	***40***	***31***	***23***	***20***	***16***	
	Relevant Grant Dollars	9,904,869	6,781,869	6,004,368	6,500,454	3,564,004	
	Number of Contracts	***40***	‡	‡	***1***	‡	
	Relevant Contract Dollars	9,904,869	‡	‡	200,000	‡	
	Total Count	***31***	***31***	***23***	***21***	***16***	
	Total Relevant Dollars	6,781,869	6,781,869	6,004,368	6,700,454	3,564,004	**-11.67**
Radiation, Magnetic Resonance Imaging	***Number of Grants***	***304***	***327***	***360***	***324***	***309***	
	Relevant Grant Dollars	74,245,038	78,242,316	80,540,821	75,059,941	71,053,694	
	Number of Contracts	***5***	***3***	***3***	***3***	***2***	
	Relevant Contract Dollars	1,337,521	366,699	217,673	416,415	625,760	
	Total Count	***309***	***330***	***363***	***327***	***311***	
	Total Relevant Dollars	75,582,559	78,609,015	80,758,494	75,476,356	71,679,454	**-1.21**
Radiation, Mammography	***Number of Grants***	***239***	***223***	***205***	***203***	***211***	**-2.95**
	Relevant Grant Dollars	35,998,329	28,018,078	28,042,754	31,642,663	26,824,376	
	Number of Contracts	***2***	***2***	***2***	***1***	***1***	
	Relevant Contract Dollars	748,527	442	452	464	999,985	
	Total Count	***241***	***225***	***207***	***204***	***212***	
	Total Relevant Dollars	36,746,856	28,018,520	28,043,206	31,643,127	27,824,361	**-5.72**
Radiation, Non-Ionizing	***Number of Grants***	***271***	***259***	***219***	***177***	***167***	
	Relevant Grant Dollars	43,811,726	38,486,311	32,101,143	27,357,488	26,918,563	
	Number of Contracts	‡	‡	‡	‡	***3***	
	Relevant Contract Dollars	‡	‡	‡	‡	476,414	
	Total Count	***271***	***259***	***219***	***177***	***170***	
	Total Relevant Dollars	43,811,726	38,486,311	32,101,143	27,357,488	27,394,977	**-10.85**
Radiation, Non-Ionizing Diagnosis	***Number of Grants***	***390***	***443***	***514***	***502***	***471***	
	Relevant Grant Dollars	109,296,293	116,159,136	132,398,533	136,372,426	125,702,669	
	Number of Contracts	***4***	***3***	***4***	***3***	***9***	
	Relevant Contract Dollars	293,590	308,514	446,969	416,415	1,675,452	
	Total Count	***394***	***446***	***518***	***505***	***480***	
	Total Relevant Dollars	109,589,883	116,467,650	132,845,502	136,788,841	127,378,121	**4.11**
Radiation, Non-Ionizing Radiotherapy	***Number of Grants***	***101***	***117***	***152***	***161***	***195***	
	Relevant Grant Dollars	20,468,935	21,061,866	31,373,416	41,460,636	40,077,552	
	Number of Contracts	***1***	***1***	***1***	***1***	***3***	
	Relevant Contract Dollars	50,000	191,815	181,796	199,735	599,386	
	Total Count	***102***	***118***	***153***	***162***	***198***	
	Total Relevant Dollars	20,518,935	21,253,681	31,555,212	41,660,371	40,676,938	**20.43**
Radiation, Ultraviolet	***Number of Grants***	***242***	***224***	***189***	***152***	***149***	
	Relevant Grant Dollars	36,302,488	31,886,944	27,465,174	23,732,686	23,686,597	
	Number of Contracts	‡	‡	‡	‡	***3***	
	Relevant Contract Dollars	‡	‡	‡	‡	476,414	
	Total Count	***242***	***224***	***189***	***152***	***152***	
	Total Relevant Dollars	36,302,488	31,886,944	27,465,174	23,732,686	24,163,011	**-9.45**

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2006 - FY2010 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2006	2007	2008	2009	2010	Average Percent Change/yr.
Radon	***Number of Grants***	***9***	***9***	***6***	***5***	***2***	
	Relevant Grant Dollars	1,877,626	1,928,547	2,177,728	1,976,301	48,624	
	Total Count	***9***	***9***	***6***	***5***	***2***	
	Total Relevant Dollars	1,877,626	1,928,547	2,177,728	1,976,301	48,624	**-22.79**
Rare Diseases	***Number of Grants***	***265***	***220***	***183***	***138***	***140***	
	Relevant Grant Dollars	42,173,309	37,126,604	30,770,735	26,634,147	29,192,350	
	Number of Contracts	***2***	‡	‡	‡	‡	
	Relevant Contract Dollars	281,419	‡	‡	‡	‡	
	Total Count	***267***	***220***	***183***	***138***	***140***	
	Total Relevant Dollars	42,454,728	37,126,604	30,770,735	26,634,147	29,192,350	**-8.38**
Rehabilitation	***Number of Grants***	***230***	***232***	***215***	***221***	***221***	
	Relevant Grant Dollars	33,176,219	36,209,824	33,557,701	37,960,259	38,584,600	
	Number of Contracts	***14***	***16***	***16***	***14***	***2***	
	Relevant Contract Dollars	1,848,430	2,094,384	1,508,881	1,131,599	76,452	
	Total Count	***244***	***248***	***231***	***235***	***223***	
	Total Relevant Dollars	35,024,649	38,304,208	35,066,582	39,091,858	38,661,052	**2.82**
Rural Populations	***Number of Grants***	***124***	***112***	***106***	***95***	***103***	
	Relevant Grant Dollars	36,940,512	36,914,134	35,317,988	38,996,059	35,157,309	
	Number of Contracts	***14***	***13***	***13***	***12***	***12***	
	Relevant Contract Dollars	12,018,025	10,687,353	11,397,326	9,846,502	10,416,108	
	Total Count	***138***	***125***	***119***	***107***	***115***	
	Total Relevant Dollars	48,958,537	47,601,487	46,715,314	48,842,561	45,573,417	**-1.69**
Sexually Transmitted Diseases	***Number of Grants***	***256***	***232***	***215***	***192***	***183***	
	Relevant Grant Dollars	48,610,852	43,581,416	35,502,090	31,951,321	30,488,788	
	Number of Contracts	***2***	***1***	***1***	***1***	***2***	
	Relevant Contract Dollars	1,748,434	3,893,007	3,621,135	3,701,779	4,439,576	
	Total Count	***258***	***233***	***216***	***193***	***185***	
	Total Relevant Dollars	50,359,286	47,474,423	39,123,225	35,653,100	34,928,364	**-8.56**
Sleep Disorders	***Number of Grants***	***82***	***67***	***65***	***54***	***70***	
	Relevant Grant Dollars	8,394,505	7,121,771	7,576,158	7,775,308	9,183,149	
	Total Count	***82***	***67***	***65***	***54***	***70***	
	Total Relevant Dollars	8,394,505	7,121,771	7,576,158	7,775,308	9,183,149	**2.99**
Small Molecules	***Number of Grants***	***437***	***439***	***429***	***386***	***407***	
	Relevant Grant Dollars	77,130,043	77,439,195	77,887,805	73,465,245	70,693,138	
	Number of Contracts	***6***	***6***	***4***	***1***	***10***	
	Relevant Contract Dollars	1,369,166	784,713	843,000	30,860	2,203,593	
	Total Count	***443***	***445***	***433***	***387***	***417***	
	Total Relevant Dollars	78,499,209	78,223,908	78,730,805	73,496,105	72,896,731	**-1.79**
Smokeless Tobacco	***Number of Grants***	***34***	***24***	***24***	***26***	***34***	
	Relevant Grant Dollars	3,964,736	3,306,451	3,957,700	5,933,701	6,896,702	
	Number of Contracts	***2***	***2***	***1***	***–***	***1***	
	Relevant Contract Dollars	1,722,264	1,761,000	1,800,000	–	453,965	
	Total Count	***36***	***26***	***25***	***26***	***35***	
	Total Relevant Dollars	5,687,000	5,067,451	5,757,700	5,933,701	7,350,667	**7.42**
Smoking, Passive	***Number of Grants***	***42***	***34***	***32***	***30***	***24***	
	Relevant Grant Dollars	6,106,281	5,124,660	4,887,736	3,425,541	3,459,579	
	Number of Contracts	***1***	‡	‡	‡	***1***	
	Relevant Contract Dollars	73,610	‡	‡	‡	453,965	
	Total Count	***43***	***35***	***32***	***30***	***25***	
	Total Relevant Dollars	6,179,891	5,124,660	4,887,736	3,425,541	3,913,544	**-9.34**

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2006 - FY2010 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2006	2007	2008	2009	2010	Average Percent Change/yr.
Structural Biology	***Number of Grants***	***1,817***	***1,750***	***1,610***	***1,456***	***1,337***	
	Relevant Grant Dollars	383,326,730	358,120,437	310,422,424	280,014,980	269,191,027	
	Number of Contracts	***19***	***18***	***16***	***17***	***11***	
	Relevant Contract Dollars	3,572,206	2,971,719	39,571,941	2,434,109	1,512,388	
	Total Count	***1,836***	***1,768***	***1,626***	***1,473***	***1,348***	
	Total Relevant Dollars	386,898,936	361,092,156	349,994,365	282,449,089	270,703,415	**-8.30**
Surgery	***Number of Grants***	***423***	***409***	***390***	***352***	***327***	
	Relevant Grant Dollars	72,096,051	67,021,084	66,059,380	63,498,562	72,591,577	
	Number of Contracts	***1***	‡	‡	‡	***2***	
	Relevant Contract Dollars	94	‡	‡	‡	1,200,000	
	Total Count	***424***	***409***	***390***	***352***	***329***	
	Total Relevant Dollars	72,096,145	67,021,084	66,059,380	63,498,562	73,791,577	**0.96**
Taxol	***Number of Grants***	***318***	***304***	***290***	***284***	***305***	
	Relevant Grant Dollars	68,367,393	69,172,683	62,261,243	68,741,615	73,441,347	
	Number of Contracts	***1***	‡	‡	‡	***1***	
	Relevant Contract Dollars	118,520	‡	‡	‡	50,000	
	Total Count	***319***	***304***	***290***	***284***	***306***	
	Total Relevant Dollars	68,485,913	69,172,683	62,261,243	68,741,615	73,491,347	**2.08**
Telehealth	***Number of Grants***	***496***	***428***	***399***	***364***	***351***	
	Relevant Grant Dollars	86,521,461	85,583,070	74,370,113	76,214,970	83,738,070	
	Number of Contracts	***34***	***34***	***39***	***26***	***10***	
	Relevant Contract Dollars	32,729,093	28,625,864	24,501,587	15,922,057	12,502,513	
	Total Count	***530***	***462***	***438***	***390***	***361***	
	Total Relevant Dollars	119,250,554	114,208,934	98,871,700	92,137,027	96,240,583	**-5.00**
Therapy	***Number of Grants***	***3,619***	***3,695***	***3,842***	***3,736***	***3,668***	
	Relevant Grant Dollars	1,243,876,269	1,273,381,182	1,256,647,167	1,253,530,990	1,289,919,675	
	Number of Contracts	***112***	***122***	***112***	***104***	***102***	
	Relevant Contract Dollars	77,205,721	80,366,537	68,675,001	100,995,788	97,314,391	
	Total Count	***3,731***	***3,817***	***3,954***	***3,840***	***3,770***	
	Total Relevant Dollars	1,321,081,990	1,353,747,719	1,325,322,168	1,354,526,778	1,387,234,066	**1.25**
Tobacco	***Number of Grants***	***558***	***494***	***465***	***493***	***470***	
	Relevant Grant Dollars	119,689,824	110,296,415	107,012,253	106,446,317	121,389,946	
	Number of Contracts	***9***	***6***	***5***	***7***	***8***	
	Relevant Contract Dollars	4,388,790	3,240,062	2,762,640	804,235	2,479,840	
	Total Count	***567***	***500***	***470***	***500***	***478***	
	Total Relevant Dollars	124,078,614	113,536,477	109,774,893	107,250,552	123,869,786	**0.35**
Tobacco Use Behavior	***Number of Grants***	***241***	***221***	***219***	***250***	***250***	
	Relevant Grant Dollars	60,779,328	57,580,022	61,173,821	65,696,233	81,176,603	
	Number of Contracts	***1***	‡	‡	***2***	***4***	
	Relevant Contract Dollars	736,102	‡	‡	144,041	1,868,571	
	Total Count	***242***	***221***	***219***	***252***	***254***	
	Total Relevant Dollars	61,515,430	57,580,022	61,173,821	65,840,274	83,045,174	**8.40**
Tropical Diseases	***Number of Grants***	***77***	***48***	***36***	***31***	***29***	
	Relevant Grant Dollars	11,102,288	8,793,217	8,218,552	7,697,801	6,535,704	
	Number of Contracts	***2***	‡	‡	‡	‡	
	Relevant Contract Dollars	389,789	‡	‡	‡	‡	
	Total Count	***79***	***48***	***36***	***31***	***29***	
	Total Relevant Dollars	11,492,077	8,793,217	8,218,552	7,697,801	6,535,704	**-12.86**

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2006 - FY2010 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2006	2007	2008	2009	2010	Average Percent Change/yr.
Tumor Markers	***Number of Grants***	***1,276***	***1,134***	***996***	***846***	***731***	
	Relevant Grant Dollars	378,996,391	319,367,043	252,452,493	218,547,902	189,955,095	
	Number of Contracts	***20***	***25***	***29***	***19***	***12***	
	Relevant Contract Dollars	6,216,616	5,365,228	4,923,691	6,788,354	4,365,645	
	Total Count	***1,296***	***1,159***	***1,025***	***865***	***743***	
	Total Relevant Dollars	385,213,007	324,732,271	257,376,184	225,336,256	194,320,740	**-15.66**
Underserved Populations	***Number of Grants***	***558***	***562***	***568***	***563***	***607***	
	Relevant Grant Dollars	176,770,599	184,506,681	173,480,427	193,637,731	210,560,355	
	Number of Contracts	***41***	***41***	***38***	***34***	***21***	
	Relevant Contract Dollars	19,647,583	18,594,280	15,803,363	14,072,123	12,245,405	
	Total Count	***599***	***603***	***606***	***597***	***628***	
	Total Relevant Dollars	196,418,182	203,100,961	189,283,790	207,709,854	222,805,760	**3.40**
Vaccine Development	***Number of Grants***	***210***	***173***	***171***	***168***	***163***	
	Relevant Grant Dollars	29,948,556	27,285,816	25,020,169	27,688,541	21,218,754	
	Number of Contracts	‡	‡	‡	***2***	‡	
	Relevant Contract Dollars	‡	74,646	‡	1,370,729	‡	
	Total Count	***210***	***174***	***171***	***170***	***163***	
	Total Relevant Dollars	29,948,556	27,360,462	25,020,169	29,059,270	21,218,754	**-7.01**
Vaccine Production	***Number of Grants***	***12***	***9***	***8***	***4***	***8***	
	Relevant Grant Dollars	2,554,459	2,813,459	1,733,938	1,679,991	1,046,919	
	Total Count	***12***	***9***	***8***	***4***	***8***	
	Total Relevant Dollars	2,554,459	2,813,459	1,733,938	1,679,991	1,046,919	**-17.26**
Vaccine Research	***Number of Grants***	***239***	***208***	***211***	***201***	***201***	
	Relevant Grant Dollars	42,967,922	36,637,670	34,486,715	37,047,110	33,377,072	
	Number of Contracts	***1***	***2***	***2***	***1***	***1***	
	Relevant Contract Dollars	55,768	132,329	14,808,841	30,860	23,100	
	Total Count	***240***	***210***	***213***	***202***	***202***	
	Total Relevant Dollars	43,023,690	36,769,999	49,295,556	37,077,970	33,400,172	**-3.79**
Vaccine Testing	***Number of Grants***	***225***	***156***	***151***	***138***	***130***	
	Relevant Grant Dollars	41,858,407	39,939,724	34,603,697	29,771,312	21,759,604	
	Number of Contracts	***1***	***1***	***1***	***1***	***1***	
	Relevant Contract Dollars	1,643,434	3,893,007	3,621,135	3,701,779	4,394,576	
	Total Count	***226***	***157***	***152***	***139***	***131***	
	Total Relevant Dollars	43,501,841	43,832,731	38,224,832	33,473,091	26,154,180	**-11.58**
Virus – Cancer Research	***Number of Grants***	***729***	***652***	***613***	***558***	***541***	
	Relevant Grant Dollars	190,728,923	172,868,916	158,577,860	151,074,096	153,628,908	
	Number of Contracts	***5***	***4***	***3***	***3***	***3***	
	Relevant Contract Dollars	2,500,689	4,042,298	18,429,976	5,230,139	4,549,461	
	Total Count	***734***	***656***	***616***	***561***	***544***	
	Total Relevant Dollars	193,229,612	176,911,214	177,007,836	156,304,235	158,178,369	**-4.72**
Virus – Epstein-Barr	***Number of Grants***	***142***	***116***	***115***	***110***	***110***	
	Relevant Grant Dollars	25,347,665	21,411,991	26,897,323	26,563,416	24,362,117	
	Number of Contracts	***1***	‡	‡	‡	‡	
	Relevant Contract Dollars	89,789	‡	‡	‡	‡	
	Total Count	***143***	***116***	***115***	***110***	***110***	
	Total Relevant Dollars	25,437,454	21,411,991	26,897,323	26,563,416	24,362,117	**0.07**
Virus – Genital Herpes	***Number of Grants***	***8***	***7***	***6***	***4***	***4***	
	Relevant Grant Dollars	***297,627***	***496,778***	***540,230***	***477,647***	***379,575***	
	Total Count	***8***	***7***	***6***	***4***	***4***	
	Total Relevant Dollars	297,627	496,778	540,230	477,647	379,575	**10.89**

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2006 - FY2010 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2006	2007	2008	2009	2010	Average Percent Change/yr.
Virus – Hepatitis B	***Number of Grants***	***51***	***51***	***50***	***54***	***51***	
	Relevant Grant Dollars	9,944,143	11,410,102	11,387,036	12,166,996	11,337,066	
	Total Count	***51***	***51***	***50***	***54***	***51***	
	Total Relevant Dollars	9,944,143	11,410,102	11,387,036	12,166,996	11,337,066	**3.64**
Virus – Hepatitis C	***Number of Grants***	***47***	***41***	***38***	***35***	***34***	
	Relevant Grant Dollars	6,080,530	6,769,322	5,322,764	6,405,143	5,719,779	
	Number of Contracts	***2***	***–***	***–***	***–***	***–***	
	Relevant Contract Dollars	184,184	–	–	–	–	
	Total Count	***49***	***41***	***38***	***35***	***34***	
	Total Relevant Dollars	6,264,714	6,769,322	5,322,764	6,405,143	5,719,779	**-0.92**
Virus – Herpes	***Number of Grants***	***256***	***225***	***228***	***208***	***206***	
	Relevant Grant Dollars	52,147,330	51,242,661	56,793,367	54,527,236	47,274,246	
	Number of Contracts	***2***	‡	‡	‡	‡	
	Relevant Contract Dollars	184,184	‡	‡	‡	‡	
	Total Count	***258***	***225***	***228***	***208***	***206***	
	Total Relevant Dollars	52,331,514	51,242,661	56,793,367	54,527,236	47,274,246	**-2.14**
Virus – HHV8	***Number of Grants***	***117***	***100***	***94***	***81***	***87***	
	Relevant Grant Dollars	19,999,456	21,779,525	23,036,760	19,737,355	18,532,843	
	Number of Contracts	***2***	‡	‡	‡	‡	
	Relevant Contract Dollars	184,184	‡	‡	‡	‡	
	Total Count	***119***	***100***	***94***	***81***	***87***	
	Total Relevant Dollars	20,183,640	21,779,525	23,036,760	19,737,355	18,532,843	**-1.69**
Virus – HTLV-I	***Number of Grants***	***49***	***31***	***27***	***23***	***22***	
	Relevant Grant Dollars	8,887,632	8,125,525	6,797,477	7,313,840	6,183,612	
	Number of Contracts	***2***	‡	‡	‡	‡	
	Relevant Contract Dollars	389,789	‡	‡	‡	‡	
	Total Count	***51***	***31***	***27***	***23***	***22***	
	Total Relevant Dollars	9,277,421	8,125,525	6,797,477	7,313,840	6,183,612	**-9.15**
Virus – HTLV-II	***Number of Grants***	***4***	***5***	***4***	***1***	‡	
	Relevant Grant Dollars	180,823	286,731	409,579	135,552	‡	
	Total Count	***4***	***5***	***4***	***1***	‡	
	Total Relevant Dollars	180,823	286,731	409,579	135,552	‡	**11.50**
Virus – Papilloma	***Number of Grants***	***226***	***191***	***178***	***166***	***169***	
	Relevant Grant Dollars	49,170,724	50,026,145	43,565,517	39,602,459	46,214,177	
	Number of Contracts	***2***	***1***	***1***	***3***	***1***	
	Relevant Contract Dollars	1,652,745	3,893,007	3,621,135	5,230,139	4,394,576	
	Total Count	***228***	***192***	***179***	***169***	***170***	
	Total Relevant Dollars	50,823,469	53,919,152	47,186,652	44,832,598	50,608,753	**0.37**
Virus – Papova	***Number of Grants***	***282***	***238***	***221***	***206***	***207***	
	Relevant Grant Dollars	63,617,172	62,029,169	54,680,936	49,970,034	55,528,827	
	Number of Contracts	***2***	***1***	***1***	***3***	***2***	
	Relevant Contract Dollars	1,652,745	3,893,007	3,621,135	5,230,139	4,544,576	
	Total Count	***284***	***239***	***222***	***209***	***209***	
	Total Relevant Dollars	65,269,917	65,922,176	58,302,071	55,200,173	60,073,403	**-1.76**
Virus – SV40	***Number of Grants***	***60***	***46***	***40***	***36***	***29***	
	Relevant Grant Dollars	10,865,846	8,818,318	7,172,313	5,967,645	5,171,617	
	Total Count	***60***	***46***	***40***	***36***	***29***	
	Total Relevant Dollars	10,865,846	8,818,318	7,172,313	5,967,645	5,171,617	**-16.91**

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2006 - FY2010 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2006	2007	2008	2009	2010	Average Percent Change/yr.
Vitamin A	***Number of Grants***	124	109	102	89	66	
	Relevant Grant Dollars	19,099,767	19,640,820	16,421,451	11,622,987	8,863,103	
	Number of Contracts		***1***	***1***	***1***	***1***	
	Relevant Contract Dollars		306,833	178,904	300,000	391,285	
	Total Count	***124***	***110***	***103***	***90***	***67***	
	Total Relevant Dollars	19,099,767	19,947,653	16,600,355	11,922,987	9,254,388	**-15.72**
Vitamin C	***Number of Grants***	***48***	***31***	***26***	***24***	***21***	
	Relevant Grant Dollars	4,681,825	2,781,603	2,020,753	2,234,318	1,843,823	
	Total Count	***48***	***31***	***26***	***24***	***21***	
	Total Relevant Dollars	4,681,825	2,781,603	2,020,753	2,234,318	1,843,823	**-18.71**
Vitamin D	***Number of Grants***	‡	‡	‡	***32***	***45***	
	Relevant Grant Dollars	‡	‡	‡	9,218,013	11,837,723	
	Number of Contracts	‡	‡	‡	***1***		
	Relevant Contract Dollars	‡	‡	‡	200,000		
	Total Count	‡	‡	‡	***33***	***45***	
	Total Relevant Dollars	‡	‡	‡	9,418,013	11,837,723	**-17.48**
Vitamins, Other	***Number of Grants***	***117***	***104***	***103***	***72***	***55***	
	Relevant Grant Dollars	22,767,084	22,228,099	20,299,917	15,499,403	12,310,882	
	Total Count	***117***	***104***	***103***	***72***	***55***	
	Total Relevant Dollars	22,767,084	22,228,099	20,299,917	15,499,403	12,310,882	**-13.82**

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.

Table 17. NCI Funding of Foreign Research Grants in FY2010

(This table reports extramural grants only; intramural grants and contracts are excluded.)

Country/ Cancer Site	Mechanism								
AUSTRALIA	**F31**	**R01**	**R03**	**R21**	**R37**	**U01**	**U10**	**U24**	**Totals**
Grants #		*3*	*1*		*1*	*1*		*1*	*7*
Funding $		*409,122*	*54,000*		*118,659*	*379,146*		*1,623,208*	*2,584,135*
Breast						379,146			379,146
Colon, Rectum		218,743						1,623,208	1,841,951
Hodgkins Lymphoma					40,344				40,344
Melanoma		190,379							190,379
Myeloma					37,971				37,971
Neuroblastoma			54,000						54,000
Non-Hodgkins Lymphoma					40,344				40,344
BELGIUM	**F31**	**R01**	**R03**	**R21**	**R37**	**U01**	**U10**	**U24**	**Totals**
Grants #							*1*		*1*
Funding $							*482,054*		*482,054*
Bone Marrow							4,229		4,229
Brain							8,457		8,457
Breast							198,741		198,741
Childhood Leukemia							59,199		59,199
Colon, Rectum							50,742		50,742
Kidney							16,914		16,914
Leukemia							59,199		59,199
Lung							12,686		12,686
Myeloma							8,457		8,457
Neuroblastoma							8,457		8,457
Non-Hodgkins Lymphoma							4,229		4,229
Not Site Specific							12,686		12,686
Ovary							12,686		12,686
Prostate							21,143		21,143
Uterus							4,229		4,229
CANADA	**F31**	**R01**	**R03**	**R21**	**R37**	**U01**	**U10**	**U24**	**Totals**
Grants #		*12*	*1*	*6*	*1*	*3*	*4*	*2*	*29*
Funding $		*3,969,739*	*66,707*	*542,594*	*344,692*	*1,675,780*	*249,088*	*3,226,863*	*10,075,463*
Bladder		67,186							67,186
Breast		615,763		369,257	86,173	651,917	191,012		1,914,122
Colon, Rectum							11,000	1,050,085	1,061,085
Head and Neck			66,707						66,707
Kidney							1,883		1,883
Leukemia		1,192,744			172,346		3,766		1,368,856
Liver		52,570							52,570
Lung		1,444,974			86,173		5,649		1,536,796
Muscle		61,448							61,448
Myeloma							11,298		11,298
Non-Hodgkins Lymphoma							1,883		1,883
Not Site Specific				173,337		722,220	5,649	2,176,778	3,077,984
Ovary						301,643			301,643
Pancreas		52,570							52,570
Prostate		262,401					15,065		277,466
Skin		61,448							61,448
Urinary System							1,883		1,883
Vascular		158,635							158,635

continued

Source: Research Analysis and Evaluation Branch.

Table 17. NCI Funding of Foreign Research Grants in FY2010

(This table reports extramural grants only; intramural grants and contracts are excluded.)

Country/ Cancer Site	Mechanism								
FRANCE	**F31**	**R01**	**R03**	**R21**	**R37**	**U01**	**U10**	**U24**	**Totals**
Grants #		*1*				*1*			*2*
Funding $		*450,692*				*858,888*			*1,309,580*
Bladder		22,535				128,833			151,368
Head and Neck		225,346							225,346
Lung		202,811				128,833			331,644
Not Site Specific						601,222			601,222
GERMANY	**F31**	**R01**	**R03**	**R21**	**R37**	**U01**	**U10**	**U24**	**Totals**
Grants #		*1*							*1*
Funding $		*379,595*							*379,595*
Ovary		379,595							379,595
INDIA	**F31**	**R01**	**R03**	**R21**	**R37**	**U01**	**U10**	**U24**	**Totals**
Grants #		*1*							*1*
Funding $		*403,444*							*403,444*
Breast		201,722							201,722
Cervix		201,722							201,722
IRELAND	**F31**	**R01**	**R03**	**R21**	**R37**	**U01**	**U10**	**U24**	**Totals**
Grants #		*1*							*1*
Funding $		*200,545*							*200,545*
Neuroblastoma		200,545							200,545
ISRAEL	**F31**	**R01**	**R03**	**R21**	**R37**	**U01**	**U10**	**U24**	**Totals**
Grants #		*6*			*2*	*1*			*9*
Funding $		*737,189*			*463,247*				*1,200,436*
Breast		118,934			237,319				356,253
Colon, Rectum					56,482				56,482
Lung		63,273			169,446				232,719
Melanoma		63,273							63,273
Not Site Specific		263,537							263,537
Ovary		51,386							51,386
Prostate		53,743							53,743
Vascular		123,043							123,043
SPAIN	**F31**	**R01**	**R03**	**R21**	**R37**	**U01**	**U10**	**U24**	**Totals**
Grants #		*5*							*5*
Funding $		*963,951*							*963,951*
Brain		348,510							348,510
Melanoma		224,100							224,100
Pancreas		391,341							391,341
SWEDEN	**F31**	**R01**	**R03**	**R21**	**R37**	**U01**	**U10**	**U24**	**Totals**
Grants #		*1*							*1*
Funding $		*386,237*							*386,237*
Prostate		386,237							386,237

continued

Table 17. NCI Funding of Foreign Research Grants in FY2010

(This table reports extramural grants only; intramural grants and contracts are excluded.)

Country/ Cancer Site	Mechanism								
SWITZERLAND	**F31**	**R01**	**R03**	**R21**	**R37**	**U01**	**U10**	**U24**	**Totals**
Grants #		*2*							*2*
Funding $		*366,050*							*366,050*
Not Site Specific		366,050							366,050
UNITED KINGDOM	**F31**	**R01**	**R03**	**R21**	**R37**	**U01**	**U10**	**U24**	**Totals**
Grants #	*1*	*6*				*1*		*1*	*9*
Funding $	*41,380*	*596,106*				*816,290*		*231,444*	*1,685,220*
Bladder		22,440							22,440
Breast	41,380					408,145			449,525
Colon, Rectum		73,654							73,654
Lung		426,358							426,358
Melanoma		73,654							73,654
Prostate						408,145			408,145
Thyroid								231,444	231,444
Total Grants	**1**	**39**	**2**	**6**	**4**	**7**	**5**	**4**	**68**
Total $ Per Grant Mechanism	**41,380**	**8,862,670**	**120,707**	**542,594**	**926,598**	**3,730,104**	**731,142**	**5,081,515**	**20,036,710**

Table 18. Foreign Components of U.S. Domestic Research Grants in FY2010

(This table reports extramural grants only; intramural grants and contracts are excluded.)

Country	Funding Mechanism																				Sub-total
	D43	F32	K01	K07	K25	P01	P50	R01	R03	R13	R21	R24	R25	R33	R37	R44	T15	U01	U19	U24	U54	
Africa (not-specified)																		1				**1**
Argentina																		1		1		**2**
Australia			1			1		13	1									4		3		**23**
Austria								4												1		**5**
Bangladesh								2														**2**
Barbados								2														**2**
Belgium																				1		**1**
Brazil								3									1	3		1		**8**
Cameroon	1																	1				**2**
Canada						1	1	23	2	5	3				1	1		9		4		**50**
Chile										1												**1**
China								15	1	1					1				1	2		**21**
Colombia		1				1														1		**3**
Costa Rica																		1				**1**
Czech Republic								3												1		**4**
Denmark							1	6			1									1		**9**
Dominican Republic								1														**1**
Egypt								3					1							1		**5**
Finland								4	1											1		**6**
France								8	1											1		**10**
Germany					1			12		1		1					1	2		2		**20**
Greece								1														**1**
Haiti								1														**1**
Honduras				1																		**1**
Hungary																				2		**2**
India							1	2										1		1		**5**
Iran																				1		**1**
Ireland								2												1		**3**
Israel								11	1						1		1			2		**16**
Italy								7	1	3	1				1					2		**15**
Japan								5		1								1		1		**8**
Kenya	1							3										2				**6**
Kuwait																				1		**1**
Latvia								1														**1**
Malawi																		1				**1**
Malaysia																				1		**1**
Mexico								2												1		**3**
Moldova															1							**1**
Morocco								1														**1**
Netherlands								9							1			4		1	1	**16**
New Zealand								3			1									2		**6**
Nigeria	1							1										1				**3**

continued

Source: Research Analysis and Evaluation Branch.

Table 18. Foreign Components of U.S. Domestic Research Grants in FY2010

(This table reports extramural grants only; intramural grants and contracts are excluded.)

Country	Funding Mechanism																				Sub-total
	D43	F32	K01	K07	K25	P01	P50	R01	R03	R13	R21	R24	R25	R33	R37	R44	T15	U01	U19	U24	U54	
Norway								1									1					**2**
Pakistan																				1		**1**
Panama																				1		**1**
Peru																					2	**2**
Philippines								1			1											**2**
Poland								1												1		**2**
Portugal																				1		**1**
Russia								2												2		**4**
Rwanda	1																					**1**
Saudi Arabia																				1		**1**
Senegal								2														**2**
Singapore				1				2												1		**4**
Slovenia																				1		**1**
South Africa	1							1										1		2		**5**
South Korea								2												1		**3**
Spain								6		1								1		2		**10**
Sweden								9		1				1						2		**13**
Switzerland						1												1		2		**4**
Taiwan								1												1		**2**
Tanzania	1																					**1**
Thailand																		1				**1**
Turkey						1		1												1		**3**
Uganda	2							1	1									2				**6**
United Kingdom						1		29	1	1	1			1			2	5		1	1	**43**
Uruguay																				1		**1**
Venezuela																				1		**1**
Vietnam								1														**1**
Zambia	1							1														**2**
Zimbabwe																		1				**1**
	D43	F32	K01	K07	K25	P01	P50	R01	R03	R13	R21	R24	R25	R33	R37	R44	T15	U01	U19	U24	U54	**391***
Totals	**9**	**1**	**1**	**2**	**1**	**6**	**3**	**209**	**10**	**15**	**8**	**1**	**1**	**2**	**6**	**1**	**6**	**44**	**1**	**60**	**4**	

*Because many grants have multiple foreign contributors, the total count (391) is greater than the total number of grants (245).

Table 19. NCI Participation in Trans-NIH ARRA Requests for Applications (RFAs) in FY2010

Sorted by Date of Publication

Date of Publication	RFA	Mechanism	Title	Division, Office and Center	Issuing NIH-IC
12/28/2009	OD10-001	RC4	ARRAOS: Recovery Act Limited Competition: Behavioral Economics for Nudging the Implementation of Comparative Effectiveness Research: Clinical Trials	DCCPS	NIH
	OD10-002		ARRAOS: Recovery Act Limited Competition: Behavioral Economics for Nudging the Implementation of Comparative Effectiveness Research: Pilot Research)		
12/28/2009	OD10-005	RC4	Recovery Act Limited Competition: NIH Directors Opportunity for Research in Five Thematic Areas	*	NIH
12/28/2009	OD10-008	RC4	Recovery Act Limited Competition: Comparative Effectiveness Research on Upper Endoscopy in Gastroesophageal Reflux Disease, Eradication Methods for Methicillin Resistant *Staphylococcus aureus* and Dementia Detection and Management Strategies	DCCPS	NIH
	OD10-009		Recovery Act Limited Competition: Methodology Development in Comparative Effectiveness Research		
1/5/2010	OD10-003	K18	Recovery Act Limited Competition: NIH Basic Behavioral and Social Science Opportunity Network (OppNet) Short-Term Mentored Career Development Awards in the Basic Behavioral and Social Sciences for Mid-career and Senior Investigators	CCT	NIH
1/13/2010	OD10-011	KM1	Recovery Act Limited Competition: Institutional Comparative Effectiveness Research Mentored Career Development Award	CCT	NIH
3/5/2010	OD10-013	DP4	Recovery Act Limited Competition: The NIH Directors ARRA Funded Pathfinder Award to Promote Diversity in the Scientific Workforce	CRCHD	NIH

*All NCI Divisions, Offices, and Centers may participate.
Source: Office of Referral, Review and Program Coordination.

Table 20. ARRA Applications Received for Referral by the NCI/DEA in FY2010*

Sorted by Mechanism

Mechanism	Activity Code	Totals by Activity	Total Costs Requested First Year
Institutional Career Enhancement Award	KM1	24	$16,329,444
Research Project	R01	30	$11,129,931
Small Research Grants	R03	5	$380,573
Academic Research Enhancement Awards (AREA)	R15	183	$69,740,312
Exploratory/Developmental Grants	R21	4	$683,204
Small Business Technology Transfer (STTR) Grants – Phase I	R41	1	$345,071
Small Business Innovation Research Grants (SBIR) – Phase I	R43	151	$31,441,734
Small Business Innovation Research Grants (SBIR) – Phase II	R44	5	$4,550,762
High Priority, Short Term Project Award	R56	8	$0
Challenge Grants and Partnerships Program – Phase I (NIAID)	RC1	22	$10,353,546
Biomedical Research, Development, and Growth to Spur the Acceleration of New Technologies (BRDG-SPAN) Program	RC3	177	$189,988,665
High Impact Research and Research Infrastructure Programs – Multi-Year Funding	RC4	494	$581,520,760
Biomedical Research Support Shared Instrumentation Grants (NCRR)	S10	1	$1,387,696
Overall Totals		**1,105**	**$917,851,698**

*Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications and withdrawn applications.

Table 21. NCI ARRA Funding by Anatomical Site for FY2010

Anatomical Site	2010 Number of Projects	2010 Relevant Project Dollars
Adrenal		
Anus	2	750,000
Bladder	7	385,581
Bone Marrow	5	474,937
Bone, Cartilage	9	2,001,511
Brain	35	12,665,323
Breast	96	26,797,335
Central Nervous System	5	514,675
Cervix	20	5,083,204
Childhood Leukemia	10	4,043,182
Colon, Rectum	58	14,132,089
Connective Tissue	4	894,977
Esophagus	9	2,558,947
Eye	2	327,295
Gastrointestinal Tract	4	756,174
Genital System, Female	2	19,607
Head and Neck	13	3,200,172
Hodgkins Lymphoma	2	479,429
Kaposi Sarcoma	13	4,767,712
Kidney	4	233,495
Leukemia	45	19,182,179
Liver	16	3,121,446
Lung	60	21,263,621
Melanoma	25	7,655,126
Muscle	3	1,420,402
Myeloma	5	805,459
Nervous System	1	1,520
Neuroblastoma	5	447,881
Non-Hodgkins Lymphoma	29	7,236,871
Oral Cavity	7	1,656,615
Ovary	18	5,520,579
Pancreas	20	3,565,823
Pharynx	2	548,074
Pituitary	1	285,664
Prostate	72	19,588,684
Reticuloendothelial System	1	279,081
Respiratory System	2	332,003
Retinoblastoma	3	2,874,237
Salivary Glands	1	1,534
Skin	13	3,266,491
Small Intestine	1	168,015
Stomach	7	1,029,174
Testis	1	14,749
Thyroid	5	1,215,198
Uterus	10	3,529,421
Vascular	4	1,048,779
Wilms Tumor	1	228,214

Source: Research Analysis and Evaluation Branch.

Table 22. NCI ARRA Dollars by Science Areas for FY2010

Science Area	2010 Number of Projects	2010 Total Relevant Dollars
Adoptive Cell Immunotherapy	11	5,358,613
Adv. Manufacturing Technology	2	840,520
Aging	55	7,129,297
AIDS	41	16,349,106
Alternative Medicine, Direct	28	6,056,611
Alternative Medicine, Indirect	2	812,387
Alzheimers Dementia	2	105,780
Angiogenesis	18	7,023,910
Arthritis	1	1,520
Ataxia Telangiectasia	2	313,334
Automimmune Diseases	4	126,372
Behavior Research	60	20,314,395
Bioengineering	23	8,622,407
Bioinformatics	49	70,885,848
Biological Carcinogenesis, Non-Viral	5	680,227
Biologics/Biological Response Modifiers	99	39,975,561
Biomarkers	36	28,100,789
Biomaterials Research	2	748,029
Biomedical Computing	35	16,564,539
Birth Defects	4	281,992
Bone Marrow Transplantation	2	338,163
Breast Cancer, Detection	15	2,856,803
Breast Cancer, Early Detection	8	1,279,021
Breast Cancer, Education	3	309,867
Breast Cancer, Epidemiology	9	1,647,726
Breast Cancer, Genetics	22	6,328,489
Breast Cancer, Prevention	10	1,963,139
Breast Cancer, Rehabilitation	5	929,592
Breast Cancer, Screening	3	452,709
Breast Cancer, Treatment	42	10,626,481
Breast Cancer, Basic	31	8,773,600
Cancer Survivorship	39	10,809,714
Carcinogenesis, Environmental	60	16,556,857
Chemoprevention	34	6,096,556
Chemoprevention, Clinical	2	839,762
Chemotherapy	79	28,272,137
Child Health	11	2,241,724
Childhood Cancers	30	13,212,593
Chronic Myeloproliferative Disorders	5	1,295,259
Clinical Trials, Diagnosis	7	3,205,008
Clinical Trials, Other	11	6,215,309
Clinical Trials, Prevention	6	2,652,197
Clinical Trials, Therapy	39	19,677,177
Combination Therapy	50	24,133,587
Cost Effectiveness	5	423,170
Diabetes	2	57,509
Diagnosis	104	77,434,329
Diethylstilbestrol	1	1,520
DNA Repair	30	6,760,833
Drug Development	125	69,383,232
Drug Discovery	19	14,665,759
Drug Resistance	27	8,780,794
Drugs, Natural Products	43	10,311,675
Early Detection	30	8,249,089
Effectiveness Research	7	1,415,004
Endocrinology	45	12,566,318
Energy Balance	9	5,702,047
Epidemiology, Biochemical	24	10,749,236
Epidemiology, Environmental	22	4,930,231
Epigenetics	52	18,074,439
Gene Mapping, Human	35	18,217,027
Gene Mapping, Non-Human	15	3,995,719
Gene Transfer, Clinical	1	335,500
Genetic Testing Research, Human	15	5,973,528
Genomics	99	125,084,446
Health Literacy	6	2,129,906
Health Promotion	18	3,279,358
Health Care Delivery	16	7,420,600
Helicobacter	3	503,837
Hematology	91	36,385,267
Hematopoietic Stem Cell Research	21	4,039,754
Hormone Replacement Therapy	3	636,737

continued

Source: Research Analysis and Evaluation Branch.

Table 22. NCI ARRA Dollars by Science Areas for FY2010

Science Area	2010 Number of Projects	2010 Total Relevant Dollars
Hospice	1	47,725
Iatrogenesis	17	4,154,786
Inflammation	21	3,446,909
Information Dissemination	28	10,448,454
Metastasis	87	25,339,004
Mind/Body Research	5	711,595
Molecular Disease	329	179,091,722
Molecular Imaging	39	13,412,402
Molecular Targeted Prevention	22	4,888,902
Molecular Targeted Therapy	79	32,255,296
Nanotechnology	23	6,205,165
Neurofibromatosis	3	705,568
Nursing Research	1	165,440
Nutrition	50	15,475,704
Nutrition Monitoring	3	655,618
Obesity	19	7,353,869
Oncogenes	104	33,604,269
Organ Transplant Research	4	1,088,044
Pain	3	305,716
Palliative Care	3	2,513,281
PAP Testing	2	1,557,340
Pediatric Research	42	16,665,279
Personalized Health Care	49	22,714,168
Prevention	75	21,888,336
Proteomics	33	7,729,640
Radiation, Ionizing	7	852,615
Radiation, Ionizing Diagnosis	22	5,494,590
Radiation, Ionizing Radiotherapy	35	10,487,287
Radiation, Magnetic Resonance Imaging	21	4,991,524
Radiation, Mammography	5	509,411
Radiation, Non-Ionizing	11	1,640,294
Radiation, Non-Ionizing Diagnosis	33	7,799,826
Radiation, Non-Ionizing Radiotherapy	7	1,741,177
Radiation, Ultraviolet	10	1,325,272
Rare Diseases	7	1,439,549
Rehabilitation	10	2,000,188
Rural Populations	5	1,667,686
Sexually Transmitted Diseases	9	3,446,044
Small Molecules	20	13,379,821
Smokeless Tobacco	3	391,727
Smoking, Passive	1	38,625
Structural Biology	59	16,313,514
Surgery	15	2,406,248
Taxol	13	1,434,539
Telehealth	15	3,243,837
Therapy	213	106,143,827
Tobacco	19	5,663,852
Tobacco Use Behavior	12	2,996,707
Tropical Diseases	1	1,520
Tumor Markers	33	10,669,355
Underserved Populations	22	8,423,073
Vaccine Development	24	8,773,669
Vaccine Research	17	6,228,046
Vaccine Testing	7	1,997,391
Virus Cancer Research	52	20,607,124
Virus, Epstein-Barr	7	2,641,676
Virus, Hepatitis B	2	399,589
Virus, Hepatitis C	6	1,233,642
Virus, Herpes	19	7,475,244
Virus, HHV8	11	4,580,699
Virus, HIV	9	4,326,415
Virus, HTLV-I	1	1,520
Virus, Papilloma	11	4,624,380
Virus, Papova	13	5,442,894
Virus, SV40	1	318,514
Vitamin A	4	432,883
Vitamin C	2	60,865
Vitamin D	3	816,844
Vitamins, Other	3	612,169

Appendix A: Activities of the National Cancer Advisory Board

Originally established as the National Advisory Cancer Council in 1937, the NCAB consists of 18 members who are appointed by the President and 12 nonvoting *ex officio* members. The NCAB advises, assists, consults with, and makes recommendations to the Secretary, HHS, and to the NCI Director with respect to the activities carried out by and through the Institute and on policies pertaining to these activities. It is authorized to recommend support for grants and cooperative agreements following technical and scientific peer review. The Director of the DEA serves as Executive Secretary of the NCAB. In fulfilling its role as the locus for second-level review of all peer reviewed applications, the Board reviewed a total of 11,007 applications in 2010 requesting $3,330,523,386 in direct costs with appropriated funds. Additionally, the Board reviewed 1,105 appilcations requesting $917,851,698 in direct costs with ARRA funds.

The Board heard presentations, discussed, and provided advice on a variety of topics and NCI activities in FY2010, such as:

- NCI Director's Report
- President's Cancer Panel Report
- Legislative Update
- Annual Delegations of Authority
- American Association for Cancer Research (AACR) Annual Report
- Barriers to Timely Activation of Clinical Trials
- RNA-Mediated Epigenetic Control of the Genome
- Understanding the Functional Significance of Variants Identified in Human Breast Cancer Susceptibility Genes
- Brain Metastasis of Breast Cancer: Molecular and Preclinical Advances
- RNA Interference Screens and Cancer Gene Resequencing to Discover the Achilles Heel of Cancer
- Genetic Basis of Kidney Cancer: Opportunity for Disease Specific Targeted Therapy
- The Impact of Occupational and Environmental Epidemiology on Public Policy
- Benzene Exposure and Risk of Leukemia and Lymphoma
- Formaldehyde Exposure and Risk of Nasopharyngeal Cancer and Leukemia
- Indoor Air Pollution From Coal Combustion and Risk of Lung Cancer
- FDA Regulation of Tobacco Products: Update and Role of NCI and NIH
- NCI Federally Funded Research and Development Center; Advanced Technology Research Facility
- NCI Cancer Human Biobank (caHUB)
- Opportunities to Collaborate and Develop Joint Clinical Programs With Walter Reed and Suburban Hospital
- SEER: Annual Report to the Nation
- Update: NCI Community Cancer Centers Program
- A National Cancer Clinical Trials System for the 21st Century; Operational Efficiency Working Group Report
- NCI Training Programs: Diversity and Extramural
- NCI Experimental Therapeutics (NExT) Program
- NCI Efforts in Healthcare Informatics
- Status Report: The Cancer Genome Atlas (TCGA)
- Status Report: Cancer Biomedical Informatics Grid (caBIG) Accomplishments
- New NCI Facilities: Shady Grove, Riverside, and Other New Facilities
- Developing a Report Card for the Clinical Trial Activation Timelines: Initial Implementation of the OEWG Report Recommendations
- NCAB *Ad Hoc* Working Group Report

As part of its mandate for oversight of NCI activities, the NCAB receives regular updates from the NCI Director, the NCI Office of Legislation and Congressional Activities, and the President's Cancer Panel.

Another major role of the Board is to monitor the overall advisory and oversight activities of the NCI as a whole. In that regard, it annually reviews the site visit outcomes of intramural review and the extramural RFA and RFP concepts acted on by the BSA. The NCAB also participates in the framing of the annual NCI Bypass Budget and considers the impact of actualized priorities as expressed by the allocation of the annual operating budget.

The full text of recent NCAB meeting summaries is available on the NCI website at: **http://deainfo.nci.nih.gov/advisory/ncabminmenu.htm**.

Appendix B: Activities of the Board of Scientific Advisors

The BSA provides scientific advice on a wide variety of matters concerning scientific program policy, progress, and future direction of NCI's extramural research programs, and concept review of extramural program initiatives.

In addition to approving a number of extramural program initiatives (see below), the BSA also heard presentations on the following in FY2010:

- Report of the NCI Director
- NCI/Congressional Relations
- Comparative Effectiveness Research (CER)—AHRQ and NCI
- Linking SEER and Medicare Claims Databases to Facilitate CER
- Update: The Cancer Genome Atlas—Progress to Date
- BSA RFA Annual Concept Report
- Imaging and Multi-Modality Navigation in Interventional Oncology
- The Cancer Initiating Cell and Stem Cell Biology
- Status Report: Patient Navigation Research Program (PNRP)
- Status Report: Nanotechnology Program
- The Cancer Target Discovery and Development Network (CTD^2)
- Alliance of Glycobiologists

RFA/Cooperative Agreements Approved

Office of the Director

- Commercial Application and Use of Emerging Molecular Analysis Technologies
- Clinical Proteomic Technologies for Cancer
- Comprehensive Partnership To Reduce Cancer Health Disparities
- SBIR Phase II Bridge Awards To Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics Toward Commercialization

Division of Cancer Biology

- NCI Tumor Microenvironment Network

Division of Cancer Control and Population Sciences

- Population-Based Research Optimizing Screening Through Personalized Regimens (PROSPR)

Division of Cancer Prevention/Division of Cancer Biology

- Barrett's Esophagus Translational Research Network (BETRNet)

Division of Cancer Treatment and Diagnosis

- Advanced *In Vivo* Imaging To Understand Cancer Systems

RFP/Cooperative Agreements Approved

Division of Cancer Prevention

- Community Clinical Oncology Program
- Minority-Based Community Clinical Oncology Program

Division of Cancer Treatment and Diagnosis

- The Blood and Marrow Clinical Trials Network

RFP Concepts Approved

Division of Cancer Treatment and Diagnosis

- Preclinical Pharmacokinetic and Pharmacological Studies With Anti-Tumor and Other Therapeutic Agents
- Preclinical Toxicology of Drugs Developed for Cancer and Other Diseases

BSA-NCI Listens Session

The BSA voted to discontinue NCI Listens Sessions. Thus, there were no sessions in FY2010.

Appendix C: List of Chartered Committees

President's Cancer Panel

Chair

LaSalle D. Leffall, Jr., M.D. ..... Howard University College of Medicine

Members

Margaret L. Kripke, Ph.D. ..... The University of Texas M.D. Anderson Cancer Center

Executive Secretary

Abby B. Sandler, Ph.D. ..... National Cancer Institute

National Cancer Advisory Board

Chair

Bruce Allan Chabner, M.D. ..... Massachusetts General Hospital Cancer Center

Members

Anthony Atala, M.D. ..... Wake Forest University School of Medicine
Victoria L. Champion, D.N.S. ..... Indiana University School of Nursing
Donald S. Coffey, Ph.D. ..... The Johns Hopkins University School of Medicine
Marcia R. Cruz-Correa, M.D., Ph.D. ..... University of Puerto Rico Comprehensive Cancer Center
Kevin J. Cullen, M.D. ..... Marlene and Stuart Greenebaum Cancer Center
William H. Goodwin, Jr., M.B.A. ..... CCA Industries, Inc.
Waun Ki Hong, M.D. ..... The University of Texas M.D. Anderson Cancer Center
Mr. Robert A. Ingram ..... Hatteras Venture Partners
Judith S. Kaur, M.D. ..... Mayo Comprehensive Cancer Center
Ms. Mary Vaughan Lester ..... University of California, San Francisco Foundation
H. Kim Lyerly, M.D. ..... Duke University Medical Center
Karen M. Meneses, Ph.D. ..... University of Alabama at Birmingham
Olufunmilayo F. Olopade, M.B.B.S., F.A.C.P. ..... University of Chicago Pritzker School of Medicine
Jennifer A. Pietenpol, Ph.D. ..... Vanderbilt University Medical Center
Jonathan M. Samet, M.D., M.S. ..... University of Southern California, Keck School of Medicine
William R. Sellers, M.D. ..... Novartis Institutes for Biomedical Research, Inc.

Ex Officio Members of the National Cancer Advisory Board

Linda S. Birnbaum, Ph.D., D.A.B.T., A.T.S. ..... National Institute of Environmental Health Sciences, NIH
Francis S. Collins, M.D., Ph.D. ..... National Institutes of Health

Margaret A. Hamburg, M.D. ..... U.S. Food and Drug Administration
John P. Holdren, Ph.D. ..... Office of Science and Technology Policy
John Howard, M.D., M.P.H., J.D., L.L.M. ..... National Institute for Occupational Safety and Health
Lisa P. Jackson, M.S. ..... U.S. Environmental Protection Agency
The Honorable Dr. Michael J. Kussman ..... U.S. Department of Veterans Affairs
Anna Palmisano, Ph.D. ..... U.S. Department of Energy
The Honorable Kathleen Sebelius, M.P.A. ..... U.S. Department of Health and Human Services
The Honorable Hilda L. Solis ..... U.S. Department of Labor
Inez Tenenbaum, M.Ed. ..... U.S. Consumer Product Safety Commission
Jonathan Woodson, M.D. ..... The Pentagon

Alternates to *Ex Officio* Members of the National Cancer Advisory Board

Michael A. Babich, Ph.D. ..... U.S. Consumer Product Safety Commission
Patricia Bray, M.D., M.P.H. ..... OSHA/U.S. Department of Labor
Michael Kelley, M.D., F.A.C.P. ..... U.S. Department of Veterans Affairs
Steven Kleeberger, Ph.D. ..... National Institute of Environmental Health Sciences
Richard Pazdur, M.D. ..... U.S. Food and Drug Administration
John F. Potter, M.D. ..... Walter Reed Army Medical Center
R. Julian Preston, Ph.D. ..... U.S. Environmental Protection Agency
Michael Stebbins, Ph.D. ..... Office of Science and Technology Policy
Marie H. Sweeney, Ph.D., M.P.H. ..... National Institute for Occupational Safety and Health
Lawrence A. Tabak, D.D.S., Ph.D. ..... National Institutes of Health
Sharlene Weatherwax, Ph.D. ..... U.S. Department of Energy

Executive Secretary

Paulette S. Gray, Ph.D. ..... National Cancer Institute

NCI Board of Scientific Advisors

Chair

Richard L. Schilsky, M.D. ..... University of Chicago Pritzker School of Medicine

Members

Paul M. Allen, Ph.D. ..... Washington University School of Medicine
Christine B. Ambrosone, Ph.D. ..... Roswell Park Cancer Institute
Andrea Califano, Ph.D. ..... Columbia University Medical Center
Michael A. Caligiuri, M.D. ..... Ohio State University Comprehensive Cancer Center
Arul M. Chinnaiyan, M.D., Ph.D. ..... University of Michigan Medical School
Curt I. Civin, M.D. ..... University of Maryland School of Medicine
Chi V. Dang, M.D., Ph.D. ..... Johns Hopkins University
Ronald A. DePinho, M.D. ..... The University of Texas M.D. Anderson Cancer Center
Robert B. Diasio, M.D. ..... Mayo Clinic Cancer Center
Jeffrey A. Drebin, M.D., Ph.D., FACS ..... Hospital of the University of Pennsylvania

Betty Ferrell, Ph.D., R.N., F.A.A.N. ..... City of Hope National Medical Center
Kathleen M. Foley, M.D. ..... Memorial Sloan-Kettering Cancer Center
Sanjiv S. Gambhir, M.D., Ph.D. ..... Stanford University
Todd R. Golub, M.D. ..... The Broad Institute of Massachusetts Institute of Technology and Harvard University
Joe W. Gray, Ph.D. ..... Oregon Health and Science University
Mary J.C. Hendrix, Ph.D. ..... Northwestern University
Timothy J. Kinsella, M.D. ..... Rhode Island Hospital
Joshua LaBaer, M.D., Ph.D. ..... Arizona State University
Mr. Don Listwin ..... Canary Foundation
Christopher J. Logothetis, M.D. ..... The University of Texas M.D. Anderson Cancer Center
Maria E. Martinez, Ph.D., M.P.H. ..... The University of Arizona
James L. Omel, M.D. ..... Volunteer
Edith A. Perez, M.D. ..... Mayo Clinic
Stuart L. Schreiber, Ph.D. ..... The Broad Institute of Massachusetts Institute of Technology and Harvard University
Bruce W. Stillman, Ph.D. ..... Cold Spring Harbor Laboratory
Victor J. Strecher, Ph.D., M.P.H. ..... University of Michigan School of Public Health
Louise C. Strong, M.D. ..... The University of Texas M.D. Anderson Cancer Center
Frank M. Torti, M.D., M.P.H. ..... Wake Forest University School of Medicine
Jean Y. Wang, Ph.D. ..... University of California, San Diego, School of Medicine
Irving L. Weissman, M.D. ..... Stanford University
James K. Willson, M.D. ..... University of Texas Southwestern Medical Center

Executive Secretary

Paulette S. Gray, Ph.D. ..... National Cancer Institute

Clinical Trials and Translational Research Advisory Committee

Chair

James L. Abbruzzese, M.D. ..... University of Texas M.D. Anderson Cancer Center

Members

Peter C. Adamson, M.D. ..... University of Pennsylvania
Susan G. Arbuck, M.D., M.Sc., F.A.C.P.† ..... Susan G. Arbuck M.D., LLC
Monica M. Bertagnolli, M.D. ..... Dana-Farber Cancer Institute
Deborah W. Bruner, Ph.D., R.N. ..... University of Pennsylvania
Curt I. Civin, M.D. ..... University of Maryland School of Medicine
Kenneth H. Cowan, M.D., Ph.D. ..... University of Nebraska Medical Center
Mr. Everett E. Dodson ..... Lombardi Comprehensive Cancer Center
Olivera J. Finn, Ph.D. ..... University of Pittsburgh School of Medicine
Stephen S. Grubbs, M.D.* ..... Medical Oncology Hematology Consultants, PA
Sandra J. Horning, M.D. ..... Genentech, Inc.
Scott M. Lippman, M.D. ..... The University of Texas M.D. Anderson Cancer Center
Nancy P. Mendenhall, M.D. ..... University of Florida Health Science Center
Lisa A. Newman, M.D., M.P.H., F.A.C.S. ..... University of Michigan Comprehensive Cancer Center
David R. Parkinson, M.D.* ..... Nodality, Inc.
Edith A. Perez, M.D. ..... Mayo Clinic Foundation
Ms. Nancy Roach ..... C3: Colorectal Cancer Coalition
Daniel J. Sargent, Ph.D. ..... Mayo Clinic Foundation
Richard L. Schilsky, M.D. ..... University of Chicago Pritzker School of Medicine
Mitchell D. Schnall, M.D., Ph.D. ..... University of Pennsylvania Medical Center
Peter G. Shields, M.D. ..... Georgetown University Medical Center
Joel E. Tepper, M.D. ..... Lineberger Comprehensive Cancer Center
James L. Wade III, M.D. ..... Decatur Memorial Hospital Cancer Care Institute

Ex Officio Members

James H. Doroshow, Ph.D. ..... National Cancer Institute
Paulette S. Gray, Ph.D. ..... National Cancer Institute
Rosemarie Hakim, Ph.D., M.S. ..... Centers for Medicare and Medicaid Services
Lee Helman, M.D. ..... National Cancer Institute
Michael J. Kelley, M.D., F.A.C.P. ..... Veterans Health Administration
Richard Pazdur, M.D., F.A.C.P. ..... U.S. Food and Drug Administration
John F. Potter, M.D. ..... Walter Reed Army Medical Center
Alan Rabson, M.D. ..... National Cancer Institute

Executive Secretary

Sheila A. Prindiville, M.D., M.P.H. ..... National Cancer Institute

*Extended.
†Pending Clearance.

Board of Scientific Counselors for Clinical Sciences and Epidemiology, NCI

Chair

Ethan Dmitrovsky, M.D. ..... Dartmouth Medical School

Members

Wadih Arap, M.D., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Edgar Ben-Josef, M.D. ..... University of Michigan
Bruce Blazar, M.D. ..... University of Minnesota
Tim Byers, M.D. ..... University of Colorado Cancer Center
William Cance, M.D. ..... Roswell Park Cancer Institute
Susan Chang, M.D. ..... University of California San Francisco School of Medicine
William Evans, Pharm.D. ..... St. Jude Children's Research Hospital
Jo Freudenheim, Ph.D. ..... State University of New York
Judy Garber, M.D. ..... Dana-Farber Cancer Institute
Marc Goodman, Ph.D. ..... University of Hawaii
Bernard Harlow Ph.D. ..... University of Minnesota
Carl June, M.D. ..... University of Pennsylvania School of Medicine
Karen Kelly, M.D. ..... UC Davis Medical Center
Alexandra Levine, M.D., MACP ..... City of Hope National Medical Center
Augusto Ochoa, M.D. ..... Louisiana State University Health Science Center
David Poplack, M.D. ..... Baylor College of Medicine
Ms. Nancy Roach ..... C3: Colorectal Cancer Coalition
Thomas Rohan, M.D., Ph.D. ..... Albert Einstein College of Medicine
Daniel Schaid, Ph.D. ..... Mayo Clinic
Thomas Sellers, Ph.D. ..... H. Lee Moffitt Cancer Center and Research Institute
Darryl Shibata, M.D. ..... University of Southern California
Robert Tigelaar, M.D. ..... Yale University School of Medicine
Walter Urba, M.D., Ph.D. ..... Providence Portland Medical Center
Elizabeth Ward, Ph.D. ..... American Cancer Society
Cheryl Willman, M.D. ..... University of New Mexico Cancer Research and Treatment Center

Executive Secretary

Brian Wojcik, Ph.D. ..... National Cancer Institute

Board of Scientific Counselors for Basic Sciences, NCI

Chair

Laurence Hurley, Ph.D. ..... University of Arizona

Members

Cory Abate-Shen, Ph.D. ..... Columbia University College of Physicians and Surgeons
Dafna Bar-Sagi, Ph.D. ..... New York University School of Medicine
Paul Bieniasz, Ph.D. ..... AARON Diamond AIDS Research Center
John Cambier, Ph.D. ..... University of Colorado Denver School of Medicine and National Jewish Health
Selina Chen-Kiang, Ph.D. ..... Weill Medical College of Cornell University
Joan Conaway, Ph.D. ..... Stowers Institute for Medical Research
Lawrence Corey, M.D. ..... Fred Hutchinson Cancer Research Center
Norman Drinkwater, Ph.D. ..... University of Wisconsin-Madison
Nelson Fausto, M.D. ..... University of Washington School of Medicine
Errol Friedberg, M.D. ..... University of Texas Southwestern Medical Center
Thomas Hamilton, Ph.D. ..... Cleveland Clinic Foundation
Daria Hazuda, Ph.D. ..... Merck and Company, Inc.
Eric Hunter, Ph.D. ..... Emory Vaccine Center
Chris Ireland, Ph.D. ..... University of Utah
Marc Jenkins, Ph.D. ..... University of Minnesota Medical School
Marcelo Kazanietz, Ph.D. ..... University of Pennsylvania School of Medicine
Jonathan Licht, M.D. ..... Northwestern University Feinberg School of Medicine
Wendell Lim, Ph.D. ..... University of California
A. Thomas Look, M.D. ..... Dana-Farber Cancer Institute
Ian Macara, Ph.D. ..... University of Virginia Health Sciences Center
Nita Maihle, Ph.D. ..... Yale University School of Medicine
Lynn Matrisian, Ph.D. ..... Vanderbilt University School of Medicine
Suzanne Ostrand-Rosenberg, Ph.D. ..... University of Maryland, Baltimore
Ann Marie Pendergast, Ph.D. ..... Duke University Medical Center
Thomas Poulos, Ph.D. ..... University of California, Irvine
James Prestegard, Ph.D. ..... University of Georgia
Kenneth Rock, M.D. ..... University of Massachusetts Medical School
Ming You, M.D., Ph.D. ..... Medical College of Wisconsin
Virginia Zakian, Ph.D. ..... Princeton University

Executive Secretary

Florence E. Farber, Ph.D. ..... National Cancer Institute

NCI Director's Consumer Liaison Group

Chair

Ms. Gwen Darien ..... Samuel Waxman Cancer Research Foundation

Vice-Chair

Mr. Everett E. Dodson ..... Georgetown Lombardi Cancer Center

Members

Jeffrey Allen, Ph.D. ..... Friends of Cancer Research
Susan G. Braun, M.A. ..... Commonweal
Marie E. Dahlstrom, M.A. ..... De La Mano Frente Al Cancer: Latino Cancer Coalition
Joyce Wilcox Graff, M.A. ..... VHL Family Alliance

Cheryl Jernigan, C.P.A., FACHE ..... Susan G. Komen for the Cure
Michelle McMurry-Heath, M.D., Ph.D. ..... Health, Biomedical Science, and Society Initiative
Deborah Morosini, M.D. ..... AstraZeneca Pharmaceuticals
Phyllis Pettit Nassi, M.S.W. ..... University of Utah
Jon G. Retzlaff, M.P.A., M.B.A. ..... American Association for Cancer Research
Ms. Wendy K.D. Selig ..... Melanoma Research Alliance
Mr. Josh Sommer ..... The Chordoma Foundation
Ms. Arlene Wahwasuck ..... Four Tribes Women's Wellness Coalition
Mr. Max Wallace ..... Accelerate Brain Cancer Cure, Inc.

Executive Secretary

Shannon K. Bell, M.S.W. ..... National Cancer Institute

NCI Initial Review Group Scientific Review Committees

Subcommittee A—Cancer Centers

Chair

Stanton L. Gerson, M.D. ..... Case Western Reserve University

Past Chair

James Marshall, Ph.D. ..... Roswell Park Cancer Institute

Members

Joseph Aisner, M.D. .....University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School
Terrance L. Albrecht, Ph.D. .....Wayne State University School of Medicine
Robert C. Bast, Jr., M.D. ..... The University of Texas M.D. Anderson Cancer Center
Barbara J. Beckwith, M.A. ..... The Ohio State University Medical Center
Marianne Berwick, Ph.D., M.P.H. .....The University of New Mexico
Edward Chu, M.D. .....University of Pittsburgh
Nancy E. Davidson, M.D. .....University of Pittsburgh
S. Gail Eckhardt, M.D. .....University of Colorado
Susan M. Gapstur, Ph.D., M.P.H. .....Northwestern University
Robert J. Gillies, Ph.D. .....H. Lee Moffitt Cancer Center and Research Institute
Barbara J. Graves, Ph.D. ..... University of Utah, Huntsman Cancer Institute
Terry Hyslop, Ph.D. .....Thomas Jefferson University
Mark A. Israel, M.D. ..... Dartmouth-Hitchcock Medical Center
Richard Jove, Ph.D. ..... City of Hope Comprehensive Cancer Center
Michael Kastan, M.D., Ph.D. .....St. Jude Children's Research Hospital
Russel E. Kaufman, M.D., F.A.C.S. .....The Wistar Institute
Linda Malkas, Ph.D. ..... Indiana University School of Medicine
Motomi Mori, Ph.D. ..... Oregon Health & Science Center
Timothy L. Ratliff, Ph.D. ..... Purdue University
Jerome Ritz, M.D. ..... Harvard Medical School
Victoria L. Seewaldt, M.D. .....Duke University Medical School
Lynn M. Schuchter, M.D. ..... The University of Pennsylvania, Abramson Cancer Center
Jill M. Siegfried, Ph.D. .....University of Pittsburgh, Hillman Cancer Center
Millicent Sims, B.S. ..... African American Cancer Support Group
Kenneth D. Tew, Ph.D., D.Sc. .....Medical University of South Carolina
Geoffrey R. Weiss, M.D. .....University of Virginia
Bamarese Wheatley, Dr.Ed., M.P.H. ..... BPW Consulting Services
Dougleas Yee, M.D. .....The University of Minnesota

Scientific Review Officer

Gail J. Bryant, M.D. ..... National Cancer Institute

Subcommittee F—Manpower and Training

Chair

Mark A. Nelson, Ph.D. ..... The University of Arizona

Members

Vicki V. Baker, M.D. ..... Independent Consultant
Steven P. Balk, M.D., Ph.D. ..... Harvard Medical School
David L. Bartlett, M.D. ..... University of Pittsburgh School of Medicine
Moray J. Campbell, Ph.D. ..... Roswell Park Cancer Institute
Herbert Chen, M.D. ..... University of Wisconsin
Fong-Fong Chu, Ph.D. ..... Beckman Research Institute of City of Hope
Craig M. Crews, Ph.D. ..... Yale University
Daniel Donoghue, Ph.D. .....University of California, San Diego
Kimberly E. Foreman, Ph.D. ..... Loyola University of Chicago
Henry S. Friedman, M.D. .....Duke University Medical Center
Juan Fueyo-Margareto, M.D. ..... The University of Texas M.D. Anderson Cancer Center
David W. Goodrich, Ph.D. ..... Roswell Park Cancer Institute
Rebecca S. Hartley, Ph.D. .....The University of New Mexico Health Sciences Center
Richard D. Hichwa, Ph.D. .....The University of Iowa
Mark R. Kelley, Ph.D. ..... Indiana University School of Medicine
Annette R. Khaled, Ph.D. ..... University of Central Florida
Barbara E. Kitchell, D.V.M., Ph.D. .....Michigan State University
James C. Lang, Ph.D. ..... The Ohio State University
Deborah A. Lannigan, Ph.D. .....University of Virginia
Christopher I. Li, M.D., Ph.D. .....Fred Hutchinson Cancer Research Center
Nipun B. Merchant, M.D., F.A.C.S. .....Vanderbilt University Medical Center
Babatunde O. Oyajobi, M.D., Ph.D. ..... The University of Texas Health Sciences Center, San Antonio
Janet S. Rader, M.D., F.A.C.O.G. .....Medical College of Wisconsin
Ming T. Tan, Ph.D. .....University of Maryland
Mary Beth Terry, Ph.D. ..... Columbia University Mailman School of Public Health
Kenneth S. Zuckerman, M.D. ..... University of South Florida College of Medicine

Scientific Review Officer

Lynn M. Amende, Ph.D. ..... National Cancer Institute

Subcommittee G—Education

Chair

Georgia Robins Sadler, Ph.D. ..... University of California, San Diego

Past Chair

Robert M. Chamberlain, Ph.D. ..... The University of Texas M.D. Anderson Cancer Center

Members

Lucile L. Adams-Campbell, Ph.D. ..... Georgetown University Medical Center
Barbara L. Anderson, Ph.D. ..... The Ohio State University
Dee M. Baldwin, Ph.D., R.N., F.A.A.N. ..... University of North Carolina at Charlotte
Deborah J. Bowen, Ph.D. ..... Boston University
John C. Byrd, M.D. ..... The Ohio State University Comprehensive Cancer Center
Raymond J. Carroll, Ph.D. ..... Texas A&M University
Concepcion R. Diaz-Arrastia, M.D. ..... The University of Texas Medical Branch
Phyllis A. Gimotty, Ph.D. ..... The University of Pennsylvania
Barbara A. Given, Ph.D., R.N., F.A.A.N. ..... Michigan State University
Marcia L. Grant, R.N., D.N.Sc., F.A.A.N. ..... City of Hope Medical Center
Kenneth R. Hande, M.D. ..... Vanderbilt University School of Medicine
Gail G. Harrison, Ph.D. ..... University of California, Los Angeles
Judy Kasey Houlette, M.A. ..... Friend For Life Cancer Support Network
Chanita A. Hughes-Halbert, Ph.D. ..... The University of Pennsylvania
Aminah Jatoi, M.D. ..... Mayo Clinic
Lovell A. Jones, Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Arthur M. Michalek, Ph.D. ..... State University of New York at Buffalo
R. Sean Morrison, M.D. ..... Mount Sinai School of Medicine
Polly A. Newcomb, Ph.D. ..... Fred Hutchinson Cancer Research Center
Joseph F. O'Donnell, M.D. ..... Dartmouth Medical School
Jamie S. Ostroff, Ph.D. ..... Memorial Sloan-Kettering Cancer Center
Timothy Pearman, Ph.D. ..... Tulane University School of Medicine
Edward A. Sausville, M.D., Ph.D. ..... University of Maryland
Peter C. Trask, Ph.D. ..... Pfizer, Inc.
Richard B. Warnecke, Ph.D. ..... University of Illinois at Chicago

Scientific Review Officer

Jeannette F. Korczak, Ph.D. ..... National Cancer Institute

Subcommittee H—Clinical Trials

Chair

Jacqueline K. Benedetti, Ph.D. ..... Fred Hutchinson Cancer Research Center

Past Chair

Richard M. Stone, M.D. ..... Harvard Medical School

Members

Karla V. Ballman, Ph.D. ..... Mayo Clinic, College of Medicine
Claudia R. Baquet, M.D. ..... University of Maryland School of Medicine
Debra L. Barton, Ph.D., R.N., A.O.C.N. ..... Mayo Clinic, College of Medicine
Arthur W. Blackstock, Jr., M.D. ..... Wake Forest University School of Medicine
John A. Blessing, Ph.D. ..... Roswell Park Cancer Institute
Jeffery A. Bogart, M.D. ..... State University of New York
Carol L. Brown, M.D. ..... Memorial Sloan-Kettering Cancer Center
Debra W. Christie, M.B.A. ..... University of Mississippi Medical Center
Susan Devine, C.C.R.P. ..... The Hospital for Sick Children, Toronto
Joshua D.I. Ellenhom, M.D., F.A.C.S. ..... City of Hope National Medical Center
Leonard G. Gomella, M.D. ..... Thomas Jefferson University
Julie R. Gralow, M.D. ..... University of Washington School of Medicine
Ramaswamy Govindan, M.D. ..... Washington University School of Medicine
Stanford E. Jeames, D.H.A. ..... University of Massachusetts, Donahue Institute
Gregory P. Kalemkerian, M.D. ..... University of Michigan Health System
Merrill S. Kies, M.D. ..... The University of Texas M.D. Anderson Cancer Center
Jeanette Y. Lee, Ph.D. ..... University of Arkansas for Medical Sciences
Neyssa M. Marina, M.D. ..... Stanford University Medical Center
Roy A. Patchell, M.D. ..... University of Kentucky Medical Center
Elizabeth Poplin, M.D. ..... The Cancer Institute of New Jersey
David I. Quinn, Ph.D. ..... University of Southern California, Keck School of Medicine
William F. Regine, M.D. ..... University of Maryland School of Medicine
Denise Reinke, M.S. ..... University of Michigan Comprehensive Cancer Center
William H. Rodgers, M.D., Ph.D. ..... Lenox Hill Hospital
Melanie E. Royce, M.D., Ph.D. ..... The University of New Mexico Cancer Research Center
Mary Scroggins, M.A. ..... In My Sister's Care
Edward G. Shaw, M.D. ..... Wake Forest University School of Medicine
Elin R. Sigurdson, M.D., Ph.D. ..... Fox Chase Cancer Center
Vernon K. Sondak, M.D. ..... H. Lee Moffitt Cancer Center and Research Institute
Alan P. Venook, M.D. ..... University of California, San Francisco
Mary K. Washington, M.D., Ph.D. ..... Vanderbilt University Medical Center
Mark A. Watson, M.D., Ph.D. ..... Washington University School of Medicine

Scientific Review Officer

Timothy C. Meeker, M.D. ..... National Cancer Institute

Subcommittee I—Career Development

Chair

William E. Gillanders, M.D. ..... Washington University School of Medicine

Past Chair

James R. Howe V, M.D. ..... The University of Iowa College of Medicine

Members

Sujit Basu, M.D., Ph.D. ..... The Ohio State University
Deepak Bastia, Ph.D. ..... Medical University of South Carolina
Christine M. Eischen, Ph.D. ..... Vanderbilt University Medical Center
Soldano Ferrone, M.D., Ph.D. ..... University of Pittsburgh Cancer Institute
James M. Ford, M.D. ..... Stanford University School of Medicine
Roland G. Henry, Ph.D. ..... University of California, San Francisco
P. Jack Hoopes, Ph.D., D.V.M. ..... Dartmouth Medical School
Jessica J. Kandel, M.D. ..... Columbia University
Marilyn L.G. Lamm, Ph.D. ..... Northwestern University Feinberg School of Medicine
John M. Lehman, Ph.D. ..... East Carolina University
Leonard Lothstein, Ph.D. ..... The University of Tennessee Health Science Center
Kathy D. Miller, M.D. ..... Indiana University School of Medicine
Carlos S. Moreno, Ph.D. ..... Emory University, Winship Cancer Institute
Neil Osheroff, Ph.D. ..... Vanderbilt University School of Medicine
Mauel L. Penichet, Ph.D. ..... University of California, Los Angeles
Russell O. Pieper, Ph.D. ..... University of California, San Francisco Comprehensive Cancer Center
Rajagopal Ramesh, Ph.D. ..... University of Oklahoma Health Sciences Center
Richard D. Schulick, M.D. ..... The Johns Hopkins School of Medicine
Protul A. Shrikant, Ph.D. ..... Roswell Park Cancer Institute
Wen-Cheng Xiong, M.D., Ph.D. ..... Medical College of Georgia

Scientific Review Officer

Sergei Radaev, Ph.D. ..... National Cancer Institute

Former Scientific Review Officer

Robert E. Bird, Ph.D. ..... National Cancer Institute

Subcommittee J—Population and Patient-Oriented Training

Chair

Michael A. Andrykowski, Ph.D. ..... University of Kentucky

Members

Virginia F. Borges, M.D., M.M.Sc. ..... University of Colorado, Denver School of Medicine
Michael Bouvet, M.D. .....University of California, San Diego-Moores Cancer Center
Malcolm V. Brock, M.D. ..... The Johns Hopkins Hospital
Mary E. Cooley, Ph.D. ..... Dana-Farber Cancer Institute
Michael E. Hagansee, M.D., Ph.D. ..... Louisiana State University
Raymond J. Hohl, M.D., Ph.D. .....The University of Iowa
Shawna V. Hudson, Ph.D. .....University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School
Paul B. Jacobson, Ph.D. .....H. Lee Moffitt Cancer Center and Research Institute
Johanna W. Lampe, Ph.D. .....Fred Hutchinson Cancer Research Center
Christopher H. Lowrey, M.D. ..... Dartmouth College School of Medicine
Guy H. Montgomery, Ph.D. .....Mount Sinai School of Medicine
Kristen B. Moysich, Ph.D. ..... Roswell Park Cancer Institute
Frank J. Penedo, Ph.D. .....University of Miami
Mark J. Ratain, M.D. .....The University of Chicago
Mary E. Reid, Ph.D., M.S.P.H. ..... Roswell Park Cancer Institute
Lillian L. Siu, M.D. ..... Princess Margaret Hospital
Scott A. Waldman, M.D., Ph.D. .....Thomas Jefferson University
Cary A.C. Zahbrock, M.S.W. .....National Coalition for Cancer Survivorship
Zuo-Feng Zhang, M.D., Ph.D. ..... University of California, Los Angeles School of Public Health

Scientific Review Officer

Ilda M. McKenna, Ph.D. ..... National Cancer Institute

Initial Review Group Subcommittees

Cancer Centers

Manpower and Training

Initial Review Group Subcommittees (continued)

Education

Career Development

Initial Review Group Subcommittees (continued)

Population and Patient Oriented Training

Cellular and Tissue Oncology

Special Emphasis Panels

Cancer Prevention, Control, and Population Sciences

Discovery, Imaging, and Therapeutics

Special Emphasis Panels (continued)

Emerging Technologies for Cancer Research

Exceptional, Unconventional Research Enabling Knowledge Acceleration (EUREKA)

Special Emphasis Panels (continued)

***In Vivo* Cellular and Molecular Imaging Centers (ICMICs)**

Molecular Mechanism and Targeted Therapies

Special Emphasis Panels (continued)

Small Business Innovation Research

Small Grants for Behavorial Research in Cancer Control

Special Emphasis Panels (continued)

SPORE in Lymphoma, Breast, Ovarian, Genitourinary, and Gastrointestinal Cancers

Therapeutic Strategies for Cancer

Appendix D: NCI Initial Review Group Consultants

1. Consultants Serving as Temporary Members on IRG Subcommittees in FY2010

A

Agarwal, Rajesh, Ph.D. ..... University of Colorado, Denver
Aisner, Joseph, M.D. ..... University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School
Anderson, Garnet L., Ph.D., M.P.H. ..... Fred Hutchinson Cancer Research Center
Anderson, Stewart J., Ph.D. ..... University of Pittsburgh
Arenberg, Douglas A., M.D. ..... University of Michigan, Ann Arbor
Augenlicht, Leonard H., Ph.D. ..... Montefiore Medical Center, New York
August, David A., M.D. ..... University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School

B

Baldwin, Dee M., Ph.D, R.N., F.A.A.N. ..... University of North Carolina at Charlotte
Barnes, Willard, M.D. ..... Georgetown University
Bastia, Deepak, Ph.D. ..... Medical University of South Carolina
Bergen, Andrew W., Ph.D. ..... SRI International
Berger, Franklin G., Ph.D. ..... University of South Carolina, Columbia
Bilchik, Anton J., M.D., Ph.D. ..... University of California, Los Angeles
Bjornsti, Mary-Ann, Ph.D. ..... University of Alabama at Birmingham
Bogart, Jeffrey A., M.D. ..... Upstate Medical University
Boise, Lawrence H., Ph.D. ..... Emory University
Bolwell, Brian, M.D. ..... Cleveland Clinic Foundation
Borges, Virginia, M.D. ..... University of Colorado, Denver
Bost, James E., Ph.D. ..... University of Pittsburgh
Brewer, Molly A., D.V.M., M.D. ..... The University of Arizona
Buchsbaum, Donald J., Ph.D. ..... University of Alabama at Birmingham
Bunz, Fred, M.D., Ph.D. ..... The Johns Hopkins University
Busch, Theresa M., Ph.D. ..... University of Rochester
Byers, Stephen W., Ph.D. ..... Georgetown University

C

Campbell, Marci K., Ph.D., M.P.H. ..... University of North Carolina at Chapel Hill
Campbell, Moray J., Ph.D. ..... Roswell Park Cancer Institute
Carey, Lisa A., M.D., Ph.D. ..... University of North Carolina at Chapel Hill
Carlos, Ruth C., M.D. ..... University of Michigan, Ann Arbor
Carlson, Cathy S., D.V.M., Ph.D. ..... The University of Minnesota, Twin Cities
Carroll, William L., M.D. ..... New York University School of Medicine
Chang, Eric C., Ph.D. ..... Baylor College of Medicine
Chao, Chun, Ph.D. ..... Kaiser Foundation Research Institute

Cody, Vivian, Ph.D. ..... Hauptman-Woodward Medical Research Institute
Cole, Michael D., Ph.D. ..... Dartmouth College
Coleman, William B., Ph.D. ..... University of North Carolina at Chapel Hill
Conforti, Laura, Ph.D. ..... The University of Cincinnati
Cronin, Walter M., M.P.H. ..... University of Pittsburgh
Curran, Walter John, M.D., Ph.D. ..... Emory University

D

Daskalakis, Constantine, Sc.D. ..... Thomas Jefferson University
Dearing, James W., Ph.D. ..... Kaiser Foundation Research Institute
Deutsch, Walter A., Ph.D. ..... Pennington Biomedical Research Center, Baton Rouge
Devine, Susan, C.C.R.P. ..... The Hospital for Sick Children, Toronto

E

Eberhart, Charles G., M.D., Ph.D. ..... The Johns Hopkins University
Elit, Laurie M., M.D. ..... Juravinski Cancer Centre
Ellenhorn, Joshua D.I., M.D. ..... City of Hope National Medical Center
Elmer, Patricia J., Ph.D. ..... National College of Naturopathic Medicine
El-Serag, Hashem B., M.D., M.P.H. ..... Baylor College of Medicine
Evers, Bernard M., M.D. ..... University of Kentucky

F

Farace, Elana, Ph.D. ..... Pennsylvania State University, Hershey Medical Center
Fero, Matthew L., M.D. ..... Fred Hutchinson Cancer Research Center
Fisch, Michael J., M.D., M.P.H. ..... The University of Texas M.D. Anderson Cancer Center
Fleming, Gini F., M.D. ..... The University of Chicago
Freeman, James, Ph.D. ..... The University of Texas Health Science Center, San Antonio

G

Gaffney, David, M.D., Ph.D. ..... University of Utah
Geahlen, Robert L., Ph.D. ..... Purdue University, West Lafayette
Gewirtz, David A., Ph.D. ..... Virginia Commonwealth University
Gorlick, Richard G., M.D. ..... Albert Einstein College of Medicine of Yeshiva University
Gotlieb, Walter, M.D., Ph.D. ..... McGill University
Gralow, Julie R., M.D. ..... University of Washington
Greggi, Stefano, M.D. ..... Istituto Tumori de Naploi, Italy
Grunberg, Steven M., M.D. ..... The University of Vermont & State Agricultural College

H

Hackett, Lauren, M.P.A. ..... New York University
Hagensee, Michael E., M.D., Ph.D. ..... Louisiana State University Health Sciences Center, New Orleans
Halabi, Susan, Ph.D. ..... Duke University
Hann, Stephen R., Ph.D. ..... Vanderbilt University

Hansen, Marc F., Ph.D. ..... University of Connecticut School of Medicine & Dentistry
Haque, Saikh J., Ph.D. ..... The University of Cincinnati
Hauck, Marlene L., D.V.M., Ph.D. ..... North Carolina State University, Raleigh
Hollingsworth, M.A., Ph.D. ..... University of Nebraska Medical Center
Hoopes, P. Jack, D.V.M., Ph.D. ..... Dartmouth College
Houghton, Janet A., Ph.D. ..... Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Houlette, Judy K., M.A. ..... Friend for Life Cancer Support Network
Howell, Gillian M., Ph.D. ..... University of Nebraska Medical Center
Hsi, Eric, M.D. ..... Cleveland Clinic Lerner College of Medicine of Case Western Reserve University

J

Jaeckle, Kurt, M.D. ..... Mayo Clinic College of Medicine, Jacksonville
Jeames, Sanford E., M.A. ..... University of Massachusetts, Amherst
Jenkins, Robert B., M.D., Ph.D. ..... Mayo Clinic
Johnson, Katherine A., J.D. ..... Virginia Commonwealth University
Jones, Richard J., M.D. ..... The Johns Hopkins University
Jove, Richard, Ph.D. ..... Beckman Research Institute of City of Hope

K

Kastan, Michael B., M.D., Ph.D. ..... St. Jude Children's Research Hospital
Kato, Ikuko, M.D., Ph.D. ..... Wayne State University
Kelley, Mark R., Ph.D. ..... Indiana University-Purdue University, Indianapolis
Khayat, Anita F., Ph.D. ..... National Childhood Cancer Foundation
Killackey, Maureen A., M.D., Ph.D. ..... Memorial Sloan-Kettering Cancer Center
Kim, William Y., M.D. ..... University of North Carolina at Chapel Hill
Krymskaya, Vera P., Ph.D, M.B.A. ..... The University of Pennsylvania
Kulesz-Martin, Molly F., Ph.D. ..... Oregon Health and Science University

L

LaFlamme, Susan, Ph.D. ..... Albany Medical College
Lampson, Lois A., Ph.D. ..... Brigham and Women's Hospital
Land, Stephanie R., Ph.D. ..... University of Pittsburgh
Lannin, Donald R., M.D. ..... Yale University
Lattime, Edmund C., Ph.D. ..... University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School
Laurie, Fran, B.S. ..... University of Massachusetts Medical School, Worcester
Le Beau, Michelle M., Ph.D. ..... The University of Chicago
Lee, Jeannette Y., Ph.D. ..... University of Arkansas Medical Sciences, Little Rock
Leifer, Cynthia A., Ph.D. ..... Cornell University
Li, King C., M.D., M.B.A. ..... Methodist Hospital Research Institute
Libermann, Towia A., Ph.D. ..... Beth Israel Deaconess Medical Center
London, Wendy B., Ph.D. ..... Dana-Farber Cancer Institute
Lord, Edith M., Ph.D. ..... University of Rochester Medical Center

M

Maley, Carlo C., Ph.D. ..... Brigham and Women's Hospital
Malkas, Linda H., Ph.D. ..... Indiana University, Indianapolis
Mamon, Harvey J., M.D., Ph.D. ..... Brigham and Women's Hospital
Marks, Lawrence B., M.D. ..... University of North Carolina at Chapel Hill
Marshall, James, Ph.D. ..... Roswell Park Cancer Institute
Marshall, M. Blair, M.D. ..... Georgetown University
Martin, Brian J., M.P.A. ..... University of Rochester
Martinez, Jesse D., Ph.D. ..... The University of Arizona
Maskarinec, Gertraud, M.D., Ph.D., M.P.H. .....University of Hawaii at Manoa
McCarthy, James B., Ph.D. .....The University of Minnesota, Twin Cities
McCormick, Beryl, M.D. ..... Memorial Sloan-Kettering Cancer Center
McGregor, William G., M.D. .....University of Louisville
Merchant, Nipun B., M.D. ..... Vanderbilt University
Meric-Bernstam, Funda, M.D. ..... The University of Texas M.D. Anderson Cancer Center
Meyer, William H., M.D. ..... University of Oklahoma Health Sciences Center
Meyers, Craig M., Ph.D. .....Pennsylvania State University, Hershey Medical Center
Meyn, Raymond E., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Miller, Donald M., M.D., Ph.D. .....University of Louisville
Milosavljevic, Aleksandar, Ph.D. ..... Baylor College of Medicine
Modiano, Jaime F., V.M.D., Ph.D. .....The University of Minnesota, Twin Cities
Mohapatra, Shyam S., Ph.D. ..... Transgenex Nanobiotech, Inc.
Montgomery, Guy H., Ph.D. .....Mount Sinai School of Medicine
Morgan, Tim, Ph.D. ..... Wake Forest University Health Sciences
Mori, Motomi, Ph.D. ..... Oregon Health and Science University
Moskowitz, Chaya, Ph.D. ..... Sloan-Kettering Institute for Cancer Research
Moysich, Kirsten B., Ph.D. .....Roswell Park Cancer Institute Corporation
Mullins, Daniel C., Ph.D. ..... University of Maryland, Baltimore
Murphy, Maureen E., Ph.D. .....Fox Chase Cancer Center
Muto, Michael G., M.D. ..... Harvard Medical School

N

Nakshatri, Harikrishna, Ph.D. ..... Indiana University-Purdue University at Indianapolis
Nilsen-Hamilton, Marit, Ph.D. .....Iowa State University
Nishimura, Michael I., Ph.D. .....Medical University of South Carolina
Normolle, Daniel P., Ph.D. .....University of Pittsburgh

O

O'Donnell, Margaret R., M.D. ..... City of Hope National Medical Center
Olshan, Andrew, Ph.D. ..... University of North Carolina at Chapel Hill
Osheroff, Neil, Ph.D. ..... Vanderbilt University
Oza, Amit M., M.D. .....Ontario Cancer Institute

P

Pandita, Tej K., Ph.D. ..... The University of Texas Southwestern Medical Center at Dallas
Passaniti, Antonino, Ph.D. ..... University of Maryland, Baltimore
Patchell, Roy A., M.D. ..... St. Joseph's Hospital and Medical Center
Perez, J. Manuel, Ph.D. ..... University of Central Florida
Pogue, Brian W., Ph.D. ..... Dartmouth College
Pollock, Bradley H., Ph.D. ..... The University of Texas Health Science Center, San Antonio

Q

Quarles, Christopher C., Ph.D. ..... Vanderbilt University

R

Rader, Janet S., M.D. ..... Medical College of Wisconsin
Radivoyevitch, Tomas, Ph.D. ..... Medical University of South Carolina
Ramesh, Rajagopal, Ph.D. ..... University of Oklahoma
Raychaudhuri, Pradip, Ph.D. ..... University of Illinois at Chicago
Reed, Nicholas S., M.D. ..... Gartnavel General Hospital
Relling, Mary V., M.D., Ph.D. ..... St. Jude Children's Research Hospital
Ritz, Jerome, M.D. ..... Dana-Farber Cancer Institute
Robertson, Gavin P., Ph.D. ..... Pennsylvania State University, Hershey Medical Center
Rodgers, William H., M.D., Ph.D. ..... Lenox Hill Hospital
Rollins, Andrew M., Ph.D. ..... Case Western Reserve University
Rosenblatt, Joseph D., M.D. ..... University of Miami School of Medicine
Royce, Melanie E., M.D., Ph.D. ..... The University of New Mexico
Runnels, Loren W., Ph.D. ..... University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School

S

Salisbury, Jeffrey L., Ph.D. ..... Mayo Clinic
Samlowski, Wolfram E., M.D. ..... Nevada Cancer Institute
Schuchter, Lynn M., M.D. ..... The University of Pennsylvania
Seewaldt, Victoria L., M.D. ..... Duke University
Sens, Donald A., Ph.D. ..... The University of North Dakota
Sentman, Charles L., Ph.D. ..... Dartmouth College
Shah, Vallabh O., Ph.D. ..... The University of New Mexico Health Sciences Center
Shaw, Edward G., M.D. ..... Wake Forest University
Shen, Zhiyuan, M.D., Ph.D. ..... University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School
Shmulevich, Ilya, Ph.D. ..... Institute for Systems Biology
Siegfried, Jill M., Ph.D. ..... University of Pittsburgh
Sims, Millicent, B.S. ..... African American Cancer Support Group
Siu, Lillian L., M.D. ..... University of Toronto
Sondak, Vernon K., M.D. ..... H. Lee Moffitt Cancer Center and Research Institute
Sotomayor, Eduardo M., M.D. ..... H. Lee Moffitt Cancer Center and Research Institute
Staley, Charles A., M.D. ..... Emory University

Stone, Richard M., M.D., M.B.A. ..... Dana-Farber Cancer Institute
Swenerton, Kenneth, M.D. ..... University of British Columbia
Syngal, Sapna, M.D., M.P.H. ..... Dana-Farber Cancer Institute

T

Tannous, Bakhos A., Ph.D. ..... Massachusetts General Hospital
Tarakhovsky, Alexander, M.D., Ph.D. ..... Rockefeller University
Telleria, Carlos M., Ph.D. ..... The University of South Dakota
Terry, Michael A., B.S. ..... University of Rochester
Thompson, Craig B., M.D. ..... The University of Pennsylvania
Thompson, John A., M.D. ..... University of Washington
Tiwari, Hemant K., Ph.D. ..... University of Alabama at Birmingham

V

Vanwuyckhuyse, Brian C. ..... University of Rochester
Vergote, Ignace, M.D. ..... Catholic University of Leuven, Belgium

W

Wachsman, William, M.D., Ph.D. ..... University of California, San Diego
Washington, Mary K., M.D., Ph.D. ..... Vanderbilt University
Welch, Danny R., Ph.D. ..... University of Alabama at Birmingham
Wetzler, Meir, M.D. ..... Roswell Park Cancer Institute
Wolff, Antonio C., M.D. ..... The Johns Hopkins University

X

Xiong, Wen-Cheng, M.D., Ph.D. ..... Medical College of Georgia School of Medicine

Y

Yang, Yu-Chung, Ph.D. ..... Case Western Reserve University
Yothers, Greg, Ph.D. ..... University of Pittsburgh
You, Ming, M.D., Ph.D. ..... Medical College of Wisconsin
Yu, Chao-Lan, Ph.D. ..... Rosalind Franklin University of Medicine and Science

Total number of Reviewers: 196

2. Consultants Serving as *Ad Hoc* Committee Members on IRG Site Visit Teams in FY2010

A

Abboud, Camille, M.D. ..... Washington University
Ackerman, Joseph J.H., Ph.D. ..... Gordon Research Conferences
Agarwal, Rajesh, Ph.D. ..... University of Colorado, Denver
Ahmed, Khalil, Ph.D. ..... The University of Minnesota
Aisner, Joseph, M.D. ..... University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School
Albertson, Donna G., Ph.D. ..... University of California, San Francisco
Albrecht, Terrance L., Ph.D. ..... Wayne State University
Ali-Osman, Francis, D.Sc. ..... Duke University
Ambinder, Richard F., M.D., Ph.D. ..... The Johns Hopkins University
Anderson, Garnet L., Ph.D. ..... Fred Hutchinson Cancer Research Center
Andreeff, Michael W., M.D., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Ashendel, Curtis L., Ph.D. ..... Purdue University, West Lafayette
Ashikaga, Takamaru, Ph.D. ..... The University of Vermont & State Agricultural College
Augenlicht, Leonard H., Ph.D. ..... Montefiore Medical Center, New York
August, David A., M.D. ..... University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School

B

Bailey, Howard H., M.D. ..... University of Wisconsin, Madison
Baquet, Claudia R., M.D. ..... University of Maryland, Baltimore
Barber, Glen N., Ph.D. ..... University of Miami School of Medicine
Basen-Engquist, Karen M., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Bast, Robert C., M.D. ..... Harvard University Medical School
Bastia, Deepak, Ph.D. ..... Medical University of South Carolina
Beckwith, Barbara J., M.A. ..... The Ohio State University
Belk, Bonnie F., M.A. ..... Private Practice
Benedetti, Jacqueline, Ph.D. ..... University of Washington
Benovic, Jeffrey L., Ph.D. ..... Thomas Jefferson University
Bernacki, Ralph J., Ph.D. ..... Roswell Park Cancer Institute Corporation
Berr, Stuart S., Ph.D. ..... University of Virginia
Berwick, Marianne, Ph.D. ..... The University of New Mexico
Bilchik, Anton J., M.D., Ph.D. ..... University of California, Los Angeles
Bjornsti, Mary-Ann, Ph.D. ..... University of Alabama at Birmingham
Bogart, Jeffrey A., M.D. ..... Upstate Medical University
Bond, Jeffrey P., Ph.D. ..... The University of Vermont & State Agricultural College
Bosl, George J., M.D. ..... Sloan-Kettering Institute for Cancer Research
Bowen, Deborah J., Ph.D. ..... Boston University Medical Campus
Bryant, Peter J., Ph.D. ..... University of California, Irvine
Buatti, John M., M.D. ..... The University of Iowa

C

Campbell, Marci K., Ph.D. ..... University of North Carolina at Chapel Hill
Caprioli, Richard M., Ph.D. ..... Vanderbilt-Ingram Cancer Center
Carlos, Ruth C., M.D. ..... University of Michigan, Ann Arbor
Carroll, William L., M.D. ..... New York University School of Medicine
Carson, William E., M.D. ..... The Ohio State University
Cesarman, Ethel, M.D., Ph.D. ..... Weill Medical College of Cornell University
Chakravarti, Debabrata, Ph.D. ..... Northwestern University
Chellappan, Srikumar P., Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Chlebowski, Jan F., Ph.D. ..... Virginia Commonwealth University
Christie, Debra W., M.B.A. ..... University of Mississippi Medical Center
Chu, Edward, M.D. ..... Yale University
Claffey, Kevin P., Ph.D. ..... University of Connecticut School of Medicine & Dentistry
Clevenger, Charles V., M.D., Ph.D. ..... Northwestern University
Cody, Vivian, Ph.D. ..... Hauptman-Woodward Medical Research Institute
Cullen, Kevin J., M.D. ..... University of Maryland, Baltimore
Curran, Walter J., M.D., Ph.D. ..... Emory University

D

Davidson, Nancy E., M.D. ..... University of Pittsburgh
Delucas, Lawrence J., Ph.D. ..... University of Alabama at Birmingham
Dent, Paul, Ph.D. ..... Virginia Commonwealth University
DeSimone, Joseph M., Ph.D. ..... University of North Carolina at Chapel Hill
Devine, Susan I., C.C.R.P. ..... The Hospital for Sick Children, Toronto
Diasio, Robert B., M.D. ..... Mayo Clinic
Dipaola, Robert S., M.D. ..... University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School
Djaballah, Hakim, Ph.D. ..... Sloan-Kettering Institute for Cancer Research
Djeu, Julie Y., Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Dong, Zigang, M.D. ..... The University of Minnesota, Twin Cities
Dove, William F., Ph.D. ..... University of Wisconsin, Madison

E

Eary, Janet F., M.D. ..... Seattle Children's Hospital
Eberlein, Timothy J., M.D. ..... Washington University
Eckhart, Walter, Ph.D. ..... Salk Institute for Biological Studies
Economou, James S., M.D., Ph.D. ..... University of California, Los Angeles
Ellenhorn, Joshua D. I., M.D. ..... City of Hope National Medical Center
Emanuel, Peter D., M.D. ..... University of Arkansas Medical Sciences, Little Rock
Engelhard, Victor H., Ph.D. ..... University of Virginia
Erlichman, Charles, M.D. ..... Mayo Clinic
Ethier, Stephen P., Ph.D. ..... Wayne State University
Evers, Bernard M., M.D. ..... University of Kentucky

F

Ferrone, Soldano, M.D., Ph.D. ..... University of Pittsburgh
Figlin, Robert, M.D. ..... Cedars-Sinai Medical Center
Fisher, Richard I., M.D., Ph.D. ..... University of Rochester
Fitzgerald-Bocarsly, Patricia, Ph.D. ..... University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School
Ford, James M., M.D. ..... Stanford University
Fracasso, Paula M., M.D., Ph.D. ..... University of Virginia
Fridman, Rafael A., Ph.D. ..... Wayne State University
Futscher, Bernard W., Ph.D. ..... The University of Arizona

G

Gapstur, Susan M., Ph.D. ..... American Cancer Society, Inc.
Gatenby, Robert A., M.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Geoghegan, Cynthia ..... Susan G. Komen Breast Cancer Foundation
Gerlach, Robert W., M.A. ..... Dartmouth College
Gerson, Stanton L., M.D. ..... Case Western Reserve University
Gewirtz, David A., Ph.D. ..... Virginia Commonwealth University
Ghandehari, Hamid, Ph.D. ..... University of Mississippi
Giger, Maryellen L., Ph.D. ..... The University of Chicago
Gillies, Robert J., Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Gimotty, Phyllis A., Ph.D. ..... The University of Pennsylvania
Girotti, Albert W., Ph.D. ..... Medical College of Wisconsin
Girvin, Mark E., Ph.D. ..... Albert Einstein College of Medicine of Yeshiva University
Goldstein, Lori J., M.D. ..... Fox Chase Cancer Center
Gomella, Leonard G., M.D. ..... Thomas Jefferson University
Gould, Michael N., Ph.D. ..... University of Wisconsin, Madison
Gralow, Julie R., M.D. ..... University of Washington
Grant, Marcia L., D.N.Sc., F.A.A.N. ..... City of Hope National Medical Center
Graves, Barbara J., Ph.D. ..... University of Utah
Greally, John, M.D., Ph.D. ..... Albert Einstein College of Medicine of Yeshiva University

H

Hackett, Lauren, M.A. ..... New York University
Hackney, David B., M.D. ..... Beth Israel Deaconess Medical Center
Hansen, Marc F., Ph.D. ..... University of Connecticut School of Medicine & Dentistry
Harrison, Anita L., M.A. ..... Medical University of South Carolina
Hartmann, Lynn C., M.D. ..... Mayo Clinic
Heslop, Helen E., M.D. ..... Baylor College of Medicine
Hichwa, Richard D., Ph.D. ..... The University of Iowa
Hiebert, Scott, Ph.D. ..... Vanderbilt University
Hill, David E., Ph.D. ..... Dana-Farber Cancer Institute
Hollingsworth, Michael A., Ph.D. ..... University of Nebraska Medical Center
Hoopes, P. Jack, Ph.D. ..... Dartmouth College
Houghton, Janet A., Ph.D. ..... Cleveland Clinic Lerner College of Medicine of Case Western Reserve University

Hsu, Edward W., Ph.D. ..... University of Utah
Hurley, Karen E., Ph.D. ..... Sloan-Kettering Institute for Cancer Research
Hyslop, Terry, Ph.D. ..... Thomas Jefferson University

I

Iannaccone, Philip M., M.D., Ph.D. ..... Children's Memorial Hospital, Chicago
Israel, Mark A., M.D. ..... Dartmouth College

J

Jacobs, Lisa K., M.D. ..... The Johns Hopkins University
Jaeckle, Kurt, M.D. ..... Mayo Clinic College of Medicine, Jacksonville
Jeames, Sanford E., D.H.A. ..... University of Massachusetts, Amherst
Jenkins, Robert B., M.D., Ph.D. ..... Mayo Clinic
Johnson, Candace S., Ph.D. ..... Roswell Park Cancer Institute Corporation
Johnson, Katherine A., J.D. ..... Virginia Commonwealth University
Jones, Judy A., M.A. ..... Cutaneous Lymphoma Foundation
Jones, Richard J., M.D. ..... The Johns Hopkins University
Jove, Richard, Ph.D. ..... Beckman Research Institute of City of Hope
Jurnak, Frances A., Ph.D. ..... University of California, Irvine

K

Kalemkerian, Gregory P., M.D. ..... University of Michigan, Ann Arbor
Kantoff, Philip W., M.D. ..... Dana-Farber Cancer Institute
Kastan, Michael B., M.D., Ph.D. ..... St. Jude Children's Research Hospital
Kaufman, Howard L., M.D. ..... Rush University Medical Center
Kaufman, Russel E., M.D. ..... The Wistar Institute
Kenney, Shannon C., M.D. ..... University of Wisconsin, Madison
Khayat, Anita F., Ph.D. ..... National Childhood Cancer Foundation
Khuri, Fadlo R., M.D. ..... Emory University
Kinney, Anita Y., Ph.D., R.N. ..... University of Utah
Klein, William H., Ph.D. ..... The University of Texas Health Science Center, Houston
Knopp, Michael V., M.D., Ph.D. ..... The Ohio State University
Kong, Ah-Ng T., Ph.D. ..... Rutgers University
Kopelman, Raoul, Ph.D. ..... University of Michigan, Ann Arbor
Kron, Stephen J., M.D., Ph.D. ..... The University of Chicago
Kukuruzinska, Maria A., Ph.D. ..... Boston University
Kulesz-Martin, Molly F., Ph.D. ..... Oregon Health and Science University
Kumar, Nagi B., Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Kung, Hsing-Jien, Ph.D. ..... University of California, Davis

L

Lannin, Donald R., M.D. ..... Yale University
Lattime, Edmund C., Ph.D. ..... University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School
Leary, James F., Ph.D. ..... Purdue University, West Lafayette

Le Beau, Michelle M., Ph.D. ..... The University of Chicago
Lee, Jeannette Y., Ph.D. ..... University of Arkansas Medical Sciences, Little Rock
Lenkinski, Robert E., Ph.D. ..... Beth Israel Deaconess Medical Center
Lennarz, William J., Ph.D. ..... State University of New York at Stony Brook
Leslie, Kimberly K., M.D. ..... The University of Iowa
Leyland-Jones, Brian, M.D., Ph.D. ..... Emory University
Li, King C., M.D., M.B.A. ..... Methodist Hospital Research Institute
Libermann, Towia A., Ph.D. ..... Beth Israel Deaconess Medical Center
Liggitt, Harry D., Ph.D. ..... University of Washington
Lin, Henry J., M.D. ..... Los Angeles Biomedical Research Institute/Harbor University of California, Los Angeles Medical Center
Link, Michael P., M.D. ..... Stanford University
Loehrer, Patrick J., M.D. ..... Indiana University-Purdue University, Indianapolis
London, Jack W., Ph.D. ..... Thomas Jefferson University
London, Wendy B., Ph.D. ..... Dana-Farber Cancer Institute
Lynch, Thomas J., M.D. ..... Yale University

M

Macoska, Jill A., Ph.D. ..... University of Michigan, Ann Arbor
Malkas, Linda H., Ph.D. ..... Indiana University, Indianapolis
Mao, Li, M.D. ..... University of Maryland, Baltimore
Marina, Neyssa M., M.D. ..... Stanford University
Marks, Lawrence B., M.D. ..... Duke University
Marshall, James, Ph.D. ..... Roswell Park Cancer Institute
Marshall, M. Blair, M.D. ..... Georgetown University
Martin, Brian J., M.A. ..... University of Rochester
Mayne, Susan T., Ph.D. ..... Yale University
McCarthy, James B., Ph.D. ..... The University of Minnesota, Twin Cities
McConkey, David J., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
McCormick, Beryl, M.D. ..... Memorial Sloan-Kettering Cancer Center
McGlave, Philip, M.D. ..... The University of Minnesota, Twin Cities
McLaren, Christine E., Ph.D. ..... University of California, Irvine
McWeeney, Shannon K., Ph.D. ..... Oregon Health and Science University
Mermelstein, Robin J., Ph.D. ..... University of Illinois at Chicago
Meropol, Neal J., M.D. ..... Case Western Reserve University
Meyer, William H., M.D. ..... University of Oklahoma Health Sciences Center
Meyers, Craig M., Ph.D. ..... Pennsylvania State University, Hershey Medical Center
Meyn, Raymond E., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Miller, Jeffrey S., M.D. ..... The University of Minnesota
Miller, Kathy D., M.D. ..... Indiana University-Purdue University, Indianapolis
Moley, Jeffrey F., M.D. ..... Washington University
Mondragon, Alfonso, Ph.D. ..... Northwestern University
Morgan, Tim, Ph.D. ..... Wake Forest University Health Sciences
Mori, Motomi, Ph.D. ..... Oregon Health and Science University
Munger, Karl, Ph.D. ..... Brigham and Women's Hospital

N

Naeve, Clayton W., Ph.D. ..... St. Jude Children's Research Hospital
Nagarajan, Rakesh, M.D., Ph.D. ..... Washington University
Nagarkatti, Mitzi, Ph.D. ..... The University of South Carolina, Columbia
Neugut, Alfred I., M.D., Ph.D. ..... Columbia University
Neuhausen, Susan L., Ph.D. ..... Beckman Research Institute of City of Hope
Nicholson, Henry S., M.D. ..... Oregon Health and Science University
Niland, Joyce C., Ph.D. ..... Beckman Research Institute of City of Hope
Nilsen-Hamilton, Marit, Ph.D. ..... Iowa State University

O

Olshan, Andrew, Ph.D. ..... University of North Carolina at Chapel Hill

P

Page, C. David, Ph.D. ..... University of Wisconsin, Madison
Patchell, Roy A., M.D. ..... St. Joseph's Hospital and Medical Center
Perez, Raymond P., M.D. ..... Dartmouth College
Petersen, Gloria M., Ph.D. ..... Mayo Clinic
Pfeifer, Gerd P., Ph.D. ..... Beckman Research Institute of City of Hope
Piazza, Gary A., Ph.D. ..... University of Alabama at Birmingham
Pierce, John A., Ph.D. ..... University of California, San Diego
Pierce, John P., Ph.D. ..... University of California, San Diego
Pitha-Rowe, Paula M., Ph.D. ..... The Johns Hopkins University
Platanias, Leonidas C., M.D., Ph.D. ..... Northwestern University
Platz, Elizabeth A., Ph.D. ..... The Johns Hopkins University
Pollock, Brad H., Ph.D. ..... The University of Texas Health Science Center, San Antonio
Poplin, Elizabeth, M.D. ..... University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School
Powell, Robert S., M.B.A. ..... Beckman Research Institute of City of Hope
Powis, Garth, D.Phil. ..... The University of Texas M.D. Anderson Cancer Center
Pui, Ching-Hon, M.D. ..... St. Jude Children's Research Hospital

Q

Quaranta, Vito, M.D. ..... Vanderbilt University
Quinn, David I., Ph.D. ..... University of Southern California

R

Raghavan, Derek, M.D., Ph.D. ..... Cleveland Clinic Foundation
Ratliff, Timothy L., Ph.D. ..... Purdue University, West Lafayette
Ray, Rahul, Ph.D. ..... Boston University School of Medicine
Raychaudhuri, Pradip, Ph.D. ..... University of Illinois at Chicago
Reddy, Sakamuri V., Ph.D. ..... Medical University of South Carolina
Regine, William, M.D. ..... University of Maryland System
Reinke, Denise, M.S. ..... University of Michigan

Ribas, Antoni, M.D. ..... University of California, Los Angeles
Ritz, Jerome ..... Dana-Farber Cancer Institute
Roberson, Paula K., Ph.D. ..... University of Arkansas Medical Sciences, Little Rock
Rock, Cheryl L., Ph.D. ..... University of California, San Diego
Rodgers, William H., M.D., Ph.D. ..... Lenox Hill Hospital
Rosenblatt, Joseph D., M.D. ..... University of Miami School of Medicine
Royce, Melanie E., M.D., Ph.D. ..... The University of New Mexico

S

Sausville, Edward A., M.D., Ph.D. ..... University of Maryland, Baltimore
Schiller, Joan H., M.D. ..... The University of Texas, Dallas
Schuchter, Lynn M., M.D. ..... The University of Pennsylvania
Schwartz, Ann G., Ph.D. ..... Wayne State University
Schwartz, Cindy L., M.D. ..... Brown University
Schwartz, Marc D., Ph.D. ..... Georgetown University
Schwendeman, Steven P., Ph.D. ..... University of Michigan, Ann Arbor
Scroggins, Mary J., M.A. ..... Independent Consultant
Seewaldt, Victoria L., M.D. ..... Duke University
Seither, Richard L., Ph.D., M.B.A. ..... Albert Einstein College of Medicine of Yeshiva University
Shaw, Edward G., M.D. ..... Wake Forest University
Sherman, Simon, Ph.D. ..... University of Nebraska Medical Center
Showe, Louise C., Ph.D. ..... Wistar Institute
Shyr, Yu, Ph.D. ..... Vanderbilt University
Siegfried, Jill M., Ph.D. ..... University of Pittsburgh
Sigurdson, Elin R., M.D., Ph.D. ..... Fox Chase Cancer Center
Sims, Millicent C. ..... African American Cancer Support Group
Slack, Frank J., Ph.D. ..... Yale University
Small, Eric J., M.D. ..... University of California, San Francisco
Smith, Elaine M., Ph.D., M.B.A. ..... The University of Iowa
Snetselaar, Linda G., Ph.D. ..... The University of Iowa
Sondak, Vernon K., M.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Sondel, Paul M., M.D., Ph.D. ..... University of Wisconsin, Madison
Sotomayor, Eduardo M., M.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Speicher, David W., Ph.D. ..... The Wistar Institute
Srour, Edward F., Ph.D. ..... Indiana University-Purdue University, Indianapolis
Staley, Charles A., M.D. ..... Emory University
Stone, Richard M., M.D. ..... Dana-Farber Cancer Institute

T

Tan, Ming T., Ph.D. ..... University of Maryland, Baltimore
Tew, Kenneth D., Ph.D. ..... Medical University of South Carolina
Thompson, Craig B., M.D. ..... The University of Pennsylvania
Townsend, Alan J., Ph.D. ..... Wake Forest University Health Sciences
Triche, Timothy J., M.D., Ph.D. ..... Children's Hospital, Los Angeles
Trock, Bruce J., Ph.D. ..... The Johns Hopkins University
Turker, Mitchell S., Ph.D. ..... Oregon Health and Science University
Tycko, Benjamin, M.D., Ph.D. ..... Gordon Research Conferences

V

Van Etten, Richard A., M.D., Ph.D. ..... Tufts Medical Center
Vanwuyckhuyse, Brian C. ..... University of Rochester
Verma, Inder M., Ph.D. ..... Salk Institute for Biological Studies

W

Wachsman, William, M.D., Ph.D. ..... University of California, San Diego
Waldman, Scott A., M.D., Ph.D. ..... Thomas Jefferson University
Washington, Mary K., M.D., Ph.D. ..... Vanderbilt University
Watanabe-Galloway, Shinobu, Ph.D. ..... Aberdeen Area Tribal Chairmen's Health Board
Weichert, Jamey P., Ph.D. ..... University of Wisconsin, Madison
Weiss, Geoffrey R., M.D. ..... University of Virginia
Welch, Danny R., Ph.D. ..... University of Alabama at Birmingham
Wells, Susanne I., Ph.D. ..... Children's Hospital Medical Center, Cincinnati
Wheatley, Bonnie P., Ed.D. ..... Alameda County Medical Center
Wiley, Patti, M.B.A. ..... On The Wings of Angels
Willson, James K., M.D. ..... The University of Texas Southwest Medical Center, Dallas
Wilson-Sanders, Susan E., D.V.M. ..... The University of Arizona
Wolff, Antonio C., M.D. ..... The Johns Hopkins University
Woods, William G., M.D. ..... Children's Healthcare of Atlanta, Inc.

Y

Yeatman, Timothy J., M.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Yee, Douglas, M.D. ..... The University of Minnesota
Yen, Yun, M.D., Ph.D. ..... Beckman Research Institute of City of Hope
Yothers, Greg, Ph.D. ..... University of Pittsburgh

Z

Zhang, Michael Q., Ph.D. ..... The University of Texas, Dallas
Zhao, Yingming, Ph.D. ..... The University of Chicago

Total number of Reviewers: 289

3. Consultants Serving on Special Emphasis Panels (SEPs) in FY2010

A

Abbruzzese, James L., M.D. ..... The University of Texas M.D. Anderson Cancer Center
Abdulkadir, Sarki A., M.D., Ph.D. ..... Vanderbilt University
Abounader, Roger, M.D., Ph.D. ..... University of Virginia
Adams, Alyce S., Ph.D. ..... Kaiser Foundation Research Institute
Adams, Mary L., Ph.D., R.N. ..... The University of Texas, Austin
Adams, Swann A., Ph.D. ..... University of South Carolina, Columbia
Adams-Campbell, Lucile L., Ph.D. ..... Georgetown University
Affonso, Dyanne D., Ph.D. ..... University of Hawaii, Hilo
Agarwal, Rajesh, Ph.D. ..... University of Colorado, Denver
Aguiar, Ricardo C., M.D., Ph.D. ..... The University of Texas Health Science Center, San Antonio
Ahles, Tim A., Ph.D. ..... Sloan-Kettering Institute for Cancer Research
Ajani, Jaffer A., M.D. ..... The University of Texas M.D. Anderson Cancer Center
Akala, Emmanuel O., Ph.D. ..... Howard University
Alavi, Abass, M.D. ..... The University of Pennsylvania
Albertson, Donna G., Ph.D. ..... University of California, San Francisco
Albright, Lisa C., Ph.D. ..... University of Utah
Alexandrow, Mark G., Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Ali-Osman, Francis, D.Sc. ..... Duke University
Almeida, Jonas S., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Amiji, Mansoor M., Ph.D. ..... Northeastern University
Amodio, David M., Ph.D. ..... New York University
Amos, Michael, Ph.D. ..... National Institute of Standards & Technology
Anandasabapathy, Sharmila, M.D. ..... Mount Sinai School of Medicine of New York University
Andersen, Barbara L., Ph.D. ..... The Ohio State University
Andersen, Marin R., Ph.D., M.P.H. ..... Fred Hutchinson Cancer Research Center
Anderson, Garth R., Ph.D. ..... Roswell Park Cancer Institute
Anderson, James R., Ph.D. ..... National Childhood Cancer Foundation
Anderson, Richard A., Ph.D. ..... University of Wisconsin, Madison
Andriole, Katherine P., Ph.D. ..... Brigham and Women's Hospital
Antonia, Scott J., M.D., Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Apelberg, Benjamin J., Ph.D. ..... The Johns Hopkins University
Aplin, Andrew E., Ph.D. ..... Thomas Jefferson University
Arbiser, Jack L., M.D., Ph.D. ..... Emory University
Archer, Kellie J., Ph.D. ..... Virginia Commonwealth University
Arenaz, Pablo, Ph.D. ..... Texas A&M International University
Arenberg, Douglas A., M.D. ..... University of Michigan, Ann Arbor
Argenbright, Keith E., M.D. ..... The University of Texas Southwestern Medical Center
Armato, Samuel G., Ph.D. ..... The University of Chicago
Armitage, Bruce A., Ph.D. ..... Carnegie-Mellon University
Arnold, Paul M., M.D. ..... The University Kansas
Arriaga, Edgar A., Ph.D. ..... The University of Minnesota, Twin Cities
Arslan, Alan A., M.D. ..... New York University School of Medicine
Ashendel, Curtis L., Ph.D. ..... Purdue University, West Lafayette

Ashikaga, Takamaru, Ph.D. ..... The University of Vermont
Ashktorab, Hassan, Ph.D. ..... Howard University
Aspinall, Mara G., M.B.A. ..... On-Q-Ity, Inc.
Atasoy, Ulus, M.D. ..... University of Missouri, Columbia
Athar, Mohammad, Ph.D. ..... University of Alabama at Birmingham
Atkins, Michael B., M.D. ..... Beth Israel Deaconess Medical Center
Atwood, Walter, Ph.D. ..... Brown University
Au, Jessie L.S., Pharm.D., Ph.D. ..... Optimum Therapeutics, LLC
Augenlicht, Leonard H., Ph.D. ..... Montefiore Medical Center
Austin, Donald F., M.D., M.P.H. ..... Oregon Health and Science University
Avraham, Hava K., Ph.D. ..... Beth Israel Deaconess Medical Center
Ayala, Gustavo, M.D. ..... Baylor College of Medicine

B

Badawi, Ramsey D., Ph.D. ..... University of California, Davis
Badve, Sunil S., M.D. ..... Indiana University-Purdue University, Indianapolis
Baezconde-Garnati, Lourdes A., Ph.D., M.P.H. ..... University of Southern California
Bahjat, Keith, Ph.D. ..... Providence Portland Medical Center
Bailey, Howard H., M.D. ..... University of Wisconsin, Madison
Bailey, Ryan C., Ph.D. ..... California Institute of Technology
Bailey-Wilson, Joan E., Ph.D. ..... National Human Genome Research Institute
Baker, Bill J., Ph.D. ..... University of South Florida
Baker, Vicki V., M.D. ..... Independent Consultant
Balch, Edith D., Ph.D. ..... Tufts University, Medford
Balch, Royal C., Ph.D. ..... Indiana University
Baldwin, Dee M., Ph.D., R.N., F.A.A.N. ..... University of North Carolina at Charlotte
Balgley, Brian M., Ph.D. ..... Bioproximity, LLC
Balk, Steven P., M.D., Ph.D. ..... Beth Israel Deaconess Medical Center
Balogh, Lajos P., Ph.D. ..... Roswell Park Cancer Institute
Balter, James M., Ph.D. ..... University of Michigan, Ann Arbor
Band, Hamid, M.D., Ph.D. ..... University of Nebraska Medical Center
Bandos, Andriy, Ph.D. ..... University of Pittsburgh
Banerjee, Sushanta K., Ph.D. ..... Kansas City VA Medical Center
Bankert, Richard B., V.M.D., Ph.D. ..... The State University of New York at Buffalo
Baquet, Claudia R., M.D., M.P.H. ..... University of Maryland, Baltimore
Bareli, Menashe, Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Barg, Frances K., Ph.D., M.Ed. ..... The University of Pennsylvania
Barker, Peter E., Ph.D. ..... National Institute of Standards & Technology
Baron, Anna E., Ph.D. ..... University of Colorado Medical Center
Baron, David A., Ph.D. ..... Takeda Pharmaceuticals, Inc.
Barrett, James C., Ph.D. ..... National Institute of Environmental Health Sciences
Barrett, Michael T., Ph.D. ..... Translational Genomics Research Inst
Barry, Stephen E., Ph.D. ..... Alnis Biosciences, Inc
Bar-Sagi, Dafna, Ph.D. ..... New York University School of Medicine
Barth, Rolf F., M.D. ..... The Ohio State University
Bartlett, David L., M.D. ..... University of Pittsburgh
Barton, Jennifer K., Ph.D. ..... The University of Arizona

Basilion, James P., Ph.D. ..... Case Western Reserve University
Baskaran, Harihara, Ph.D. ..... Case Western Reserve University
Bastiaans, Glenn J., Ph.D. ..... Intelligent Optical Systems, Inc.
Bastian, Lori A., M.D., M.P.H. ..... Duke University
Basu, Ashis K., Ph.D. ..... University of Connecticut, Storrs
Basu, Hirak S., Ph.D. ..... University of Wisconsin, Madison
Batra, Surinder K., Ph.D. ..... University of Nebraska Medical Center
Baumch-Reardon, Lisa L., Ph.D. ..... University of Miami School of Medicine
Baxter, Gregory T., Ph.D. ..... U.S. National Science Foundation
Baxter, Nancy N., M.D., Ph.D. ..... St. Michael's Hospital
Baxter-Lowe, Lee A., Ph.D. ..... Palmetto Health, Richland
Beauchamp, Robert D., M.D. ..... Vanderbilt University
Beaudoin, Christopher E., Ph.D. ..... Texas A&M University
Beck, John R., M.D. ..... Fox Chase Cancer Center
Beckman, Robert A., M.D., Ph.D. ..... Daiichi-Sankyo Pharma Development
Beckwith, Barbara J., M.A. ..... The Ohio State University
Bedu-Addo, Frank, Ph.D. ..... PDS Biotechnology Corporation
Befeler, Alex S., M.D. ..... Saint Louis University School of Medicine
Behrns, Kevin E., M.D. ..... University of Florida
Benaron, David A., M.D. ..... Spectros Corporation
Benedyk, Mark J., Ph.D. ..... The Pfizer Incubator, LLC
Beningo, Karen A., Ph.D. ..... Wayne State University
Bennett, Charles L., M.D., Ph.D. ..... Medical University of South Carolina
Berens, Michael E., Ph.D. ..... Translational Genomics Research Institute
Berezney, Ronald, Ph.D. ..... State University of New York at Buffalo
Bergen, Harold R., Ph.D. ..... Mayo Proteomic Research Center
Berger, Nathan A., D.V.M., M.D. ..... Case Western Reserve University
Berkowitz, Dawn S., M.P.H. ..... Maryland State Department of Health and Mental Hygiene
Berman, Barbara A., Ph.D. ..... University of California, Los Angeles School of Public Health
Berman, David M., M.D., Ph.D. ..... The Johns Hopkins University
Bernstein, Steven L., M.D. ..... Yale University
Berry, Donna L., Ph.D., R.N., A.O.C.N., F.A.A.N. ..... Dana-Farber Cancer Institute
Bertics, Paul J., Ph.D. ..... University of Wisconsin, Madison
Bessler, Monica, M.D., Ph.D. ..... The University of Pennsylvania
Betancourt, Hector M., Ph.D. ..... Loma Linda University
Bhalla, Kapil, M.D. ..... The University of Kansas Medical Center
Bharti, Ajit K., Ph.D. ..... Dana-Farber Cancer Institute
Bhatia, Smita, M.D., M.P.H. ..... City of Hope National Medical Center
Bhiladvala, Rustom B., Ph.D. ..... University of Victoria
Bickers, David R., M.D. ..... Columbia University Health Sciences
Biernat, Monica R., Ph.D. ..... The University of Kansas, Lawrence
Bies, Robert R., Ph.D., Pharm.D. ..... Indiana University-Purdue University, Indianapolis
Bigatti, Silvia M., Ph.D. ..... Indiana University-Purdue University, Indianapolis
Billings, Steven, M.D. ..... Cleveland Clinic Lerner Foundation
Billingsley, Melvin L., Ph.D. ..... Pennsylvania State University, University Park
Binswanger, Ingrid A., M.D., M.P.H. ..... University of Colorado, Denver
Bird, Richard C., Ph.D. ..... Auburn University
Biris, Alexandru S., Ph.D. ..... University of Arkansas, Little Rock

Bishop, Gail A., Ph.D. ..... The University of Iowa
Black, Margaret E., Ph.D. ..... Washington State University
Blobe, Gerard C., M.D., Ph.D. ..... Duke University
Blonder, Josip, M.D. ..... Science Applications International Corporation, Frederick
Blum, Terry C., Ph.D. ..... Georgia Institute of Technology
Bluthenthal, Ricky N., Ph.D. ..... California State University, Dominguez Hills
Bocan, Thomas M., Ph.D. ..... Pfizer, Inc.
Bock, Cathryn H., Ph.D., M.P.H. ..... Wayne State University
Bogdanov, Alexei A., Ph.D., Sc.D. ..... University of Massachusetts Medical School, Worcester
Bogen, Steven A., M.D., Ph.D. ..... Medical Discovery Partners, LLC
Bogler, Oliver, Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Bollag, Wendy B., Ph.D. ..... Medical College of Georgia
Boman, David A., Ph.D. ..... The University of Texas Southwestern Medical Center, Dallas
Borrell, Luisa N., D.D.S., Ph.D. ..... Herbert H. Lehman College
Bosenberg, Marcus W., M.D., Ph.D. ..... Yale University
Bourland, John D., Ph.D. ..... Wake Forest University Health Sciences
Boushey, Carol J., Ph.D., M.P.H. ..... Purdue University, West Lafayette
Bouton, Amy H., Ph.D. ..... University of Virginia
Bouvet, Michael, M.D. ..... University of California, San Diego
Bowen, Deborah J., Ph.D. ..... Boston University Medical Campus
Bowers, William J., Ph.D. ..... University of Rochester
Boyd, Jeffrey, Ph.D. ..... Fox Chase Cancer Center
Brady, James P., Ph.D. ..... Maxcyte, Inc.
Brard, Laurent, M.D., Ph.D. ..... Women and Infants Hospital-Rhode Island
Brat, Daniel J., M.D., Ph.D. ..... Emory University
Brattain, Michael G., Ph.D. ..... University of Nebraska Medical Center
Braun, Latoya J., Ph.D. ..... University of Colorado, Denver
Braun, Pascal, Ph.D. ..... Dana-Farber Cancer Institute
Brem, Steven, M.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Brenner, Malcolm K., M.D., Ph.D. ..... Baylor College of Medicine
Brewer, Molly A., D.V.M., M.D. ..... The University of Arizona
Brewer, Noel T., Ph.D. ..... University of North Carolina at Chapel Hill
Broaddus, William C., M.D., Ph.D. ..... Virginia Commonwealth University
Brock, Malcolm V., M.D. ..... The Johns Hopkins University
Brockbank, Kelvin G.M., Ph.D. ..... Cell and Tissue Systems, Inc.
Brockhausen, Inka, Ph.D. ..... Queen's University
Broderson, Hal S., M.D. ..... Kingston General Hospital
Brosh, Robert M., Ph.D. ..... National Institute on Aging
Brown, John M., Ph.D. ..... Stanford University
Brown, Kathlynn C., Ph.D. ..... The University of Texas Southwestern Medical Center at Dallas
Bruchez, Marcel P., Ph.D. ..... Carnegie-Mellon University
Brunengraber, Henri, M.D., Ph.D. ..... Case Western Reserve University
Brunicardi, Francis C., M.D. ..... Baylor College of Medicine
Brunner, Lane J., Ph.D. ..... The University of Texas, Austin
Bu, Zimei, Ph.D. ..... City College of New York
Buchsbaum, Donald J., Ph.D. ..... University of Alabama at Birmingham
Bueno, Raphael, M.D. ..... Brigham and Women's Hospital
Bulik, Robert J., Ph.D. ..... The University of Texas Medical Branch

Bult, Carol J., Ph.D. ..... Jackson Laboratory at Galveston
Bunn, Janice Y., Ph.D. ..... The University of Vermont & State Agricultural College
Buolamwini, John K., Ph.D. ..... The University of Tennessee Health Science Center
Burbulis, Ian E., Ph.D. ..... Molecular Sciences Institute
Burdette, Everette C., Ph.D. ..... Acoustic Medical Systems, LLC
Burgess, Diane J., Ph.D. ..... University of Connecticut, Storrs
Burke, Harry B., M.D., Ph.D. ..... George Washington University
Burtness, Barbara, M.D. ..... Fox Chase Cancer Center
Buttyan, Ralph, Ph.D. ..... Ordway Research Institute, Inc.
Byers, Stephen W., Ph.D. ..... Georgetown University
Byrd, John C., M.D., Ph.D. ..... The Ohio State University

C

Cabral, Guy A., Ph.D. ..... Society on Neuroimmune Pharmacology
Caffrey, Michael S., Ph.D. ..... University of Illinois at Chicago
Cairncross, J. Gregory, M.D. ..... University of Calgary
Cairns, Paul, Ph.D. ..... Fox Chase Cancer Center
Cairo, Mitchell S., M.D. ..... Columbia University Health Sciences
Calderwood, Stuart K., Ph.D. ..... Boston University Medical Campus
Calin, George A., M.D., Ph.D. ..... The Johns Hopkins University
Callahan, Edward J., Ph.D. ..... University of California, Davis
Callas, Peter, Ph.D. ..... The University of Vermont
Campbell, Catherine E., Ph.D. ..... Noblis, Inc.
Campbell, Janis E., Ph.D. ..... University of Oklahoma Health Sciences Center
Campbell, Moray J., Ph.D. ..... Roswell Park Cancer Institute
Cannon, Martin J., Ph.D. ..... DCV Technologies, Inc.
Cantor, Alan B., M.D., Ph.D. ..... University of Alabama at Birmingham
Cao, Han, Ph.D. ..... Bionanomatrix, Inc.
Capobianco, Anthony J., Ph.D. ..... University of Miami School of Medicine
Carbone, Michele, M.D., Ph.D. ..... Cancer Research Center of Hawaii
Cardon, Lon R., Ph.D. ..... Fred Hutchinson Cancer Research Center
Carey, Robert, M. ..... RPC Associates, Inc.
Carney, Patricia A., Ph.D. ..... Oregon Health and Science University
Carpenter, Charles C.J., M.D. ..... Miriam Hospital
Carpenter, Everett E., Ph.D. ..... Virginia Commonwealth University
Carraway, Kermit L., Ph.D. ..... University of Miami School of Medicine
Carroll, Raymond J., Ph.D. ..... Texas A&M University
Carroll, Steven L., M.D., Ph.D. ..... University of Alabama at Birmingham
Casiano, Carlos A., Ph.D. ..... Loma Linda University
Castor, Trevor P., Ph.D. ..... Aphios Corporation
Castro, Maria G., Ph.D. ..... Cedars-Sinai Medical Center
Caterina, Michael J., M.D., Ph.D. ..... The Johns Hopkins University
Cavalli, Luciane R., Ph.D. ..... Georgetown University
Celebi, Julide T., M.D. ..... Columbia University Health Sciences
Chak, Amitabh, M.D. ..... Case Western Reserve University
Chakravarti, Arnab, M.D. ..... The Ohio State University
Chalfant, Charles E., Ph.D. ..... Virginia Commonwealth University

Chambers, Setsuko K., M.D. ..... The University of Arizona
Chandran, Bala, Ph.D. ..... Rosalind Franklin University of Medicine & Sciences
Chang, Alfred E., M.D. ..... University of Michigan, Ann Arbor
Chang, Chawnshang, Ph.D. ..... University of Rochester
Chang, Chih-Hung, Ph.D. ..... Northwestern University
Chang, Mayland F., Ph.D. ..... University of Notre Dame
Chang, Shine, Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Chang, Stephen M., Ph.D. ..... Simplx Pharmaceuticals
Chao, K. Clifford, M.D. ..... Columbia University Health Sciences
Chaput, John C., Ph.D. ..... Arizona State University, Tempe
Chaurand, Pierre, Ph.D. ..... University of Montreal
Chelsky, Daniel, Ph.D. ..... Pharmacopeia Drug Discovery, Inc.
Chen, Changyan, M.D., Ph.D. ..... Beth Israel Deaconess Medical Center
Chen, Ching-Shih, Ph.D. ..... The Ohio State University
Chen, Chu, Ph.D. ..... Fred Hutchinson Cancer Research Center
Chen, Colin, Ph.D. ..... Fannie Mae
Chen, Hongwu, D.V.M., Ph.D. ..... University of California, Davis
Chen, Jake, Ph.D. ..... Indiana University-Purdue University, Indianapolis
Chen, Jinbo, Ph.D. ..... The University of Pennsylvania
Chen, Suzie, Ph.D. ..... Rutgers, The State University of New Jersey, New Brunswick
Chen, Thomas C., M.D., Ph.D. ..... University of Southern California
Chen, Wen-Tien, Ph.D. ..... Vitatex, Inc.
Chen, Xiaoyuan, Ph.D. ..... National Institute of Biomedical Imaging and Bioengineering
Chen, Xinbin, D.V.M., Ph.D. ..... University of California, Davis
Chen, Yong Q., Ph.D. ..... Wake Forest University Health Sciences
Chenevert, Thomas L., Ph.D. ..... University of Michigan, Ann Arbor
Cheng, Jin Q., M.D., Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Cheng, Liang, M.D. ..... Indiana University
Chernoff, Jonathan D., M.D., Ph.D. ..... Institute for Cancer Research
Chesney, Jason A., M.D., Ph.D. ..... University of Louisville
Chesson, Charles V., Ph.D. ..... Social & Scientific Systems
Chiao, Elizabeth, M.D., M.P.H. ..... Baylor College of Medicine
Chiles, Thomas C., Ph.D. ..... Boston College
Chilkoti, Ashutosh, Ph.D. ..... Duke University
Chilton, Beverly S., Ph.D. ..... Texas Tech University Health Sciences Center
Chiocca, E. Antonio, M.D., Ph.D. ..... The Ohio State University
Chiosis, Gabriela, Ph.D. ..... Sloan-Kettering Institute for Cancer Research
Cho, Bongsup P., Ph.D. ..... University of Rhode Island
Cho, Moo J., Ph.D. ..... University of North Carolina Eshelman School of Pharmacy
Chorney, Michael J., Ph.D. ..... Pennsylvania State University, Hershey Medical Center
Christie, Debra W., M.B.A. ..... University of Mississippi Medical Center
Chu, Fong-Fong, Ph.D. ..... City of Hope National Medical Center
Chun, Jerold, M.D., Ph.D. ..... Scripps Research Institute
Chung, Daniel C., M.D. ..... Massachusetts General Hospital
Chung, Fung-Lung, Ph.D. ..... Georgetown University
Chung, Leland W., Ph.D. ..... Cedars-Sinai Medical Center
Ciccolo, Joseph T., Ph.D. ..... Brown University
Claffey, Kevin P., Ph.D. ..... University of Connecticut School of Medicine & Dentistry

Clapper, Margie L., Ph.D. ..... Fox Chase Cancer Center
Clark, Paige B., M.D. ..... Wake Forest University Health Sciences
Clawson, Gary A., M.D., Ph.D. ..... Pennsylvania State University, Hershey Medical Center
Cleary, Kevin R., Ph.D. ..... Children's Research Institute
Clifford, Gary M., Ph.D. ..... International Agency for Research on Cancer
Clukey, Lory, Ph.D., Psy.D. ..... University of Northern Colorado
Clunie, David A., M.B.B.S. ..... Radpharm, Inc
Coale, Howard, M., M.F.A. ..... Tacitus, Inc.
Coetzee, Gerhard A., Ph.D. ..... University of Southern California
Cohen, Edward P.P., M.D. ..... University of Illinois at Chicago
Cohen, Michael B., M.D. ..... The University of Iowa
Cohen, Susan M., D.S.N., A.P.R.N., F.A.A.N. ..... University of Pittsburgh
Colbert, Lisa H., Ph.D, M.P.H. ..... University of Wisconsin, Madison
Colgate, James E., Ph.D. ..... Northwestern University
Coller, Hilary A., Ph.D. ..... Princeton University
Collins, Scott D., Ph.D. ..... University of Maine, Orono
Colwell, Brian, Ph.D. ..... Texas A&M University Health Science Center
Conaway, Mark R., Ph.D. ..... University of Virginia
Connor, Joseph P., M.D., Ph.D. ..... University of Wisconsin, Madison
Conzen, Suzanne D., M.D. ..... The University of Chicago
Cooke, William J., Ph.D. ..... Eastern Virginia Medical School
Cooney, Kathleen A., M.D. ..... University of Michigan, Ann Arbor
Cooper, Laurence J.N., M.D., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Corey, Linda A., Ph.D. ..... Virginia Commonwealth University
Corey, Seth J., M.D., M.P.H. ..... Northwestern University
Cosford, Nicholas D., Ph.D. ..... Sanford-Burnham Medical Research Institute
Cote, Michele L., Ph.D., M.P.H. ..... Wayne State University
Coussens, Lisa M., Ph.D. ..... University of California, San Francisco
Cox, Adrienne D., Ph.D. ..... University of North Carolina School of Medicine
Craighead, Harold G., Ph.D. ..... Cornell University
Cramer, Scott D., Ph.D. ..... Wake Forest University Health Sciences
Cristofanilli, Massimo, M.D. ..... The University of Texas M.D. Anderson Cancer Center
Cronan, Thereasa A., Ph.D. ..... San Diego State University
Crott, Jimmy W., Ph.D. ..... Tufts University
Cunningham, John M., M.D. ..... The University of Chicago
Curbow, Barbara A., Ph.D. ..... University of Florida
Curiel, Tyler J., M.D., M.P.H. ..... The University of Texas Health Science Center, San Antonio
Curley, Steven, M.D. ..... The University of Texas M.D. Anderson Cancer Center
Cutler, David J., Ph.D. ..... Emory University
Czuczman, Myron S., M.D. ..... Roswell Park Cancer Institute

D

Dagostino, Ralph B., Ph.D. ..... Wake Forest University Health Sciences
Darcy, Kathleen M., Ph.D. ..... Roswell Park Cancer Institute
Das, Bhaskar C., Ph.D. ..... Albert Einstein College of Medicine of Yeshiva University
Das Gupta, Abhijit, Ph.D. ..... Thomas Jefferson University
Datar, Ram H., Ph.D. ..... University of Miami School of Medicine

Datta, Somnath, Ph.D. ..... University of Louisville
Davidoff, Andrew M., M.D. ..... St. Jude Children's Research Hospital
Davies, Neal M., Ph.D. ..... Washington State University
Davis, Mark M., Ph.D. ..... Stanford University
Davis, Roger J., Ph.D. ..... University of Massachusetts Medical School, Worcester
Davis-King, Donna T., Ph.D. ..... Charles R. Drew University of Medicine & Science
Davison, Kirsten, Ph.D. ..... State University of New York at Albany
Davisson, Vincent J., Ph.D. ..... Purdue University, West Lafayette
Day, Billy W., Ph.D. ..... University of Pittsburgh
Day, Roger S., Sc.D. ..... University of Pittsburgh
Daynard, Richard A., Ph.D. ..... Northeastern University
Deapen, Dennis M., Ph.D., M.P.H. ..... University of Southern California
Debinski, Waldemar, M.D., Ph.D. ..... Wake Forest University Health Sciences
Decoster, Mark A., Ph.D. ..... Louisiana State University Health Sciences Center
Decuzzi, Paolo, Ph.D. ..... The University of Texas Health Science Center, Houston
Deeg, H. Joachim, M.D. ..... Fred Hutchinson Cancer Research Center
Deeken, John F., M.D. ..... Georgetown University
Dees, Elizabeth C., M.D. ..... University of North Carolina at Chapel Hill
De Graffenried, Linda A., Ph.D. ..... The University of Texas, Austin
De Groot, Mary K., Ph.D. ..... Indiana University-Purdue University, Indianapolis
Deininger, Prescott L., Ph.D. ..... Tulane University
Del Rio, Carlos, M.D. ..... Emory University
Deluca, Neal A., Ph.D. ..... University of Pittsburgh
Demark-Wahnefried, Wendy, Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
De Marzo, Angelo M., M.D., Ph.D. ..... The Johns Hopkins University
Demirci, Utkan, Ph.D. ..... Brigham and Women's Hospital
Dennis, Leslie K., Ph.D. ..... The University of Iowa
Desai, Pankaj B., Ph.D. ..... The University of Cincinnati
Desai, Tejal A., Ph.D. ..... University of California, San Francisco
Descour, Michael R., Ph.D. ..... Sandia National Laboratories
Deshong, Philip, Sc.D. ..... University of Maryland, College Park
Deutsch, Walter A., Ph.D. ..... Louisiana State University Pennington Biomedical Research Center
Dewhirst, Tim, Ph.D. ..... University of Guelph
Diamond, Alan, Ph.D. ..... University of Illinois at Chicago
Dignan, Mark B., Ph.D., M.P.H. ..... University of Kentucky
Ding, George X., Ph.D. ..... Vanderbilt University
Ding, Wei-Qun, Ph.D. ..... University of Oklahoma Health Sciences Center
Divine, George W., Ph.D. ..... Henry Ford Health System
Dixit, Rakesh, Ph.D. ..... Merck Research Laboratories
Dmochowski, Ivan J., Ph.D. ..... The University of Pennsylvania
Dolnick, Bruce J., Ph.D. ..... Roswell Park Cancer Institute
Donehower, Lawrence A., Ph.D. ..... Baylor College of Medicine
Donoghue, Daniel J., Ph.D. ..... University of California, San Diego
Donovan, Kristine A., Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Donovan, Maureen D., Ph.D. ..... The University of Iowa
Dontu, Gabriela, M.D., Ph.D. ..... University of Michigan, Ann Arbor
Dooley, William C., M.D. ..... University of Oklahoma Health Sciences Center
Dorgan, Joanne F., Ph.D., M.P.H. ..... Fox Chase Cancer Center

Downs, Levi S., M.D. ..... The University of Minnesota, Twin Cities
Doyle, Terrence W., Ph.D. ..... Vion Pharmaceuticals, Inc.
Drake, Richard R., Ph.D. ..... Eastern Virginia Medical School
Drees, Beth E., Ph.D., M.B.A. ..... University of Utah
Driehuys, Bastiaan, Ph.D. ..... Medi-Physics, Inc.
Dubinett, Steven M., M.D. ..... University of California, Los Angeles
Duffy, David C., Ph.D. ..... Twin Lights Bioscience, Inc.
Duggal, Priya, Ph.D., M.P.H. ..... National Human Genome Research Institute
Duncan, James S., Ph.D. ..... Yale University
Dupont, Pierre E., Ph.D. ..... Children's Hospital, Boston
Dy, Sydney M., M.D. ..... The Johns Hopkins University
Dzenis, Yuris A., Ph.D. ..... University of Nebraska, Lincoln

E

Eckelman, William C., Ph.D., M.P.H. ..... Molecular Insight Pharmaceuticals, Inc.
Eckhart, Walter, Ph.D. ..... Salk Institute for Biological Studies
Edelman, Martin J., M.D. ..... University of Maryland, Baltimore
Edgerton, Mary E., M.D., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Edwards, Jeremy S., Ph.D. ..... The University of New Mexico Health Sciences Center
Egan, Kathleen M., Sc.D., M.P.H. ..... H. Lee Moffitt Cancer Center & Research Institute
Eibl, Guido E. M., M.D. ..... University of California, Los Angeles
Elashoff, Robert M., Ph.D. ..... University of California, Los Angeles
Elber, Ron, Ph.D. ..... The University of Texas, Austin
Elder, David E., M.D. ..... The University of Pennsylvania
Elder, John P., Ph.D., M.P.H. ..... San Diego State University
Elgavish, Gabriel A., Ph.D. ..... University of Alabama at Birmingham
Eliason, James F., Ph.D. ..... Wayne State University
Ellington, Andrew D., Ph.D. ..... The University of Texas, Austin
Elliot, Diane L., M.D. ..... Oregon Health and Science University
Elmquist, William, Ph.D., Pharm.D. ..... The University of Minnesota, Twin Cities
El-Samad, Hana, Ph.D. ..... University of California, San Francisco
Elson, Paul J., Sc.D. ..... Cleveland Clinic Foundation
Emelianov, Stanislav Y., Ph.D. ..... The University of Texas, Austin
Emerson, Jane, M.D., Ph.D ..... University of Southern California
Emmons, Karen M., Ph.D. ..... Dana-Farber Cancer Institute
Emrick, Todd S., Ph.D. ..... University of Massachusetts, Amherst
Enns, Caroline, Ph.D. ..... Oregon Health and Science University
Epstein, Alan L., M.D., Ph.D. ..... University of Southern California
Erdmann, Christine A., Ph.D., M.P.H. ..... University of Michigan, Ann Arbor
Erickson, David, Ph.D. ..... Cornell University
Eriksen, Michael P., Sc.D. ..... Georgia State University
Esterowitz, Leon, Ph.D. ..... National Science Foundation
Evan, Gerard I., Ph.D. ..... The University of New Mexico
Evans, Christopher P., M.D. ..... University of California, Davis
Evans, David M., Ph.D. ..... Sirnaomics, Inc.
Evelhoch, Jeffrey L., Ph.D. ..... Merck Research Laboratories
Evers, Bernard M., M.D. ..... University of Kentucky

F

Fahmy, Tarek, Ph.D. ..... Yale University
Fahrig, Rebecca, Ph.D. ..... Stanford University
Falk, Gary W., M.D. ..... The University of Pennsylvania
Falo, Louis D., M.D., Ph.D. ..... University of Pittsburgh
Fan, Z. Hugh, Ph.D. ..... University of Florida
Fatouros, Panos P., Ph.D. ..... Virginia Commonwealth University
Febbo, Phillip G., M.D. ..... University of California, San Francisco
Fedowitz, Michele B., M.D. ..... U.S. Food and Drug Administration
Felsburg, Peter J., V.M.D., Ph.D. ..... The University of Pennsylvania
Fenniri, Hicham, Ph.D. ..... University of Alberta
Fenster, Aaron, Ph.D. ..... Robarts Research Institute
Fernander, Anita F., Ph.D. ..... University of Kentucky
Fero, Matthew L., M.D. ..... Fred Hutchinson Cancer Research Center
Ferrara, James L.M., Sc.D., M.D. ..... University of Michigan, Ann Arbor
Ferrell, Betty R., Ph.D., R.N., F.A.A.N. ..... Beckman Research Institute of the City of Hope
Ferrone, Soldano, M.D., Ph.D. ..... University of Pittsburgh
Fiez, Julie A., Ph.D. ..... University of Pittsburgh
Figlin, Robert, M.D. ..... Cedars-Sinai Medical Center
Figueiredo, Jane C., Ph.D. ..... University of Southern California
Finer-Moore, Janet S., Ph.D. ..... University of California, San Francisco
Finkelstein, Dianne M., Ph.D. ..... Massachusetts General Hospital
Fisher, Richard I., M.D., Ph.D. ..... University of Rochester
Fishman, David A., M.D. ..... Mount Sinai School of Medicine of New York University
Fitzgerald, Thomas J., M.D. ..... University of Massachusetts Medical School, Worcester
Fleming, Donna M., M.P.H. ..... U.S. Department of Health and Human Services
Fleming, Jason B., M.D. ..... The University of Texas M.D. Anderson Cancer Center
Flemington, Erik K., Ph.D. ..... Tulane University
Fobair, Patricia A., M.P.H. ..... Patient Advocate
Fong, Lawrence, M.D. ..... University of California, San Francisco
Fontham, Elizabeth H., Ph.D., M.P.H. ..... Louisiana State University Health Science Center
Ford, James M., M.D. ..... Stanford University
Foreman, Kimberly E., Ph.D. ..... Loyola University, Chicago
Forry, Sam, Ph.D. ..... National Institute of Science and Technology
Fortina, Paolo M., M.D., Ph.D. ..... Thomas Jefferson University
Foss, Francine M., M.D. ..... Yale University
Foster, David A., Ph.D. ..... City University of New York
Fox, Bernard A., Ph.D. ..... Providence Portland Medical Center
Fraass, Benedick A., Ph.D. ..... University of Michigan, Ann Arbor
Franck, Richard W., Ph.D. ..... Hunter College
Frank, David A., M.D., Ph.D. ..... Dana-Farber Cancer Institute
Frank, Markus H., M.D. ..... Brigham and Women's Hospital
Franklin, Michael R., Ph.D. ..... University of Utah
Frazier, Marsha L., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Freeman, Burgess, Pharm.D. ..... Array BioPharma, Inc
Freeman, James, Ph.D. ..... The University of Texas Health Science Center, San Antonio
Freimuth, Robert R., Ph.D. ..... Mayo Clinic

Freitas, Michael A., Ph.D. ..... The Ohio State University
Fresco, Jacques R., Ph.D. ..... Princeton University
Freyer, David R., M.S. ..... Helen DeVos Children's Hospital
Freyer, James P., Ph.D. ..... The University of New Mexico
Fridman, Rafael A., Ph.D. ..... Wayne State University
Friedenreich, Christine M., Ph.D. ..... University of Calgary
Friedman, Daniela, Ph.D. ..... University of South Carolina, Columbia
Friedman, Debra L., M.D. ..... Fred Hutchinson Cancer Research Center
Frost, Andra R., M.D. ..... University of Alabama at Birmingham
Fu, Bingmei M., Ph.D. ..... City College of New York
Fueyo, Juan, M.D. ..... The University of Texas M.D. Anderson Cancer Center
Fuqua, Suzanne A., Ph.D. ..... Baylor College of Medicine
Furdui, Cristina, Ph.D. ..... Wake Forest University Health Sciences
Furge, Kyle A., Ph.D. ..... Van Andel Research Institute
Furgeson, Darin Y., Ph.D. ..... University of Utah

G

Gabrielson, Edward W., M.D. ..... The Johns Hopkins University
Gabrilove, Janice L., M.D. ..... Mount Sinai School of Medicine of New York University
Gajewski, Thomas F., M.D., Ph.D. ..... The University of Chicago
Galipeau, Jacques, M.D. ..... Emory University
Gallick, Gary E., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Gamcsik, Michael, Ph.D. ..... North Carolina State University
Ganapathi, Ram N., Ph.D. ..... Cleveland Clinic Foundation
Gandjbakhche, Amir H., Ph.D. ..... The Eunice Kennedy Shriver National Institute of Child Health and Human Development
Gany, Francesca M., M.D., Ph.D. ..... New York University School of Medicine
Gao, Jinming, Ph.D. ..... The University of Texas Southwestern Medical Center, Dallas
Garber, Judy E., M.D., M.P.H. ..... Dana-Farber Cancer Institute
Gardiner, Phillip, Ph.D. ..... University of California
Garg, Pradeep K., Ph.D. ..... Wake Forest University Health Sciences
Garrett-Mayer, Elizabeth, Ph.D. ..... Medical University of South Carolina
Gartenhaus, Ronald B., M.D. ..... University of Maryland, Baltimore
Garza, Mary A., Ph.D., M.P.H. ..... University of Maryland, College Park
Gaston, Sandra M., Ph.D. ..... Beth Israel Deaconess Medical Center
Gatenby, Robert A., M.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Gatewood, Joe M., Ph.D. ..... Seirad, Inc.
Gatley, Samuel J., Ph.D. ..... Northeastern University
Gatsonis, Constantine A., Ph.D. ..... Brown University
Gau, Vincent J. Jr., Ph.D. ..... Genefluidics, Inc.
Gaudet, Mia M., Ph.D. ..... American Cancer Society, Inc.
Gavai, Ashvinikumar, Ph.D. ..... Bristol-Myers Squibb Pharmaceutical Research Institute
Gee, James C., Ph.D. ..... The University of Pennsylvania
Geiger, Ann M., Ph.D., M.P.H. ..... Wake Forest University Health Sciences
Gellibolian, Robert, Ph.D. ..... N-Abl Therapeutics, Inc.
George, Jay, Ph.D. ..... Trevigen, Inc.
Gera, Joseph F., Ph.D. ..... Sepulveda Research Corporation

Gershman, Susan T., Ph.D., M.P.H. ..... Massachusetts Department of Public Health
Gerson, Stanton L., M.D. ..... Case Western Reserve University
Giaccia, Amato J., Ph.D. ..... Stanford University
Gibson, Raymond E., Ph.D. ..... Merck Research Laboratories
Gilbertson, Scott R., Ph.D. ..... University of Houston
Gillespie, G. Yancey, Ph.D. ..... University of Alabama at Birmingham
Gillies, Robert J., Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Gimotty, Phyllis A., Ph.D. ..... The University of Pennsylvania
Glantz, Stanton A., Ph.D. ..... University of California, San Francisco
Glass, Andrew G., M.D. ..... Kaiser Foundation Research Institute
Glass, Charles A., Ph.D. ..... Zacharon Pharmaceuticals, Inc.
Glazer, Robert I., Ph.D. ..... Psychogenics, Inc.
Glick, Stephen J., Ph.D. ..... University of Massachusetts Medical School, Worcester
Glickson, Jerry D., Ph.D. ..... The University of Pennsylvania
Glinsky, Gennadi V., M.D., Ph.D. ..... Ordway Research Institute, Inc.
Glunde, Kristine, Ph.D. ..... The Johns Hopkins University
Go, Vay Liang W., M.D. ..... University of California, Los Angeles
Godfrey, Tony E., Ph.D. ..... University of Rochester
Godwin, Andrew K., Ph.D. ..... The University of Kansas Medical Center
Godzik, Adam, Ph.D. ..... Sanford-Burnham Medical Research Institute
Goel, Ajay, Ph.D. ..... Baylor University Medical Center
Goggins, Michael G., M.D. ..... The Johns Hopkins University
Goldberg, Ilya G., Ph.D. ..... National Institute on Aging
Goldberg, Judith D., Sc.D. ..... New York University School of Medicine
Goldblum, Simeon E., M.D. ..... University of Maryland, Baltimore
Goldgar, David E., Ph.D. ..... International Agency for Research on Cancer
Goldin, Barry R., Ph.D. ..... Tufts University
Goldkorn, Amir, M.D. ..... University of Southern California
Gollnick, Sandra O., Ph.D. ..... Roswell Park Cancer Institute
Golovlev, Val V., Ph.D. ..... Sci-Tec, Inc.
Gonzales, Melissa, Ph.D. ..... The University of New Mexico
Goodman, Steven L., Ph.D. ..... University of Connecticut School of Medicine & Dentistry
Goodsaid, Federico, Ph.D. ..... U.S. Food and Drug Administration
Goodwin, Edwin H., Ph.D. ..... Kromatid, Inc.
Goodwin, W.J., M.D. ..... University of Miami School of Medicine
Gordon, Nahida H., Ph.D. ..... Case Western Reserve University
Goswami, Prabhat C., Ph.D. ..... The University of Iowa
Gotay, Carolyn C., Ph.D. ..... University of British Columbia
Goutsias, John I., Ph.D. ..... The Johns Hopkins University
Govindan, Ramaswamy, M.D. ..... Washington University
Goydos, James S., M.D. ..... University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School
Grant, Steven, M.D. ..... Virginia Commonwealth University
Graves, David E., Ph.D. ..... University of Alabama at Birmingham
Grdina, David J., Ph.D., M.B.A. ..... The University of Chicago
Greco, William R., Ph.D. ..... The State University of New York at Buffalo
Greene, Mark I., M.D., Ph.D. ..... The University of Pennsylvania
Gregg, Jeffrey P., M.D. ..... University of California, Davis

Gregorio, David I., Ph.D. ..... University of Connecticut School of Medicine & Dentistry
Greis, Kenneth D., Ph.D. ..... The University of Cincinnati
Griffin, Robert J., Ph.D. ..... University of Arkansas Medical Sciences, Little Rock
Griffin, Tim J., Ph.D. ..... University of Washington
Griffith, Derek M., Ph.D. ..... University of Michigan, Ann Arbor
Grigsby, Perry W., M.D. ..... Washington University
Grimm, Elizabeth A., Ph.D. ..... Introgen Research Institute, Inc.
Grimm, Jan, M.D., Ph.D. ..... Memorial Sloan-Kettering Cancer Center
Groden, Joanna L., Ph.D. ..... The Ohio State University
Grody, Wayne W., M.D., Ph.D. ..... University of California, Los Angeles
Gross, Mitchell E., M.D., Ph.D. ..... University of Southern California
Gross, Myron D., Ph.D. ..... The University of Minnesota, Twin Cities
Grossniklaus, Hans E., M.D. ..... Emory University
Grufferman, Seymour, M.D., Ph.D. ..... The University of New Mexico
Grundfest, Warren S., M.D. ..... University of California, Los Angeles
Grupp, Stephan A., M.D., Ph.D. ..... Children's Hospital, Philadelphia
Gudkov, Andrei V., Ph.D., Sc.D. ..... Roswell Park Cancer Institute
Guha, Abhijit, M.D. ..... The Hospital for Sick Children, Toronto
Guise, Theresa A., M.D. ..... Indiana University-Purdue University at Indianapolis
Gunawardana, Geewananda, Ph.D. ..... Abbott Laboratories
Guo, Peixuan, Ph.D. ..... The University of Cincinnati
Gupta, Sanjay, Ph.D. ..... Case Western Reserve University
Gusev, Yuriy, Ph.D. ..... Georgetown University

H

Haab, Brian B., Ph.D. ..... Van Andel Research Institute
Haas-Kogan, Daphne A., M.D. ..... University of California, San Francisco
Habermann, Thomas M., M.D. ..... Mayo Clinic
Hackney, David B., M.D. ..... Beth Israel Deaconess Medical Center
Hagedorn, Curt H., M.D. ..... University of Utah
Hagensee, Michael E., M.D., Ph.D. ..... Louisiana State University Health Sciences Center
Haley, John D., Ph.D. ..... OSI Pharmaceuticals, Inc.
Hamilton, Thomas C., Ph.D. ..... Fox Chase Cancer Center
Hammarskjold, Marie-Louise, M.D., Ph.D. ..... University of Virginia
Han, James, Ph.D. ..... Ambergen, Inc
Han, Misop, M.D. ..... The Johns Hopkins University
Han, Sang M., Ph.D. ..... The University of New Mexico
Hande, Kenneth R., M.D. ..... Vanderbilt University
Hanis, Craig L., Ph.D. ..... The University of Texas Health Sciences Center, Houston
Hannink, Mark, Ph.D. ..... University of Missouri, Columbia
Hansen, Laura A., Ph.D. ..... Creighton University
Hansen, Marc F., Ph.D. ..... University of Connecticut School of Medicine & Dentistry
Hardin, Christopher D., Ph.D. ..... University of Missouri, Columbia
Hardy, Jerry L. ..... Patient Advocate
Harrington, Maureen A., Ph.D. ..... Indiana University School of Medicine
Harris, Lyndsay N., M.D. ..... Yale University
Harrop, James S., M.D. ..... Thomas Jefferson University

Hartman, John L., M.D. ..... University of Alabama at Birmingham
Harvey, Jennifer A., M.D. ..... University of Virginia
Hasan, Tayyaba, Ph.D. ..... Massachusetts General Hospital
Haura, Eric B., M.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Hawthorn, Lesleyann, Ph.D. ..... Medical College of Georgia
Hay, Jennifer L., Ph.D. ..... Sloan-Kettering Institute for Cancer Research
Hayes, Wendelin S., D.O. ..... Novartis Pharmaceuticals Corporation
Hazle, John D., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
He, Huixin, Ph.D. ..... Rutgers, The State University of New Jersey, Newark
He, Xiaolin, Ph.D. ..... Northwestern University
Hebrok, Matthias, Ph.D. ..... University of California, San Francisco
Hei, Tom K., Ph.D. ..... Columbia University
Hejazi, Shahram, Ph.D. ..... BioAdvance
Held, Jason M., Ph.D. ..... Buck Institute for Age Research
Hellstrom, Ingegerd E., M.D., Ph.D. ..... University of Washington
Hemann, Michael, Ph.D. ..... Massachusetts Institute of Technology
Henderson, Barbara W., Ph.D. ..... Roswell Park Cancer Institute Corporation
Henderson, Katherine D., Ph.D. ..... Beckman Research Institute of City of Hope
Henry, Charles S., Ph.D. ..... Colorado State University, Fort Collins
Henry, Roland Gilbert, Ph.D. ..... University of California, San Francisco
Hernandez, Brenda Y., Ph.D., M.P.H. ..... University of Hawaii, Manoa
Hesketh, Peter J., Ph.D. ..... Georgia Institute of Technology
Hesselink, John R., M.D. ..... University of California, San Diego
Heston, Warren D., Ph.D. ..... Cleveland Clinic Foundation
Hettich, Robert L., Ph.D. ..... Oak Ridge National Laboratory
Hichwa, Richard D., Ph.D. ..... The University of Iowa
Hickey, Matthew S., Ph.D. ..... Colorado State University, Fort Collins
Hilakivi-Clarke, Leena A., Ph.D. ..... Georgetown University
Hill, David E., Ph.D. ..... Dana-Farber Cancer Institute
Hill, Steven M., Ph.D. ..... Tulane University
Hilsenbeck, Susan G., Ph.D. ..... Baylor College of Medicine
Hinds, Philip W., Ph.D. ..... Tufts Medical Center
Hiroi, Noboru, Ph.D. ..... Albert Einstein College of Medicine of Yeshiva University
Hirschowitz, Edward A., M.D. ..... University of Kentucky
Hlady, Vladimir, Sc.D. ..... University of Utah
Hlatky, Lynn, Ph.D. ..... Caritas St. Elizabeth's Medical Center
Hlavacek, William S., Ph.D. ..... Los Alamos National Laboratory
Ho, Dean, Ph.D. ..... Northwestern University
Ho, Peter T.C., M.D., Ph.D. ..... GlaxoSmithKline
Hock, Janet M., Ph.D. ..... Indiana University-Purdue University, Indianapolis
Hodge, Felicia S., Ph.D. ..... University of California, Los Angeles
Hoffmann, Alexander, Ph.D., M.A. ..... University of California, San Diego
Hogan, Michael E., Ph.D. ..... The University of Arizona
Hogan, Paul F., M.S. ..... Lewin Group, Inc.
Hoh, Josephine, Ph.D. ..... Yale University
Hohl, Raymond J., Ph.D., M.D. ..... The University of Iowa
Holiday, David B., Ph.D. ..... Research Triangle Institute International
Holland, James F., Sc.D., M.D ..... Mount Sinai School of Medicine of New York University

Holland, Lisa A., Ph.D. ..... West Virginia University
Holland, Nina T., Ph.D. ..... University of California, Berkeley
Hollingsworth, Jennifer A., Ph.D. ..... Los Alamos National Laboratory
Holmes, Michelle D., M.D., Ph.D. ..... Harvard School of Public Health
Holt, Jeffrey T., M.D. ..... Tissue Genetics, Inc.
Honavar, Vasant G., Ph.D. ..... Iowa State University
Hood, Brian L., Ph.D. ..... University of Pittsburgh
Hoon, Dave S.B., Ph.D. ..... John Wayne Cancer Institute
Hoopes, P. Jack, D.V.M., Ph.D. ..... Dartmouth College
Hoque, Ashraful, M.D., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Hord, Norman G., Ph.D., M.P.H. ..... Michigan State University
Horska, Alena, Ph.D. ..... The Johns Hopkins University
Houchen, Courtney W., M.D. ..... University of Oklahoma Health Sciences Center
Houghton, Peter J., Ph.D. ..... St. Jude Children's Research Hospital
Houlette, Judy K. ..... Friend for Life Cancer Support Network
Hout, David R., Ph.D. ..... Insight Genetics, Inc.
Howe, Louise R., Ph.D. ..... Cornell University
Howell, Gillian M., Ph.D ..... University of Nebraska Medical Center
Hrkach, Jeff, Ph.D. ..... Bind Biosciences, Inc.
Hu, Chengcheng, Ph.D. ..... The University of Arizona
Hu, Guanghui, Ph.D. ..... Merck & Co., Inc.
Hu, Hong-Ming, Ph.D. ..... Providence Portland Medical Center
Hu, Jennifer J., Ph.D. ..... University of Miami School of Medicine
Hu, Longqin, Ph.D. ..... Rutgers, The State University of New Jersey, New Brunswick
Huang, Jie, Sc.D. ..... Genentech, Inc.
Huang, Peng, Ph.D. ..... The Johns Hopkins University
Huang, Tim H., Ph.D. ..... The Ohio State University
Hubbard, Karen, Ph.D. ..... City College of New York
Hubel, Allison, Ph.D. ..... The University of Minnesota, Twin Cities
Hudson, Melissa M., M.D. ..... St. Jude Children's Research Hospital
Hughes, Steven J., M.D. ..... University of Pittsburgh
Hui, Sek-Wen, Ph.D. ..... Roswell Park Cancer Institute
Hung, Chien-Fu, Ph.D. ..... The Johns Hopkins University
Hung, Mien-Chie, Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Huo, Qun T., Ph.D. ..... University of Central Florida
Hurley, Karen E., Ph.D. ..... Sloan-Kettering Institute for Cancer Research
Hurt, Richard D., M.D. ..... Mayo Clinic
Hurtado-Ziola, Nancy, Ph.D. ..... GC-Free, Inc.
Hutt-Fletcher, Lindsey M., Ph.D. ..... Lousiana State University Health Science Center
Hwang, Jeeseong C., Ph.D. ..... National Institute of Standards & Technology
Hyder, Dewan Syed F., Ph.D. ..... Yale University
Hylton, Nola M., Ph.D. ..... University of California, San Francisco
Hyslop, Terry, Ph.D. ..... Thomas Jefferson University

I

Ibrahim, Jennifer K., M.P.H., Ph.D. ..... Temple University
Iglehart, James D., M.D. ..... Dana-Farber Cancer Institute

Ikle, David N., Ph.D. ..... Rho Federal Systems Division, Inc.
Im, Eun-Ok, Ph.D., M.P.H., R.N., F.A.A.N. ..... The University of Texas, Austin
Intaglietta, Marcos, Ph.D. ..... University of California, San Diego
Isales, Carlos M., M.D. ..... Medical College of Georgia
Istfan, Nawfal W., M.D., Ph.D. ..... Boston University Medical Campus
Ivanov, Alexander R., Ph.D. ..... Harvard School of Public Health
Iversen, Edwin S., Ph.D. ..... Duke University

J

Jackson, Edward F., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Jacobs, Michael A., Ph.D. ..... The Johns Hopkins University
Jacobson, Myron K., Ph.D. ..... The University of Arizona
Jadvar, Hossein, M.D., Ph.D. ..... University of Southern California
Jaffe, Harold W., M.D. ..... Centers for Disease Control and Prevention
James, Aimee S., Ph.D., M.P.H. ..... Washington University
Jatoi, Aminah, M.D. ..... Mayo Clinic
Jay, Daniel G., Ph.D. ..... Tufts University
Jeffery, Elizabeth H., Ph.D. ..... University of Illinois at Urbana-Champaign
Jelinek, Diane F., Ph.D. ..... Mayo Clinic
Jensen, Roy A., M.D. ..... The University of Kansas Medical Center
Jett, James R., M.D. ..... Mayo Clinic
Jewell, William R., M.D. ..... The University of Kansas Medical Center
Ji, Jiuping J., Ph.D. ..... University of Alabama at Birmingham
Jiang, Yi, Ph.D. ..... Los Alamos National Laboratory
Jimbo, Masahito, M.D., Ph.D. ..... University of Michigan, Ann Arbor
Jimeno, Antonio, M.D., Ph.D. ..... University of Colorado, Denver
John, Constance M., Ph.D. ..... Carantech, Inc.
Jones, Joshua D., M.D. ..... Chicago Department of Public Health
Jones, Judy A., M.S. ..... Cutaneous Lymphoma Foundation
Jones, Richard J., M.D. ..... The Johns Hopkins University
Jones, Stephen, Ph.D. ..... University of Massachusetts Medical School, Worcester
Jove, Richard, Ph.D. ..... Beckman Research Institute of City of Hope
Ju, Jingfang, Ph.D. ..... State University of New York at Stony Brook
Jurisson, Silvia S., Ph.D. ..... University of Missouri, Columbia

K

Kabanov, Alexander V., Ph.D., Sc.D. ..... University of Nebraska Medical Center
Kahl, Brad, M.D. ..... University of Wisconsin, Madison
Kaifer, Angel E., Ph.D. ..... University of Miami, Coral Gables
Kalluri, Raghu, M.D., Ph.D. ..... Beth Israel Deaconess Medical Center
Kam, Lance C., Ph.D. ..... Columbia University
Kameoka, Jun, Ph.D. ..... Texas Engineering Experiment Station
Kane, Madeleine A., M.D., Ph.D. ..... University of Colorado, Denver
Kannan, Rangaramanujam M., Ph.D. ..... Wayne State University
Kantoff, Philip W., M.D. ..... Dana-Farber Cancer Institute
Karczmar, Gregory S., Ph.D. ..... The University of Chicago

Kasid, Usha N., Ph.D. ..... Georgetown University
Kasper, Susan, Ph.D. ..... The University of Cincinnati
Kassis, Amin I., Ph.D. ..... Harvard Medical School
Kastan, Michael B., Ph.D., M.D. ..... St. Jude Children's Research Hospital
Katti, Kattesh V., Ph.D., Sc.D. ..... University of Missouri, Columbia
Katzenellenbogen, John A., Ph.D. ..... University of Illinois at Urbana-Champaign
Katzman, Michael, M.D. ..... Pennsylvania State University, Hershey Medical Center
Kaufman, David G., M.D., Ph.D. ..... University of North Carolina at Chapel Hill
Kaufman, Howard L., M.D. ..... Rush University Medical Center
Kaufmann, William K., Ph.D. ..... University of North Carolina at Chapel Hill
Kaul, Karen L., M.D., Ph.D. ..... Northshore University Health System Research Institute
Kaumaya, Pravin T.P., Ph.D. ..... The Ohio State University
Kay, Brian K., Ph.D. ..... University of Illinois at Chicago
Kay, Mark A., M.D., Ph.D. ..... Stanford University
Kazanietz, Marcelo G., Ph.D. ..... The University of Pennsylvania
Kedes, Dean H., M.D., Ph.D. ..... University of Virginia
Keku, Temitope O., Ph.D., M.P.H. ..... University of North Carolina at Chapel Hill
Kelley, George A., D.A. ..... West Virginia University
Kelley, Mark R., Ph.D. ..... Indiana University-Purdue University, Indianapolis
Kelly, Kimberly A., Ph.D. ..... University of Virginia
Kennedy, Ronald C., Ph.D. ..... Texas Tech University Health Science Center
Keranen, Lisa, Ph.D. ..... University of Colorado
Kester, Mark, Ph.D. ..... Pennsylvania State University Hershey Medical Center
Khaled, Annette R., Ph.D. ..... University of Central Florida
Khan, Nadeem, Ph.D. ..... Dartmouth College
Khan, Seema A., M.D. ..... Northwestern University
Khuri, Fadlo R., M.D. ..... Emory University
Kilbourn, Michael R., Ph.D. ..... University of Michigan, Ann Arbor
Killackey, Maureen A., M.D., Ph.D. ..... Memorial Sloan-Kettering Cancer Center
Kilpatrick, Michael W., Ph.D. ..... Ikonisys, Inc.
Kim, Youngmee, Ph.D. ..... University of Miami, Coral Gables
Kimler, Bruce F., Ph.D. ..... The University of Kansas Medical Center
Kinghorn, Alan D., Ph.D., Sc.D. ..... University of Illinois at Chicago
Kinter, Michael, Ph.D. ..... Oklahoma Medical Research Foundation
Kirshner, Jeffrey J., M.D. ..... Hematology-Oncology Associates of Central New York
Klassen, Ann C., Ph.D. ..... The Johns Hopkins University
Klein, Alison P., Ph.D. ..... The Johns Hopkins University
Klemke, Richard L., Ph.D. ..... University of California, San Diego
Klingemann, Hans, M.D., Ph.D. ..... Tufts Medical Center
Klinke, David J., Ph.D. ..... West Virginia University
Knopp, Michael V., M.D., Ph.D. ..... The Ohio State University
Knutson, Keith L., Ph.D. ..... Mayo Clinic
Koch, Cameron J., Ph.D. ..... The University of Pennsylvania
Kohandel, Mohammad, Ph.D. ..... University of Waterloo
Kohler, Betsy A., M.P.H. ..... North American Association of Central Cancer Registries
Koide, Shohei, Ph.D. ..... The University of Chicago
Kolasa, Kathryn M., Ph.D. ..... East Carolina University
Kolesnick, Richard N., M.D. ..... Memorial Sloan-Kettering Cancer Center

Koper, Olga B., Ph.D. ..... Nanoscale Materials, Inc.
Korc, Murray, M.D. ..... Dartmouth College
Kortagere, Sandhya, Ph.D. ..... Drexel University
Koser, Hur, Ph.D. ..... Yale University
Koshinsky, Heather, Ph.D. ..... Investigen, Inc.
Kosorok, Michael R., Ph.D. ..... University of North Carolina at Chapel Hill
Koumenis, Constantinos, Ph.D. ..... The University of Pennsylvania
Kourakine, Alexei, Ph.D. ..... Beth Israel Deaconess Medical Center
Kow, Yoke W., Ph.D. ..... Emory University
Koyama, Tatsuki, Ph.D. ..... Vanderbilt University
Kramer, Fred R., Ph.D. ..... Public Health Research Institute
Kristal, Bruce S., Ph.D. ..... Brigham and Women's Hospital
Kroll, David J., Ph.D. ..... North Carolina Central University
Kron, Stephen J., M.D., Ph.D. ..... The University of Chicago
Kronauge, James F., Ph.D. ..... Molecular Insight Pharmaceuticals, Inc.
Kuebbing, Daniel, Ph.D. ..... University of M.D. Biotechnology Institute
Kufe, Donald W., M.D. ..... Dana-Farber Cancer Institute
Kulesz-Martin, Molly F., Ph.D. ..... Oregon Health and Science University
Kumar, Challa S., Ph.D. ..... Louisiana State University A&M College, Baton Rouge
Kumar, Nagi B., Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Kumar, Rakesh, Ph.D. ..... George Washington University
Kumar, Sanjay, M.D., Ph.D. ..... University of California, Berkeley
Kunicki, Thomas J., Ph.D. ..... Children's Hospital, Orange County
Kuperwasser, Charlotte, Ph.D. ..... Tufts University
Kusewitt, Donna F., D.V.M., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Kushi, Lawrence H., Sc.D. ..... Kaiser Foundation Research Institute
Kutob, Randa M., M.D., M.P.H. ..... The University of Arizona
Kuziemsky, Craig, Ph.D. ..... University of Ottawa
Kwiatkowski, David J., M.D., Ph.D. ..... Harvard University
Kyprianou, Natasha, Ph.D. ..... University of Kentucky

L

Labhasetwar, Vinod D., Ph.D. ..... Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Lachenbruch, Peter, Ph.D. ..... Oregon State University
Lackland, Daniel T., Ph.D., M.P.H. ..... Medical University of South Carolina
Lackner, Mark R., Ph.D. ..... Genentech, Inc.
Laderoute, Keith R., Ph.D. ..... Northwestern University
Ladisch, Stephan, M.D. ..... Children's National Medical Center
Lafleur, Bonnie, Ph.D., M.P.H. ..... The University of Arizona
Laframboise, William A., Ph.D. ..... University of Pittsburgh
Laird, Beverly L., Ph.D. ..... 3D Medical Concepts, LLC
Lal, Ratneshwar, Ph.D. ..... University of California, San Diego
Lam, Wan L., Ph.D. ..... British Columbia Cancer Agency
Lando, Harry A., Ph.D. ..... The University of Minnesota, Twin Cities
Landsittel, Douglas P., Ph.D. ..... University of Pittsburgh
Lane, Joseph M., M.D. ..... Hospital for Special Surgery

Lang, James C., Ph.D. ..... The Ohio State University
Langer, Mark P., M.D. ..... Indiana University-Purdue University, Indianapolis
Langevin, Anne-Marie, M.D. ..... The University of Texas Health Science Center, San Antonio
Languino, Lucia R., Ph.D. ..... Thomas Jefferson University
Lantz, Olivier J., M.D., Ph.D. ..... Institut Curie
Lapotko, Dmitri O., Ph.D., Sc.D. ..... Rice University
Larson, Dale N., M.S. ..... Charles Stark Draper Laboratory
Larson, Richard S., M.D., Ph.D. ..... The University of New Mexico
Larson, Steven M., M.D. ..... Sloan-Kettering Institute for Cancer Research
Lattemann, Dianne F., Ph.D. ..... University of Washington
Laubenbacher, Reinhard, Ph.D. ..... Virginia Polytechnic Institute and State University
Laurence, Jennifer S., Ph.D. ..... The University of Kansas, Lawrence
Lavasseur, Beth I., M.S. ..... St. Joseph Mercy Health Center
Lawrence, Richard Y., M.D. ..... Thomas Jefferson University
Lazar, Maria I., Ph.D. ..... Virginia Polytechnic Institute and State University
Leachman, Sancy A., M.D., Ph.D. ..... University of Utah
Leal, Juan A., Ph.D. ..... The University of Minnesota, Twin Cities
Leary, James F., Ph.D. ..... Purdue University, West Lafayette
Leblanc, Michael L., Ph.D. ..... Fred Hutchinson Cancer Research Center
Lebovitz, Russell M., M.D., Ph.D. ..... Marval Biosciences, Inc.
Lechene, Claude P., M.D. ..... Brigham and Women's Hospital
Lee, Burton Hoyt, Ph.D. ..... Stanford University
Lee, Chung, Ph.D. ..... Northwestern University
Lee, Hongzhe, Ph.D. ..... The University of Pennsylvania
Lee, Jae K., Ph.D. ..... University of Virginia
Lee, Ji-Hyun, Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Lee, Robert J., Ph.D. ..... The Ohio State University
Lee, Sam W., Ph.D. ..... Massachusetts General Hospital
Lee, Terry D., M.D., Ph.D. ..... Beckman Research Institute of City of Hope
Lee, W. David, Ph.D. ..... Stanford University
Leeper, Dennis B., M.D., Ph.D. ..... Thomas Jefferson University
Leiby, Benjamin, Ph.D. ..... Thomas Jefferson University
Lemmon, Mark A., Ph.D. ..... The University of Pennsylvania
Lengerich, Eugene J., D.V.M. ..... Pennsylvania State University, Hershey Medical Center
Lenz, Heinz J., M.D., Ph.D. ..... CTRC Research Foundation
Leong, Stanley P.L., M.D. ..... University of California, San Francisco
Le Poole, Isabelle C., Ph.D. ..... Loyola University, Chicago
Lernhardt, Waldemar W., Ph.D. ..... Proveri, Inc.
Leslie, Kimberly K., M.D. ..... The University of Iowa
Leslie-Pelecky, Diandra L., Ph.D. ..... West Virginia University
Lesniak, Maciej S., M.D. ..... The University of Chicago
Lesser, Martin L., Ph.D. ..... Feinstein Institute for Medical Research
Levenson, Richard M., M.D. ..... Cambridge Research Instruments
Lever, John R., Ph.D. ..... University of Missouri, Columbia
Levin, Albert M., Ph.D., M.P.H. ..... Henry Ford Health Systems
Lewis, Brian C., Ph.D. ..... University of Massachusetts Medical School, Worcester
Lewis, Jane, Ph.D. ..... University of Medicine & Dentistry of New Jersey-School of Public Health

Lewis, Jason S., Ph.D. ..... Sloan-Kettering Institute for Cancer Research
Lewis, Lavonna B., Ph.D., M.P.H. ..... University of Southern California
Lewis, Michael T., Ph.D. ..... Baylor College of Medicine
Lewis, Norman G., Ph.D. ..... Washington State University
Leyland-Jones, Brian, M.D., Ph.D. ..... Emory University
Li, Christopher I., M.D., Ph.D. ..... Fred Hutchinson Cancer Research Center
Li, Chuan-Yuan, Ph.D. ..... University of Colorado, Denver
Li, Jian Jian, M.D., Ph.D. ..... Purdue University, West Lafayette
Li, King C., M.D. ..... Methodist Hospital Research Institute
Li, Lang, Ph.D. ..... Indiana University-Purdue University, Indianapolis
Li, Sara A., Ph.D. ..... The University of Kansas Medical Center
Li, Shuyu D., Ph.D. ..... Eli Lilly and Company
Li, Xingde, Ph.D. ..... The Johns Hopkins University
Li, Yan C., Ph.D. ..... The University of Chicago
Liang, Jie, Ph.D. ..... University of Illinois at Chicago
Libermann, Towia A., Ph.D. ..... Beth Israel Deaconess Medical Center
Lieberman, David A., M.D. ..... Oregon Health and Science University
Lim, Carol S., Ph.D. ..... University of Utah
Lim, Jung-Won, Ph.D. ..... Case Western Reserve University
Lim, Mark, Ph.D. ..... Ambergen, Inc
Lin, Haiqun, M.D., Ph.D. ..... Yale University
Lin, Ming-Fong, Ph.D. ..... University of Nebraska Medical Center
Lin, P. Charles, Ph.D. ..... Vanderbilt University
Lin, Shili, Ph.D. ..... The Ohio State University
Lin, Xihong, Ph.D. ..... Harvard School of Public Health
Lindamood, Charles I., Ph.D. ..... Southern Research Institute
Link, Brian K., M.D. ..... The University of Iowa
Linske-O'Connell, Lisa, Ph.D. ..... LLO Consulting, LLC
Listowsky, Irving, Ph.D. ..... Albert Einstein College of Medicine of Yeshiva University
Little, Julian, Ph.D. ..... University of Ottawa
Liu, Dexi, Ph.D. ..... University of Pittsburgh
Liu, Fei-Fei, M.D. ..... University of Toronto
Liu, Guodong, Ph.D. ..... North Dakota State University
Liu, Jun O., Ph.D. ..... The Johns Hopkins University
Liu, Ke J., Ph.D. ..... The University of New Mexico Health Sciences Center
Livingston, Philip O., M.D. ..... Sloan-Kettering Institute for Cancer Research
Lo, Yu-Hwa, Ph.D. ..... University of California, San Diego
Lobach, Iryna, Ph.D. ..... New York University School of Medicine
Loboa, Elizabeth G., Ph.D. ..... North Carolina State University
Lochhead, Michael J., Ph.D. ..... MBIO Diagnostics, Inc.
Logsdon, Craig D., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Loh, Mignon Lee-Cheun, M.D. ..... University of California, San Francisco
Lokeshwar, Bal L., Ph.D. ..... University of Miami School of Medicine
Lokshin, Anna E., Ph.D. ..... University of Pittsburgh
Lonial, Sagar, M.D. ..... Emory University
Lord, Edith M., Ph.D. ..... University of Rochester Medical Center
Lossos, Izidore S., M.D. ..... University of Miami School of Medicine
Lotze, Michael T., M.D. ..... Cellumen, Inc.

Lounsbury, David W., Ph.D. ..... Albert Einstein College of Medicine of Yeshiva University
Lowe, Scott W., Ph.D. ..... Cold Spring Harbor Laboratory
Lowe, Val J., M.D. ..... Mayo Clinic
Lowenstein, Pedro R., M.D., Ph.D. ..... Cedars-Sinai Medical Center
Lowy, Andrew M., M.D. ..... University of California, San Diego
Lu, Mei, Ph.D. ..... Henry Ford Health System
Lubaroff, David M., Ph.D. ..... The University of Iowa
Lukasik, Victoria M., D.V.M. ..... Southwest Veterinary Anesthesiology
Luker, Gary D., M.D. ..... University of Michigan, Ann Arbor
Lum, Lawrence G., M.D., Sc.D. ..... Wayne State University
Luo, Peter, Ph.D. ..... Merck & Co., Inc.
Lustig, Arthur J., Ph.D. ..... Tufts University
Lutfiyya, May N., Ph.D. ..... University of Manitoba
Lynch, John P., M.D., Ph.D. ..... The University of Pennsylvania
Lynch, Kevin R., Ph.D. ..... University of Virginia
Lynch, Patrick M., M.D. ..... The University of Texas M.D. Anderson Cancer Center
Lyn-Cook, Beverly A., Ph.D. ..... U.S. Food and Drug Administration
Lyss, Alan P., M.D. ..... Missouri Baptist Medical Center
Lyubchenko, Yuri L., Ph.D., Sc.D. ..... University of Nebraska Medical Center

M

Ma, Grace X., Ph.D. ..... Temple University
Ma, Haiching, Ph.D. ..... Reaction Biology Corporation
MacCoss, Michael J., Ph.D. ..... University of Washington
MacDonald, Ruth S., Ph.D. ..... Iowa State University
MacDonald, Tobey J., M.D. ..... Emory University
Mach, Robert H., Ph.D. ..... Washington University
Machtay, Mitchell, M.D. ..... Thomas Jefferson University
MacKay, Trudy F., Ph.D. ..... North Carolina State University
MacKinnon, Jill A., Ph.D. ..... University of Miami, Miller
Macoska, Jill A., Ph.D. ..... University of Michigan, Ann Arbor
Madsen, Mark T., Ph.D. ..... The University of Iowa
Maguire, Patrick D., M.D. ..... New Hanover Regional Medical Center
Mahadevan, Daruka, M.D., Ph.D. ..... The University of Arizona
Mahadevia, Ankit A., M.D. ..... Atlas Venture
Mahalingam, Meera, M.D., Ph.D. ..... Boston University Medical Campus
Maheswaran, Shyamala, Ph.D. ..... Massachusetts General Hospital
Maizels, Nancy, Ph.D. ..... Yale University
Majumdar, Basanti, Ph.D., R.N. ..... McMaster University
Makarov, Sergei S., Ph.D. ..... Attagene, Inc.
Maki, Wusi, Ph.D. ..... Integrated Molecular Senors, Inc.
Makrigiorgos, G. Mike, Ph.D. ..... Dana-Farber Cancer Institute
Maley, Carlo C., Ph.D. ..... University of California, San Francisco
Malkas, Linda H., Ph.D. ..... Indiana University, Indianapolis
Malone, Ruth E., Ph.D., F.A.A.N. ..... University of California, San Francisco
Maloney, David G., M.D., Ph.D. ..... Fred Hutchinson Cancer Research Center
Maluccio, Mary A., M.D., M.P.H. ..... Indiana University-Purdue University, Indianapolis

Mandal, Diptasri M., Ph.D. ..... Louisiana State University Health Science Center
Mandelblatt, Jeanne, M.D., Ph.D. ..... Georgetown University
Mandrekar, Sumithra J., Ph.D. ..... Mayo Clinic
Mane, Ketan, Ph.D. ..... University of North Carolina at Chapel Hill
Manfredi, James J., Ph.D. ..... Mount Sinai School of Medicine of New York University
Mani, Sendurai, Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Mankoff, David A., M.D., Ph.D. ..... University of Washington
Manne, Upender, Ph.D. ..... University of Alabama at Birmingham
Manning, David R., Ph.D. ..... The University of Pennsylvania
Manning, Keefe B., Ph.D. ..... Pennsylvania State University, University Park
Manola, Judith B., M.S. ..... Dana-Farber Cancer Institute
Mansfield, Elaine S., Ph.D. ..... Affymetrix
Mao, Li, M.D. ..... University of Maryland, Baltimore
Marcucci, Guido, M.D. ..... The Ohio State University
Maresca, Theresa, M.D. ..... Seattle Indian Health Board
Marinkovich, Matt P., M.D. ..... Stanford University
Markman, Maurie, M.D. ..... The University of Texas M.D. Anderson Cancer Center
Marks, Lawrence B., M.D. ..... Duke University
Marr, David W.M., Ph.D. ..... Metafluidics, Inc.
Marrero, Jorge A., M.D. ..... University of Michigan, Ann Arbor
Marshall, James, Ph.D. ..... Roswell Park Cancer Institute
Martin, Daniel B., M.D. ..... Institute for Systems Biology
Martin, Sandra L., Ph.D. ..... University of Colorado, Denver
Mason, Ralph P., Ph.D. ..... The University of Texas Southwestern Medical Center, Dallas
Matsuyama, Robin K., Ph.D. ..... Virginia Commonwealth University
Mattern, Michael R., Ph.D. ..... Progenra, Inc.
Mattoussi, Hedi, Ph.D. ..... Naval Research Laboratory
Matusik, Robert J., Ph.D. ..... Vanderbilt University
Max, Wendy B., Ph.D. ..... University of California, San Francisco
May, William A., M.D. ..... Children's Hospital, Los Angeles
Mayo, Kevin H., Ph.D. ..... Actiprep Biotechnology, Inc.
Mayo, Matthew S., Ph.D. ..... The University of Kansas Medical Center
Mayr, Nina A., M.D. ..... The Ohio State University
McCabe, George P., Ph.D. ..... Purdue University, West Lafayette
McCabe, Laura R., Ph.D. ..... Michigan State University
McCarthy, James B., Ph.D. ..... The University of Minnesota, Twin Cities
McCarthy, Tim J., Ph.D. ..... Pfizer Global Research and Development
McCarty, Owen J., Ph.D. ..... Oregon Health and Science University
McConkey, David J., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
McCracken, John L., Ph.D. ..... Michigan State University
McCrory, Megan A., Ph.D. ..... Bastyr University
McDonald, Paul W., Ph.D. ..... University of Waterloo
McGown, Linda B., Ph.D. ..... Rensselaer Polytechnic Institute
McGregor, William G., M.D. ..... University of Louisville
McIntyre, James O., Ph.D. ..... Vanderbilt University
McKeithan, Tim W., M.D., Ph.D. ..... University of Nebraska Medical Center
McKnight, Tim E., M.S. ..... Oak Ridge National Laboratory
McMahon, Martin, Ph.D. ..... University of California, San Francisco

McMahon, Pamela M., Ph.D. ..... Massachusetts General Hospital
McMurray, Cynthia T., Ph.D. ..... Lawrence Berkeley National Laboratory
McShane, Mike, Ph.D. ..... Texas Engineering Experiment Station
Meade, Cathy D., Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Meade, Thomas J., Ph.D. ..... Northwestern University
Meadows, Gary G., Ph.D. ..... Washington State University College of Pharmacy
Means, Robert T., M.D. ..... University of Kentucky
Mecozzi, Sandro, Ph.D. ..... University of Wisconsin, Madison
Medintz, Igor, Ph.D. ..... Naval Research Laboratory
Melancon, Donald J., Ph.D. ..... The International Ovarian Cancer Connection
Menon, Usha, Ph.D. ..... Arizona State University, Tempe
Menter, David G., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Merad, Miriam, M.D., Ph.D. ..... Mount Sinai School of Medicine of New York University
Merajver, Sofia D., M.D., Ph.D. ..... University of Michigan, Ann Arbor
Merchant, Nipun B., M.D. ..... Vanderbilt University
Meric-Bernstam, Funda, M.D. ..... The University of Texas M.D. Anderson Cancer Center
Mermelstein, Robin J., Ph.D. ..... University of Illinois at Chicago
Mesri, Enrique A., Ph.D. ..... University of Miami School of Medicine
Metaxas, Dimitris N., Ph.D. ..... Rutgers, The State University of New Jersey, New Brunswick
Meyer, Laurence J., M.D., Ph.D. ..... University of Utah
Meyerowitz, Beth E., Ph.D. ..... University of Southern California
Meza, Jane, Ph.D. ..... University of Nebraska Medical Center
Michels, Karin B., Ph.D., Sc.D., M.P.H. ..... Brigham and Women's Hospital
Miele, Lucio, M.D., Ph.D. ..... University of Mississippi Medical Center
Mikkelsen, Tom, M.D. ..... Henry Ford Health System
Miller, Alexandra C., Ph.D. ..... Armed Forces Institute of Pathology
Miller, Donald M., M.D., Ph.D. ..... University of Louisville
Miller, Jeffrey S., M.D. ..... The University of Minnesota
Minko, Tamara, Ph.D. ..... Rutgers, The State University of New Jersey, New Brunswick
Mintun, Mark A., M.D., Ph.D. ..... Washington University
Misek, David E., Ph.D. ..... University of Michigan, Ann Arbor
Mishra, Lopa, M.D. ..... The University of Texas M.D. Anderson Cancer Center
Mishra, Shiraz I., Ph.D. ..... University of Maryland, Baltimore
Mitchell, Beverly S., M.D. ..... Stanford University
Mitchell, Braxton D., Ph.D., M.P.H. ..... University of Maryland, Baltimore
Mitchell, Edith P., M.D. ..... Thomas Jefferson University
Mitchell, Malcolm, M.D. ..... The University of Texas, El Paso
Mitra, Sankar, Ph.D. ..... The University of Texas Medical Branch at Galveston
Mittal, Vivek, Ph.D. ..... Cornell University
Modak, Shakeel, M.D. ..... Sloan-Kettering Institute for Cancer Research
Modeste, Naomi N., Ph.D., M.P.H. ..... Loma Linda University
Moffatt, Robert J., Ph.D., M.P.H. ..... Florida State University
Mohammad, Ramzi M., Ph.D. ..... Wayne State University
Mohammed, Sulma I., D.V.M., Ph.D. ..... Purdue University, West Lafayette
Moldovan, Nicanor I., Ph.D. ..... The Ohio State University
Montaner, Silvia V., Ph.D., M.P.H. ..... University of Maryland, Baltimore
Montano, Monica, Ph.D. ..... Case Western Reserve University
Monteiro, Alvaro N., Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute

Mooberry, Susan L., Ph.D. ..... The University of Texas Health Science Center, San Antonio
Moody-Thomas, Sarah, Ph.D. ..... Louisiana State University Health Science Center
Moon-Howard, Joyce L., Ph.D. ..... Columbia University Health Sciences
Moore, Anna, Ph.D. ..... Massachusetts General Hospital
Moraru, Ion I., M.D., Ph.D .....University of Connecticut School of Medicine & Dentistry
Moreland, John, Ph.D. ..... National Institute of Standards & Technology
Morgan, Tim, Ph.D. ..... Wake Forest University Health Sciences
Morgan, William F., Ph.D., Sc.D. .....Battelle Pacific Northwest Laboratories
Moritz, Robert L., Ph.D. .....Institute for Systems Biology
Morris, Jeffrey S., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Morris, Joyce B., Ph.D., M.P.H. .....Oklahoma State Department of Health
Morris, Marilyn E., Ph.D. .....The State University of New York at Buffalo
Morrison, Alanna C., Ph.D. .....The University of Texas Health Science Center, Houston
Morrison, Sherie L., Ph.D. ..... University of California, Los Angeles
Morrow, Gary R., Ph.D. ..... University of Rochester
Morton, Kathryn A., M.D. ..... University of Utah
Moscow, Jeffrey A., M.D. ..... University of Kentucky
Moseley, Martin A., Ph.D. .....Duke University
Moskal, Joseph R., Ph.D. .....Northwestern University
Moss, Steven F., M.D. .....Rhode Island Hospital
Motamedi, Massoud, Ph.D. .....The University of Texas Medical Branch at Galveston
Motl, Robert W., Ph.D. .....University of Illinois at Urbana-Champaign
Motsinger, Brenda M., M.D. ..... North Carolina Department of Environmental Health & Natural Resources
Mrksich, Milan, Ph.D. .....The University of Chicago
Muddiman, David C., Ph.D. .....North Carolina State University
Mukherjee, Bhramar, Ph.D. ..... University of Michigan, Ann Arbor
Mukherjee, Sach, Ph.D. ..... University of Warwick
Mukherji, Bijay, M.D. .....University of Connecticut School of Medicine & Dentistry
Mukhtar, Hasan, Ph.D. .....University of Wisconsin, Madison
Mullan, Patricia B., Ph.D. ..... University of Michigan, Ann Arbor
Mulshine, James L., M.D. ..... Rush University Medical Center
Munden, Reginald F., M.D., D.M.D. ..... University of Alabama at Birmingham
Munn, David H., M.D. .....Medical College of Georgia
Munshi, Nikhil C., M.D. ..... Dana-Farber Cancer Institute
Munster, Pamela N., M.D. .....University of California, San Francisco
Murali, T.M., Ph.D. ..... Virginia Polytechnic Institute and State University
Murphy, Maureen E., Ph.D. .....Fox Chase Cancer Center
Murphy, William J., Ph.D. .....University of Nevada, Reno
Murray, Kermit K., Ph.D. ..... Louisiana State University
Mustian, Karen M., Ph.D., M.P.H. ..... University of Rochester
Muti, Paola C., M.D. ..... Italian National Cancer Institute

N

Nagarkatti, Mitzi, Ph.D. .....University of South Carolina, Columbia
Nagrath, Sunitha, Ph.D. ..... Massachusetts General Hospital
Nahrendorf, Matthias, M.D., Ph.D. ..... Harvard Medical School

Nairn, Rodney S., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Nalcioglu, Orhan, Ph.D. ..... University of California, Irvine
Naughton, Michelle J., Ph.D., M.P.H. ..... Wake Forest University
Navarro, Ana M., Ph.D. ..... University of California, San Diego
Neamati, Nouri, Ph.D. ..... University of Southern California
Nedelkov, Dobrin, Ph.D. ..... Intrinsic Bioprobes, Inc.
Needham, David, Ph.D. ..... Duke University
Negrin, Robert S., M.D. ..... Stanford University
Nelson, Miriam E., Ph.D. ..... Tufts University
Nelson, Peter S., M.D. ..... Fred Hutchinson Cancer Research Center
Nelson, Sarah J., Ph.D. ..... University of California, San Francisco
Nelson, William G., M.D., Ph.D. ..... The Johns Hopkins University
Nephew, Kenneth P., Ph.D. ..... Indiana University-Purdue University, Indianapolis
Nettles, Kendall W., Ph.D. ..... Scripps Research Institute
Neuwelt, Edward A., M.D. ..... Vanderbilt University
Ng, Hanna, Ph.D. ..... SRI International
Nicosia, Santo V., M.D. ..... University of South Florida
Nie, Shuming, Ph.D. ..... Emory University
Nielsen, Torsten, M.D., Ph.D. ..... Vancouver Hospital & Health Sciences Centre
Nieva, Jorge J., M.D. ..... Billings Clinic Foundation
Nimer, Stephen D., M.D. ..... Memorial Sloan-Kettering Cancer Center
Ning, Ruola, Ph.D. ..... University of Rochester
Nishimura, Michael I., Ph.D. ..... Medical University of South Carolina
Noonan, Curtis W., Ph.D. ..... University of Montana
Normolle, Daniel P., Ph.D. ..... University of Pittsburgh
Norris, James S., Ph.D. ..... Medical University of South Carolina
Nucifora, Giuseppina, Ph.D., Sc.D. ..... The University of Chicago
Nunn, Adrian D., Ph.D. ..... Bracco Research USA, Inc.
Nwariaku, Fiemu E., M.D. ..... The University of Texas Southwestern Medical Center, Dallas
Nyalwidhe, Julius O., Ph.D. ..... Eastern Virginia Medical School

O

O'Brien, Tim J., Ph.D. ..... University of Arkansas Medical Sciences, Little Rock
O'Connor, Richard J., Ph.D. ..... Roswell Park Cancer Institute
O'Dorisio, M. Sue, M.D., Ph.D. ..... The University of Iowa
O'Halloran, Thomas V., Ph.D. ..... Northwestern University
O'Keefe, Stephen, M.D., J.D. ..... University of Pittsburgh
O'Leary, Tim y J., M.D., Ph.D. ..... Department of Veterans Affairs
O'Neil, Bert H., M.D. ..... University of North Carolina at Chapel Hill
Ochs, Michael F., Ph.D. ..... The Johns Hopkins University
Odedina, Folakemi T., Ph.D. ..... University of Florida
Odunsi, Kunle O., M.D., Ph.D. ..... Roswell Park Cancer Institute
Oeffinger, Kevin C., M.D. ..... Sloan-Kettering Institute for Cancer Research
Okada, Craig Y., M.D., Ph.D. ..... Oregon Health and Science University
Oleinick, Nancy L., Ph.D. ..... Case Western Reserve University
Oliver, Janet M., Ph.D. ..... The University of New Mexico Health Sciences Center
Olopade, Olufunmilayo I., M.D. ..... The University of Chicago

Omary, M. Bishr, M.D., Ph.D. ..... University of Michigan, Ann Arbor
Omel, James L., M.D. (Retired) ..... Independent Consultant
Omenn, Gilbert S., M.D., Ph.D. ..... University of Michigan, Ann Arbor
Ondrey, Frank G., M.D., Ph.D. ..... The University of Minnesota, Twin Cities
Onel, Kenan, M.D., Ph.D. ..... The University of Chicago
Onyuksel, Hayat, Ph.D. ..... University of Illinois at Chicago
Osheroff, Neil, Ph.D. ..... Vanderbilt University
Osley, Mary A., Ph.D. ..... The University of New Mexico
Ostrowski, Michael C., Ph.D. ..... The Ohio State University
Osunkoya, Adeboye O., M.D. ..... Emory University
Ota, David M., M.D. ..... University of Missouri, Ellis Fischel Cancer Center
Ouchi, Toru, Ph.D. ..... Northshore University Health System Research Institute
Owens, S. Michael, Ph.D. ..... University of Arkansas Medical Sciences, Little Rock
Owens, Scott G., Ph.D. ..... University of Mississippi
Oyajobi, Babatunde O., Ph.D. ..... The University of Texas Health Science Center, San Antonio

P

Paciorek, Christopher J., Ph.D. ..... Harvard School of Public Health
Paciotti, Giulio F., Ph.D. ..... Cytimmune Sciences, Inc.
Pack, Daniel W., Ph.D. ..... University of Illinois at Urbana-Champaign
Padilla, Geraldine V., Ph.D. ..... University of California, San Francisco
Page, Rebecca, Ph.D. ..... Brown University
Pagoto, Sherry L., Ph.D. ..... University of Massachusetts Medical School, Worcester
Pai Panandiker, Atmaram S., M.D. ..... St. Jude Children's Research Hospital
Palecek, Sean P., Ph.D. ..... University of Wisconsin, Madison
Palesch, Yuko Y., Ph.D. ..... Medical University of South Carolina
Pallas, David C., Ph.D. ..... Emory University
Pallavicini, Maria G., Ph.D. ..... University of California, Merced
Palmby, Todd R., Ph.D. ..... U.S. Food and Drug Administration
Pan, Wei, Ph.D. ..... The University of Minnesota, Twin Cities
Pan, Xiaochuan, Ph.D. ..... The University of Chicago
Pankratz, Vernon S., Ph.D. ..... Mayo Clinic
Park, Ben H., M.D., Ph.D. ..... The Johns Hopkins University
Park, John W., M.D. ..... University of California, San Francisco
Park, Peter J., Ph.D. ..... Harvard Medical School
Parker, Laurie L., Ph.D. ..... Purdue University, West Lafayette
Parker, Mark A., Ph.D. ..... University of Colorado, Denver
Parsons, Ramon E., M.D., Ph.D. ..... Columbia University Health Sciences
Pasa-Tolic, Ljiljana, Ph.D. ..... Battelle Pacific Northwest Laboratories
Pasche, Boris, M.D., Ph.D. ..... University of Alabama at Birmingham
Pasick, Rena J., Ph.D., M.P.H. ..... University of California, San Francisco
Patel, Divya A., Ph.D., M.P.H. ..... University of Michigan, Ann Arbor
Pauza, Charles D., Ph.D. ..... University of Maryland Biotechnology Institute
Pearman, Tim P., Ph.D. ..... Tulane University
Peehl, Donna M., Ph.D. ..... Stanford University School of Medicine
Pegg, Anthony E., Ph.D. ..... Pennsylvania State University Hershey Medical Center
Pelizzari, Charles A., Ph.D. ..... The University of Chicago

Pellecchia, Maurizio, Ph.D. ..... Sanford-Burnham Medical Research Institute
Penberthy, Lynne T., M.D., M.P.H. ..... Virginia Commonwealth University
Pence, Barbara C., Ph.D. ..... Texas Tech University Health Sciences Center
Pereira, Deidre B., Ph.D. ..... University of Florida
Perkins, Susan M., Ph.D. ..... Indiana University
Person, Sharina D., Ph.D. ..... University of Alabama at Birmingham
Petasis, Nicos A., Ph.D. ..... University of Southern California
Peter, Marcus E., Ph.D. ..... Northwestern University
Petereit, Daniel G., M.D. ..... Rapid City Regional Hospital
Peters, Edward S., D.M.D., Sc.D., S.M. ..... Louisiana State University Health Sciences Center, New Orleans
Peterson, Douglas E., D.M.D., Ph.D. ..... University of Connecticut
Petrick, Nicholas, Ph.D. ..... U.S. Food and Drug Administration
Petroni, Gina R., Ph.D. ..... University of Virginia
Petzold, Linda R., Ph.D. ..... University of California, Santa Barbara
Pfefer, Josh, Ph.D. ..... U.S. Food and Drug Administration
Pfeffer, Lawrence M., Ph.D. ..... The University of Tennessee, Memphis
Philip, Philip A., M.D., Ph.D. ..... Wayne State University
Phinney, Karen, Ph.D. ..... National Institute of Standards & Technology
Piazza, Gary A., Ph.D. ..... University of Alabama at Birmingham
Pienta, Kenneth J., M.D. ..... University of Michigan, Ann Arbor
Pieper, Russell O., Ph.D. ..... University of California, San Francisco
Pinto, Harlan A., M.D. ..... Stanford University
Pittet, Mikael, Ph.D. ..... Massachusetts General Hospital
Piwnica-Worms, David R., M.D., Ph.D. ..... Washington University
Platanias, Leonidas C., M.D., Ph.D. ..... Northwestern University
Plate, Janet M.D., Ph.D. ..... Rush University Medical Center
Pledger, Warren J., Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Podack, Eckhard R., M.D., Ph.D. ..... University of Miami, Coral Gables
Podolsky, Robert H., Ph.D. ..... Medical College of Georgia
Pollack, Jonathan R., M.D., Ph.D. ..... Stanford University
Pollock, Brad H., Ph.D., M.P.H. ..... The University of Texas Health Science Center, San Antonio
Popescu, Gabriel, Ph.D. ..... University of Illinois at Urbana-Champaign
Portnow, Jana, M.D. ..... City of Hope
Posner, Marshall R., M.D. ..... Mount Sinai School of Medicine of New York University
Powell, Charles A., M.D. ..... Columbia University Health Sciences
Prados, Michael D., M.D. ..... University of California, San Francisco
Prendergast, George C., Ph.D. ..... Lankenau Institute for Medical Research
Primack, Brian A., M.D. ..... University of Pittsburgh
Prins, Robert M., Ph.D. ..... University of California, Los Angeles
Prior, Fred William, Ph.D. ..... Washington University
Pullman, James M., M.D., Ph.D. ..... Montefiore Medical Center, New York
Pumiglia, Kevin M., Ph.D. ..... Albany Medical College

Q

Qian, Wei-Jun, Ph.D. ..... Battelle Pacific Northwest Laboratories
Quackenbush, John, Ph.D. ..... Dana-Farber Cancer Institute

Quaranta, Vito, M.D. ..... Vanderbilt University
Quarles, Christopher C., Ph.D. ..... Vanderbilt University
Quelle, Dawn E., Ph.D. ..... The University of Iowa
Quesenberry, Peter J., M.D. ..... Rhode Island Hospital
Quong, Andrew A., Ph.D. ..... Thomas Jefferson University

R

Rabius, Vance, Ph.D. ..... The University of Texas, Austin
Rader, Christoph, Ph.D. ..... Scripps Research Institute
Radhakrishnan, Ravi, Ph.D. ..... The University of Pennsylvania
Raftery, Daniel, Ph.D. ..... Purdue University, West Lafayette
Raghunand, Natarajan, Ph.D. ..... The University of Arizona
Ragin, Camille C., Ph.D., M.P.H. ..... University of Pittsburgh
Raleigh, James A., Ph.D. ..... Natural Pharmacia International, Inc.
Ramos, Daniel M., D.D.S., Ph.D. ..... University of California, San Francisco
Rampersaud, Arfaan, Ph.D. ..... Columbus Nanoworks, Inc.
Ransom, Sean, Ph.D. ..... Tulane University
Rao, Chinthalapally V., Ph.D. ..... University of Oklahoma Health Sciences Center
Rapchak, Barbara A. ..... Leap of Faith Technologies, Inc.
Ratliff, Tim L., Ph.D. ..... Purdue University, West Lafayette
Rauscher, Garth H., Ph.D., M.P.H. ..... University of Illinois at Chicago
Raz, Avraham, Ph.D. ..... Wayne State University
Ready, Joseph M., Ph.D. ..... The University of Texas Southwestern Medical Center, Dallas
Recht, Lawrence D., M.D. ..... Stanford University
Reddick, Wilburn E., Ph.D. ..... St. Jude Children's Research Hospital
Reddy, Srinivasa, Ph.D. ..... University of California, Los Angeles
Reddy, Vijayapal R., D.V.M., Ph.D. ..... Lilly Research Laboratories
Redmond, Carol K., Sc.D. ..... University of Pittsburgh
Reich, Daniel H., Ph.D. ..... The Johns Hopkins University
Reid, Gavin E., Ph.D. ..... Michigan State University
Reinhart-King, Cynthia A., Ph.D. ..... Cornell University
Ren, Bing, Ph.D. ..... Ludwig Institute for Cancer Research
Renne, Rolf F., Ph.D. ..... University of Florida
Reshetnyak, Yana K., Ph.D. ..... University of Rhode Island
Ressom, Habtom W., Ph.D. ..... Georgetown University
Retterer, Scott T., Ph.D. ..... Oak Ridge National Laboratory
Revzin, Alexander, Ph.D. ..... University of California, Davis
Rhode, Peter R., Ph.D. ..... Altor Bioscience Corporation
Rhodes, Charles H., M.D., Ph.D. ..... Dartmouth College
Richards, Nigel G.J., Ph.D. ..... University of Florida
Richardson, Adam D., Ph.D. ..... Sanford-Burnham Medical Research Institute
Richardson, Virginia, Ph.D. ..... The Ohio State University
Riehn, Robert, Ph.D. ..... North Carolina State University
Riethman, Harold C., Ph.D. ..... The Wistar Institute
Riggin, Ralph M., Ph.D. ..... Marcadia Biotech, Inc.
Rinaldi, Carlos, Ph.D. ..... University of Puerto Rico, Mayaguez
Ritchie, Marylyn D., Ph.D. ..... Vanderbilt University

Ro, Marguerite J., Ph.D. ..... Asian & Pacific Islander American Health Forum
Roberge, Michel, Ph.D. ..... University of British Columbia
Roberson, Noma L., Ph.D. ..... Roberson Consulting International
Roberts, Charles T., Ph.D. ..... Oregon Health and Science University
Robertson, Fredika M., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Robertson, Gavin P., Ph.D. ..... Pennsylvania State University, Hershey Medical Center
Rodeck, Ulrich, M.D., Ph.D. ..... Thomas Jefferson University
Rodland, Karin D., Ph.D. ..... Battelle Pacific Northwest Laboratories
Roemer, Robert, Ph.D. ..... The University of Arizona
Rogers, Jimmy A., Ph.D. ..... University of Nebraska, Omaha
Rogers, Rick, Ph.D. ..... Harvard School of Public Health
Rollison, Dana E., Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Romkes, Marjorie, Ph.D. ..... University of Pittsburgh
Roper, Michael G., Ph.D. ..... Florida State University
Rose, Jed E., Ph.D. ..... Duke University
Rose, William C., Ph.D. ..... University of Delaware
Rosen, Eliot M., M.D., Ph.D. ..... Georgetown University
Rosenberg, Daniel W., Ph.D. ..... University of Connecticut School of Medicine & Dentistry
Rosenberg, Susan M., Ph.D. ..... University of Alberta
Rosenfeld, Cheryl S., D.V.M., Ph.D. ..... University of Missouri, Columbia
Rosenfeld, Steven S., M.D., Ph.D. ..... Columbia University Health Sciences
Ross, Ashley M., M.P.H. ..... The District of Columbia Department of Health
Ross, Hana, Ph.D. ..... American Cancer Society, Inc.
Roy, Hemant K., M.D. ..... Northshore University Health System Research Institute
Roy-Chowdhury, Jayanta, M.D. ..... Albert Einstein College of Medicine of Yeshiva University
Rozek, Laura, Ph.D. ..... University of Michigan, Ann Arbor
Rubnitz, Jeffrey E., M.D., Ph.D. ..... St. Jude Children's Research Hospital
Rudchenko, Sergei, Ph.D. ..... Hospital for Special Surgery
Rudd, Pauline M., Ph.D. ..... University College, Dublin
Ruggero, Davide, Ph.D. ..... University of California, San Francisco
Rusling, James F., Ph.D. ..... University of Connecticut, Storrs
Russo, Jose, M.D. ..... Fox Chase Cancer Center
Ryu, Samuel, M.D. ..... Henry Ford Health System

S

Saban, Ricardo, D.V.M., Ph.D. ..... University of Oklahoma Health Sciences Center
Sabbadini, Roger A., Ph.D. ..... Lpath Therapeutics, Inc.
Sadik, Omowunmi A., Ph.D. ..... State University of New York at Binghamton
Sadler, Georgia R., Ph.D. ..... University of California, San Diego
Safa, Ahmad R., Ph.D. ..... Indiana University-Purdue University, Indianapolis
Safe, Stephen H., Ph.D. ..... Texas A&M University Health Science Center
Sahasrabuddhe, Vikrant, Ph.D., M.P.H. ..... Vanderbilt University
Sahiner, Berkman, Ph.D. ..... University of Michigan, Ann Arbor
Saiz, Leonor, Ph.D. ..... University of California, Davis
Salazar, Lupe G., M.D. ..... University of Washington
Salisbury, Jeffrey L., Ph.D. ..... Mayo Clinic
Salsberg, Edward S., M.P.A. ..... Association of American Medical Colleges

Samei, Ehsan, Ph.D. ..... Duke University
Samlowski, Wolfram E., M.D. ..... Nevada Cancer Institute
Samuel, Charles E., Ph.D. ..... University of California, Santa Barbara
Sandler, Howard M., M.D. ..... Cedars-Sinai Medical Center
Santalucia, John, Ph.D. ..... Wayne State University
Sarikaya, Mehmet, Ph.D. ..... University of Washington
Sarkar, Fazlul H., Ph.D. ..... Wayne State University
Sartell, Karen, M.A. ..... Nevada Cancer Research Foundation
Sasieni, Peter D., Ph.D. ..... Wolfson Institute of Preventive Medicine
Satia, Jessie A., Ph.D., M.P.H. (Deceased) ..... University of Washington
Sauro, Herbert M., Ph.D. ..... University of Washington
Sausville, Edward A., M.D., Ph.D. ..... University of Maryland, Baltimore
Savard, Josee, Ph.D. ..... Laval University
Sayre, James W., Ph.D. ..... University of California, Los Angeles
Scadeng, Miriam, M.D. ..... University of California, San Diego
Scarlata, Suzanne F., Ph.D. ..... State University of New York at Stony Brook
Scarpinato, Karin D., Ph.D. ..... Wake Forest University Health Sciences
Schbaath, Matthew B., Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Schad, Peter A., Ph.D. ..... Research Triangle Institute International
Schepkin, Victor D., Ph.D. ..... Florida State University
Scher, Howard I., M.D. ..... Sloan-Kettering Institute for Cancer Research
Scherer, Philipp E., Ph.D. ..... The University of Texas Southwestern Medical Center, Dallas
Scheurer, Michael E., Ph.D., M.P.H. ..... Baylor College of Medicine
Schiff, David, M.D. ..... University of Virginia
Schmitt, Carol L., Ph.D. ..... Research Triangle Institute International
Schmittgen, Thomas D., Ph.D. ..... The Ohio State University
Schnitzer, Jan E., M.D. ..... Proteogenomics Research Institute for Systems Medicine
Schulick, Richard D., M.D. ..... The Johns Hopkins University
Schultz, Kirk R., M.D. ..... University of British Columbia
Schwartz, Ann G., Ph.D., M.P.H. ..... Wayne State University
Schwartz, David C., Ph.D. ..... University of Wisconsin, Madison
Schwartz, Gary J., Ph.D. ..... Albert Einstein College of Medicine of Yeshiva University
Schwartz, Gary K., M.D. ..... Sloan-Kettering Institute for Cancer Research
Schwartz, Jeffrey L., Ph.D. ..... University of Washington
Schwartz, Joel L., D.M.D., M.D. ..... University of Illinois at Chicago
Schwartz, Lawrence H., M.D. ..... Columbia University Health Sciences
Schwartz, Randy H. ..... Maine State Department of Health & Human Services
Schymura, Maria J., Ph.D. ..... Center for Community Health
Seal, Sudipta, Ph.D. ..... University of Central Florida
Seewaldt, Victoria L., M.D. ..... Duke University
Seftor, Richard E.B., Ph.D. ..... Children's Memorial Hospital, Chicago
Seigel, Carole, M.S. ..... Nathan S. Kline Institute
Sen, Saunak, Ph.D. ..... University of California, San Francisco
Senderowicz, Adrian, M.D. ..... AstraZeneca Pharmaceuticals, LP
Sens, Donald A., Ph.D. ..... The University of North Dakota
Serkova, Natalie J., Ph.D. ..... University of Colorado, Denver
Servoss, Shannon L., Ph.D. ..... University of Arkansas at Fayetteville
Shannon, Jackilen, Ph.D., M.P.H. ..... Oregon Health and Science University

Shapiro, Benjamin, Ph.D. ..... University of Maryland, College Park
Shapiro, Pamela J., Ph.D. ..... Fox Chase Cancer Center
Shappell, Brian, M.B.A. ..... University of Notre Dame
Sharlow, Elizabeth R., Ph.D. ..... University of Pittsburgh
Sharp, John G., Ph.D. ..... University of Nebraska Medical Center
Shaw, Chris C., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Sheng, Shijie, Ph.D. ..... Wayne State University
Sherman, David H., Ph.D. ..... Alluvium Biosciences, Inc.
Shi, Hua, M.D., Ph.D. ..... State University of New York at Albany
Shi, Huidong, Ph.D. ..... Medical College of Georgia
Shibata, Darryl K., M.D. ..... University of Southern California
Shields, Anthony F., M.D., Ph.D. ..... Wayne State University
Shilatifard, Ali, Ph.D. ..... Stowers Institute for Medical Research
Shin, Dong M., M.D. ..... Emory University
Shipp, Gregory W., M.D. ..... Nanosphere, Inc.
Showe, Louise C., Ph.D. ..... The Wistar Institute
Shroyer, Kenneth R., M.D., Ph.D. ..... State University of New York at Stony Brook
Shulkin, Barry L., M.D. ..... St. Jude Children's Research Hospital
Shyr, Yu, Ph.D. ..... Vanderbilt University
Siefker-Radtke, Arlene O., M.D. ..... The University of Texas M.D. Anderson Cancer Center
Siegel, Eliot L., M.D. ..... University of Maryland, Baltimore
Siegfried, Jill M., Ph.D. ..... University of Pittsburgh
Siemann, Dietmar W., Ph.D. ..... University of Florida
Silver, Robert B., Ph.D. ..... Wayne State University
Simko, Jeff P., M.D., Ph.D. ..... University of California, San Francisco
Simoneau, Anne R., M.D. ..... University of California, Irvine
Simpson, Kit N., Ph.D., M.P.H. ..... Medical University of South Carolina
Singer, Mendel E., Ph.D. ..... Case Western Reserve University
Singh, Karan P., Ph.D. ..... University of North Texas Health Science
Singh, Rakesh K., Ph.D. ..... University of Nebraska Medical Center
Singh, Shivendra, Ph.D. ..... University of Pittsburgh
Single, Richard M., Ph.D. ..... The University of Vermont & State Agricultural College
Sinko, Patrick J., Ph.D. ..... Rutgers, The State University of New Jersey, New Brunswick
Sirica, Alphonse E., Ph.D. ..... Virginia Commonwealth University
Siu, Lillian L., M.D. ..... University of Toronto
Slingluff, Craig L., M.D. ..... University of Virginia
Sloan, Andrew E., M.D., Ph.D. ..... Case Western Reserve University
Slovin, Susan F., M.D., Ph.D. ..... Sloan-Kettering Institute for Cancer Research
Small, Eric J., M.D. ..... University of California, San Francisco
Smela, Elisabeth, Ph.D. ..... University of Maryland, College Park
Smith, David I., Ph.D. ..... Mayo Clinic
Smith, Eva D., Ph.D., R.N, F.A.A.N. ..... University of Illinois at Chicago
Sohn, Lydia L., Ph.D. ..... University of California, Berkeley
Sokolov, Konstantin V., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Soliman, Amr, M.D., Ph.D. ..... University of Michigan, Ann Arbor
Solit, David B., M.D. ..... Sloan-Kettering Institute for Cancer Research
Sondak, Vernon K., M.D. ..... H. Lee Moffitt Cancer Center & Research Institute

Sondel, Paul M., M.D., Ph.D. ..... University of Wisconsin, Madison
Song, Chang W., Ph.D. ..... The University of Minnesota, Twin Cities
Sowers, Lawrence C., Ph.D. ..... City of Hope National Medical Center
Spiegelman, Donna L., Sc.D. ..... Harvard School of Public Health
Spinella, Michael J., Ph.D. ..... Dartmouth College
Srivastava, Rakesh K., Ph.D. ..... The University of Kansas Medical Center
Steck, Susan E., Ph.D., M.P.H. ..... University of South Carolina, Columbia
Steer, Clifford J., M.D. ..... The University of Minnesota, Twin Cities
Stehr, Mark F., Ph.D. ..... Drexel University
Steinman, Ralph M., M.D. ..... Rockfeller University
Stevens, Victoria L., Ph.D. ..... American Cancer Society, Inc.
Stewart, Clinton F., Ph.D. ..... St. Jude Children's Research Hospital
Stewart, John H., M.D. ..... Wake Forest University Health Sciences
Stick, Roberta S., J.D. ..... Leukemia and Lymphoma Society
Stidley, Christine A., Ph.D. ..... The University of New Mexico
Stiles, Alan D., M.D. ..... University of North Carolina at Chapel Hill
Stokoe, David H., Ph.D. ..... University of California, San Francisco
Stolowitz, Mark L., Ph.D. ..... Stratos Biosystems, LLC
Stone, Michael P., Ph.D. ..... Vanderbilt University
Storer, Barry E., Ph.D. ..... Fred Hutchinson Cancer Research Center
Storkus, Walter J., Ph.D. ..... University of Pittsburgh
Strano, Michael S., Ph.D. ..... Massachusetts Institute of Technology
Strasser, Andrew, Ph.D. ..... The University of Pennsylvania
Stratakis, Constantine A., M.D., Sc.D. ..... Eunice Kennedy Shriver National Institute of Child Health & Human Development
Strath, Scott J., Ph.D. ..... University of Wisconsin, Milwaukee
Strome, Scott E. ..... University of Maryland, Baltimore
Stroobant, Paul, Ph.D. ..... Differential Proteomics, Inc.
Strouse, Geoffrey F., Ph.D. ..... Florida State University
Su, Ying-Hsiu, Ph.D. ..... Drexel University College of Medicine
Subbaiah, Papasani V., Ph.D. ..... University of Illinois at Chicago
Suman, Vera J., Ph.D. ..... Mayo Clinic
Sumner, Susan J., Ph.D. ..... Research Triangle Institute International
Sun, Duxin, Ph.D. ..... University of Michigan, Ann Arbor
Sun, Mingui, Ph.D. ..... University of Pittsburgh
Sutfin, Erin L., Ph.D. ..... Wake Forest University Health Sciences
Suva, Larry J., Ph.D. ..... University of Arkansas Medical Sciences, Little Rock
Swaminathan, Sankar, M.D. ..... University of Florida
Swanson, Basil I., M.D., Ph.D. ..... Los Alamos National Laboratory
Swartz, James R., Sc.D., Ph.D. ..... Stanford University
Sweda, Edward L., J.D. ..... Public Health Advocacy Institute, Inc.
Swede, Helen, Ph.D. ..... University of Connecticut School of Medicine & Dentistry
Sweeney, Carol, Ph.D. ..... University of Utah
Symanowski, James T., Ph.D. ..... Nevada Cancer Institute
Synold, Tim W., Ph.D. ..... Beckman Research Institute of City of Hope
Szmacinski, Henryk, Ph.D. ..... University of Maryland, Baltimore

T

Tackett, Alan J., Ph.D. ..... University of Arkansas Medical Sciences, Little Rock
Taghian, Alphonse G., M.D., Ph.D. ..... Massachusetts General Hospital
Taichman, Russell S., D.M.D. ..... University of Michigan, Ann Arbor
Tainsky, Michael A., Ph.D. ..... Wayne State University
Taioli, Emanuela, M.D., Ph.D. ..... State University of New York at Downstate Medical Center
Takeuchi, David T., Ph.D. ..... University of Washington
Tan, Ming T., Ph.D. ..... University of Maryland, Baltimore
Tang, Dean G., M.D., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Tanguay, Robert L., Ph.D. ..... Oregon State University
Tannous, Bakhos A., Ph.D. ..... Massachusetts General Hospital
Tanski, Susanne E., M.D., M.P.H. ..... Dartmouth College
Taren, Douglas L., Ph.D. ..... The University of Arizona
Tasciotti, Ennio, Ph.D. ..... The University of Texas Health Sciences Center, Houston
Taylor, Douglas D., Ph.D. ..... Tekshifa, Inc.
Taylor, Jeremy M.G., Ph.D. ..... University of Michigan, Ann Arbor
Taylor, Lynne S., Ph.D. ..... Purdue University, West Lafayette
Taylor, Richard E., Ph.D. ..... University of Notre Dame
Terrazas, Alejandro, Ph.D. ..... Mediabalance, Inc.
Thigpen, James T., M.D. ..... University of Mississippi Medical Center
Thomas, James P., M.D., Ph.D. ..... University of Wisconsin, Madison
Thomas-Tikhonenko, A., Ph.D. ..... The University of Pennsylvania
Thompson, Beti, Ph.D. ..... Fred Hutchinson Cancer Research Center
Thompson, Cheryl L., Ph.D. ..... Case Western Reserve University
Thompson, E.A., Ph.D. ..... Mayo Clinic, Jacksonville
Thomson, Cynthia A., Ph.D. ..... The University of Arizona
Timmerman, John M., M.D. ..... University of California, Los Angeles
Tindall, Donald J., Ph.D. ..... Mayo Clinic
Tok, Jeffery B.H., Ph.D. ..... Micropoint Biosciences, Inc.
Toker, Alex, Ph.D. ..... Beth Israel Deaconess Medical Center
Tomalia, Donald A., Ph.D. ..... Dendritic Nanotechnologies, Inc.
Tomaszewski, John E., M.D. ..... The University of Pennsylvania
Torchilin, Vladimir P., Ph.D., Sc.D. ..... Northeastern University
Torok-Storb, Beverly J., Ph.D. ..... Fred Hutchinson Cancer Research Center
Torres-Roca, Javier F., M.D ..... H. Lee Moffitt Cancer Center & Research Institute
Tosteson, Tor D., Sc.D. ..... Dartmouth College
Towner, Rheal A., Ph.D. ..... Oklahoma Medical Research Foundation
Tracy, J. Kathleen, Ph.D. ..... University of Maryland, Baltimore
Trapido, Edward J., Sc.D. ..... Louisiana State University Health Science Center
Treadwell, Henrie M., Ph.D. ..... Morehouse School of Medicine
Triche, Tim Y.J., M.D., Ph.D. ..... Children's Hospital, Los Angeles
Tricot, Guido J., M.D., Ph.D. ..... University of Utah
Triozzi, Pierre L., M.D. ..... Cleveland Clinic Foundation
True, Lawrence D., M.D. ..... University of Washington
Tschetter, Loren K., M.D ..... Sanford Cancer Center
Tsourkas, Andrew, Ph.D. ..... The University of Pennsylvania

Turchi, John J., Ph.D. ..... Indiana University-Purdue University, Indianapolis
Turk, Benjamin E., Ph.D. ..... Yale University
Turkson, James K., Ph.D. ..... University of Central Florida
Tuschl, Thomas, Ph.D. ..... New York Academy of Sciences
Tweardy, David J., M.D. ..... Baylor College of Medicine
Tworek, Cindy, Ph.D., M.P.H. ..... West Virginia University
Tycko, Benjamin, M.D., Ph.D. ..... Gordon Research Conferences
Tyler, Douglas S., M.D. ..... Duke University

U

Ukoli, Flora A., M.D., M.P.H. ..... Meharry Medical College
Unger, Evan C., M.D. ..... NuvOx Pharma, LLC
Urba, Walter J., M.D., Ph.D. ..... Providence Portland Medical Center

V

Vail, David M., D.V.M. ..... University of Wisconsin, Madison
Vakser, Ilya, Ph.D. ..... The University of Kansas, Lawrence
Valentovic, Monica A., Ph.D. ..... Marshall University
Vanbrocklin, Henry F., Ph.D. ..... University of California, San Francisco
Van Horn, Linda V., Ph.D. ..... Northwestern University
Van Ness, Brian G., Ph.D. ..... The University of Minnesota, Twin Cities
Varadi, Gyula, Ph.D. ..... Radiation Monitoring Devices, Inc.
Varner, Jeffrey D., Ph.D. ..... Cornell University
Varshavsky, Alexander J., Ph.D. ..... California Institute of Technology
Vasmatzis, George, Ph.D. ..... Mayo Clinic
Velie, Ellen M., Ph.D., M.P.H. ..... Michigan State University
Venook, Alan P., M.D. ..... University of California, San Francisco
Ventura, Andrea, M.D., Ph.D. ..... Sloan-Kettering Institute for Cancer Research
Verderame, Michael F., Ph.D. ..... Pennsylvania State University, Hershey Medical Center
Verma, Ajit K., Ph.D. ..... Southern University A&M College, Baton Rouge
Versalovic, James, M.D., Ph.D. ..... Baylor College of Medicine
Verschraegen, Claire F., M.D. ..... The University of New Mexico Health Sciences Center
Vicini, Paolo, Ph.D. ..... Pfizer, Inc.
Vidrine, Damon J., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Vidrine, Jennifer I., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Vile, Richard G., Ph.D. ..... Mayo Clinic
Vinogradov, Serguei V., Ph.D. ..... University of Nebraska Medical Center
Virshup, Gary, M.S. ..... Varian Medical Systems, Inc.
Visovsky, Constance G., Ph.D., R.N., A.C.N.P. ..... University of Nebraska Medical Center
Vohra, Yogesh K., Ph.D. ..... University of Alabama at Birmingham
Volpert, Olga V., Ph.D. ..... Northwestern University
Vona-Davis, Linda C., Ph.D. ..... West Virginia University
Von Mehren, Margaret, M.D. ..... Fox Chase Cancer Center
Vouros, Paul, Ph.D. ..... Northeastern University

W

Wachsman, William, M.D., Ph.D. ..... University of California, San Diego
Wagman, Lawrence D., M.D. ..... City of Hope National Medical Center
Wagner, Kay-Uwe, Ph.D. ..... University of Nebraska Medical Center
Wagner, Lynne I., Ph.D. ..... Northwestern University
Wali, Ramesh K., Ph.D. ..... Northshore University Health System Research Institute
Walker, Barbara W., Ph.D., J.D. ..... Patient Advocate
Walkosz, Barbara, Ph.D. ..... University of Colorado, Denver
Waller, Edmund K., M.D., Ph.D. ..... Emory University
Wang, Binghe, Ph.D. ..... Georgia State University
Wang, Deli, M.D., Ph.D. ..... Children's Memorial Hospital, Chicago
Wang, Denong, Ph.D. ..... SRI International, Inc.
Wang, Edwin, Ph.D. ..... National Research Council, Canada
Wang, Ge, Ph.D. ..... Virginia Polytechnic Institute and State University
Wang, Henry Y., Ph.D. ..... University of Michigan, Ann Arbor
Wang, Hong-Gang, Ph.D. ..... Pennsylvania State University, Hershey Medical Center
Wang, Jean C.Y., M.D., Ph.D. ..... University of Toronto
Wang, Judy Huei-yu, Ph.D. ..... Georgetown University
Wang, Kenneth K., M.D. ..... Mayo Clinic
Wang, Mu, Ph.D. ..... Indiana University-Purdue University, Indianapolis
Wang, Peng G., Ph.D. ..... The Ohio State University
Wang, Rong, Ph.D. ..... Illinois Institute of Technology
Wang, Shan X., Ph.D. ..... Stanford University
Wang, Shaomeng, Ph.D. ..... University of Michigan, Ann Arbor
Wang, Shizhen E., Ph.D. ..... Beckman Research Institute of City of Hope
Wang, Tim C., M.D. ..... University of Massachusetts Medical School, Worcester
Ward, John H., M.D. ..... University of Utah
Ward, Pamela, Ph.D. ..... University of California, Irvine
Wargovich, Michael, Ph.D. ..... Medical University of South Carolina
Warnecke, Richard, Ph.D. ..... University of Illinois at Chicago
Washington, Mary Kay, M.D., Ph.D. ..... Vanderbilt University
Wasik, Mariusz A., M.D. ..... The University of Pennsylvania
Waterman, Marian L., Ph.D. ..... University of California, Irvine
Watkins, Simon C., Ph.D. ..... University of Pittsburgh
Watson, Peter, M.B., B.Chir., F.R.C.P.C. ..... British Columbia Cancer Center
Watson, Ronald R., Ph.D. ..... Mentors of Challenged Adults, Inc.
Watts, David C., Ph.D. ..... U.S. Food and Drug Administration
Webster, Thomas J., Ph.D. ..... Brown University
Wei, Alexander, Ph.D. ..... Purdue University, West Lafayette
Wei, Esther, Sc.D. ..... California Pacific Medical Center Research Institute
Weichert, Jamey P., Ph.D. ..... University of Wisconsin, Madison
Weier, Heinz-Ulrich G., Ph.D. ..... Lawrence Berkeley National Laboratory
Weinberg, David S., M.D. ..... Fox Chase Cancer Center
Weindruch, Richard, Ph.D. ..... American Aging Association
Weir, Hannah K., Ph.D. ..... Centers for Disease Control and Prevention
Weir, Scott J., Ph.D., Pharm.D. ..... The University of Kansas Medical Center
Weiss, Geoffrey R., M.D. ..... University of Virginia

Weiss, Heidi L., Ph.D. ..... The University of Texas Medical Branch at Galveston
Weiss, Nancy S., Ph.D., M.P.H. ..... Texas Department of Health
Weiss, Rick, M.S. ..... Viocare, Inc.
Weiss, Robert H., M.D. ..... University of California, Davis
Wek, Ronald C., Ph.D. ..... Indiana University-Purdue University, Indianapolis
Welch, Michael J., Ph.D. ..... Washington University
Welling, Monica A. ..... Strategic Links Inc.
West, Dee W., Ph.D. ..... Cancer Prevention Institute of California
Wethington, Elaine, Ph.D. ..... Cornell University
Wetzler, Meir, M.D. ..... Roswell Park Cancer Institute Corporation
Wheatley, Bonnie P., Ed.D., M.P.H. ..... Alameda County Medical Center
Whiteside, Theresa L., Ph.D. ..... University of Pittsburgh
Whitfield, Michael L., Ph.D. ..... Dartmouth College
Whitlatch, Carol J., Ph.D. ..... Benjamin Rose Institute
Whitley, Elizabeth M., Ph.D., R.N. ..... Denver Health and Hospital Authority
Wiggins, Charles L., Ph.D. ..... The University of New Mexico
Wilbur, W.J., M.D., Ph.D. ..... National Library of Medicine
Wiley, H. Steven, Ph.D. ..... Battelle Pacific Northwest Laboratories
Wilkinson, Keith D., Ph.D. ..... Emory University
Willett, Christopher G., M.D. ..... Duke University
Willey, James C., M.D. ..... Medical College of Ohio
Williams, Carla D., Ph.D. ..... Howard University
Williams, Donna L., Ph.D., M.P.H. ..... Louisiana State University Health Science Center
Williams, Robert L., M.D., M.P.H. ..... The University of New Mexico Health Sciences Center
Williamson, Patrick, Ph.D. ..... Amherst College
Williard, Paul G., Ph.D. ..... Brown University
Wilson, Brian C., Ph.D. ..... University of Toronto
Wilson, David L., Ph.D. ..... Case Western Reserve University
Wilson, David M., Ph.D. ..... National Institute on Aging
Wilson, Keith T., M.D. ..... Vanderbilt University
Winn-Deen, Emily S., Ph.D. ..... Cepheid
Wiseman, Robert W., Ph.D. ..... Michigan State University
Wisoff, Jeffrey H., M.D. ..... New York University, Langone Medical Center
Wojcik, Eva M., M.D. ..... Loyola University Chicago
Wolff, Steven N., M.D. ..... Meharry Medical College
Wong, Lucas, M.D. ..... Scott and White Memorial
Wong, Season S.S., Ph.D. ..... Lynntech, Inc.
Wong, Stephen T.C., Ph.D. ..... Methodist Hospital Research Institute
Wood, Charles, Ph.D. ..... University of Nebraska, Lincoln
Wood, Marie E., M.D. ..... The University of Vermont & State Agricultural College
Woodall, W.G., Ph.D. ..... The University of New Mexico
Woods, Erik J., Ph.D. ..... General Biotechnology, LLC
Woods, Virgil L., M.D. ..... University of California, San Diego
Wooley, Karen L., Ph.D. ..... Texas A&M University
Worsham, Maria J., Ph.D. ..... Henry Ford Health System
Wren, Jonathan D., Ph.D. ..... Oklahoma Medical Research Foundation
Wright, Kenneth L., Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Wu, Christine C., Ph.D. ..... University of Pittsburgh

Wu, Hao, Ph.D. ..... Cornell University
Wu, Mingming, Ph.D. ..... Cornell University
Wu, T.C., M.D., Ph.D. ..... The Johns Hopkins University
Wu, Xifeng, M.D., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Wu-Pong, Susanna, Ph.D. ..... Virginia Commonwealth University

X

Xia, Younan, Ph.D. ..... Washington University
Xie, Yubing, Ph.D. ..... State University of New York at Albany
Xu, Yan, Ph.D. ..... Indiana University-Purdue University, Indianapolis
Xu, Yang, Ph.D. ..... University of California, San Diego

Y

Yadrick, Kathleen, Ph.D. ..... University of Southern Mississippi
Yang, Chung S., Ph.D. ..... Rutgers, The State University of New Jersey, New Brunswick
Yang, Guoliang, Ph.D. ..... Drexel University
Yang, Lily, M.D., Ph.D. ..... Emory University
Yang, Wei, Ph.D. ..... National Institute of Diabetes and Digestive and Kidney Diseases
Yang, Xiao-Feng, M.D., Ph.D. ..... Temple University
Yang, Yu-Chung, Ph.D. ..... Case Western Reserve University
Yannelli, John R., Ph.D. ..... University of Kentucky
Yao, Qizhi C., M.D., Ph.D. ..... Emory University
Yeger, Herman, Ph.D. ..... University of Toronto
Yeh, Jen Jen, M.D. ..... University of North Carolina at Chapel Hill
Yen, Yun, M.D., Ph.D. ..... Beckman Research Institute of City of Hope
Yeung, Anthony T., Ph.D. ..... Institute for Cancer Research
Yi, Qing, M.D., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Yost, David A., Ph.D. ..... Innovative Biosensors, Inc.
You, Ming, M.D., Ph.D. ..... Medical College of Wisconsin
Younes, Anas, M.D. ..... The University of Texas M.D. Anderson Cancer Center
Young, Jeanne P., B.A. ..... Childhood Brain Tumor Foundation
Young, M. Rita, Ph.D. ..... Ralph H. Johnson Veteran's Administration Medical Center
Yuan, Chun-Su, M.D., Ph.D. ..... The University of Chicago
Yuan, Jian-Min, M.D., Ph.D. ..... The University of Minnesota, Twin Cities
Yung, W.K. Alfred, M.D. ..... The University of Texas M.D. Anderson Cancer Center

Z

Zacharias, Wolfgang, Ph.D. ..... University of Louisville
Zamboni, William C., Ph.D., Pharm.D. ..... University of North Carolina at Chapel Hill
Zand, Jason M., M.D. ..... Surgisense Corporation
Zanzonico, Pat B., Ph.D. ..... Memorial Sloan-Kettering Cancer Center
Zaren, Howard A., M.D. ..... John H. Stroger Jr. Hospital
Zborowski, Maciej, Ph.D. ..... Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Zeller, Mitchell, J.D. ..... American Legacy Foundation
Zelterman, Daniel, Ph.D. ..... Yale University

Zemel, Michael B., Ph.D. ..... The University of Tennessee, Knoxville
Zhang, David Y., M.D., Ph.D. ..... Mount Sinai School of Medicine of New York University
Zhang, Hongjie, Ph.D. ..... University of Illinois at Chicago
Zhang, Jian-Ting, Ph.D. ..... Indiana University-Purdue University, Indianapolis
Zhang, Ruiwen, M.D., Ph.D. ..... Texas Tech University Health Sciences Center
Zhang, Yanping, Ph.D. ..... University of North Carolina at Chapel Hill
Zhang, Yawei, M.D., Ph.D. ..... Yale University
Zhang, Zuo-Feng, M.D., Ph.D. ..... University of California, Los Angeles
Zhao, Yingming, Ph.D. ..... The University of Chicago
Zhao, Yutong, M.D., Ph.D. ..... University of Pittsburgh
Zheng, Qi, Ph.D. ..... Texas A&M University Health Science Center
Zheng, Yi, Ph.D. ..... Children's Hospital Medical Center, Cincinnati
Zhou, Jin-Rong, Ph.D. ..... Beth Israel Deaconess Medical Center
Zi, Xiaolin, M.D., Ph.D. ..... University of California, Irvine
Zondlo, Neal J., Ph.D. ..... University of Delaware

Total number of Reviewers: 1,700

Appendix E: NCI Grant Mechanisms and Descriptions

Below is a brief description of NIH funding mechanisms. Additional information on grants, contracts, and extramural policy notices may be found by viewing the NCI DEA Web page on Grants Guidelines and Descriptions at: http://deainfo.nci.nih.gov/flash/awards.htm.

C Series: Research Construction Programs	
C06	**Research Facilities Construction Grants** To provide matching Federal funds, up to 75 percent, for construction or major remodeling to create new research facilities, which in addition to basic research laboratories may include, under certain circumstances, animal facilities and/or limited clinical facilities where they are an integral part of an overall research effort.
D Series: Training Projects	
D43	**International Training Grants in Epidemiology** To improve and expand epidemiologic research and the utilization of epidemiology in clinical trials and prevention research in foreign countries through support of training programs for foreign health professionals, technicians, and other health care workers.
F Series: Fellowship Programs	
F31	**Predoctoral Individual National Research Service Award (NRSA)** To provide predoctoral individuals with supervised research training in specified health and health-related areas leading toward a research degree (e.g., Ph.D.).
F31	**Predoctoral Fellowship—Minority Students** A fellowship award that provides predoctoral minority students with supervised research training in specified health and health-related areas leading toward a research degree (e.g., Ph.D.).
F31	**National Research Service Award for Individual Postdoctoral Fellows** To provide postdoctoral research training to individuals to broaden their scientific background and extend their potential for research in specified health-related areas.
F32	**National Research Service Award for Individual Postdoctoral Fellows** To provide postdoctoral research training to individuals to broaden their scientific background and extend their potential for research in specified health-related areas.
F33	**National Research Service Award for Senior Fellows** To provide opportunities for experienced scientists to make major changes in the direction of research careers, broaden scientific backgrounds, acquire new research capabilities, enlarge command of an allied research field, or take time from regular professional responsibilities to increase capabilities to engage in health-related research.

K Series: Career Development Programs	
K01	**The Howard Temin Award (no longer supported through use of the K01 by the NCI; see the K99/R00)** A previously used NCI-specific variant of the NIH Mentored Research Scientist Development Award that was designed to provide research scientists with an additional period of sponsored research experience as a way to gain expertise in a research area new to the applicant or in an area that would demonstrably enhance the applicant's scientific career.
K01	**Mentored Career Development Award for Underrepresented Minorities** To support scientists committed to research who are in need of both advanced research training and additional experience.
K05	**Established Investigator Award in Cancer Prevention, Control, Behavioral, and Population Research** To support scientists qualified to pursue independent research that would extend the research program of the sponsoring institution, or to direct an essential part of this program.
K07	**Cancer Prevention, Control, Behavioral, and Population Sciences Career Development Award** To support the postdoctoral career development of investigators who are committed to academic research careers in cancer prevention, control, behavioral, epidemiological, and/or the population sciences. It supports up to 5 years of combined didactic and supervised (i.e., mentored) research experiences to acquire the methodological and theoretical research skills needed to become an independent scientist. The very broad nature of the prevention, control, and population sciences makes it applicable to those individuals doctorally trained in the basic sciences, medicine, behavioral sciences, and/or public health. The K07 award has been expanded from a scope limited to "preventive oncology" to include the entire spectrum of fields that are of vital importance to cancer prevention and control such as nutrition, epidemiology, and behavioral sciences.
K08	**Mentored Clinical Scientists Development Award** To provide the opportunity for promising medical scientists with demonstrated aptitude to develop into independent investigators, or for faculty members to pursue research in categorical areas applicable to the awarding unit, and to aid in filling the academic faculty gap in specific shortage areas within U.S. health professions institutions.
K08	**Mentored Clinical Scientists Development Award—Minorities in Clinical Oncology** A specialized type of Mentored Clinical Scientist Developmental Award (K08s) that supports the development of outstanding clinical research scientists, with this type being reserved for qualified individuals from underrepresented minority groups. Both types of K08 awards support periods of specialized study for clinically trained professionals who are committed to careers in research and who have the potential to develop into independent investigators. The K08 awards for Minorities in Clinical Oncology are distinct and important because they provide opportunities for promising medical scientists with demonstrated aptitudes who belong to underrepresented minority groups to develop into independent investigators, or for faculty members who belong to underrepresented minority groups to pursue research aspects of categorical areas applicable to the awarding unit(s), and aid in filling the academic faculty gaps in these shortage areas within U.S. health professions institutions.

K12	**Institutional Clinical Oncology Research Career Development Award** To support a newly trained clinician appointed by an institution for development of independent research skills and experience in a fundamental science within the framework of an interdisciplinary research and development program.
K22	**The NCI Transition Career Development Award for Underrepresented Minorities** To provide support to outstanding newly trained basic or clinical investigators to develop their independent research skills through a two-phase program: an initial period involving an intramural appointment at the NIH and a final period of support at an extramural institution. The award is intended to facilitate the establishment of a record of independent research by the investigator to sustain or promote a successful research career.
K22	**The NCI Scholars Program** To provide an opportunity for outstanding new investigators to begin their independent research careers, first within the special environment of the NCI and then at an institution of their choice. Specifically, this Program provides necessary resources to initiate an independent research program of 3 to 4 years at the NCI, followed by an extramural funding mechanism (K22) to support their research program for 2 years at the extramural institution to which they are recruited.
K23	**Mentored Patient-Oriented Research Career Development Award** To provide support for the career development of investigators who have made a commitment to focus their research endeavors on patient-oriented research. This mechanism provides support for a 3-year minimum up to a 5-year period of supervised study and research for clinically trained professionals who have the potential to develop into productive clinical investigators.
K23	**Mentored Patient-Oriented Research Career Development Award for Underrepresented Minorities** To support the career development of investigators who have made a commitment to focus their research on patient-oriented research. This mechanism provides support for a period of supervised study and research for clinically trained professionals who have the potential to develop into productive clinical investigators in patient-oriented research.
K24	**Mid-Career Investigator Award in Patient-Oriented Research** To provide support for clinicians to allow them protected time to devote to patient-oriented research and to act as mentors for beginning clinical investigators. The target candidates are outstanding clinical scientists engaged in patient-oriented research who are within 15 years of their specialty training, who can demonstrate the need for a period of intensive research focus as a means of enhancing their clinical research careers, and who are committed to mentoring the next generation of clinical investigators in patient-oriented research.
K25	**Mentored Quantitative Research Career Development Award** This award allows an independent scientist in a highly technical field of research to identify an appropriate mentor with extensive experience in cancer research and to receive the necessary training and career development required to become involved in multidisciplinary cancer research.

K99/ R00	**NIH Pathway to Independence (PI) Award** The Pathway to Independence Award, which is part of the NIH Roadmap Initiative but is known as the Howard Temin Award within the NCI, will provide up to 5 years of support consisting of two phases. The initial phase will provide 1 to 2 years of mentored support for highly promising postdoctoral research scientists. This phase will be followed by up to 3 years of independent support contingent on securing an independent research position. Award recipients will be expected to compete successfully for independent R01 support from the NIH during the career transition award period. The PI Award is limited to post-doctoral trainees within 5 years of completion of their training who propose research relevant to the mission of one or more of the participating NIH Institutes and Centers.
P Series: Research Program Projects and Centers	
P01	**Research Program Projects** To support multidisciplinary or multifaceted research programs that have a focused theme. Each component project should be directly related to and contribute to the common theme.
P20	**Exploratory Grants** To support planning for new programs, expansion or modification of existing resources, and feasibility studies to explore various approaches to the development of interdisciplinary programs that offer potential solutions to problems of special significance to the mission of the NIH. These exploratory studies may lead to specialized or comprehensive centers.
P30	**Center Core Grants** To support shared use of resources and facilities for categorical research by investigators from different disciplines who provide a multidisciplinary approach to a joint research effort, or by investigators from the same discipline who focus on a common research problem. The core grant is integrated with the Center's component projects or Program Projects, though funded independently from them. By providing more accessible resources, this support is expected to assure greater productivity than that provided through the separate projects and Program Projects.
P50	**Specialized Center Grants** To support any part of the full range of research and development from very basic to clinical; may involve ancillary supportive activities such as protracted patient care necessary to the primary research or R&D effort. This spectrum of activities comprises a multidisciplinary attack on a specific disease or biomedical problem area. These grants differ from Program Project grants in that they are usually developed in response to an announcement of the programmatic needs of an Institute or Division, and subsequently receive continuous attention from its staff. Centers also may serve as regional or national resources for special research purposes.

R Series: Research Projects	
R01	**Research Project** Grants are awarded to institutions to allow a Principal Investigator to pursue a scientific focus or objective in his or her area of interest and competence. Institutional sponsorship assures the NIH that the institution will provide facilities necessary to conduct the research and will be accountable for the grant funds. Applications are accepted for health-related research and development in all areas within the scope of the NIH's mission.
R03	**Small Research Grants** Small grants provide research support, specifically limited in time and amount, for activities such as pilot projects, testing of new techniques, or feasibility studies of innovative, high-risk research, which would provide a basis for more extended research.
R13	**Conferences** The NIH provides funding for conferences to coordinate, exchange, and disseminate information related to its program interests. Generally, such awards are limited to participation with other organizations in supporting conferences rather than provision of sole support. Costs eligible for support include salaries, consultant services, equipment rental, travel, supplies, conference services, and publications. Prospective applicants are encouraged to inquire in advance concerning possible interest on the part of an awarding Institute/Center (IC), and to obtain more information on application procedures and costs.
R15	**The NIH Academic Research Enhancement Awards (AREA)** To enhance the research environment of educational institutions that have not been traditional recipients of NIH research funds, this award provides limited funds to those institutions' faculty members to develop new research projects or expand ongoing research activities in health sciences and to encourage students to participate in the research activity. As funds are anticipated to continue to be available each year, the NIH is now inviting applications for AREA grants through a standing, ongoing Program Announcement.
R21	**Exploratory/Developmental Grants** To encourage the development of new research activities in categorical program areas. (Support generally is restricted in the level of support and duration.)
R24	**Resource-Related Research Projects** To support research projects that will enhance the capability of resources to serve biomedical research.

R25E	**Cancer Education Grant Program (CEGP)** A flexible, curriculum-driven program aimed at developing and sustaining innovative educational approaches that ultimately will have an impact on reducing cancer incidence, mortality, and morbidity, as well as on improving the quality of life of cancer patients. The CEGP accepts investigator-initiated grant applications that pursue a wide spectrum of objectives ranging from short courses; to the development of new curricula in academic institutions; to national forums and seminar series; to hands-on workshop experiences for the continuing education of health care professionals, biomedical researchers, and the lay community; to structured short-term research experiences designed to motivate high school, college, medical, dental, and other health professional students to pursue careers in cancer research. Education grants can focus on education activities before, during, and after the completion of a doctoral-level degree, as long as they address a need that is not fulfilled adequately by any other grant mechanism available at the NIH, and are dedicated to areas of particular concern to the National Cancer Program.
R25T	**Cancer Education and Career Development Program** To support the development and implementation of curriculum-dependent, team-oriented programs to train predoctoral and postdoctoral candidates in cancer research team settings that are highly interdisciplinary and collaborative. This specialized program is particularly applicable to the behavioral, prevention, control, nutrition, and population sciences but should also be considered by other areas of research (e.g., imaging, pathology) that will require sustained leadership, dedicated faculty time, specialized curriculum development and implementation, interdisciplinary research environments, and more than one mentor per program participant to achieve their education and research career development objectives.
R33	**Exploratory/Developmental Grants, Phase II** To provide a second phase for support of innovative exploratory and developmental research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants who demonstrate program competency equivalent to that expected under R33.
R37	**Method to Extend Research in Time (MERIT) Award** To provide long-term grant support to investigators whose research competence and productivity are distinctly superior and who are highly likely to continue to perform in an outstanding manner. Investigators may not apply for a MERIT Award. Program staff and/or members of the cognizant National Advisory Council/Board will identify candidates for the MERIT Award during the course of review of competing research grant applications prepared and submitted in accordance with regular Public Health Service (PHS) requirements.

Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs

The NIH welcomes grant applications from small businesses in any biomedical or behavioral research area as described in the solicitations below. Support under the SBIR program is normally provided for 6 months/$100,000 for Phase I, and 2 years/$500,000 for Phase II. However, applicants may propose longer periods of time and greater amounts of funds necessary for completion of the project.

R41	**STTR Grants, Phase I** To support cooperative research and development (R&D) projects between small business concerns and research institutions, limited in time and amount; to establish the technical merit and feasibility of ideas that have potential for commercialization.
R42	**STTR Grants, Phase II** To support in-depth development of cooperative R&D projects between small business concerns and research institutions, limited in time and amount, whose feasibility has been established in Phase I and that have potential for commercial products or services.
R43	**SBIR Grants, Phase I** To support projects, limited in time and amount, to establish the technical merit and feasibility of R&D ideas that may ultimately lead to commercial products or services.
R44	**SBIR Grants, Phase II** To support in-depth development of R&D ideas whose feasibility has been established in Phase I and that are likely to result in commercial products or services.
R55	**James A. Shannon Director's Award** To provide a limited award to investigators to further develop, test, and refine research techniques; perform secondary analysis of available data sets; test the feasibility of innovative and creative approaches; and conduct other discrete projects that can demonstrate their research capabilities and lend additional weight to their already meritorious applications.
R56	**High-Priority, Short-Term Project Award** Begun in FY2005, this grant provides funds for 1- or 2-year high-priority new or competing renewal R01 applications that fall just outside the limits of funding of the participating NIH Institutes and Centers (ICs); recipients of R56 awards will be selected by IC staff from R01 applications that fall at or near the payline margins.

S Series: Research-Related Programs	
SC1	**Research Enhancement Award** Individual investigator-initiated research projects aimed at developing researchers at minority-serving institutions (MSIs) to a stage where they can transition successfully to other extramural support (R01 or equivalent).
SC2	**Pilot Research Project** Individual investigator-initiated pilot research projects for faculty at minority-serving institutions (MSIs) to generate preliminary data for a more ambitious research project.
S06	**Minority Biomedical Research Support (MBRS)** To strengthen the biomedical research and research training capability of ethnic minority institutions, and thus establish a more favorable milieu for increasing the involvement of minority faculty and students in biomedical research.
S07	**Biomedical Research Support Grants (NCRR BRSG)** As an example of this funding mechanism, the NIH issued a Request for Applications (RFA) in FY2004 to provide short-term interim support for institutional activities that will strengthen oversight of human subjects research at institutions that receive significant NIH support for clinical research. Although there is considerable flexibility in the types of activities that could be supported under the BRSG program, that RFA emphasized the importance of efforts to enhance the protection of research subjects by means that would be sustained by the recipient institution after the award period ends. Awardees also are required to collaborate with other institutions conducting human subjects research and are not currently funded under this program, and to share educational resources, computer technologies, best practices, etc. Although all NIH components supporting clinical research (including the NCI) are providing support for this program, it is administered by the National Center for Research Resources (NCRR).
S10	**Biomedical Research Support Shared Instrumentation Grants (NCRR SIG)** The National Center for Research Resources (NCRR) initiated its competitive Shared Instrumentation Grant (SIG) Program in FY1982. Shared Instrumentation Grants provide support for expensive state-of-the-art instruments utilized in both basic and clinical research. This program is designed to meet the special problems of acquisition and updating of expensive shared-use instruments that are not generally available through other NIH funding mechanisms, such as the regular research project, program project, or center grant programs. Applications for funds to design or to advance the design of new instruments are not accepted. The objective of the program is to make available to institutions with a high concentration of NIH-supported biomedical investigators expensive research instruments that can only be justified on a shared-use basis and for which meritorious research projects are described.
S21	**Research and Institutional Resources Health Disparities Endowment Grants—Capacity Building** To strengthen the research and training infrastructure of the institution, while addressing current and emerging needs in minority health and other health disparities research.

T Series: Training Programs	
T15	**Continuing Education Training Grants** To assist professional schools and other public and nonprofit institutions in the establishment, expansion, or improvement of programs of continuing professional education, especially for programs of extensive continuation, extension, or refresher education dealing with new developments in the science and technology of the profession.
T32	**NIH National Research Service Award—Institutional Research Training Grants** To enable institutions to make National Research Service Awards to individuals selected by them for predoctoral and postdoctoral research training in specified shortage areas.
U Series: Cooperative Agreements	
U01	**Research Projects—Cooperative Agreements** To support a discrete, specified, circumscribed project to be performed by the named investigators in an area representing their specific interests and competencies.
U10	**Cooperative Clinical Research—Cooperative Agreements** To support clinical evaluation of various methods of therapy and/or prevention in specific disease areas. These represent cooperative programs between participating institutions and Principal Investigators, and are usually conducted under established protocols.
U13	**Conference—Cooperative Agreements** To coordinate, exchange, and disseminate information related to its program interests, an NIH Institute or Center can use this type of award to provide funding and direction for appropriate scientific conferences. These cooperative agreements allow the NCI to partner with one or more outside organizations to support international, national, or regional meetings, conferences, and workshops that are of value in promoting the goals of the National Cancer Program.
U19	**Research Program—Cooperative Agreements** To support a research program of multiple projects directed toward a specific major objective, basic theme, or program goal, requiring a broadly based, multidisciplinary, and often long-term approach.
U24	**Resource-Related Research Projects—Cooperative Agreements** To support research projects contributing to improvement of the capability of resources to serve biomedical research.

U54	**Specialized Center—Cooperative Agreements** To support any part of the full range of research and development from very basic to clinical; may involve ancillary supportive activities such as protracted patient care necessary to the primary research or R&D effort. The spectrum of activities comprises a multidisciplinary attack on a specific disease entity or biomedical problem area. These differ from program projects in that they are usually developed in response to an announcement of the programmatic needs of an Institute or Division and subsequently receive continual attention from its staff. Centers also may serve as regional or national resources for special research purposes, with assistance from staff of the funding component in identifying appropriate priority needs.
U56	**Exploratory Grants—Cooperative Agreements** To support planning for new programs, expansion or modification of existing resources, and feasibility studies to explore various approaches to the development of interdisciplinary programs that offer potential solutions to problems of special significance to the mission of the NIH. These exploratory studies may lead to specialized or comprehensive centers. Substantial Federal programmatic staff involvement is intended to assist investigators during performance of the research activities, as defined in the terms and conditions of award.

Appendix F: Glossary of Acronyms

AACR	American Association for Cancer Research
AERIO	Agency Extramural Research Integrity Officer
AHRQ	Agency for Healthcare Research and Quality
AIDS	Acquired Immune Deficiency Syndrome
AISB	Applied Information Systems Branch
AITRP	AIDS International Training and Research Program
ANSWHR	Advancing Novel Science in Womens Health Research
ARA	Awaiting Receipt of Application
AREA	Academic Research Enhancement Award
ARRA	American Recovery and Reinvestment Act
BETRNet	Barrett's Esophagus Translational Research Network
BMT	Blood and Marrow Transplant
BRP	Bioengineering Research Partnership
BRSG	Biomedical Research Support Grant
BSA	Board of Scientific Advisors
BSC	Board of Scientific Counselors
C&A	Certification and Accreditation
caHUB	Cancer Human Biobank
CAM	Complementary and Alternative Medicine
CBIIT	NCI Center for Biomedical Informatics and Information Technology
CCCT	Coordinating Center for Clinical Trials
CCNE	Center of Cancer Nanotechnology Excellence
CCR	Center for Cancer Research
CCSB	Centers for Cancer Systems Biology
CCSG	Cancer Center Support Grant
CCT	Center for Cancer Training
CD	Career Development
CDC	Centers for Disease Control and Prevention
CEGP	Cancer Education Grant Program
CGB	Cooperative Group Banks
CISNET	Cancer Intervention and Surveillance Modeling Network
CIT	Center for Information Technology
CITN	Cancer Immunotherapy Trials Network
CMO	Committee Management Office
CMUG	Committee Management Users Group
CNP	Community Network Program
CNTC	Cancer Nanotechnology Training Center
COI	Conflict of Interest
CPHHD	Centers for Population Health and Health Disparities
CPTC	Clinical Proteomic Technologies for Cancer Initiative
CRCHD	Center to Reduce Cancer Health Disparities
CRP	Collaborative Research Partnership
CSO	Common Scientific Outline
CSR	Center for Scientific Review
CSSI	Center for Strategic Scientific Initiatives
CTAC	Clinical Trials and Translational Research Advisory Committee
CTEP	Clinical Trials Evaluation Program
DCB	Division of Cancer Biology
DCCPS	Division of Cancer Control and Population Sciences
DCEG	Division of Cancer Epidemiology and Genetics
DCLG	Director's Consumer Liaison Group
DCP	Division of Cancer Prevention
DCTD	Division of Cancer Treatment and Diagnosis
DEA	Division of Extramural Activities
DEAS	Division of Extramural Activities Support
DHHS	U.S. Department of Health and Human Services (now HHS)
EEC	Electronic Early Concurrence
EDRN	Early Detection Research Network
EEC	Electronic Early Concurrence
EPMC	Extramural Program Management Committee
eRA	Electronic Research Administration
ESA	Extramural Support Assistant
EUREKA	Exceptional, Unconventional Research Enabling Knowledge Acceleration

FACA	Federal Advisory Committee Act
FDA	Food and Drug Administration
FIC	Fogarty International Center
FLARE	Fiscal Linked Analysis of Research Emphasis
FOA	Funding Opportunity Announcements
FOIA	Freedom of Information Act
FY	Fiscal Year
GWAS	Genome Wide Association Studies
HHS	Department of Health and Human Services (replaces DHHS)
HTMS	High Throughput Molecular Screening
I2E	IMPAC II Extensions
IC	Institute/Center
ICBP	Integrative Cancer Biology Program
ICMIC	*In Vivo* Cellular and Molecular Imaging Center
ICRP	ICR Partners
IeDEA	International Epidemiological Databases to Evaluate AIDS
IDeA	Institutional Development Award
IMPAC	Information for Management, Planning, Analysis, and Coordination
IRG	Initial Review Group
IRM	Information Resources Management
IT	Information Technology
LOI	Letter of Intent
LRP	Loan Repayment Program
MBRS	Minority Biomedical Research Support
MEPI	Medical Education Partnership Initiative
MERIT	Method to Extend Research in Time
MI/CCP	Minority Institution Cancer Center Partnership
MSI	Minority-Serving Institution
NCAB	National Cancer Advisory Board
NCCAM	National Center for Complementary and Alternative Medicine
NCI	National Cancer Institute
NCMHD	National Center on Minority Health and Health Disparities
NCRR	National Center for Research Resources
NDPA	NIH Director Pioneer Award
NExT	NCI Experimental Therapeutics
NFRP	NCI Funded Research Portfolio
NHGRI	National Human Genome Research Institute
NHLBI	National Heart, Lung and Blood Institute
NIA	National Institute on Aging
NIAAA	National Institute on Alcohol Abuse and Alcoholism
NIAID	National Institute of Allergy and Infectious Diseases
NIBIB	National Institute of Biomedical Imaging and Bioengineering
NICHD	Eunice Kennedy Shriver National Institute of Child Health and Human Development
NIDA	National Institute on Drug Abuse
NIDDK	National Institute of Diabetes and Digestive and Kidney Diseases
NIEHS	National Institute of Environmental Health Sciences
NIGMS	National Institute of General Medical Sciences
NIH	National Institutes of Health
NIMH	National Institute of Mental Health
NINR	National Institute of Nursing Research
NLM	National Library of Medicine
NRSA	National Research Service Award
OBF	Office of Budget and Finance
OBSSR	Office of Behavioral and Social Sciences Research
OCAM	Office of Complementary and Alternative Medicine
OCC	Office of Cancer Centers
OD	Office of the Director
OEA	Office of Extramural Applications
OER	Office of Extramural Research
OFACP	Office of Federal Advisory Committee Policy
OHAM	Office of HIV and AIDS Malignancies
OPERA	Office of Policy for Extramural Research Administration
ORRPC	Office of Referral, Review, and Program Coordination
ORWH	Office of Research on Women's Health
PA	Program Announcement
PAR	Reviewed Program Announcement
PAT	Process Analytic Technologies
PCP	President's Cancer Panel
PCRB	Program Coordination and Referral Branch
PHS	Public Health Service (HHS)

PI	Principal Investigator
PNRP	Patient-Navigation Research Program
PRESTO	Program Review and Extramural Staff Training Office
PROSPR	Population-Based Research Optimizing Screening Through Personalized Regimens
RAEB	Research Analysis and Evaluation Branch
R&D	Research and Development
REAP	Research Enhancement Awards Program
RFA	Request for Applications
RFP	Request for Proposals
RIO	Research Integrity Officer
RM	Road Map
RO	Referral Officer
RPG	Research Project Grant
RPRB	Research Programs Review Branch
RTRB	Resources and Training Review Branch
RUG	Review Users Group
SACGHS	Secretary's Advisory Committee on Genetics, Health, and Society
SBIR	Small Business Innovation Research
SBIRDC	SBIR Development Center
SEER	Surveillance, Epidemiology, and End Results
SEP	Special Emphasis Panel
SGE	Special Government Employee
SIC	Special Interest Category
SIG	Shared Instrumentation Grant
SITE	Organ Site Codes
SPECS	Strategic Partnering to Evaluate Cancer Signatures
SPORE	Specialized Program of Research Excellence
SPRS	Secure Payee Reimbursement System
SREA	Scientific Review and Evaluation Activities
SRLB	Special Review and Logistics Branch
SRO	Scientific Review Officer (formerly Scientific Review Administrator)
SSL	Secure Sockets Layer
STTR	Small Business Technology Transfer Research
TCGA	The Cancer Genome Atlas Research Network
T&E	Training and Education
TMEN	Tumor Microenvironment Network
TRWG	Translational Research Working Group

Appendix G: Cancer Information Sources on the Internet

NCI Web Site

The National Cancer Institute maintains a number of websites containing information about the Institute and its programs. All NCI websites, including those designed to provide cancer-related information to the general public and physicians, can be reached from the NCI home page at http://www.cancer.gov/.

DEA Web Sites

The following websites are maintained by the DEA to provide detailed information to researchers and the public about NCI funding opportunities and the Advisory Boards and groups supported by the DEA.

http://deainfo.nci.nih.gov/index.htm
DEA home page links to the individual DEA Web pages listed below; mission of the Division; contact information for DEA staff.

Advisory Boards and Groups

http://deainfo.nci.nih.gov/advisory/boards.htm
Links to the home page of each NCI Advisory Board, Committee, etc.

http://deainfo.nci.nih.gov/advisory/pcp/pcp.htm
President's Cancer Panel Charter; meeting agendas, meeting minutes, annual reports.

http://deainfo.nci.nih.gov/advisory/ncab/ncab.htm
National Cancer Advisory Board Charter; members of subcommittees, meeting agendas.

http://deainfo.nci.nih.gov/advisory/ncab/ncabmeetings.htm
NCAB meeting summaries.

http://deainfo.nci.nih.gov/advisory/bsa/bsa.htm
Board of Scientific Advisors Charter; members of subcommittees, meeting agendas.

http://deainfo.nci.nih.gov/advisory/bsa/bsameetings.htm
BSA meeting summaries.

http://deainfo.nci.nih.gov/advisory/bsc/bs/bs.htm
Board of Scientific Counselors Charter; members of subcommittees.

http://deainfo.nci.nih.gov/advisory/ctac/ctac.htm
Clinical Trials and Translational Research Advisory Committee Charter; members, minutes, and agendas.

http://deainfo.nci.nih.gov/advisory/dclg/dclg.htm
NCI Director's Consumer Liaison Group Charter; meeting schedules, agendas, minutes, and meeting summaries.

http://deainfo.nci.nih.gov/advisory/bsa/bsa_program/pogprogramfo.pdf
Program Review Group reports.

http://deainfo.nci.nih.gov/advisory/irg/irg.htm
Initial Review Group Charter; subcommittee members.

http://deainfo.nci.nih.gov/advisory/sep/sep.htm
Special Emphasis Panel Charter; rosters of recent meetings.

Funding Opportunities/Policies

http://deainfo.nci.nih.gov/funding.htm
Comprehensive information about funding for cancer research; lists of active PAs and RFAs; recently cleared concepts; grant policies and guidelines; downloadable application forms.

http://deais.nci.nih.gov/Public/RFA-PA.jsp?nt=P
Active PAs, with links to detailed descriptions.

http://deais.nci.nih.gov/Public/RFA-PA.jsp
Active RFAs, with links to detailed descriptions.

http://deainfo.nci.nih.gov/grantspolicies/index.htm
Links to full-text NCI and NIH policies related to grants and grant review (e.g., Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research and Instructions to Reviewers for Evaluating Research Involving Human Subjects in Grant and Cooperative Agreement Applications).

http://deainfo.nci.nih.gov/flash/awards.htm
Grant Guidelines and Descriptions (descriptions of NCI funding mechanisms, with links to PAs, RFAs, guidelines, and supplemental materials).

http://fundedresearch.cancer.gov
NCI Funded Research Portfolio: A visitor can search the database for information about research grant and contract awards made by the NCI. It includes awards for the current and past 5 fiscal years for both intramural and extramural projects. The website provides the ability to search the database in various ways, including a text search of the project abstract, and a search of the Special Interest Category (SIC), and anatomic site codes assigned to the project.

http://grants.nih.gov/grants/new_investigators/index.htm
New and Early Stage Investigator Policies.

http://www.cancer.gov/researchandfunding/training
The Center for Cancer Training (CCT).

http://report.nih.gov/index.aspx
Research Portfolio Online Reporting Tools (RePORT). Reports, Data, and Analyses of NIH Research Activities.

Other NIH Web Sites

http://www.nih.gov
http://grants.nih.gov/grants/ElectronicReceipt/
http://grants.nih.gov/grants/policy/policy.htm
http://grants.nih.gov/grants/guide/index.html
http://grants.nih.gov/training/extramural.htm
http://report.nih.gov

NATIONAL® CANCER INSTITUTE

September 2011